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ABSTRACT 
Rosetting (binding of infected erythrocytes to uninfected ones) is a parasite 
adhesion phenotype thought to be mediated by Plasmodium falciparum 
erythrocyte membrane protein 1 (PfEMP1). Despite the association between 
rosetting and severe malaria in Africa, rosette-mediating PfEMP1 variants from 
African-derived strains are yet to be characterized. 
I initially attempted to detect the predominantly expressed var genes in recently 
culture-adapted Kenyan P. falciparum isolates selected for rosetting. 
Unfortunately no clear rosetting-associated genes were detected, possibly 
because of incomplete selection and lack of a clear phenotype in the selected 
parasites. 
I then went on to study another Kenyan parasite line, SA075, whose predominant 
expressed var gene had interesting sequence features previously linked to 
rosetting. Using peR walking, cloning and sequencing, I identified the full-length 
var gene corresponding to the expressed tag sequence, called SA075var1. 
Subsequent experiments failed to confirm a role for the PfEMP1 variant encoded 
by SA075var1 in rosetting. However, SA075var1 had domain cassette DC 8-like 
features which have lately been linked to severe disease. 
Antibodies raised in rabbits against recombinant proteins from SA075var1 
domains revealed functional antibodies with an ability to recognize the surface of 
parasite infected erythrocytes and to mediate phagocytosis. Although mainly 
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variant-specific, the antibodies showed limited cross-reactivity with one other 
parasite strain. 
Using plasma pairs from Kenyan malaria patients in acute and convalescent 
stages of malaria, I examined antibody responses against SA075 and four other 
rosetting P.fa/ciparum strains selected to enrich for single rosette-mediating 
variants. Antibody responses were seen against particular rosette-selected strains 
suggesting that some variants may be important for particular severe malaria 
syndromes. 
Overall, the data described here demonstrates the need for continued research 
into functional and immunological characterization of PfEMP1 variants, especially 
in field isolates. Antibody data, however, showed clinical relevance of some 
rosette-mediating variants that could become important targets for malaria 
intervention studies. 
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CHAPTER 1 
General Introduction 
1.1: P.fa/ciparum malaria-a perspective 
Although a recent world health organization report (2011) showed an overall 
reduction in global malaria mortality by 26%, it still continues to be a major public 
health problem (WHO, 2011). An estimated 216 million cases were reported 
globally in 2010 with an estimated 655,000 deaths occurring in children under the 
age of 5 living in sub-Saharan Africa within the same year. In a malaria atlas 
project study (MAPS), the burden of clinical malaria which is potentially life 
threatening was shown to be high in certain regions of sub-Saharan Africa and 
Asia (Figure 1.1) (Hay, Okiro et al. 2010). It is evident from these reports that 
despite numerous efforts that have led to reduced malaria mortality, more still 
needs to be done to understand the pathogenesis of severe malaria which often 
leads to malaria mortality. Definitive understanding of the molecular mechanisms 
that cause severe malaria is still lacking, hence limiting advances towards 
development of therapeutics or anti-disease vaccines. This thesis will address an 
aspect of molecular pathogenesis of severe malaria. 
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Figure 1.1: Estimates of global clinical burden of Plasmodium falciparum malaria 
in 2007. Figure from Hay et al. , 2010 (Hay, Okiro et al. 2010). 
1.2 Severe malaria 
Severe malaria is a complicated syndrome whose manifestation is influenced by 
parasite, host and environmental factors (Figure 1.2) (Miller, Baruch et al. 2002). 
The overall clinical outcome of malaria infection ranges from asymptomatic 
infections to severe malaria and death with severe malaria presenting mainly as 
multi-organ failure, respiratory distress, severe anemia and impaired 
consciousness (Marsh, Forster et al. 1995; Dondorp, Lee et al. 2008). Severe 
malaria which is often seen in children in Sub-Saharan Africa may present either 
as a single syndrome or as overlapping syndromes and at times results in death 
within 12-24 hours of hospital admission. Another form of severe malaria is the 
pregnancy-associated malaria (PAM) which causes maternal anemia, low birth 
weight, premature delivery and increased child mortality (Kane and Taylor-
Robinson 2011). 
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Figure 1. 2: Interplay between parasite, host and environmental factors in 
development of clinical malaria. Also shown is the spectrum of clinical outcome 
which ranges from asymptomatic infections to severe malaria and death. Figure 
from Miller L.H et al.2002 (Miller, Baruch et al. 2002). 
In a prospective study carried out by Marsh and colleagues on 1844 children in 
Kilifi, Kenya (Marsh, Forster et al. 1995), the spectrum of severe malaria was 
defined and classified into three major syndromes: - impaired consciousness, 
respiratory distress and severe malarial anemia (Marsh, Forster et al. 1995). 
Impaired consciousness is a neurological complication whose assessment is 
based on Blantyre coma Score (BCS). The score is based on motor and verbal 
response as well as eye movement to determine the extent of the syndrome 
(Molyneux, Taylor et al. 1989; Waller, Krishna et al. 1995). In the Kilifi study, a 
BCS score of 4 or less was used as a cut-off for impaired consciousness (Marsh, 
Forster et al. 1995). Cerebral malaria , which is a form of severe impaired 
consciousness, is characterized by deep coma and inability to make localizing 
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response with a BCS of <3 (Molyneux, Taylor et al. 1989; Newton, Chokwe et al. 
1997) and no other cause of coma at least 1 hour after termination of a seizure or 
correction of hypoglycaemia (World Health Organization 2000). 
Respiratory distress on the other hand is an important syndrome found to occur in 
relatively younger children as compared to impaired consciousness (Marsh, 
Forster et al. 1995). Although traditionally thought to be as a result of cardiac 
failure (Molyneux 1989; Lackritz, Campbell et al. 1992), respiratory distress is 
characterized by deep breathing with metabolic acidosis (Marsh, Forster et al. 
1995) that mayor may not be accompanied by low hemoglobin levels as seen in 
malarial anemia. The parasite's contribution of acids is often difficult to determine 
but it is thought to be minor. Thus, fluid replacement and blood transfusion are 
associated with resolution of acidosis and clinical improvement (English, 
Sauerwein et al. 1997) 
Severe malarial anemia is defined as hemoglobin level of < 5g/dL (Marsh, Forster 
et al. 1995) and is also thought to contribute to metabolic acidosis by impairing 
tissue oxygenation. Although rupture of infected erythrocytes by mature parasites 
is thought to account for the profound anaemia encountered in many malaria 
patients, other potential causes of may include increased immune haemolysis, 
phagocytosis (Yuthavong, Bunyaratvej et al. 1990) and splenic clearance (Ho, 
White et al. 1990) of both infected and uninfected erythrocytes following 
sensitisation with IgG (Scholander, Carlson et al. 1998) or complement and 
changes in deformability (Waitumbi, Opollo et al. 2000; Dondorp, Nyanoti et al. 
2002). 
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An overlap of these syndromes was observed in Kilifi and resulted in a mortality 
rate of up to 34.7% (Marsh, Forster et al. 1995). 
There are numerous clinical and epidemiological differences in the presentation of 
severe malaria syndromes. For example in S.E. Asia, half of the severe P. 
fa/ciparum cases are cerebral malaria (Tran, Day et al. 1996), while in other 
places, like Papua New Guinea, this number decreases to about 17% (Lalloo, 
Trevett et al. 1996). Severe malarial anemia has on the other hand been shown to 
be commoner in areas of high transmission than in areas of low transmission 
(Snow, Omumbo et al. 1997; Marsh and Snow 1999). Age differences in the 
manifestation of severe malaria cases are also noted with S.E. Asia reporting 
more adult cases (Pongponratn, Riganti et al. 1991; Silamut, Phu et al. 1999) 
while sub-Saharan Africa reports more childhood cases (Taylor, Fu et al. 2004). 
Even within children in sub-Saharan Africa, clinical manifestations tends to occur 
at different age-groups with severe malarial anemia occurring in the youngest 
children while impaired consciousness occurs in slightly older children (Marsh, 
Forster et al. 1995; Snow, Omumbo et al. 1997; O'Meara, Bejon et al. 2008). A 
detailed understanding of the molecular basis of severe malaria thus remains 
crucial. In this thesis, variant specific antibody responses against rosette-
mediating variants will be examined to determine whether the variants are linked 
to any of the clinical syndromes described above. 
1.3: What is the molecular basis of severe malaria? 
1.3.1: P.fa/ciparum sequestration 
P. fa/ciparum sequestration is thought to be the key virulence factor in the 
pathogenesis of severe malaria. It occurs when mature forms of the paraSite 
disappear from peripheral circulation and adhere onto various host endothelial 
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cells in different vital organs (Miller 1969; Luse and Miller 1971). It is unknown why 
parasites sequester but it is thought that they do so to escape from spleen-
mediated clearance mechanisms (Mebius and Kraal 2005). 
When the P.fa/ciparum parasites (in form of sporozoites) get inoculated into the 
host by the mosquito, they migrate into the bloodstream and invade liver cells 
where they grow and divide for about 8-10 days (Life cycle shown in Figure 1.3). 
Daughter cells called merozoites are then released from the liver into the 
bloodstream where they invade red blood cells (RBCs). The merozoites then go 
into an erythrocytic cycle where they develop into ring-stage then to trophozoite 
and SChizont-stage parasites within the infected RBCs. The mature schizonts then 
rupture to release more merozoites which then invade new cells. The entire cycle 
takes about 48 hours from merozoite invasion to rupture of the infected RBCs, 
leading to an exponential increase in parasites. It is during the late stages that the 
parasite modifies the surface of infected RBCs by expressing parasite derived 
proteins such as Plasmodium falciparum erythrocyte membrane protein 1 
(PfEMP1). This protein binds to receptors on the surface of vascular endothelial 
cells, thereby sequestering the infected cells within various tissues. Sequestration 
is thought to be a crucial factor underlying the pathogenic and virulent nature of P. 
falciparum malaria (Miller, Baruch et al. 2002). One major hypothesis as to how 
sequestration leads to severe malaria is that the binding of parasites onto the 
endothelium or to non-infected RBCs (rosettes) may result in occlusion of 
microvascular blood flow hence impaired oxygen delivery and ultimately 
dysfunction of affected organs (Kaul, Roth et al. 1991; Dondorp, Ince et al. 2008). 
This is supported by postmortem studies in which massive sequestration of 
parasites on the brain endothelium has been observed (MacPherson, Warrell et al. 
1985; Pongponratn, Riganti et al. 1991; Taylor, Fu et al. 2004; Ponsford, Medana 
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et al. 2012), which has been thought to be the underlying cause of coma in 
cerebral malaria. 
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Figure 1.3: Life cycle of Plasmodium falciparum. Figure from Rowe et al., 2009 
(Rowe, Claessens et al. 2009). Details of the life cycle are in the text. 
1.3.2: Host ligands involved in sequestration 
Different host receptor molecules have been shown to playa key role mediating 
sequestration. A review by Rowe et al. , 2009 (Rowe, Claessens et al. 2009) 
highlighted 18 receptors involved in P. falciparum cytoadhesion. 12 of these were 
involved in endothelial adhesion, 3 were involved in rosetting and 3 were involved 
in platelet-mediated clumping. Other specialised receptors like chondroitin 
sulphate A (CSA) are involved in binding of infected erythrocytes onto 
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syncytiotrophoblasts to bring about placental sequestration (Bray and Sinden 
1979). 
Although not all receptors have been studied for their relationship with severe 
disease, there are differences in results from association studies done in African 
and S.E. Asia (Ho, Singh et al. 1991; Newbold, Warn et al. 1997; Heddini, Chen et 
al. 2001; Heddini, Pettersson et al. 2001). The adhesion molecules involved in 
rosetting will be discussed later in this chapter. 
1.3.3: Parasite ligands involved in sequestration 
1.3.3.1 PfEMP1 
As mentioned in section 1.3.2 above, the parasite ligand that is thought to playa 
key role in mediating sequestration is Plasmodium fa/ciparum erythrocyte 
membrane protein 1 (PfEMP1) (Gardner, Pinches et al. 1996). It is encoded by a 
family of about 50-60 var genes in a haploid genome, which are expressed in a 
mutually exclusive manner (Roberts, Craig et al. 1992; Baruch, Pasloske et al. 
1995; Smith, Chitnis et al. 1995; Chen, Fernandez et al. 1998; Gardner, Hall et al. 
2002). This controlled antigenic variation of surface-exposed antigenic 
determinants is a prime immune evasion mechanism used by P.fa/ciparum as well 
as other pathogenic protozoa amd bacterium e.g. African trypanosomes and 
Haemophilus influenza, to maintain a chronic infection in the presence of constant 
immune pressure exerted by their hosts (Borst and Greaves 1987; Deitsch, Moxon 
et al. 1997). 
Var genes are made up of two exons:- Exon I and Exon II. The extracellular region 
of PfEMP1 which is encoded by Exon I has an N-terminal segment (NTS) followed 
by several cysteine-rich domains known as DBL (duffy-binding-like) and CIDR 
(cysteine-rich interdomain regions) that have been classified into distinct types 
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based upon sequence similarity (Smith, Subramanian et al. 2000). The number, 
position and type of OBL and CIOR domains vary among the different PfEMP1 
variants in a genome. It is this variable domain composition and extensive 
sequence polymorphism that is thought to provide great flexibility in sequestration 
and phenotypic properties (Taylor, Kyes et al. 2000). On the other hand, Exon II 
which encodes the acidic terminal segment (ATS) is fairly conserved in all var 
genes. The OBLa. domain is the most conserved and this feature has been 
exploited to design "universal primers" that have been used in var gene 
transcription profiling studies (Taylor, Kyes et al. 2000). Figure 1.4 shows an 
example of domain architecture for a hypothetical var gene encoded PfEMP1. 
Exonl Exon II 
~(--------------------------------------------~) ( ) 
Figure 1.4: Schematic architecture of a P. falciparum var gene-encoded PfEMP1 
protein. The N-terminal extracellular region and the short transmembrane (TM) 
sequence are encoded by Exon I while the conserved acidic terminal sequence 
(A TS) is encoded by Exon II. The number and combinations of domains vary 
considerably between the different PfEMP1 molecules in a genome. NTS: N-
terminal segment; DBL: Duffy binding-like; CIDR: cysteine-rich interdomain region; 
A TS: acidic terminal segment. 
One important aspect of studies on var genes has been establishing a link 
between specific var genes with particular adhesion phenotypes and clinical 
syndromes of severe malaria (Kyriacou, Stone et al. 2006). These attempts have 
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been made difficult by the extensive intergenomic and intragenomic variation as 
well as high rates of recombination and mosaicism of var genes described in both 
laboratory and field isolates (Kraemer, Kyes et al. 2007; Bull, Buckee et al. 2008). 
Nonetheless, different var gene classification methods have been adopted and 
their biological or functional relevance tested in both field and laboratory isolates 
that exhibit different phenotypes. All the three methods described below will be 
used in this thesis for classification of var genes from field isolates. 
1.3.3.2 Classification of var genes 
j) Classification based on Upstream (Ups) sequences 
This has been the classical method of classification of var genes but it is still 
applicable to date (Smith, Subramanian et al. 2000; Gardner, Hall et at. 2002). 
Based on sequence homology, upstream sequences (Ups) which are fairly 
conserved have been classified into 3 major groups: - UpsA, UpsB, UpsC. UpsA 
var genes are found at the sub-telomeric chromosomal locations and are 
transcribed towards the telomeres. UpsB var genes are also mainly located at the 
sub-telomeric regions but are transcribed away from the telomeres while UpsC are 
centrally located and are transcribed away from the telomeres (Kraemer and Smith 
2006). The clinical relevance of this classification method is evident in field studies 
in which Ups A var and/or Ups B var genes are generally transcribed in parasites 
from children with severe malaria (Kaestli, Cockburn et at. 2006; Rottmann, 
Lavstsen et al. 2006) while Ups C genes are transcribed in parasites from children 
with asymptomatic malaria (Kaestli, Cockburn et at. 2006). 
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iil Cys/PoLV and block sharing (B8) group classification methods 
Due to the highly polymorphic nature of var genes. sequence analysis methods 
based on semi-conserved regions within the DBLo. domain have been used to 
classify var genes and to study their relationship with severe disease (Bull. 
Berriman et al. 2005; Normark. Nilsson et al. 2007). Bull et al.. 2005 (Bull. 
Berriman et al. 2005) classified var genes into six groups (Table 1.1) using an 
algorithm that is based on a 300-400bp semi-conserved region of DBLo., also 
known as the DBLo. "tag" (Bull. Berriman et al. 2005; Bull. Kyes et al. 2007). The 
main feature of this classification method is the number of cysteine residues within 
the tag region (hence Keys") and amino acid motifs occurring at four fixed positions 
known as positions of limited variability (PoLV) within the tag region. Unique motifs 
MFK and REY which are mutually exclusively found within the tag sequences have 
also been incorporated in the algorithm. Cys/PoLV groups 1,2 and 3 have two 
cysteine residues while groups 4 and 5 have four cysteine residues. Group 6 has 
either 1. 3. 5 or 6 cysteine residues and is hence referred to Cys X. Also of interest 
was the observation that cys2 sequences were generally significantly shorter than 
Cys4 sequences. a feature that could be incorporated in var gene sequence 
analysis. Considering that the high recombination rate between var genes which 
results to extreme diversity, the Cys/PoLV classification method allows for 
comparison of sequences especially between field isolates (Bull. Berriman et al. 
2005; Bull, Buckee et al. 2008; Warimwe. Keane et al. 2009; Warimwe, Fegan et 
al. 2012). In this thesis, the six groups referred to as "CP" groups will be used in 
sequence analysis. Table 1.1 shows the 6 CP groups while the Venn diagram 
(Figure 1.5) shows how they fit in the larger Cys2 or Cys4 sequence types. 
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Further analysis has been done on the tag sequences. The string of four amino 
acids at each of the PoL Vs together with the cysteine count forms a sequence 
signature also known as "sign, which has also been used to further classify DBLa 
sequences (Bull, Berriman et al. 2005). 
Further to this, var genes were grouped into seven block sharing groups (BS) in 
which sequences within a BS group carried exact matches to a collection of 573 
14-aa-sequence blocks within highly polymorphic regions of the sequence 
(Bull, Buckee et al. 2008). At a sensitivity of about 90% and specificity of 100%, 
307 var gene sequences in BS1 group were exclusively found to be of group A 
type. BS2 on the other hand did not contain any group A sequences but contained 
about 58% cys2 sequences most of which were from CP2. The biological 
relevance of these classification methods has been tested in several studies with 
CP1 being associated with impaired consciousness and CP2 being associated 
with severe malaria anaemia (Bull, Buckee et' al. 2008; Warimwe, Keane et al. 
2009; Warimwe, Fegan et al. 2012). On the other hand, sequences falling in 
Group A as well as those in CP2/BS1, CP2/BS2 and CP6/BS6 groups have been 
associated with rosetting (Bull, Buckee et al. 2008). Sequences of sig2 type have 
also been associated with rosetting (Bull, Berriman et al. 2005; Bull, Kyes et al. 
2007). 
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Table 1.1: A summary table of classification of var gene sequences into CysiPoL V 
groups as described by Bull and colleagues (Bull, Berriman et al. 2005). 
Sequence groups Number of cysteine Unique motif 
residues within the tag identifying the group 
region 
CP1 2 MFK 
CP2 2 REY 
CP3 2 -
CP4 4 -
CP5 4 REY 
CP6 X (1 ,35 or 6) -
cys4 
• CPl jCYS2 o CP2 
o CP3 
• CP4 ]CYS4 CPS 
o CP6 
All DBlu tag sequences 
Figure 1.4: Venn diagram showing DBLa tag sequences by CysiPoLV (CP) 
classification method. CP1 and CP2 which contain mutually exclusive MFK and 
REY motifs respectively are subgroups of Cys 2. CP3 on the other hand is a Cys 2 
without any of these 2 motifs. CP4 contains 4 cysteine residues with CP5 being a 
subgroup that has a REY motif. CP6 contains either 1, 3, 5, 6 or X number of 
cysteine residues. 
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iii) Classification based on domain cassettes -DC 
Domain cassette is the latest approach in the classification of var genes which is 
based on the entire gene sequence rather than smaller regions such as the 
upstream and the DBLa tag region (Rask, Hansen et al. 2010). A domain cassette 
is defined as two or more consecutive domains belonging to particular subclasses 
and present in three or more of the 7 P.fa/ciparum genomes that were studied. 
Currently, 24 domain cassettes have been described (Rask, Hansen et al. 2010; 
Berger, Turner et al. 2013) with two of them showing evidence of association with 
severe disease. These are DC a and DC13 which have both been associated with 
severe malaria, mainly cerebral malaria and respiratory distress (Lavstsen, Turner 
et al. 2012; Bertin, Lavstsen et al. 2013). Lately DCa and 13 have been linked to 
binding onto endothelial protein C receptor (EPCR) (Turner, Lavstsen et al. 2013), 
a receptor involved in anticoagulation and endothelial cytoprotective pathways. 
Although DC4 has been associated with binding to Intracellular adhesion molecule 
1 (ICAM1), (Bengtsson, Joergensen et al. 2013) there was no link to severe 
malaria. DC5 on the other hand was associated with binding to Platelet endothelial 
cell adhesion molecule 1 (PECAM1) in a Tanzanian study (Berger. Turner et al. 
2013) in which anti-DCS antibodies IgG levels were associated with protection 
from malaria and correlated positively with hemoglobin levels. 
Lately. sequencing and identification of var genes has been made easier by the 
high throughput sequencing techniques (Liu, Li et al. 2012) (Gandhi. Thera et al. 
2012). Full-length var genes are also being sequenced and assembled thus 
making studies on var transcription easier. Additionally, the Vardom 1.0 Server 
(http://www.cbs.dtu.dklservicesNarDom/). a free software has been constructed 
for the classification analysis of PfEMP1 sequences. It is based on var gene 
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sequences from 7 parasite genomes (Rask, Hansen et al. 2010) and has improved 
the study on classification and definition of domain boundaries of var genes 
especially in un-annotated field isolates. 
1.4 Rosetting 
Rosetting is the spontaneous binding of two or more uninfected erythrocytes to 
erythrocytes infected with mature asexual parasites (David, Handunnetti et al. 
1988) (Figure 1.6). It is one of the most studied adhesion phenotypes of 
P.fa/ciparum. Among the earliest studies to report on rosetting was by 
Udomsangpetch et a/.,1989 (Udomsangpetch, Wahlin et al. 1989) where rosetting 
was seen in both established laboratory isolates as well as fresh isolates from 
malaria patients. Although mainly described in P.falciparum, rosetting occurs in 
other Plasmodium species i.e. P. vivax, P. ovale and P. ma/ariae (Udomsanpetch, 
Thanikkul et al. 1995; Angus, Thanikkul et al. 1996; Lowe, Mosobo et al. 1998) as 
well as rodent and primate species such as P.chabaudi and P fragile respectively 
(David, Handunnetti et al. 1988; Mackinnon, Walker et al. 2002). It is not clear why 
parasites form rosettes but it is speculated that it could be a mechanism for 
immune evasion (Ruangjirachuporn, Afzelius et al. 1992) or a mechanism to 
facilitate quick invasion of merozoites onto the non-infected cells (Clough, Atilola 
et al. 1998). However, an experiment to test whether rosettes allow quick invasion 
by protecting against invasion-inhibitory antibodies showed no evidence in support 
of this (Deans and Rowe 2006). 
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Figure 1.6: A) Electron micrograph photo showing a rosette in which an infected 
cell is surrounded by 3 non-infected RBGs. (Image courtesy of David Fergurson, 
Oxford). B) Routine examination of rosetting parasites under a fluorescent 
microscope where parasites were stained with 20Jlg/ml of ethidium bromide and 
viewed under x40 objective lens. The rosettes shown have 3 and 5 uninfected 
RBGs bound to an infected RBG. 
1.5 Rosetting and severe malaria 
Studies done in sub-saharan Africa from early 1990s to date have consistently 
shown an association between rosetting and severe disease (Table 1.2). However, 
this association is not often seen in parts of S.E Asia (Udomsangpetch, Taylor et 
al. 1996; Angkasekwinai, Looareesuwan et al. 1998). This may be attributed to 
differences in endemic situations, different parasite population, host genetic 
makeup, differences in host-parasite interactions and evolution (Mercereau-
PUijalon, Guillotte et al. 2008). Table 1.2 is a summary of different studies done in 
Africa on the association between rosetting and severe malaria (% RF i.e 
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percentage rosetting frequency as used in the table is a score of the percentage of 
200 mature trophozoites that adhered to at least two uninfected erythrocytes ). 
Table 1.2: Rosetting and severe malaria in Africa 
Study site Study details 
The Gambia 
The Gambia 
Madagascar 
Kenya 
24 children with cerebral malaria were 
compared to 57 children with mild malaria. 
There was a significant difference in % RF 
between the two groups (P<0.001) 
A larger study by the same group as 
described in (Carlson , Helmby et al. 1990) 
above. 24 children with cerebral malaria 
were compared to 106 children with 
uncomplicated malaria. There was a 
significant differences in % RF between the 
two groups (P<0.000001) 
A small study in which three clinical groups 
were compared . 6 cerebral malaria (CM), 6 
severe malaria (SM) and 9 uncomplicated 
malaria (UM) cases. Both the CM and SM 
cases had significantly higher % RF than the 
UM cases. P<0.05 and P<0.002 
respectively. 
Reference 
(Carlson, Helmby et al. 
1990) 
(Treutiger, Hedlund et al. 
1992) 
(Ringwald , Peyron et al. 
1993) 
Three clinical categories were compared: - (Rowe, Obeiro et al. 1995) 
Kenya 
36 severe malaria , 64 moderate malaria and 
54 mild malaria cases. There was a 
significant difference in % RF between 
severe malaria and mild malaria. 
P<0.003.No difference was seen between 
severe malaria and moderate malaria 
P<0.15. A comparison of cerebral malaria 
versus all other severe malaria cases 
showed no difference in %RF. P<OA. 
49 severe malaria cases and 45 cerebral 
malaria cases were compared against 50 
children with mild malaria. Severe cases 
had higher % RF compared to mild malaria. 
However, a comparison of cerebral malaria 
against mild malaria showed no difference in 
%RF. 
(Newbold, Warn et al. 
1997) 
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Kenya 
A study done to compare different adhesion 
phenotypes between severe and mild 
malaria cases. Rosetting data showed that 
57 severe cases had significantly higher % 
RF than 64 mild malaria cases. 
P<0.02. 
(Pain, Ferguson et al. 
2001 ) 
Kenya 
A study done to compare different adhesion 
phenotypes between 21 severe and 45 mild 
malaria cases. In addition to % RF, size of 
rosettes and the tightness of rosettes was 
also evaluated. Severe cases had higher % 
RF compared to mild malaria cases 
P<0.001. 
(Heddini, Pettersson et al. 
2001) 
Malawi 
% RF was determined in fresh isolates from 
the field. 64 severe malaria cases were 
compared 32 to cerebral malaria cases 
(CM), 18 severe malarial anaemia cases 
(SMA) and 46 CM with or without SMA and 
uncomplicated malaria. There was no 
difference in the median % RF for all the 
groups. 
(Rogerson, Tembenu et al. 
1999) 
Gabon 
Mali 
A matched case control study in which 47 
severe malaria cases were matched to 47 
mild malaria cases. The severe cases had 
significantly higher % RF in the severe 
cases than the mild malaria cases P<0.05. 
One of the latest reports on association 
between rosetting and severe disease. 78 
children with severe malaria had 
significantly higher % RF compared to 91 
children with uncomplicated malaria and 40 
children with non-severe hyperparasitaemia 
P<0.0001. No difference was seen in % RF 
between the different sub-categories of 
severe malaria 
(Kun, Schmidt-Ott et al. 
1998) 
(Doumbo, Thera et al. 
2009) 
Although rosetting is generally associated with severe disease, the link with 
specific disease syndromes is uncertain. While most of the studies above showed 
a clear association between rosetting and severity of clinical malaria (Newbold, 
Warn et al. 1997; Heddini, Pettersson et al. 2001), only a few of them showed a 
link between rosetting and specific syndromes such as cerebral malaria (Carlson, 
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Helmby et al. 1990) (Treutiger, Hedlund et al. 1992) (Ringwald, Peyron et al. 
1993). The study by Doumbo et al., 2009 (Doumbo, Thera et al. 2009), however, 
sought to clarify the association between rosetting and specific disease 
syndromes. High levels of rosetting were seen in patients with cerebral malaria, 
severe malarial anemia, non-comatose neurological impairment and repeated 
seizures without long-lasting neurological impairment. There was no statistically 
significant difference in the rosetting frequencies between the different syndromes. 
In Chapter 6 of this thesis, antibody responses against rosette-mediating PfEMP1 
variants will help determine whether rosetting is linked to any specific disease 
syndrome. 
Overall, despite these data, there is still limited information as to how exactly 
rosetting causes severe disease. The positive association between rosetting and 
severe disease in the studies described above (Table 1.2) does not prove a causal 
link between the two. It is possible that rosetting mayor may not be directly 
important in pathogenesis or may simply be a marker for some other factors that 
affect the disease process. However, human genetic studies have shown high 
prevalence of RBC variants in malaria endemic areas, suggesting their protective 
role against severe malaria (Hill 1992; Miller 1994). Such polymorphisms that are 
linked to rosetting include CR1 polymorphisms like SI(a-) and McC(b-) (Moulds, 
Kassambara et al. 2000) CR1 deficiency (Cockburn, Mackinnon et al. 2004) and 
blood group a antigens (Rowe, Handel et al. 2007). 
1.6 Molecular mechanisms of rosetting 
1.6.1 Which receptors on uninfected RBCs are involved in rosetting? 
Different parasites use different host receptors expressed on the uninfected cells 
to mediate rosetting. As mentioned in section 1.3.2 of this Chapter, three major 
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receptors on the surface of RBCs have been implicated in rosetting (Rowe, 
Claessens et al. 2009). These are complement receptor 1 (CR1), heparan 
sulphate-like molecules and ABO blood group antigens. 
CR1 (also CD35) is a receptor on the surface of RBCs thought to be involved in 
rosetting, with sufficient evidence from a well characterized laboratory isolate 
(Rowe, Moulds et al. 1997). It is an immune regulatory molecule that binds to 
activated complement component C3b and C4b to clear away immune complexes 
(Ahearn and Fearon 1989). 
A study by Rowe et aI, 1997 (Rowe, Moulds et al. 1997) showed that CR1 was the 
receptor on RBCs that mediates rosetting in R29 parasites. There is also evidence 
to show the involvement of CR1 in rosetting of field isolates from Kenya and 
Malawi where rosettes were reversed by an anti-CR1 antibody (J3B11) (Rowe, 
Rogerson et al. 2000). Using deletion mutants and monoclonal antibodies, this 
study further showed that the region of CR1 required for the formation of P. 
falciparum rosettes was localized to the area of long homologous repeat regions B 
and C of the molecule that also acts as the binding site for the activated 
complement component C3b. Human genetic studies on CR1 polymorphisms 
provide indirect evidence CR1-mediated rosetting is important in the pathogenesis 
of severe disease (Moulds, Kassambara et al. 2000; Cockburn, Mackinnon et al. 
2004). 
Heparan sulphate is a type of glycosaminoglycan (GAG) thought to be involved in 
rosetting. Although an earlier study on the FCR3S1.2 parasite clone (Chen, 
Barragan et al. 1998) suggested that heparan-sulphate like molecules were 
involved in rosetting of this clone, a recent study on the same parasite clarified that 
39 
a different PfEMP1 variant may be involved in rosetting whose receptor ligand is 
not well known (Albrecht, Moll et al. 2011). Nonetheless, field studies done in 
Cameroon showed that low anticoagulant heparin (LAH), which are related GAGs, 
had the ability to disrupt rosettes in fresh isolates from children, thus providing 
evidence that the molecules could be important for rosetting (Leitgeb, Blomqvist et 
al. 2011). 
ABO blood group antigens which are sugars attached to glycoprotein and 
glycolipids on the surface of RBCs have been shown to playa key role in rosetting 
(Carlson and Wahlgren 1992; Barragan, Kremsner et al. 2000). ABO blood group 
antigens have recently been shown to be the main receptor for VarO expressing 
Palo Alto 89F5 rosetting clone (Vigan-Womas, Guillotte et al. 2012). There 
seemed to be preference for blood group A as opposed to blood groups Band 0 
in the VarO expressing parasites. Additionally, the protective effect of blood group 
o against malaria by mechanism of reduced rosetting (Rowe, Handel et al. 2007) 
suggests these antigens are involved in rosetting and that they play a role in 
pathogenesis of severe malaria. 
Binding of parasites to non-immune IgM has lately become a phenotype of interest 
in rosetting of both laboratory and field isolates. Although not directly used as a 
receptor for rosetting, IgM binding has been shown to be important for rosetting in 
IT/PAR+ strain where reduced rosetting was seen when IgM was depleted 
(Clough, Atilola et al. 1998). However, its importance in other IgM-binding rosetting 
parasites like TM284R+ and HB3R+ is unknown. It is thought that IgM binding acts 
by either strengthening rosettes (Somner, Black et al. 2000) or by blocking access 
of variant specific IgG through steric hinderance (Czajkowsky, Salanti et al. 2010). 
The link between IgM-binding, rosetting and severe disease was first described in 
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clinical isolates by Rowe et al., 2002 (Rowe, Shafi et al. 2002). More recently, a 
study by Ghumra et al., 2012 (Ghumra, Semblat et al. 2012) using antibodies to 
the NTS-DBLu domain of different rosetting isolates showed cross reactivity of the 
antibodies that seemed to be limited within the parasites with the IgM-binding 
phenotype. Coupled with the positive association with severe disease in clinical 
isolates (Rowe, Shafi et al. 2002), IgM-binding in rosetting isolates may be 
important in the pathogenesis of severe disease and also a good target in 
intervention studies. 
Although the receptors described above have specifically been linked to rosetting, 
it is reported that there are multiple other possible receptors that could be involved 
(Chen, Heddini et al. 2000; Heddini, Pettersson et al. 2001), thus highlighting the 
complexity of this interaction. Complement factors and other serum proteins which 
are present in the culture media are thought to be important in rosetting 
(Mercereau-Puijalon, Guillotte et al. 2008). In FCR3S1.2 and Malayan Camp 
rosetting parasites, complement factor D, serum albumin and natural antibodies to 
band3 are required for rosetting (Luginbuhl, Nikolic et al. 2007). More studies need 
to be done especially on clinical isolates to determine the relevant receptors 
involved in rosetting. 
1.6.2: PfEMPI as rosetting ligand on infected RBCs 
Although previous studies had showed that rosettins (Helmby, Cavelier et al. 
1993) and rifins (Kyes, Rowe et al. 1999) may be involved in rosetting, there is 
sufficient evidence to show that PfEMP1 is the key ligand involved in this 
adhesion. Among the early lab-based evidence to show involvement of PfEMP1 in 
rosetting is by Rowe et a/1997 (Rowe, Moulds et al. 1997). In that study, reverse 
transcription of the var genes showed that R29var1 (ITvar9) was uniquely 
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expressed in rosetting population of R29 strain and not in the isogenic non-
rosetting population. Similar evidence on the role of PfEMP1 in rosetting has been 
shown for VarO expressing parasites in both primate and human infections (Vigan-
Womas, Guillotte et al. 2008). In a different strain called FCR3S1.2, rosetting was 
recently shown to be mediated by FCRvar2 (also ITvar60) (Albrecht, Moll et al. 
2011). In addition to R29, Ghumra et al., 2012 (Ghumra, Semblat et al. 2012) also 
characterised 5 other rosette mediating PfEMP1 variants that were able to induce 
functional antibodies, including a subset of them that had cross-reactive 
antibodies. Table 1.3 is a list of PfEMP1 variants that are thought to mediate 
rosetting in laboratory isolates. 
Other than the laboratory-based studies, there is sufficient evidence to suggest 
that PfEMP1 is involved in rosetting in- clinical isolates. Through expression 
profiling of DBLa. tags, data from field isolates suggests that a distinct sub-group of 
var genes is implicated in rosetting in natural parasite populations (Bull, Berriman 
et al. 2005; Bull, Buckee et al. 2008) and these are also linked to specific disease 
syndromes (Warimwe, Keane et al. 2009). Var gene sequences within Cys 2 or 
Group A-like were found to be associated with rosetting and severe disease in 
studies done in Kilifi, Kenya (Bull, Berriman et al. 2005; Bull, Pain et al. 2005; 
Warimwe, Keane et al. 2009; Warimwe, Fegan et al. 2012). A different sequence 
analysis approach by Normark et al., 2007, which is also based on motifs within 
the DBLa. tag region, was able to identify three degenerate sequence motifs that 
correlated with rosetting and severe malaria clinical samples from Uganda 
(Normark, Nilsson et al. 2007). The mapping of one of the Normark sequences 
called H3 onto a network of 3D7 and P.reichenowi sequences (also known as Kilifi 
network) described by Bull and others (Bull, Buckee et al. 2008) suggests that it 
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corresponds to those identified in Kilifi. These are encouraging results and they 
suggest that there is a limited subset of rosette-mediating variants in natural 
populations which raises the possibility that a vaccine could be developed 
specifically against this phenotype. 
Table 1.3: PfEMP1 variants associated with rosetting in laboratory isolates 
Isolate/Strain/Clone PfEMP1 variant References 
linked to 
rosetting 
TM284R+ TM284var1 (Ghumra, Semblat et al. 
2012) 
HB3R+ HB3var6 (Ghumra, Semblat et al. 
2012) 
PAR+ (also known as ITvar60 (Ghumra, Semblat et al. 
FCR3S1.2) 2012) (Albrecht, Moll et 
al. 2011) 
R29R+ ITvar9 (Rowe, Moulds et al. 
1997) 
TM180R+ TM180var1 (Ghumra, Semblat et al. 
2012) 
Muz12R+ Muz12var1 (Ghumra, Semblat et al. 
2012) 
Palo alto 89F5 VarO (Vigan-Womas, 
Guillotte et al. 2008) 
307 PF13-003 (Vigan-Womas, 
Guillotte et al. 2011) 
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1.7: Rosetting and immunity to malaria 
Acquired immunity to malaria develops in individuals following repeated exposure 
to infection (Langhorne, Ndungu et al. 2008; Doolan, Dobano et al. 2009). 
Consequently, in endemic areas, manifestation of clinical disease becomes less 
severe with age as immunity develops (Marsh and Kinyanjui 2006; Doolan, 
Dobano et al. 2009). Similarly, immunity against variant surface antigen (VSAs) 
such as PfEMP1 is thought to occur in a piecemeal manner. During the first 
exposure, individuals develop antibodies that are specific to the infecting VSA 
variant (Marsh and Howard 1986; Iqbal, Perlmann et al. 1993; Bull, Lowe et al. 
1999). Following repeated exposure, a repertoire of variant-specific antibodies 
develops that can recognize other VSAs expressed by most parasite isolates (Bull, 
Lowe et al. 1999; Giha, Staalsoe et al. 2000). Evidence for development of variant 
specific immunity was shown as early as in the 60s using in vivo experiments in P. 
knowlesi (Brown and Brown 1965; Brown, Brown et al. 1968). Overall, these 
observations may suggest that immunity to disease may involve acquisition of 
antibodies directed against polymorphic target antigens. In this thesis, antibody 
responses against rosette-mediating variants will be evaluated during (acute) and 
after (convalescent) clinical disease. Responses generated using the acute 
plasma will represent antibodies against the current or previous infections carried 
by the patient while the difference between the acute and convalescent responses 
will represent variant specific antibody responses. 
The protective mechanisms of immunity against rosetting parasites are thought to 
be in the ability of the antibodies to inhibit rosette formation, disrupt already formed 
rosettes or to mediate phagocytosis. In laboratory isolates, antibodies generated 
from recombinant proteins had the ability to inhibit rosette formation or disrupt 
already formed rosettes (Ghumra, Khunrae et al. 2011; Ghumra, Semblat et al. 
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2012). The same antibodies were used to opsonize parasites and were able to 
mediate phagocytosis of mature infected RBCs (Ghumra, Khunrae et al. 2011; 
Ghumra, Semblat et al. 2012). Although the antibody function was mainly strain 
specific, there was limited cross reactivity that seemed to be restricted within 
parasites with the IgM binding phenotype (Ghumra, Semblat et al. 2012). 
In clinical isolates, the ability of serum to disrupt rosettes in homologous or 
heterologous parasite has been demonstrated. Carlson et a/., 1990 showed how 
the presence of anti-rosetting antibodies in plasma could have played a role in 
modifying the outcome of cerebral malaria. In that study which was carried out in 
The Gambia (Carlson, Helmby et al. 1990), only 2 out of 12 sera (17%) from 
children with cerebral malaria tested against the patient's own (homologous) 
parasites in vitro exhibited anti-rosetting activity; while as many as 93% (25 out of 
27) of the sera from children with uncomplicated disease had the ability to disrupt 
rosettes in homologous parasites. A different study by Barragan et al., 1998 
(Barragan, Kremsner et al. 1998) using plasma samples from Kenya and Gabon, 
showed an age related build-up of anti-rosetting serum activity against two 
rosetting strains: -FCR3S1 and TM284 (Barragan, Kremsner et al. 1998). This 
suggested that the PfEMP1 variants circulating in that population were 
antigenically similar to FCR3S1 and TM284 and that rosette mediating variants 
may be limited in a population. More recently, humoral responses against VarO 
rosetting variant were associated with protection against malaria in samples from 
Benin where severe malaria cases were compared to uncomplicated malaria 
(Vigan-Womas, Lokossou et al. 2010). Although the protection was independent of 
rosette disruption in the Benin study, it suggested a possible cytophylic role of the 
antibodies. Clinical plasma samples have also been tested against recombinant 
proteins from rosetting variants such as R29 (Mayor, Rovira-Vallbona et al. 2009) 
4S 
and VarO (Vigan-Womas, Lokossou et al. 2010) in ELISA, with results showing 
sero-prevalence of these antibodies in endemic populations. It is therefore evident 
that individuals do mount antibody responses specifically against rosette-
mediating variants. Whether these variants are of clinical relevance remains to be 
known. 
An interesting observation about immunity to rosetting variants is that while most 
forms of severe disease decline with age following build-up of naturally acquired 
immunity, rosetting which is associated with severe disease does not seem to 
have a clear age profile. There is no clear evidence that rosetting diminishes with 
age among children admitted to the hospital (Smith, Subramanian et al. 2000; 
Warimwe, Fegan et al. 2012). However, this may be due to the fact that children 
admitted to the hospital (such as those we intend to use in the current study) 
already have relatively high parasitaemia which may bias the samples towards 
rosette positivity. 
1.8 Scope of the thesis 
A gap still remains in the study of rosetting parasites that would directly show the 
importance of rosetting in the pathogenesis of specific clinical syndromes of 
severe disease. Using plasma from children who have recovered from severe 
disease, I aimed to evaluate the clinical relevance of rosette mediating variants 
from well established laboratory isolates and from a putative PfEMP1 variant 
identified from a field isolate. 
Although rosetting is among the most studied adhesion phenotypes of 
P.fa/ciparum, the molecular mechanisms and the exact role of rosetting in severe 
disease are not well known. This may partly be due to lack of in vivo models that 
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can exactly mimic rosetting and the subsequent development of severe disease in 
humans. In vivo significance of rosette mediating variants therefore needs to be 
assessed. As discussed in the introduction, the clinical outcome of severe malaria 
partly depends on parasite and environmental factors. While many in vitro studies 
have been carried out to understand the molecular mechanisms of rosetting, none 
of them have involved rosetting parasites from sub-Saharan Africa. This is 
unfortunate because the most consistent association between rosetting and 
severe disease has been seen in African populations (Table 1.2). 
The initial aim of this thesis was to characterize a rosette-mediating PfEMP1 
variant from a Kenyan field isolate and to examine the development of rosette-
inhibiting antibodies in a Kenyan population exposed to malaria. The hypotheses 
to be tested were: 
1) That there is a limited subset of rosette-mediating PfEMP1 variants in the 
parasite population, and that individuals living in malaria endemic areas would 
raise antibodies against the common rosette-mediating variant types. 
2) That due to the limited number of rosette-mediating variants in the population, 
antibodies to rosetting PfEMP1 variants will show cross-reactivity against multiple 
rosetting isolates. 
Chapter 3 of this thesis contains results on preliminary var gene transcriptional 
profiling in rosette-selected culture-adapted clinical isolates from Kilifi. However, 
no clear rosette-associated var genes were identified. This work was done at the 
KEMRI-Kilifi laboratory. 
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Chapter 4 then focused on one recently culture-adapted field isolate called SA075 
in an attempt to identify, clone and sequence a full-length PfEMP1 variant thought 
to be involved in rosetting. The SA075 parasite was chosen for this analysis 
because the DBLa. tag sequences had been previously characterized and shown 
to be of interest (Bull, Buckee et al. 2008). By sequence classification, the 
dominant SA075 var gene transcript belonged to Cys/PoLV group 2, block sharing 
group 2 and had sequence signature 2 (sig2), all of which have previously been 
linked to rosetting (Bull, Berriman et al. 2005; Bull, Buckee et al. 2008). Following 
identification of the full-length gene expressed in SA075 (called SA075var1), 
assays were optimized for expression of recombinant proteins and raising of 
antibodies from the different domains of the identified PfEMP1 variant. Also 
presented in this chapter was an interesting finding that SA075var1 had DC8-like 
features based on the recent classification by domain cassettes. DC8 has recently 
been linked to severe disease (Lavstsen, Turner et al. 2012) and binding to 
endothelial protein C receptor (EPCR) (Turner. Lavstsen et al. 2013) and therefore 
further characterization of SA075var1 was of interest. This work was done in Alex 
Rowe's lab, University of Edinburgh. 
Chapter 5 focuses on functional and immunological assays used in characterizing 
rabbit polyclonal antibodies raised against recombinant domains of SA075var1. An 
important assay described in this chapter was the development of a cell sorting 
protocol using the antibodies generated in Chapter 4. The cell-sorted parasites 
(frozen as trophozoites) were shipped back to the Kilifi labs and used in surface 
recognition assays described in Chapter 6. 
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Finally, Chapter 6 examines the clinical relevance of SA075 parasites and four 
well-characterised P. fa/ciparum rosetting laboratory strains. Plasma samples from 
malaria patients collected during and after a disease episode were tested against 
different cell sorted parasites to investigate whether any of these parasite lines are 
antigenically similar to parasites causing severe malaria in Kenyan children. 
Further analysis on induced antibodies suggested that despite not being linked to 
severe disease, some PfEMP1 variants may be more common in natural 
populations than others. 
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CHAPTER 2 
Materials and methods 
This chapter provides detailed methods of techniques that were used in more than 
one chapter of this thesis. Further additional methods which are specific for each 
chapter are given within the chapter. 
2.1: Study area 
The work presented in this thesis was mainly carried out in Kilifi , a district in Kenya 
that lies along the Indian Ocean coastline (Figure 2.1, left side map). The study 
area from which the clinical samples were collected lies within the Kilifi Health and 
Demographic surveillance system (KHDSS) (Figure 2.1, right side map), in which 
the District Hospital is located. Samples were collected as part of an integrated 
study on development of natural immunity to malaria in children within Kilifi district 
(See Appendix 8.1 for the protocol). 
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Figure 2.1: Situation of Kilifi District in Kenya (left) and map of Kilifi District (right) 
showing the boundary of the KHDSS and the rate of paediatric admissions to Kilifi 
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District Hospital by administrative sublocation. Map from Scott et al. , 2012 (Scott, 
Bauni et al. 2012). 
Kilifi is a malaria endemic area with transmission increasing after the long rains 
(April-June) and after the short rains (October-November) each year (O'Meara, 
Bejon et al. 2008). However, as in many coastal towns in Kenya, malaria in Kilifi 
has been declining in the last 20 years (Okiro, Hay et al. 2007), with a marked 
change of pattern in parasite prevalence (O'Meara, Bejon et al. 2008) (Figure 2.2) 
and a subsequent decline in hospital admissions for malaria (Okiro, Alegana et al. 
2009) (Figure 2.3). These changes in malaria epidemiology have been attributed 
to multiple factors including bed net usage, replacement of chloroquine with 
sulfadoxine-pyrimethamine as the first line therapy and other social-economic 
factors (Okiro, Hay et al. 2007). Recent data on the vector population (Mwangangi, 
Mbogo et al. 2013) also reports a decline in the densities of the major malaria 
vectors (Anopheles gambiae complex) and a shift from human to animal feeding 
that may have contributed to the decreased burden of malaria along the Kenyan 
coast. 
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Figure 2.2: Graph showing a decline in annual parasite prevalence in patients 
admitted with trauma in Kilifi between 1990 and 2007 (p<O. 0001) as described by 
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O'meara et al. ,2008 (O 'Meara, 8ejon et al. 2008). The bars represent 95% 
confidence intervals around the mean . 
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Figure 2.3: Decline in pediatric admission for malaria (blue line), non-malaria (red 
line) and all cause-admission (black line) in Kilifi between 1999-2008 expressed 
per 1,000 children aged 0 to 14 years at risk per annum and 95% confidence 
intervals as described by Okiro et al. ,2009 (Okiro, Alegana et al. 2009). 
2.2: Patient recruitment and sample processing 
This study was covered for ethical approval by the Kenya Medical Research 
Institute (KEMRI) national ethical review board and the Oxford Tropical Research 
Ethics committee (OXTREC) under protocol SSC no. 1131 (Appendix 8.1). 
Following informed consent from parents/guardians, acute samples including 
malaria infected red blood cells (RBCs) as well as plasma samples were collected 
from children who presented to Kilifi district Hospital. Convalescent plasma 
samples were collected after 2,4 and 12 weeks from the same children who were 
enrolled in the study. Malaria positivity was defined as parasitaemia level of ~1 
parasite per 500 RBCs on a thin film or 100 parasites per 100 white blood cells 
(WBCs) on a thick film. 
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Upon arrival in the lab, the blood sample, usually about 2-5mls in polypropylene 
tubes (Falcon®, USA) containing 50 units of heparin (CP Pharmaceuticals Ltd, 
UK) was spun down to remove plasma. This was then carefully collected using a 
pipette and stored in freezing tubes at -BO°C. The remaining RBCs were re-
suspended in 5 ml of incomplete culture media made up of RPMI 1640 (Gibco, 
UK) supplemented with 25mM HEPES (Gibco, UK), 2mM L-glutamine (Gibco, 
UK), 25 mM Glucose (Gibco, UK), 25 Jlg/ml Gentamicin (Gibco, UK), adjusted with 
1M NaOH to a pH of 7.2-7.4. The RBC suspension was then gently layered into a 
15 ml centrifuge tube containing 3ml Lymphoprep ™ (Axis-Shield PoC AS, 
Norway) to separate out peripheral blood mononuclear cells (PBMCs). This was 
then followed by centrifugation (Heraeus, Thermo Fisher Scientific Inc.) at 440g for 
20 minutes with the brakes off, after which granulocytes were separated by 
plasmagel flotation. For samples that were malaria positive, the packed RBCs that 
remained after plasmagel separation were washed twice in incomplete media and 
divided into 3 portions which were processed differently. Note that the volumes 
described in i, ii and iii below would vary depending on the original pellet volume 
obtained from the blood sample. 
i. 100JlI of ring infected RBCs were frozen down in 1000J.l1 of pre-warmed 
Trizol® (Invitrogen UK) for RNA extraction. 
ii. 100JlI of ring infected RBCs was frozen in 1 ml aliquots of glycerolyte at -
BO°C in cryovials (Nunc™, Thermo Fisher Scientific Inc.). The glycerolyte 
solution contained 42.25 % glycerol, 0.1 M sodium lactate, 4mM KCI, 
NaH2P04, pH 6.B(all from Sigma Aldrich). 
iii. Remaining cells were set up in culture as described in section 2.3.1 of this 
chapter to be frozen down the following day at trophozoite stage. 
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2.3: Laboratory techniques 
The work described in this thesis was done both at the KEMRI labs in Kilifi and at 
Rowe's lab in University of Edinburgh. There were slight differences in some of the 
protocols used in the two labs e.g. for rosette selection and preparation of sample 
for rosette counting. The different methods will be described in section 2.3.4 and 
2.3.5. 
2.3.1: Parasite culture methods 
Parasites were routinely cultured in fresh blood group 0 RBCs, which were 
obtained from volunteers in Nairobi. The culture media used to maintain the 
cultures (herein referred to as complete culture media) was made of RPMI 1640 
(Gibco, UK) supplemented with 25mM HEPES (Gibco, UK), 2mM L-glutamine 
(Gibco, UK), 25 mM Glucose (Gibco, UK), 25 Jlg/ml Gentamicin (Gibco, UK) and 
adjusted with 1 M NaOH to a pH of 7.2-7.4. This was further supplemented with 
10% pooled serum obtained from non-immune donors in Europe. Parasitaemia 
was maintained up to a maximum of about 10% and media changed daily while 
conSistently maintaining the culture at 2% hematocrit. Culture flasks were 
incubated in the presence of 3% carbon dioxide, 1 % oxygen and 96 % nitrogen 
(gas mixture was supplied by BOC Kenya). 
In order to obtain specific developmental stages of the parasites, synchronization 
was regularly done on ring stage parasites using 5 % D-Sorbitol (Sigma Aldrich) 
(Lambros and Vanderberg 1979). To synchronize, the culture was spun down and 
the supernatant carefully aspirated out. 5 mls of sterile 5% D-Sorbitol solution was 
added to the cells and incubated for about 15 minutes at 37°C in a water bath. 
This was then washed twice in incomplete media and re-cultured. 
S4 
Parasitaemia was determined by Giemsa staining. A 10).11 drop of parasite culture 
resuspended at 40% haematocrit was smeared on a glass slide to make a thin 
blood film. This was air dried and fixed with methanol (Analar®, VWR 
International), before being stained with Giemsa (Sigma) diluted to 10% in Giemsa 
buffer, pH7.2 for 20 minutes. Slides were rinsed with water, air dried for a few 
minutes and then examined using a 100x objective lens with immersion oil (BDH). 
Parasitaemia was assessed under a light microscope (Leica Microsystems) by 
counting 500 RBCs and expressed as the percentage of infected RBCs. 
2.3.2: Adaptation of field isolates into in vitro culture 
Parasite samples from patients infected with malaria were adapted into in vitro 
culture conditions. Based on criteria established in KEMRI lab, a sample was 
considered adapted if it stayed in continuous culture for at least 20 cycles to 
achieve a steady growth and could successfully be frozen down at 5% 
parasitaemia in at least 10 aliquots that could be re-grown. During the first 
trophozoite stage in vitro, the parasites were tested for rosetting (as described 
below) and rosetting frequency (% RF) was scored. Field samples took different 
lengths of time to achieve steady growth in culture, with some taking at least 15 
cycles while others taking up to 25 cycles. 
2.3.3: Parasites used in this study 
Both laboratory and field isolates were used in this study. Field isolates from Kilifi 
were identified that had different levels of rosetting frequencies for adaptation into 
culture (Table 2.1). Another rosetting field isolate called SA075, a kind gift from 
Jose Stoute, was also used. It was obtained from a high transmission area of 
Kisumu, Kenya. The sample was highly rosetting ex-vivo and was obtained from a 
patient who had severe malarial anemia. It had been previously characterized for 
var gene expression based on Duffy binding like domain {DB La) tag analysis {Bull, 
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Berriman et al. 2005). However, the full-length PfEMP1 responsible for rosetting in 
SA075 was unknown. 
Table 2.1: Field isolates that were selected for long term adaptation in culture. 
Also shown are the original rosetting frequencies (% RF) of the samples, their 
disease syndromes, hemoglobin (Hb) level, Blantyre coma score (BeS) and age of 
the child at the time of presentation to hospital. 
Sample 10 Rosetting Disease syndrome Age (in 
frequency months) 
(%) 
9197 11 Impaired consciousness, Hb 7.1, BCS 27 
4, No deep breathing 
8148 23 Non-severe 51 
8211 12 Impaired consciousness 34 
Hb 10, BCS 2, No deep breathing 
9106 9 Impaired consciousness and 11 
respiratory distress, Hb 5.6, BCS 3, 
with deep breathing 
9166 3 Impaired consciousness 46 
Hb 8.7 , BCS 3, No deep breathing 
To examine the clinical relevance of rosetting variants as will be discussed in 
Chapter 6, five laboratory strains were used in the analysis (Table 2.2). The 
PfEMP1 variants from the five isolates have previously been characterized in Alex 
Rowe's lab, University of Edinburgh. 
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Table 2.2: Rosetting laboratory strains that will be used in Chapter 6 to examine 
the clinical relevance of rosetting variants. Also shown are the origin of the 
parasites, the PfEMP1 variant responsible for rosetting and their IgM binding 
phenotype. 
Parasite strain Origin Rosetting IgM binding 
gene phenotype 
HB3R+ Honduras HB3var6 IgM positive 
TM284R+ Thailand TM284var1 IgM positive 
IT/PAR+ South East Asia ITvar60 IgM positive 
TM180R+ Thailand TM180var1 IgM negative 
IT/R29R+ South East Asia ITvar9 IgM negative 
2.3.4 Rosette selection 
Rosette selection for the field isolates started immediately after culture adaptation. 
Laboratory strains were continuously being selected whenever they were in 
culture. Selection was routinely done on synchronized trophozoite stage parasites 
using gelatin flotation (Handunnetti, Gilladoga et al. 1992) and Percoll in alternate 
cycles every week. Two methods of gelatin-based flotation were used. In the first 
method which was routinely used in the Kilifi lab, the culture was spun down to 
remove supernatant and later re-suspended in equal volume of incomplete RPMI 
in a 15 ml Falcon tube. Pre-warmed 0.75% sterile gelatin made from Porcine Skin, 
Type A (Sigma Aldrich) was added at an equal volume to the culture suspension. 
This was followed by a 30-minute incubation in a 37°C water bath until the two 
layers were clearly visible. By virtue of their density, the rosettes sedimented 
together with uninfected cells that form rouleaux under these conditions 
(Handunnetti, Gilladoga et al. 1992). The supernatant containing non-rosetting 
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trophozoites was obtained, washed with incomplete media and put back into 
culture as the rosette negative (R-) line while the bottom pellet was maintained as 
the isogenic rosette positive line (R+). The rosetting frequency was routinely taken 
for the R+ and R- isogenic lines. This method, however, when done repeatedly 
could potentially select for knob-negative parasites and eventually make rosette 
selection difficult. To ensure that the selected R+ lines were also knob positive, 
rosettes in the R+ culture were periodically disrupted using heparin prior to gelatin 
selection. This would allow the knob positive parasites to float while the knob 
negatives would sink to the bottom, hence maintaining knob positive rosetting 
parasite. To do this, sterile heparin solution (Sigma) was added to 0.75 % gelatin 
to a final concentration of 3mg/ml. Equal volume of the gelatin/heparin solution 
was then added to a culture suspension and incubated at 37°C for 30 minutes until 
there was a clear separation of the two layers. The supernatant containing knob 
positive-rosetting trophozoites was obtained, washed 3 times incomplete media 
and put back into culture as before. This procedure was done at least once a 
month. 
The second method of gelatin flotation (a protocol used in the University of 
Edinburgh Lab) involved gelatin-based solution called Gelofusin (Rhone-Poulenc 
Rorer). Selection was done at least weekly in alternating cycles with the Percoll 
method. The culture was first spun down to remove supernatant and later re-
suspended in equal volume of incomplete RPMI in a 15 ml Falcon tube. Pre-
warmed Gelofusin was added at an equal volume to the culture suspension 
followed by 10-15 minute incubation in a 37°C water bath until the two layers were 
clearly visible. The top and bottom layers containing R- and R+ populations 
respectively were then washed once in incomplete media and once in complete 
media and re-cultured as described above. 
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The Percoll method was done at least once or twice a week to enrich rosettes 
especially in knobless parasites like IT/PAR+(Handunnetti, Gilladoga et al. 1992). 
A 90 % stock Percoll was first made using 10X RPMI and sterile Percoll (Sigma 
Aldrich) at a ratio of 1:10 and a pH of approximately 7.0. On the day of selection, 
further dilutions with 1x incomplete RPMI were done to make a 60 % Percoll 
solution by adding 5 ml of the 90% Percoll to 2.5 ml of incomplete RPMI in a 15 ml 
Falcon tube. Parasites were spun down and re-suspended in 5 ml of complete 
RPMI. This was then gently layered onto the 7.5 ml layer of 60% Percoll and 
centrifuged at 1500g for 10 minutes with the brakes off. A successful selection had 
a pellet of uninfected RBCs together with mature-infected rosetting RBCs at the 
bottom of the tube. A thin layer of non-rosetting mature trophozoites/schizonts was 
observed at the Percoll/RPMI interface. The supernatant was gently removed by 
suction and the pellet washed three times in incomplete media before re-culturing. 
Samples for RNA extraction were collected during the ring stage prior to rosette 
selection. About 100 III of pellet was frozen in Trizol for RNA extraction and 
subsequent transcript profiling. Stabilates of the parasites were also frozen down 
in glycerolyte at different points of the selection. Rosetting frequency was recorded 
at each step of selection. 
2.3.5: Assessment of rosetting frequency 
Two different methods were used to assess rosetting frequencies. In the first 
method (done in Kilifi), 0.5 III of infected RBC pellet at trophozoite stage was re-
suspended in 9.5 III of RPMI containing 5\Jg/ml Acridine orange (Sigma-Aldrich). 
2.5 III of non-immune AB serum was then added followed by a 30 minutes rotation 
on a vertical rotator at 24 rpm. 10 III of the sample was pi petted onto a glass slide, 
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observation under X40 power of fluorescence microscope (Nikon, Tokyo, Japan). 
Rosetting frequency was scored as a percentage of 200 mature trophozoites that 
adhered to at least two uninfected erythrocytes. Examples of rosettes are shown in 
Figure 2.4. Although this method was mainly used to determine the rosetting 
frequency in thawed out trophozoites, it could equally be used on trophozoites in 
an ongoing culture. 
The alternative method of determining rosetting frequency (done in Edinburgh) 
involved taking out 200-500 ~I aliquot of culture suspension into a 1.5 ml 
Eppendorf tube. This was then stained with 25 ~g/ml of ethidium bromide for about 
2-5 minutes at 37°C. Following a gentle mix by flicking the tube, 1 0 ~I of the 
stained culture was placed on a slide. A cover slip sealed with petroleum jelly was 
gently lowered and counting done as described above. 
Figure 2.4: Rosetting parasites stained with 5f..Lg/ml Acridine orange as viewed 
under a fluorescent microscope on x40 objective lens. Shown are infected 
erythrocytes bound to 3 and 4 uninfected erythrocytes. 
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2.3.6: Freezing and thawing of samples 
Parasites were frozen down either at ring stage (for re-culturing) or trophozoite 
stage (to be used once in an assay). Prior to freezing down, a culture at high 
parasitaemia (usually greater than 5% parasitaemia) was spun down by 
centrifugation at 400g (Heraeus, Thermo Fisher Scientific Inc.) for 5 minutes in a 
50 ml Falcon tube. To 3 volumes of packed cell volume (peV), 5 volumes of 
glycerolyte were added in a drop wise manner while gently agitating the tube to 
ensure even mixing. The first 100lli of Glycerolyte was added and the tube left to 
stand for 5 minutes before the remaining volume was added in a drop wise 
manner. 1 ml of the mixture was then transfered into Nunc tubes with proper 
labelling of the isolate name, parasitaemia, date of freezing and the rosetting 
frequency. The tubes were then temporarily stored in a -80 freezer before being 
transferred to liquid nitrogen the following day. 
Thawing out of samples was done using three concentrations of sodium chloride 
(Sigma Aldrich). These were 12%, 1.8% and 0.9%. The latter concentration was 
supplemented with 20% glucose solution. Frozen parasite samples were removed 
from liquid nitrogen and allowed to thaw out at room temperature before 
transferring into a 50 ml tube. 200 III of the 12% salt was first added in a drop wise 
manner and left to stand for 5 minutes. This was followed by 10 ml of the second 
salt (1.8%) and finally 10 ml of the 0.9% salt solution, both in a drop wise manner. 
The salts were spun down and aspirated followed by two washes with incomplete 
media. The parasites were then gassed and re-cultured in complete culture media. 
Frozen trophozoites were thawed out for single use on the day of the assay and 
were not re-cultured (Kinyanjui, Howard et al. 2004). 
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2.3.7 :Mycop/asma testing 
Mycoplasma are small free-living prokaryotes lacking a cell wall and have widely 
been known to affect 15-80% of all long term cell lines (Rottem and Barile 1993). 
While Mycoplasma does not seem to affect rosetting and cytoadhesion (Rowe, 
Scragg et al. 1998), it may have an effect on cloning and sequencing of 
P.falciparum genes since its genome is equally AT-rich (Bove 1993; Rowe, Scragg 
et al. 1998). Mycoplasma PCR was therefore routinely done on cultured parasites 
using a protocol adapted from Tang et al., 2000 (Tang, Hu et al. 2000). The PCR 
involved a nested technique targeting the 16s and 23s rRNA spacer regions and 
was able to detect Mycoplasma M.pirum as well as acheoplasma A. laidlawii, 
yielding predicted band sizes of between 200-400 base pairs. The PCR was done 
alongside one commercial control sample of Mycoplasma, two positively identified 
samples of Mycoplasma from previously ongoing lab cultures and a no-template 
negative control. DNA was extracted (Qiagen kit) from 200 J..l1 of culture sample 
which was spun down and resuspended in 200 J..l1 of 1XPBS. 20 J..l1 of Qiagen 
protease (or Proteinase K) was pipetted into an Eppendorf tube before the 200 III 
sample together with 200 J..l1 of AL buffer and the mixture vortexed for 15 seconds. 
This was followed by a 10 minute incubation at 56°C after which the tube was 
centrifuged to remove drops from the inside of the lid. 200 J..l1 of absolute ethanol 
was added to the sample, mixed and pulse vortexed for 15 seconds. This again 
was centrifuged to remove drops from the inside of the lid. The mixture was then 
carefully applied onto a QIAmp Mini spin column followed by a 1 minute 
centrifugation at 8,OOOrpm. The spin column was placed in a fresh collection tube 
and 500 J..l1 of AW1 buffer added and spun down as before. 500 J..l1 of AW2 buffer 
was then added and spun down at 13,OOOrpm for 3 minutes after which the empty 
column was transferred onto the same tube and spun at 13,OOOrpm for 1 minute to 
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remove any residual buffer. The column was placed in a clean Eppendorf tube and 
200 I.tI of elution buffer (AE) added followed by a 1 minute incubation and a final 
spin at 8,000rpm for 1 minute to elute the DNA. 
Seven primers, mixed to a final concentration of 1 mM were used in two sets 
(Table 2.3, mix 1 and 2) in a nested PCR. The primers were capable of detecting 
all eight common Mycoplasma contaminants of cell culture. The PCRs were done 
in a 25 III reaction containing 1X NH4 PCR buffer (670mM Tris-HCI (pH 8.8) at 
25°C), 160mM (NH4)2S04, 0.1% stabilizer), 1.SmM MgCI2, 1mM dNTP mix, 20llM 
of either primer mix 1 or 2, SUlIlI of Taq polymerase (all from Bioline Biotaq 
polymerase kit, UK), 19f.l1 of DNase free water and 1 f.ll of DNA. Reactions for both 
PCRs were done at similar conditions i.e. initial denaturation of 94°C for 3 minutes, 
followed by a 30 cycles of 94°C for 30 seconds, 50°C for 30 seconds and 72°C for 
1 minute. 10 III of PCR products were run on a 1 % agarose gel at 90V for 1 hour 
(described in section 2.3.9.4). Staining was done using O.Sf.lg/ml ethidium bromide 
solution and de-stained using distilled water. Visualization was done using Bio-rad 
Geldoc. 
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Table 2.3: Primers used in Mycoplasma peR. Mix 1 was used for the first step 
while Mix 2 was used in the second step peR. 
Mix 1 
1 ACACCATGGGAG(Cff)TGGT AA T 
2 CTTC(Aff)TCGACTT(Cff)CAGACCCAAGGCAT 
3 AAAGTGGGCAATACCCAACGCATCC 
4 TCACGCTT AGATGCTTTCAGCG ATCC 
Mix2 
5 GTG(C/G)GG(AlC)TGGATCACCTCCT 
6 GCATCCACCA(Aff)A(Aff)AC(Cff)CTT 
7 CCACTGTGTGCCCTTTGTTCCT 
2.3.8: Parasite genotyping using Merozoite surface protein 1 and 2 
(MSP1IMSP2) markers 
When carrying out studies such as this one, it is imperative to associate specific 
phenotype characteristics of the parasite with specific genotype lexpression 
profiles. However, previous studies have shown that in vitro adaptation of malaria 
parasites into culture often resulted to loss of strains or clones (Nsobya, Kiggundu 
et al. 2008; Cheeseman, Gomez-Escobar et al. 2009). Parasite genotyping was 
therefore done on both acute and rosette selected samples using MSP1/MSP2 
PCR that targets the polymorphic merozoite surface protein gene to detect three 
different allelic variants: -A) MSP2 (IC allele) 8) MSP2 (FC allele) and C) MSP1 
(Mad20 allele). This was done to check whether the parasite genotypes at acute 
stage were similar to the genotypes in the rosette selected lines. It was also 
important to ensure that the R+ and R- lines were isogenic and that they were the 
same as the original parasite. 
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A PCR method described by Snounou et al., 1999 (Snounou, Zhu et al. 1999) was 
adapted but with modifications:- only the allelic family specific primers were used 
and not the outer primers that flank the conserved regions of the genes. 
Sequences for the allele specific primers that flank the polymorphic region were as 
follows: -Mad 20 Forward 5'-MA TGA AGA AGA AAT TAC TAC MA AGG TGC -
3', Mad 20 Reverse 5'- GCT TGC ATC AGC TGG AGG GCT TGC ACC AGA -3', 
FC Forward 5'- AAT ACT AAG AGT GTA GGT GCA RAT GCT CCA- 3', FC 
Reverse 5' -TIT TAT TIG GTG CAT TGC CAG AAC TIG AAC-3', IC Forward 5'-
AGA AGT ATG GCA GAA AGT AAK CCT YCT ACT 3' IC Reverse 5'-GAT TGT 
AA T TCG GGG GAT TCA GTI TGT TCG-3'. The 25 JlI PCR reaction was carried 
out in 1x PCR buffer II (100 mM Tris-HCI, 1.5mM NaCI pH 8.3,500 mM KCI), 2mM 
dNTPs, 25 mM MgCb, 10 J.LM forward and reverse primers, 5U1JlI of Taq 
polymerase (AmpliTaq® gold) and 100ng of DNA (All from Applied Biosystems). 
The amplification conditions were:-Initial denaturation of 94°C for 3 minutes, 
followed by 30 cycles of 94°C for 30 seconds, annealing at *45°C for 30 seconds 
and 72°C for 2 minutes. A final extension was then done at 72°C for 10 minutes. 
The annealing temperature represented by the asterix mark differed for MSP1 and 
MSP2 alleles (58°C and 45°C respectively). PCR products were run on 2 % 
agarose gels (described in section 2.3.9.4) using 0.5X TBE buffer for one and half 
hours at 90V. The gel was stained using 0.5Jlg/ml ethidium bromide solution and 
later de-stained using distilled water. Visualization was done using Bio-rad Geldoc. 
2.3.9: Var gene expression profiling 
This section describes a series of steps leading to profiling of var gene transcripts 
in field isolates. They include RNA extraction, generation of cDNA, amplification of 
var gene transcripts using universal primers, sequencing of the DBLu-tag, 
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classification of sequences and finally identification of the dominantly expressed 
vargene. 
2.3.9.1: RNA extraction 
Trizol samples from section 2.2 were obtained from storage at -80De and allowed 
to thaw for 3-5 minutes at room temperature in the fume hood. Once thawed out, 
the samples were transferred into a 1.5 ml RNase free screw-cap tube (Starlab, 
Germany). If the volume of Trizol was less than 11 OO~I, it was topped up using 
pre-warmed Trizol in a fume hood. Using P1000 filter tips, 200~I of chloroform 
(Sigma Aldrich) was added and mixed vigorously for 15 seconds before allowing it 
to stand for 2-3 minutes. This was followed by spinning at 1400g on a microfuge 
(Heraeus Biofuge pico) for 35 minutes at 4°C. 
While the sample was spinning, fresh RNA tubes were labelled and 2~I Glycoblue 
™ (Ambion, UK) added into each of them to allow for subsequent visualization of 
the pelleted precipitate. The spun samples were gently removed from the 
centrifuge and allowed to rest for 2 minutes since this tended to increase the yield 
of the aqueous phase. The clear aqueous phase was then carefully harvested 
using a pipette into the Glycoblue-containing RNA tubes and 500~1 isopropanol 
(IPA) (Sigma-Aldrich) added. For those with less than 500~I aqueous layer, an 
equivalent volume of IPA was added. This was then mixed thoroughly by inverting 
at least 10 times before incubating overnight at 4DC to allow for RNA precipitation. 
The remaining thin aqueous layer and Trizol pellet was kept in the fridge for 
harvesting lower quality DNA. 
The following day, samples were spun on the microfuge at 16060g for 30 minutes 
at room temperature and the pellet gently washed with 500~1 ice-cold 75% ethanol 
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by inverting and pouring off the supernatant. During this time, care was taken so 
that the blue pellet was not washed off in the process. A short spin (2 seconds) 
was done to bring down the pellet and to completely aspirate off the remaining 
ethanol using a P20 pipette and filter tip. 
The tubes were then inverted on tissue paper and allowed to dry for no longer than 
5 minutes. 20~1 RNA secure (Invitrogen, UK), a non-enzymatic reagent that 
irreversibly inactivate RNases, was added into all tubes using a fresh tip each time 
before heating the sample at 60·C for 10 minutes. The RNA suspension was 
gently mixed by pipetting up and down using a P20 pipette then finally spun on the 
microfuge at 380g for 10 seconds to ensure that the 20J.lI volume was at the 
bottom of the tube and not on the sides. Finally the RNA was stored at -80·C 
awaiting reverse transcription PCR (RT-PCR). 
2.3.9.2: eDNA preparation 
cDNA preparation was done in a PCR hood in room that was free from 
contaminating PCR products. 2J.lI of RNA (about 1 J.lg) was transferred into 500J.lI 
RNAse treated tubes (Neptune) for cDNA synthesis. The process started by DNA 
digestion, in which 1~1 of enzyme DNase (Ambion Inc., UK) was added to the RNA 
sample in the presence of 1X DNase buffer (100 mM Tris, pH 7.5, 25 mM MgCI2, 5 
mM CaCh) (Ambion Inc., UK) diluted in Ambion DEPC water and incubated for 20 
minutes at 37°C. To inactivate the enzyme, 3J.lI of DNase inactivation slurry 
(Ambion Inc., UK) was added, mixed and incubated for 2 minutes at room 
temperature. This was then spun down on the microfuge for 1.5 minutes at 9500g 
to pellet down the inactivation slurry. 
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8 J.lI of the DNase digested preparation was then carefully transferred into peR 
strip tubes. For each sample, two aliquots were made which were to be processed 
with and without reverse transcriptase enzyme (RT + and RT -). All reagents for this 
step were from Invitrogen UK. 50ngl J.lI of random hexamers and 10mM dNTPs 
were first added into each of the tubes and placed on a thermocycler for 5 minutes 
. at 65°C followed by 1 minute at 4°C. The reverse transcription reaction was then 
done using 1X first strand buffer (250 mM Tris-HCI (pH 8.3 at room temperature), 
375 mM KCI, 15 mM MgCb), 25mM MgCI2 ,0.1 M Dithiothreitol (DTT) and 1 J.lI of 
RNase inhibitor i.e. RNAseOUT. In every RT + tube, 1 J.lI of Superscript II ™ 
enzyme was added. For the RT- control reaction, 1 J.lI of DEPC-treated water was 
added. The tubes were then incubated under the following conditions on a 
thermocycler :- 25°C for 1 Om in utes, 42°C for 50 minutes, 70°C for 15 minutes 
and a final 4°C for 1 minute. 
Following the incubation, 0.25 J.lI of 2U/J.lI RNase H (Invitrogen UK) was added and 
incubated at 37°C for 20 minutes. The role of RNase H was to digest any 
remaining RNA template after the first strand cDNA synthesis. Finally, two aliquots 
of 10 J.lI volumes were made for each sample and stored at -20°C, with one being 
for back up. 1 J.lI of the cDNA was used for PCR amplification of DBLo sequence 
tags as described in the section 2.3.9.3. For genomic DNA, 1 J.lI of the 
DNAsePMuntreated RNA sample was used at a dilution of 1:10 
(diluted in 1X Tris EDTA, Sigma-Aldrich). 
2.3.9.3: Cloning and sequencing of DBL alpha tag· 
The amplification of DBLa "tag" as described in this chapter refers to a 300-400bp 
region of the DBLa domain of the PfEMP1 molecule (Figure 2.5). It has 
consistently been used to characterize the PfEMP1 molecule since it contains a 
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semi-conserved region that can be successfully amplified in most of the 60 var 
genes in a genome. The DBLa tag sequences were generated as previously 
described by Bull et al., 2005 (Bull, Berriman et a!. 2005). Briefly, cDNA was 
amplified using primers DBLaAF 5' GCACG (A/C) AGTTT(C*/T) GC3' and 
DBLaBR 5' GCCCATTC (G/C) TCGAACCA 3' that were a modified from the 
originally described AF and BR primers (Taylor, Kyes et a!. 2000). The nucleotide 
marked with an asterisk on the DBLaAF primer indicates the modification that was 
introduced to broaden the range of sequences that could be amplified. In each of 
the cDNA amplifications, negative controls (without reverse transcriptase 
treatment) were included to ensure that the cDNA was not contaminated with 
gDNA. A parallel gDNA from the each of the sample was also amplified and the 
var gene profiles analyzed to check for any primer bias (Taylor, Kyes et a!. 2000). 
GCACGMAGTTTTGC 
A R S F A 
-a ·AF 
OBL2jl OBLn 
TGGTTCG ASGAATGGGC 
W FX EWA 
-a·BR 5 . • _______________________ •• 
3
. 
Figure 2.5: Schematic representation of a PfEMP1 molecule showing the semi-
conserved tag region (marked in a rectangle) within the DBL 1 a domain. The tag 
region which is approximately 300-400bp was amplified using the DBLaAF and 
DBLaBR primers as shown. 
Following successful amplification of the DBLa tags, the products were purified 
using Sephacryl S-400TM columns (Amersham Biosciences, UK). 700~LI of the 
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Sephacryl S-400 was added into empty microspin columns and centrifuged at 
380g for 1 minute. The collection tube was emptied after which two further washes 
were done on the Sephacryl using 200~1 of 1 X TE buffer. The microspin column 
was then transferred into clean collection tube after which the 20~1 PCR product 
was added. A short 2 minute incubation was done followed by a 2 minute spin at 
380g. The purified product was collected and frozen down in -20°C. 
2~1 of the cleaned PCR product was then ligated into pCR®2.1-TOPO® vector 
(Invitrogen, UK) by mixing it with 1 ~I of salt solution (1.2M NaCI, 0.06M MgCIz), 
2.5~1 of water and 0.5~1 of the vector. The mixture was incubated for 5 minutes at 
room temperature to allow for ligation. Transformation of bacterial cells was done 
by taking 2~1 of the reaction mix and gently mixing with 25~1 of One Shot® TOP 10 
Chemically Competent E. coli (Invitrogen, UK) followed by a 30 minute incubation 
in ice. A heat shock reaction was done at 42°C for 30 seconds in a water bath 
immediately followed by 2 minute incubation in ice. The transformed cells were 
then re-suspended in 500 ~I SOC medium (Invitrogen, UK) and incubated for 1 
hour in a shaking incubator (200 rpm) at 37°C. Meanwhile, pre-made Luria Bertani 
(LB-Ampicillin) agar plates were warmed at 37°C. The plates were made by 
adding 35g of LB agar powder (Sigma) into one litre of water followed by 
autoclaving. On cooling down, Ampicillin was added to a final concentration of 
50~g/ml and the solution poured out onto 100mm petri dishes. 50~1 of the bacteria 
was plated together with 40~1 of 20 ~g/ml of 5-bromo-4-chloro-3-indolyl-b-D-
galactoside (X-Gal) for blue/white screening of colonies and 40 ~I of 20~M 
isopropylthiogalactoside (IPTG) which induces the expression of the protein 
followed by an overnight incubation at 3rC in the presence of 5% C02. 
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Successfully transformed cells formed white colonies while poorly transformed or 
those in which transformation was unsuccessful formed blue colonies. 16 white 
colonies were then picked and placed in 3 ml of LB broth in a 15 ml Falcon tube, 
followed by another overnight incubation on a shaking incubator (200rpm) at 3rC. 
The following day, plasmid DNA was extracted from the bacterial cells using a 
miniprep kit QIAprep Spin miniprep kit (Qiagen) in which 1 ml of bacterial cultures 
from individual colonies was first centrifuged at 13000 rpm for 3 minutes. The 
pellet was then resuspended in 250 ~I buffer P1 (6.06g/l Tris base, 3.72 gIl EDTA, 
pH 8.0) before lysis with 250 ~I of P2 buffer (8g/l NaOH, 1 % (w/v) SDS in water) 
and subsequent neutralization with 350 ~I N3 buffer (confidential composition). 
Cell debris were removed by centrifugation at 13000rpm for 10 minutes before 
transferring the suspension to a spin column. This was spun down at 8,000rpm for 
1 minute followed by centrifugation of an empty spin column to remove residual 
reagents. Elution buffer was added followed by a final elution of the plasmid DNA. 
A big dye reaction was done on the DNA and it consisted of 5 ~I of the plasmid, 4 
~I of big dye and 1 ~I of M13 forward primer 5'-GTAAAACGACGGCCAG-3. The 
reaction mix was incubated for 25 cycles of 96°C for 30 seconds, 50°C for 15 
seconds and 60°C for 4 minutes followed by sequencing on an Applied 
Biosystems 3730 sequencer. 
2.3.9.4 Agarose gel electrophoresis 
All PCR products were run on approximately 1-2 % agarose gels which were 
prepared using 1-2 g electrophoresis grade agarose (Invitrogen) in 100mls of 1X 
TBE (1M Tris, 0.9M boric acid and 0.01 M EDTA, Invitrogen). This mixture was 
warmed in a microwave oven until all agarose dissolved. The liquid was then 
careful poured in a cast and left to cool down to solidify. PCR products were then 
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loaded with 1 III of dye buffer (60mM Tris-HCI, pH 7.5, 60mM EDTA, pH 8.0, 
0.36% Xylene Cyanol FF, 2.4% Orange G, 30% glycerol. DNA ladder was also 
loaded alongside the products. Gels were run at 80V-100V for 45-60 minutes after 
which they were removed and stained with 0.5 Ilg/ml ethidium bromide for 5 
minutes before destaining for a further 5 minutes. DNA products were visualized 
under UV. 
2.3.9.5: DBLa tag sequence analysis 
DBLa sequence tags from each parasite isolate were classified based on 
cys/PoLV, a sequence homology grouping algorithm previously described by Bull 
and colleagues (Bull, Berriman et al. 2005). The raw sequences were run on a 
Perl script called "raw reads sequence organizer 4" written by Pete Bull which 
performs DNA orientation, trimming off both the vector and primer sequences 
before translating them to amino acids. Due to the small number of sequences, 
translated sequences were aligned using BioEdit sequence editor and checked 
manually for the presence of a consensus motif DIGDI within homology block D 
and a consensus motif paYLR within homology block H at the start and end of the 
tag sequence respectively. The sequences were then classified into one of six 
sequence groups based on a count of the number of cysteine residues within the 
tag region and a set of sequence motifs at four positions of limited variability 
(PoLV1-4) (Bull, Berriman et al. 2005). Unique sequence herein referred to as 
sequence Mtypes· were counted for each isolate and expressed as a proportion of 
the total number of sequences obtained from that isolate. 
2.3.10: Flow cytometry and immunofluorescence assays for recognition of 
PfEMP1 on live infected erythrocytes 
Fluorescent Activated Cell-Sorter (FACS) and Immunofluorescence assay (IFA) 
were done to investigate antibody responses to the native PfEMP1 expressed on 
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the surface of mature trophozoites. The antibodies used for these assays were 
polyclonal, targeting different domains of rosette-mediating PfEMP1, and were 
raised in rabbits. Rabbit pre-immune and immune anti-serum was also used. The 
assays were done for the following reasons: -
i) To screen the pre-immune sera prior to immunization of rabbits. This was 
due to the presence of heterophile antibodies in some rabbit sera that 
would otherwise react with human RBCs (Rowe, Shafi et al. 2002). 
ii) To determine which rabbit anti-sera with the greatest signal was to be 
selected for IgG purification. 
iii) To test for surface recognition of homologous parasites using rabbit anti-
PfEMP1 IgG to the different domains of the rosette mediating PfEMP1. 
iv) To test for cross reactivity of the purified IgGs, i.e. anti-NTS-DBLa 
antibodies of the rosette-mediating PfEMP1 variant across a panel of 
different P.fa/ciparum strains. 
v) To work out the proportion of PfEMP1 positive cells in rosetting parasites 
before and after cell sorting and to compare them with % RF. 
From the same material used in the FACS assay, a thin smear was made and 
used for the IFA microscopy. A working protocol for the combined FACS/IFA 
assay is in appendix 8.2. A different FACS protocol (described in Chapter 6) was 
used specifically for the assays involving plasma from clinical samples. 
Briefly, 1.2 ml of culture suspension (mature pigmented trophozoites) at 2% 
haematocrit was aliquoted into an Eppendorf tube. 2111 of Hoechst 33342 dye 
(Invitrogen molecular probes) used to stain parasite DNA was then added to a final 
concentration of 1.25 Ilg/ml followed by 20 minute incubation at 37°C. This was 
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then washed twice in 750~1 of 1X PBS and re-suspended in 1.2 ml of1% Ig-free 
BSA in I XPBS also containing 1.25~g/ml Hoechst and 50~g/ml Fucoidan (Sigma). 
The role of the Fucoidan was to keep the rosettes disrupted throughout the 
staining and acquisition process. 
Apart from assays that were to determine the effectiveness of the antibodies by 
serial dilution, the antibody concentration used for surface recognition was 
optimized to 400~g/ml. From a 7.5mg/ml working stock, 5.4 ~I of antibody was 
added to 94.6 ~I of parasite suspension and incubated on ice for 1 hour, flicking 
the tubes every 10 minutes to keep the cells in suspension. This was followed by 
three washes using 750 ~I of 1X PBS. The secondary antibody, Alexa Fluor 488-
labeled goat anti-rabbit IgG (Catalogue number A11034, Invitrogen Ltd, Paisley, 
UK) was diluted 1:1000 and 100 ~I added to each tube. This was also followed by 
a 1 hour, incubation on ice while flicking the tubes every 10 minutes. After another 
three washes in 750 ~I of cold 1X PBS containing 50~g/ml Fucoidan the sample 
was splitinto two tubes labeled 1-11 (for IFA) and 1*-11* (for FACS). 
For IFA, the supernatant was removed from the final wash and the pellet re-
suspended to 20-30% haematocrit in 1 XPBS/1 % Ig-free BSA followed by thin 
smears which were air dried and a drop of mountant added Le.1.25 rng/ml of 
diazabicyclo-[2,2,2]octane (DAPCO) in 50% glycerol/50% PBS. These were then 
covered with 22mm X 22mm cover slips and sealed at the edges with a nail polish 
before storing at 4°C. IFA slides were viewed under X 100 magnification with oil 
using a Leica DM LB2 fluorescence microscope and images taken with a Leica 
DFC300FX digital camera. The percentage of PfEMP1-positive cells was 
determined by counting them against 100 positive infected RBCs per slide. All 
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adjustments to the photos were applied equally to PfEMP1 antibody and control 
images. 
For FACS assays, the supernatant was removed from the final wash and the pellet 
re-suspended in 200lli of 0.5 % paraformaldehyde (Sigma-Aldrich) followed by a 
20 minute incubation for fixation on ice. This was then spun down to remove the 
supernatant followed by one wash with FACS buffer containing 1XPBS, 0.5% BSA 
. and 0.01 % sodium azide. The final pellet was re-suspended in 500lli of the FACS 
buffer and transferred into a FACS tube. 25111 of 1mg/ml Fucoidan was added into 
each tube and incubated for 20 min at room temperature. Tubes were wrapped in 
foil paper and kept in the fridge until the FACS run (preferably within two days of 
staining). 
Acquisition was done on a Becton-Dickinson LSRII Flow cytometer in which 
500,000 events per sample were analyzed. Flow cytometer settings were first 
adjusted to achieve a clear separation of uninfected (Hoechst-negative) and 
infected (Hoechst-positive) erythrocytes in a Forward scatter (FSC)/ Hoechst dot 
plot. Finally data was acquired on FL 1 (Alexa 488) and FL2 (Hoechst). The data 
files usually in FCS format, were exported and analyzed using FlowJo software 
(Tree Star Inc.). The Alexa 488 fluorescence was used to quantify antibody 
recognition of PfEMP1. This was expressed either as the mean or median 
fluorescent intensity or as percentage positive cells. 
2.3.11: Mamalian cell culture_ THP-1 cells 
THP-1 cells (ATCC®rIB-202™) were used for antibody mediated phagocytosis 
assays. These are monocytic cell lines originally derived from a one year old boy 
with leukemia and which express complement (C3) Fc receptors (Tsuchiya, 
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Yamabe et al. 1980). Routine maintenance of the cells was done as described by 
Ataide ef al .• 2011 (Ataide. Mwapasa et al. 2011) in which cells were maintained in 
RPMI 1640 media (GIBCO) supplemented with 10% heat-inactivated Foetal 
Bovine Serum (FBS) (GIBCO). 1 % penicillin-streptomycin (GIBCO). 2 mM L-
Glutamine (GIBCO). 25mM HEPES (GIBCO) and 5.5 J.lM 2-mercapto-ethanol 
(Sigma). Cells were grown to a concentration of not more than 1X106 cells/ml and 
the media was changed every 2 to 3 days. As a recommendation by the 
manufacturer, THP-1 cells were used up to around 5 passages to avoid a possible 
change in properties. 
To thaw out THP-1 cells, the vial containing the cells was warmed in a water bath 
at 37°C. 5 mls of warm culture media was then added into a 15 ml Falcon tube 
and THP-1 cells were gently pipetted into the media. This was then spun for 5 
minutes at 300g. The supernatant was gently poured out and the cells were 
transferred into a flask containing 10 mls of warm THP-1 media. 10 J.l1 of 2-rJ 
mercaptoethanol (Stock was at 1000X) (Sigma-Aldrich) was added and the flask 
placed into a 37°C C02 humified incubator in an upright position. 
Freezing of THP-1 cells was done when the density was about 1 x1 06 cells in 20 
mls of media. The cells were centrifuged at 1000g and gently re-suspended in 5 
mls of Foetal Calf Serum (FCS) supplemented with 10% DMSO as a 
cryoprotectant. This was then stored in -80°C for not longer than 24 hours before 
transferring to liquid nitrogen. 
2.3.12 Phagocytosis assays 
The protocol used in phagocytosis assays was adopted from Ataide ef al., 2010 
(Ataide, Hasang et al. 2010) and later slightly modified as described in (Ghumra, 
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Semblat et al. 2012). Undifferentiated THP-1 cells (ATCC~IB-202TM) were used. 
On the day of the assay, parasites at trophozoite stage were spun down and re-
suspended in RPMI containing 2% heat inactivated FCS with 200 J.lg/ml Fucoidan. 
This was run down through a pre-equilibrated magnetic-activated cell separation 
(MACS) column and the stuck parasites eluted with the RPMI media. A drop of the 
eluted parasites was used to make a thin smear which was giemsa-stained and 
viewed under a microscope to ensure that the purification was successful before a 
parasite count was done with the heamocytometer and diluted down to the 
optimized parasitaemia of 3.3 X107 parasites/ml. Ethidium bromide was then 
added to the parasites to a concentration of 1 o J.lg/m I and the mixture incubated for 
15 minutes. This was followed by 3 washes and the pellet re-suspended back to 
3.3 X107 parasites Iml. 30 J.lI of parasite suspension was then opsonized with 3.3 
J.l1 of antibodies that were serially diluted to give concentrations ranging from 
100J.lg/ml down to 6.25J.lg/ml in a 96 well-U bottomed plate pre-coated with heat 
inactivated FBS. The plate was then incubated for 1 hour at room temperature in 
the dark to allow for opsonization. 
Meanwhile, the THP-1 cells were prepared by first counting the number of cells 
and diluting them down to 500,000 cells/ml. These were then co- incubated with 
the opsonized parasite pellet in a volume of 150 J.lI in duplicate wells for 45 
minutes at 37°C in a CO2 humified incubator. This incubation step allowed for 
phagocytosis of the opsonised parasites. The non-phagocytosed RBCs were then 
lysed using a FACs lysis solution (BO Biosciences) at a 1:10 dilution in distilled 
water for 10 minutes. Lysis was stopped by the addition of 50 J.lI of cold PBS (-
Ca2+, -Mg2+) 2% FBS and 0.02% NaN03 (FACS Buffer). The plates were spun 
down at 350 g for 3 minutes at 4°C. After three washes with 150 J.l1 of cold FACS 
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buffer the cells were fixed in 150 J-li cold 2 % paraformaldehyde in PBS and left on 
ice before acquiring. Samples were also kept at 4°C if acquisition was to be done 
the following day. 
Acquisition was done using FACSCalibur flow cytometer where THP-1 cells were 
first gated based on forward scatter (FSC) and side scatter (SSC). A gate was 
then set on FL2 channel to allow for gating of phagocytosed versus non-
phagocytosed THP-1-cells. 10,000 of ethidium bromide-positive THP-1 cells were 
then acquired at the rate of 200-300 cells Isecond. The controls in this assay were 
a polyclonal rabbit anti-human RBC IgG antibody «ABCAM ab34858), non-
immune rabbit IgG control and one well with no parasite (THP-1 alone control). 
The average proportion of positive cells was calculated by Flowjo for each 
duplicate wells at different concentrations for the different test antibodies. The 
negative control (Rabbit IgG) was then subtracted from each of these reads. Final 
data was expressed as a percentage of the positive control (anti-human RBC IgG 
antibody). A working protocol is shown in appendix 8.3. 
2.3.13 Statistical methods 
Comprehensive details of the specific statistical methods are described in each of 
the results chapters. 
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CHAPTER 3 
Preliminary characterization of PfEMP1 variants associated with rosetting in 
field isolates 
3.1 INTRODUCTION 
In PfEMP1 studies, the most abundant var gene transcript(s) found at the ring 
stage of the asexual parasite is thought to be expressed and therefore reflective of 
adherent specificity of the parasite. However, there is extensive intergenomic and 
intragenomic variation, as well as high rates of recombination and mosaicism 
surrounding the study of var genes in both laboratory and field isolates (Ward, 
Clottey et al. 1999; Taylor, Kyes et al. 2000; Kraemer, Kyes et al. 2007; Bull, 
Buckee et al. 2008; Zilversmit, Chase et al. 2013). The promoter or upstream 
(Ups) sequence which is fairly conserved has nonetheless been frequently used to 
classify var genes in clinical isolates (Voss, Thompson et al. 2000; Lavstsen, 
Salanti et al. 2003; Kraemer and Smith 2006). The other approach in the study of 
var genes, which will be used in this chapter, is based on the first duffy binding-like 
domain (DBLa) of the PfEMP1 and a set of degenerate primers commonly known 
as universal primers (Taylor, Kyes et al. 2000) have successfully been used to 
amplify a small region of the domain called the "tag" in both field and laboratory 
isolates (Kyes, Taylor et al. 1997; Ward, Clottey et al. 1999; Taylor, Kyes et al. 
2000). Classification of tag sequences has made DBLa. a target of var gene 
transcription studies and has allowed functionally relevant data on var genes to be 
obtained in clinical isolates (Bull, Berriman et al. 2005; Bull, Kyes et al. 2007; 
Warimwe, Keane et al. 2009; Warimwe, Fegan et al. 2012). 
79 
With resetting being one of the important adhesion phenotypes associated with 
severe malaria, studies on var gene transcription focusing specifically on rosetting 
isolates have been done (Rowe, Moulds et al. 1997; Vigan-Womas, Lokossou et 
al. 2010; Albrecht, Moll et al. 2011; Ghumra, Khunrae et al. 2011). Such studies 
have led to the identification and characterization of PfEMP1 variants associated 
with rosetting in several laboratory isolates (Rowe, Moulds et al. 1997; Vigan-
Womas, Guillotte et al. 2008; Albrecht, Moll et al. 2011; Ghumra, Semblat et al. 
2012). For field isolates, expression profiling of the DBLa tags suggests that 
distinct sub-groups of var genes are implicated in rosetting in natural parasite 
populations (Kyriacou, Stone et al. 2006; Normark, Nilsson et al. 2007; Bull, 
Buckee et al. 2008; Warimwe, Fegan et al. 2012) (Bull, Berriman et al. 2005) 
(Kaestli, Cockburn et al. 2006). However, it is important to note that field isolates 
unlike laboratory isolates are under intense pressure by host immune responses. 
The effects of in vitro adaptation of patient isolates to laboratory populations may 
therefore have different selective forces from those affecting the parasite in its 
native state hence changing the transcription profile of var genes (Peters, Fowler 
et al. 2007). There is therefore need for more information on sequence diversity 
and transcription profiles of P.fa/ciparum parasites especially on culture-adapted 
field isolates. Caution must however be taken when performing transcription 
analysis by DBLa RT-PCR on midllate rings due to the presence of conserved var 
genes such as var1 csa which have been shown to be constitutively expressed in 
parasite populations regardless of the phenotype (Winter, Chen et al. 2003; Kyes, 
Christodoulou et al. 2007). Although transcription of var1csa occurs at pigmented 
trophozoite stage, it is important that such sequences be identified and removed 
during analysis of var gene transcripts, especially if the RNA was extracted from a 
not so well synchronized culture. 
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This chapter describes the sequence diversity and transcription profiles 
of var gene transcripts from five culture-adapted field isolates from Kilifi, Kenya. 
The parasites were obtained from children who presented to Kilifi District Hospital 
with different syndromes of malaria and varied levels of rosetting frequencies 
(Chapter 2, Table 2.1). Transcription patterns were compared at the time of 
disease (acute stage) and after several rounds of rosette selection. Similarly, a 
comparison was done between isogenic rosette positive (R+) and rosette negative 
(R-) populations. 
3.2: CHAPTER AIMS 
The specific aims of this chapter were:-
1. To adapt five clinical isolates into in vitro culture conditions and to enrich for 
rosettes. 
2. To clone and sequence var genes transcribed by these isolates. 
3. To compare sequence diversity and var gene transcription profiles before 
and after in vitro adaptation and between isogenic rosette positive (R+) and 
rosette negative (R-) populations. 
3.3: MATERIALS AND METHODS 
The methods used in this chapter have been described in details in Chapter 2. 
They include: - adaptation of field isolates into in vitro culture (section 2.3.2), 
rosette selection (section 2.3.4), extraction of RNA, generation of cDNA, 
amplification of OSLo. tag, sequencing and classification of OSLo. tag sequences 
(all in section 2.3.9). Mycoplasma PCR and parasite genotyping were also carried 
out as described in sections 2.3.7 and 2.3.8 respectively. Sequence analysis on 
the OSLo. tag sequences were done by the Cys/PoL V classification method as 
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described by Bull et a/., 2005 (Bull, Berriman et al. 2005). Details of the 
classification method have been discussed in Chapter 1 section 1.3.3.2. 
Using samples that were being received in an Immunology study at Kilifi (Chapter 
2, section 2.2), (Appendix 8.1, Protocol SSC 1131), five P.falciparum positive 
samples were selected from children who presented with different syndromes of 
malaria and had intermediate levels of rosetting (Chapter 2, Table 2.1). The 
starting rosetting frequency was determined during the first trophozoite stage in 
vitro. Adaptation into in vitro culture was then done as previously described 
(section 2.3.2). The parasites were rosette-selected weekly by gelatin flotation 
method (section 2.3.4) to obtain isogenic rosetting (R+) and non-rosetting (R-) 
sub-populations. Figure 3.1 below illustrates the process of rosette selection by 
gelatin flotation method done on the five isolates. This was routinely done until the 
highest possible % RF was obtained for each isolate or above 60%. Ring stage 
parasites (about 16-20 hours post invasion) were then obtained and the pellet 
solubilised in Trizol for RNA extraction. This was followed by cDNA preparation, 
amplification of DBLa. tag, sequencing and transcript profiling (Chapter 2, section 
2.3.9). Genomic DNA (gDNA) from each sample was also sequenced and var 
gene profiles were used in checking for primer bias in the transcripts. During the 
process of in vitro adaptation and rosette selection, the parasites were genotyped 
for MSP1/MSP2 alleles (Chapter 2, section 2.3.8) to compare the parasite 
genotypes before and during the process of adaptation and selection. Throughout 
this work all cultures were routinely tested for Mycoplasma contamination as 
described in Chapter 2, section 2.3.7. 
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R+ 
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Figure 3.1: An illustration of the process of rosette selection on culture-adapted 
field isolates using the gelatin flotation method (Handunnetti, Gilladoga et al. 
1992). After the initial gelatin selection, the upper layer which contained rosette 
negative parasites (R-) was obtained and re-cultured separately for subsequent 
enrichment of the R- population as shown. The isogenic rosette positive parasites 
(R+) in the bottom layer were equally re-cultured separately and enriched for 
rosettes. The process was repeated until the highest and lowest possible % RF 
was obtained for the R+ and R- respectively. The black arrows at the bottom 
represent the time-points at which Trizol sample was collected for RNA extraction. 
To ensure that the R+ population was also knob positive (K+) rosette selection by 
gelatin method alternated with selection for knob positive parasite (K+) using 
heparin/gelatin as described in Chapter 2, section 2.3.4. 
3.4: RESULTS 
Five field isolates namely 9197,9106,8211, 9166 and 8148 were successfully 
adapted into in vitro culture. Details of clinical information of the isolates at the 
time of disease are listed in Chapter 2 Table 2.1. The isolates took different 
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lengths of time to exhibit a steady growth and multiplication rate. However, by the 
20th cycle, all samples were considered adapted and were each frozen down in 
more than 5 aliquots that could be thawed out and re-cultured at ease. Due to 
persistent Mycoplasma contamination, sample 9166 was later excluded from this 
analysis. The results presented here are for the remaining 4 field isolates: - 9197, 
9106,8211 and 8148. 
3.4.1: peR genotyping using merozoite surface protein 1 and 2 (MSP1 and 
MSP2) markers in acute and rosette selected parasites 
It is well known that majority of P.falciparum field isolate infections contain multiple 
clones (Tanner, Beck et al. 1999) some of which could be lost in the process of in 
vitro adaptation. MSP1/MSP2 genotyping was therefore done prior to var gene 
transcriptional profiling to compare the parasite genotypes at acute stage (Figure 
3.2, left side gels) and after rosette selection (Figure 3.2, right side gels). The 
genotypes for R+ and R- populations were also compared. Genes for three allelic 
variants were amplified: - MSP2 (Ie allele), MSP2 (Fe allele) and MSP1 (Mad20 
allele) (Snounou, Zhu et al. 1999). PCR details are described in Chapter 2 section 
2.3.8. 
In sample 9197, the R+ and R- rosette-selected samples had fragments of slightly 
different size for the MSP2-IC allele but this was missing in the acute sample 
suggesting that they are all different clones. For the Fe allele of the same isolate, 
a faint band approximately 330bp was detected in acute sample but this was lost 
on adaptation. The Mad20 allele of 9197 however showed identical fragments for 
both the acute and the two rosette-selected parasites. 
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In sample 8148, no fragment was detected in both the acute and rosette selected 
samples for the Ie allele. For the Fe allele, the acute sample had a similar band 
pattern to the R+ and not the R- population. The latter had lost the approximately 
420 bp fragment. At the Mad20 allele, the R+ and R- parasites had similar band 
patterns but which were different from the acute sample. 
In sample 8211, the bands for Ie allele in the acute and rosette-selected samples 
were of the same size. However, the R+ and R- bands were of different intensities. 
This could have been due to less DNA template in the latter at the time of 
genotyping. The Fe allele on the other hand had no bands in both the acute and 
the selected parasites. However, results on Mad20 allele of the same sample 
suggests that the R+ and R- were of different genotypes due to the slight 
difference in band size. 
Finally, sample 9106 showed no product for the Ie allele for both the acute and 
selected parasites. However, on the Fe and Mad20 alleles, the R+ and R-
populations showed slight differences in the sizes of the bands suggesting 
differences in genotypes. 
Overall, results from parasite genotyping suggest that the process of in vitro 
adaptation of field isolates and the subsequent rosette selection into R+ and R-
was accompanied by changes in clones. 
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Figure 3.2: Ethidium bromide-stained agarose gels showing PCR products from 
genotyping of polymorphic alleles in merozoite surface proteins. These were:-IC 
allele (MSP2), FC allele (MSP2) and Mad20 (MSP1). Genotypes for acute 
samples (gels on the left panel) were compared to rosette selected R+ and R-
samples (gels on the right panel). The order of the sample on the gels was 9197, 
8148, 8211 and 9106. The molecular weight marker used was a 100bp ladder 
(New England Biolabs). NTC represents a no-template control that was included in 
all PCRs. 
3.4.2: Rosette selection by gelatin flotation 
Weekly enrichment of rosettes by gelatin flotation (Chapter 2, section 2.3.4) 
allowed for maintenance of increasing levels of rosettes in some but not all 
isolates. It is important to note that the increase was not steady and in most cases 
took several rounds of selection to see a significant increase in the % RF. Only 3 
out of the 4 samples (9197,8211 and 8148) had their rosette frequencies enriched 
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to high levels with an average % RF of about 60% (Figure 3.3). Sample 9106 did 
not achieve high % RFs even after several rounds of selection. However, the initial 
rosetting frequency for this sample was low (9%) compared to the rest of the 
samples. It could also be that these parasites have inherently low rosetting 
frequencies that could not be enriched even after several rounds of selection. 
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Figure 3.3: Rosette selection of 4 isolates into R+ (black line) and R- (red line) 
populations by gelatin flotation method (section 2.3.4 of chapter 2). The graphs 
show changes in % RF (y axis) for the two isogenic populations during rounds of 
selection (x axis), Selection was done until the highest possible and the lowest % 
RF was attained for each R+ and R- respectively. RNA samples for the 
transcriptional profiling were collected at the final point of selection for each of the 
samples, 
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3.4.3: Amplifica tion of DBL a tag regIo n of the PfEMP1 
Amplification of th DBLu 1 g r glon of 11'1 P MP1 nd tr nscri lion I profiling 
(d t lis in Ch t r 2, s ction 2.3.9) was don on RNA call cl d from the ring 
st g of R nd R- populations at the nd of ros tt s I ctlon. or til acul 
samples, the RNA was repar from the ring stage sample th t w s fro z n 
straight from the patient's arm. cDNA was then made from all the RNA s mples 
and amplification done using modified DBLaAF and DBLaBR primers which target 
a 300-400bp region between the homology blocks D and H of the DBL domain 
(Bull, Berriman et al. 2005). Resul ts of the PCR amplification for the reverse 
transcribed sample (RT pas) are shown in Figure 3.4. For each of the 
amplifications, a control was included that was not trea ted with reverse 
transcriptase enzyme denoted (RT neg) to ensure that there was no contaminating 
DNA in the RNA preparation. 
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Figure 3.4: 2% agarose gels stained with ethidium bromide showing PCR 
products from amplification of DBLa tag of the cDNA samples. The product sizes 
range from between 350-400bp. Gel 1 shows amplification products from acute 
samples while Gel 2 shows the PCR products for isogenic R+ and R-. Samples 
were treated with and without reverse transcriptase enzyme represented as "RT 
pas" and "RT neg" respectively. DNA from 307 was amplified as a positive control 
and a no-template control (NTC) was included as a negative control. The 
molecular weight marker used was a 100bp ladder (New England Biolabs). 
3.4.4 Sequence analysis and var gene transcription profiling 
Sequencing of the cloned DBLa tag was done using the capillary method (Big Dye 
Terminator v3.1 cycle sequencing kit-Applied Biosystems). The sequences were 
then analyzed by cys/PoLV (CP) classification method (Chapter 1, section 1.3.3.2) 
in which the six CP groups were represented by different colours (Figure 3.5, 
legend). Identical sequences herein referred to as sequence "types" were 
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identified for each isolate and assigned arbitrary identity numbers (Figures 3.5-3.8) 
which were then assigned to one of the CP groups. However, it was possible that 
two different sequence types could fall within the same CP group, and therefore 
the two different slices of the pie would be represented by the same colour. The 
number of slices in each pie chart therefore shows the number of unique 
sequence types for each sample and the size represents their relative proportion 
to the total number of sequences. Since the profiling involved few samples, 
identification of sequence types was done by a manual count of the unique 
sequences following clustal W alignment on Bio-edit Sequence alignment editor. 
Sequences from gDNA sequences were also profiled in a similar manner. The aim 
of including the gDNA profiles was to check for primer bias. For instance, if the 
dominant cDNA sequence was also the dominant gDNA sequence, this would be 
indicative of primer bias. In Figure 3.5-3.8, only the gDNA sequences types that 
were identical to any of the transcribed sequences are labelled. All sequences in 
FASTA format are shown in the appendix 8.4. 
For each isolate, a var gene thought to be involved in rosetting was identified as 
the dominant sequence type transcribed by the R+ population, but which was also 
rare or absent in the R- population. In 9106 (Figure 3.5), the dominant gene in R+ 
(sequence_2, belonging to CP1 group -63.64%) was also dominant in R- (90.91%) 
and therefore was ruled out as the gene responsible for rosetting. The gene was 
also present in the acute sample. It was however interesting that sequence_2 was 
expressed in such a high proportion despite the low rosetting frequency in 9106. 
Sequence_2 bears the MFK motif (CP1), a group A type that has previously been 
linked to rosetting and severe disease (Bull, Berriman et al. 2005; Bull, Kyes et al. 
2007; Warimwe, Keane et al. 2009; Warimwe, Fegan et al. 2012). Whether 
selection away from rosetting led to the enrichment of another virulent var gene 
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remains unknown. The possibility of primer bias was ruled out since sequence_2 
was not dominantly expressed in gDNA of R+ and R-. 
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Figure 3.5: Var gene transcription profiles of the acute samples and the isogenic 
R+ and R- populations in sample 9106. The pie charts show the cDNA and gDNA 
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var gene profiles for the acute, R+ and R- samples. The different sequences and 
their proportion of the total sequences are listed on the table below the charts. The 
different colours represent the CP groups to which the unique sequence types 
belong. The labelled sequences at the gONA level represent only those 
sequences that were identical to a cDNA sequence, as a way of checking for any 
form of primer bias. 
Sample 8148 (Figure 3.6), had two dominant sequences at acute stage 
(sequence_1 and 2) and which were in equal proportions (33.33%). The two 
sequences also came up in the R+ selected sample. Although sequence_1 was 
dominant in R+ and was not seen in R-, it could not convincingly be referred to as 
the gene responsible for rosetting due to the small number of sequences. 
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Figure 3.6: Var gene transcription profiles of the acute samples and the isogenic 
R+ and R- populations in sample 8148. The pie charts show the cDNA and gDNA 
var gene profiles for the acute, R+ and R- samples. The different sequences and 
their proportion of the total sequences are listed on the table below the charts. The 
different colours represent the CP groups to which the unique sequence types 
belong. The labelled sequences at the gDNA level represent only those 
sequences that were identical to a cDNA sequence, as a way of checking for any 
form of primer bias. 
Sample 9197 (Figure 3.7) also had 2 dominant CP4 sequences (sequence_1 and 
2) at acute stage. In the R+ sample, sequence_6 was dominant (33.33%) but was 
also dominant in R- (15.38 %). The second dominant sequence in R+ 
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(sequence_3) was not present in R- and could be possibly be the gene 
responsible for rosetting . Sequence_3. which belongs to CP2. was also present in 
the acute sample although not as a dominant gene. There were more group A 
sequence types in R+ and none in the R- in support of previous association 
between Group A genes and rosetting . 
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9197R- 9197 _sequence_ 6 2 (15.38%) 
9197_sequence_ 15 1 (7.69%) 
9197_sequence_ 16 1 (7.69%) 
9197_sequence_ 17 1 (7.69%) 
9197_sequence_ 18 1 (7.69%) 
9197_sequence_ 19 1 (7.69%) 
9197 _sequence_ 20 1 (7.69%) 
9197_sequence_ 21 1 ( 7.69%) 
9197_sequence_ 24 1 (7.69%) 
9197_sequence_ 25 1 (7.69%) 
9197_sequence_ 26 1 (7.69%) 
9197_sequence_ 27 1 (7.69%) 
Total 13 
Figure 3.7: Var gene transcription profiles of the acute samples and the isogenic 
R+ and R- populations in sample 9197. The pie charts show the cDNA and gDNA 
var gene profiles for the acute, R+ and R- samples. The different sequences and 
their proportion of the total sequences are listed on the table below the charts. The 
different colours represent the CP groups to which the unique sequence types 
belong. The labelled sequences at the gDNA level represent only those 
sequences that were identical to a cDNA sequence, as a way of checking for any 
form of primer bias. 
Sample 8211 (Figure 3.8), was the most heterogenous of the four with varied 
sequence types in acute, R+ and R- samples that were all expressed in low 
proportions. There was no clear dominant gene in R+ that could be linked to 
rosetting. 
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8211_sequence_ 24 
8211_sequence_ 25 
8211_sequence_ 26 
Total 
1 (9.09 %) 
1 (9.09 %) 
1 (9.09 %) 
10 (100 %) 
Figure 3.8: Var gene transcription profiles of the acute samples and the isogenic 
R+ and R- populations in sample 8211. The pie charts show the cDNA and gDNA 
var gene profiles for the acute, R+ and R- samples. The different sequences and 
their proportion of the total sequences are listed on the table below the charts. The 
different colours represent the CP groups to which the unique sequence types 
belong. The labelled sequences at the gDNA level represent only those 
sequences that were identical to a cDNA sequence, as a way of checking for any 
form of primer bias. 
There were possible limitations in this sequence analysis approach, some of which 
were addressed. These included:-
i. Presence of var1 sequences that would constitutively be expressed regardless 
of the phenotype and hence confound the analysis (Winter, Chen et al. 2003). 
ii. Possible primer bias (Taylor, Kyes et al. 2000; Kraemer, Gupta et al. 2003) 
iii. Rapid switching off of the Group A s in vitro as described in Peters et al., 2007 
(Peters, Fowler et al. 2007) and Frank et al.,2007 (Frank, Dzikowski et al. 
2007). 
iv. Inability to select and identify rosetting genes of clinical importance or those 
expressed at the time of disease. 
v. Limited number of sequences. 
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i) Checking for presence of varl sequences 
Var1 sequences have been shown to be constitutively expressed in pigmented 
trophozoites regardless of the parasite phenotype (Winter, Chen et al. 2003; Kyes, 
Christodoulou et al. 2007). Prior to compiling the final transcript profile, all 
sequences were checked for the presence of two types of var 1 sequence which 
could otherwise have confounded the analysis. The first is in CP1 (MFK+ REV") 
and was identified using the motif NVHDKVEKlTGLREVF and corresponded to var 
1 genes from four other isolates: -TM180, TM284 (Rowe, Kyes et al. 2002), FCR3, 
and HB3 (Kraemer, Kyes et al. 2007). The second falls in cys/PoLV group 2 (MFK-
REY+) and was identified using the motif APNKEKIKLEENLKK corresponding to 
var 1 from 3D7 and "common" (Winter, Chen et al. 2003). A perl script written by 
Pete Bull that could identify the var 1 motif was run on all samples. None of the 
sequences generated from the acute and rosette-selected samples contained the 
var 1 sequence. 
ii) Assessing primer bias using gDNA 
Primer bias was checked by comparing the dominant sequence of the gDNA 
profiles with that of the transcript profiles. Identical sequences between the 
dominant transcript sequence and a dominant gDNA sequence would be indicative 
of bias towards amplification of that gene. The pie charts for the gDNA sequences 
(Figure 3.5-3.8) show only those sequences that were identical to any of the cDNA 
sequences. There was no evidence of primer bias in any of the four isolates. 
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iii) Were any of the var genes in the acute samples present in the rosette 
selected samples? 
To check whether sequences in the acute sample were maintained after in vitro 
adaptation and rosette selection, acute sequences were compared against those 
from rosette selected lines. It is assumed that any dominant sequence at acute 
stage was responsible for the clinical syndrome exhibited by the patient at the time 
of disease. In 3 of the isolates (9106, 8148 and 9197), some transcript sequence 
present in the acute sample was also present in the rosette selected sample. 
Although they were not necessarily the dominant sequences at acute stage, they 
represent sequences that may have been important for the disease process. While 
the dominant CP groups were maintained in 9197 and 8211, the actual individual 
sequence types were different. Two samples i.e. 8148 and 9106 showed a major 
switch of genes from the acute to the rosette selected lines, with only a few acute 
sequences coming up in rosette selected samples. Although the 91 06R+ could not 
be selected to high rosetting frequencies, an interesting finding was that the 
dominant sequences in R+ and R- were exactly the same i.e 9106_sequence 2. 
Furthermore, despite the inability to select 91 06R+ to high % RF (Figure 3.3), the 
sequence_2 contained one of the motifs DKVEKG termed "H3", classified by 
Normark and colleagues (Normark, Nilsson et al. 2007) as a high rosetting motif. 
Primer bias was ruled out since none of the gDNA sequences were identical to this 
sequence. 
iv) Inability to select and identify rosetting genes of clinical importance 
Due to the differences in selective forces between the parasites in in vivo and in 
vitro conditions, it is possible that the process of adaptation and subsequent 
process of rosette selection of parasites described in this chapter resulted in 
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expression of PfEMP1 variants that are not clinically relevant. Previous studies 
have reported that the effects of in vitro adaptation of patient isolates to laboratory 
populations resulted in changes in transcription profiles of var genes (Peters, 
Fowler et al. 2007). Although clinical relevance was not directly tested, an indirect 
way would be to check if any of the dominant sequences at acute stage 
(presumably those responsible for the disease) were also dominantly expressed 
after selection as described in (iii) above. 
v) Limited number of sequences 
For all the four isolates, the number of good quality sequences that were analyzed 
ranged between 9-29. The probability of picking a dominant sequence could be 
limited by few sequences. However, the acute samples in 3 of the 4 isolates 
(9106, 8211 and 9197) were further sequenced by next generation sequencing 
technique (454 platform) which gives more sequences. A comparison of the 
transcription profiles by capillary method versus 454 method (section 3.4.5 below), 
showed the same dominant sequence was picked by both methods. 
3.4.5 Comparison of acute transcript's sequences by capillary method 
versus next-generation 454 sequencing method 
Next generation sequencing techniques such as the 454 platform have been 
shown to be efficient in sequencing of polymorphic sites, while producing longer 
reads with deeper coverage (Gandhi, Thera et al. 2012). The transcript sequences 
of samples 9106, 9197 and 8211 described in this chapter have recently been 
sequenced in Sanger on the 454-platform. Unlike the capillary method where 5-27 
clones were sequenced per isolate, the 454 method had more depth with more 
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sequences being obtained per isolate (9197=118 sequences, 9106=447 
sequences and 8211 =521 sequences). Sequences generated by 454 were 
compared to those obtained by capillary method to determine if the limited number 
of sequences by the capillary method could have affected the precision of the 
estimate of proportional abundance. Figure 3.9 shows the transcript profiles for 
acute samples using both methods. It was encouraging to note that despite the 
small number of sequences by the capillary method in comparison with the 454 
method, the dominant sequences type in all the 3 isolates were identical by the 
two methods. However, the 454 method was able to pick up more sequences than 
the capillary method. It is therefore likely that the rosette-selected samples which 
were all sequenced by the capillary method gave the correct dominant sequence. 
454 sequencing 
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sequencing 
(used in this 
chapter) 
Acute 8211 
S I"l1 
-q ,,~, 
Acute 9106 Acute 9197 
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• Group 4 (Cys4) 
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Figure 3.9: A comparison of transcript profiles by 454 and capillary methods in 3 
of the acute cDNA samples. The transcripts were generated from different aliquots 
of the acute sample. The pie charts show the proportion of unique sequence types 
to the total number of sequences by each method and colours represent different 
sequence groups by Cys/PoL V classification method as previously described. The 
dominant sequences were the same by both methods i.e. 821 Csequence_1, 
9106_sequence_1 and 9197_sequence_1. The total numbers of individual 
sequences for each isolate by 454 were: 8211=521 sequences, 9106=447 
sequences and 9197 =118 sequences while the capillary method had between 9-
10 sequences per isolate. Despite the difference in number of reads between the 
two methods, the dominant sequences for each isolate were identical. 
3.5 DISCUSSION 
While a lot of rosetting PfEMP1 variants in laboratory strains have been 
characterised (Rowe, Moulds et al. 1997; Vigan-Womas, Guillotte et al. 2008; 
Albrecht, Moll et al. 2011), little information is available concerning var genes 
associated with rosetting in field isolates. Many field studies that have looked at 
var gene transcription in rosetting isolates were generally examining the 
association between genes and severe malaria (Kyriacou, Stone et al. 2006; 
Normark, Nilsson et al. 2007; Bull, Buckee et al. 2008; Warimwe, Fegan et al. 
2012). I aimed to specifically examine the composition of var gene transcripts in 
culture adapted field isolates and their transcription patterns before and after 
rosette selection. Following successful adaptation of the field isolates into in vitro 
culture, transcriptional profiling of var gene sequences was done before and after 
rosette selection. 
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Var genes transcribed during acute stage were identified in four field isolates. At 
this stage however, it was not possible to link any of the var genes to rosetting 
phenotype since all the samples had relatively low % RF (range 9-23%). It was 
however expected that any of the dominant gene upon rosette selection, and 
which was present in the acute transcripts, would be potentially linked to rosetting. 
None of the dominant transcripts in the rosette-selected samples were present in 
the acute samples. This could have been due to the limited number of clones that 
were sampled for sequencing. The dominant var gene transcribed at the acute 
stage could have been responsible for severe disease through other mechanisms 
than rosetting. It is also likely that there is a change of genotypes during the 
process of in vitro adaptation as seen in the MSP1/MSP2 results. 
To identify var genes responsible for rosetting, transcripts from R+ were compared 
to those from R- (Figure 3.5-3.8). Putative rosette-mediating variants in each 
isolate were identified as a dominant sequence type transcribed by the R+ 
population, and which was rare or absent in the R- population. It was expected 
that var genes responsible for rosetting in 8211, 9197 and 8148 would be easily 
identified since they were all selected to relatively high % RF ranging from 56-
63%. However this was not the case. Only in sample 9197R+ was there a 
dominant sequence in the CP2 group that was absent in the isogenic R-
population. In samples 8211 and 8148, no clear dominant sequence came up in 
the R+ population. It is possible that the rosette-selected parasite population was 
heterogenous and contained rosettes that were mediated by different variants. In 
such a case, a dominant var gene may not have been easily identified. This is 
possible considering that previously characterised ITvar9 and ITvar60 PfEMP1 
variants, both of which mediate rosetting are present within the IT genome (Rowe, 
Moulds et al. 1997; Albrecht, Moll et al. 2011). Interestingly, despite not achieving 
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high % RF, it was the rosette-selected sample 9106 that showed a homogenous 
transcriptional profiling pattem with a single dominant var gene (up to 63.64% 
CP1) upon selection. The same sequence was also seen in the R- population 
(90.91 %) It remains unknown the importance of high level transcription of this 
gene. 
While in vitro systems provide insights into the biological processes of parasites, 
major differences between in vivo and in vitro P. falciparum growth conditions 
have been highlighted, as reviewed by LeRoux et al., 2009 (LeRoux, Lakshmanan 
et al. 2009). One major difference between in vivo and in vitro parasites that could 
have been a caveat in the approach described here is the possibility that immune 
pressure is exerted on the parasite inside the host while no similar pressure is 
exerted under in vitro conditions. This could potentially alter the expression of 
PtEMP1 which is thought to be an important immune target in the host. It also 
implies that the process of in vitro adaptation and subsequent rosette selection as 
described in this chapter could have been selecting for clinically irrelevant variants 
or that the highly relevant variants which were strongly recognized by the immune 
response cannot survive in vitro conditions. Only a few genes, although not 
necessarily the dominant ones, were identical in both the acute and rosette 
selected transcripts. 
PtEMP1 variants associated with rosetting in laboratory isolates are mostly of 
group A type, which is characterised by two cysteine residues (Rowe, Moulds et 
al. 1997; Vigan-Womas, Guillotte et al. 2008; Albrecht, Moll et al. 2011; Ghumra, 
Khunrae et al. 2011). In this analysis, only sample 9197 R+ had a Group A var 
gene (CP2) that could be linked to rosetting. Samples 8148 and 8211 had non-
Group A-like genes as the dominant genes. The proportions of these sequences 
were however not convincingly higher than the rest of the sequences and 
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therefore they could not be definitively linked to rosetting. It is suggested that 
genes from Group A have a higher switch off rate in vitro than genes from Ups B 
and C (Peters, Fowler et al. 2007). It is possible that the rosetting field isolates 
described in this chapter lost some of their expressed Group A genes due to 
switching during the process of in vitro adaptation. This hypothesis may however 
be questionable since sample 9106 was able to maintain high levels of a Group A 
sequence in vitro in both the R+ and R- populations. 
Previous studies have shown that in vitro adaptation of malaria parasites in culture 
could result in loss of clones (Nsobya, Kiggundu et al. 2008; Cheeseman, Gomez-
Escobar et al. 2009). In this study, a comparison of parasite clones before and 
after selection by MSP genotyping showed evidence of loss or change of 
genotypes in all the 4 isolates. Although the dominant var gene transcripts would 
possibly be from the dominant genotype, it is possible that the comparison of var 
gene transcripts was affected by these differences in parasite genotypes 
especially in cases where the R+ and R- parasites. This could have greatly 
contributed to the inability to identify a single dominant gene responsible for 
rosetting. 
In conclusion, sequence diversity and transcription profiles from 4 culture-adapted 
field isolates were evaluated. Unlike previous work using P. fa/ciparum laboratory 
strains (Ghumra, Semblat et al. 2012), it was not possible to identify a 
predominant var gene in any of the rosette-selected parasites. Later examination 
of the rosette-selected Kenyan parasites in the Rowe lab suggested that the 
rosette frequencies of the selected lines were much lower than were initially 
estimated in Kilifi. The most likely explanation for the failure to identify 
predominant var genes linked to rosetting is that the parasites were not sufficiently 
well selected to high rosette frequency to give a clear phenotype. Related to this is 
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the possibility that the rosette selection method using gelatin flotation resulted in 
retention of a heterogenous parasite population consisting of rosetting parasites 
and knob-negative non-rosetting parasites, that would hinder clear transcriptional 
profiling. The culture-adapted field isolate described in chapter 4 and 5 was 
characterized following cloning by limiting dilution to attempt to obtain highly 
distinct but isogenic R+/R- lines with a more stable phenotype. Another 
explanation for the lack of a predominant var gene linked to rosetting is the 
possibility that the Kenyan parasites might rosette using non-PfEMP1 ligands such 
as rifins or stevors. Further work will be needed to examine this possibility. 
Another limitation of the work presented here is the lack of depth in the 
sequencing of R+ and R- clones, which could be addressed in future work either 
by sequencing more colonies or by using next generation sequencing methods like 
454, as was done on the acute samples. 
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CHAPTER 4 
Cloning and sequencing of full-length PfEMP1 in a field isolate, protein 
expression and raising of antibodies from individual recombinant 
domains 
4.1 INTRODUCTION 
Although PfEMP1 is encoded by a large and diverse var gene family of about 60 in 
a haploid genome (Kyes, Horrocks et al. 2001), only one (out of the possible 60) is 
expressed at a time, reviewed by Scherf et al., 2008 (Scherf, Lopez-Rubio et al. 
2008). It is this mutually exclusive expression of a single var gene in an infected 
cell that determines the antigenic, cytoadherent, and virulence phenotypes such 
as rosetting. Many studies, including this one, aim at identifying PfEMP1 variants 
that are associated with particular adhesion phenotypes in P. falciparum isolates. 
4.1.2: Rosette-mediating PfEMP1 variants 
Various attempts have previously been made to identify and characterize PfEMP1 
variants that are associated with rosetting in P. falciparum. Three examples of well 
characterized rosette-mediating PfEMP1 variants are R29var1 (also known as 
ITvar9) expressed by the IT/R29 clone (Rowe, Moulds et al. 1997), ITvar60 in the 
FCR3S 1.2 clone (Albrecht, Moll et al. 2011) and Var 0 in the Palo Alto strain 
(Vigan-Womas, Guillotte et al. 2008). The GeneBank accession numbers for these 
variants are: -YI3402, EF158099 and EU9082205 respectively. Following their 
identification, assays have been done using recombinant proteins or antibodies 
raised to the variant proteins in order to determine their functional and 
immunological properties. 
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First to be identified and characterized was the rosette-mediating variant in IT/R29 
clone (Rowe, Moulds et al. 1997). A comparison of Duffy-binding-like domain 
(DBL-1) transcripts from isogenic rosette positive (R29+) and rosette negative 
(R29-) parasites showed ITvar9 gene to be exclusively expressed in R29+ and not 
in R29-. The full-length ITvar9 (8.2 kb), a group A var gene, was then identified by 
PCR walking, cloning and sequencing using vectorette libraries (Arnold and 
Hodgson 1991). Complement receptor 1 (CR1) was shown to be the host receptor 
on un infected red cells involved in rosetting in IT/R29. 
A second rosetting parasite whose PfEMP1 variant has been characterized is 
FCR3S 1.2 (Chen, Barragan et al. 1998), a clone derived from FCR3S 1 by 
micromanipulation (Fernandez, Treutiger et al. 1998). An initial report (Chen, 
Barragan et al. 1998) had shown that rosetting in FCR3S1.2 was mediated by a 
non-group A PfEMP1 variant, FCR3S 1.2var1 (also referred to as ITvar21) by 
binding to heparan sulphate-like molecules. However, using semi-quantitative and 
quantitative (qPCR) methods, a recent follow-up study on the same parasite 
showed that rosetting was mediated by FCR3S1.2var2 (also known as ITva(60) 
(Albrecht, Moll et al. 2011). ITvar60, which is a group A var gene, was consistently 
shown to emerge as the dominant transcript immediately after cloning of 
FCR3S1.2 and even after 100 generations. ITvar60 was also identified as the 
rosette-mediating variant in the same parasite line (also called IT/PAR+) by 
Ghumra et a/., 2012 (Ghumra, Semblat et al. 2012). It is not clear which receptors 
on uninfected red cells are involved in mediating rosetting in FCR3S 1.2. However, 
the infected erythrocytes have been shown to bind soluble heparin, non-immune 
IgM and to form larger rosettes with blood group A red cells compared to 0 or B 
cells (Albrecht, Moll et al. 2011). 
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Var 0 is the third group A rosette-mediating PfEMP1 variant that has been 
extensively characterized (Vigan-Womas, Guillotte et al. 2008; Juillerat, Igonet et 
al. 2010; Vigan-Womas, Lokossou et al. 2010; Juillerat, Lewit-Bentley et al. 2011). 
It is expressed by Palo Alto 89F5, a clone that was originally used in an in vivo 
experimental model in Saimiri sciureus monkey but later cultured in human RBCs 
(Vigan-Womas, Guillotte et al. 2008). Var 0 rosetting parasites dominantly 
expressed this variant that was absent in isogenic parasites expressing non-
rosetting var R (Fandeur, Le Scanf et al. 1995; Contamin, Behr et al. 2000). Full-
length PfEMP1 (7.3kb) was identified by reverse transcriptase RCR (RT-PCR), 
chromosomal walking and sequencing using gene specific as well as degenerate 
primers (Kraemer, Gupta et al. 2003; Vigan-Womas, Guillotte et al. 2008). 
In all these three variants described above, the N-terminal DBLa. domain was 
shown to be the functional region that binds red cells to mediate rosetting (Rowe, 
Moulds et al. 1997; Vigan-Womas, Guillotte et al. 2008; Albrecht, Moll et al. 2011). 
Four other rosette-mediating variants (shown in Table 4.1 )were recently identified 
by Ghumra et al., 2012 (Ghumra, Semblat et al. 2012). In each case, the var gene 
identified as encoding the probable rosette-mediating variant was the 
predominantly transcribed gene in rosetting (R+) parasites and was not 
transcribed, or transcribed at low frequency, in isogenic non-rosetting (R-) 
parasites. In three cases (HB3var6, TM284var1 and Muz12var1) the rosetting 
function was confirmed by the ability of specific antibodies to the variant to inhibit 
rosetting (Ghumra, Semblat et al. 2012). However, antibodies to the NTS-DBLa. 
domain of TM180var1 did not inhibit TM180R+ rosetting, suggesting either that 
this variant does not mediate rosetting, or that domains other than NTD-DBLa. are 
involved. TM180var1 should therefore be considered a "possible" rosetting variant, 
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which requires further study. PF13_0003 is another UpsA var gene found to have 
orthologous adhesion domain in 307 (Gardner, Hall et a!. 2002). Parasites 
expressing this gene were shown to be rosetting (Vigan-Womas, Guillotte et al. 
2011) and antibodies to NTS-DBLu domain had the ability to disrupt rosettes in 
homologous parasites. 
Table 4.1: Rosette-mediating PfEMP1 variants, including the name of the parasite, 
its geographical origin and GeneBank accession number for the var gene. 
TM180var1 * is characterized as a possible rosetting gene in TM180R+ parasites. 
Rosetting Origin Rosetting GeneBank 
Parasite PfEMP1 variant accession 
Number 
HB3R+ Honduras HB3var6 PFHG_02274.1. 
TM284R+ Thailand TM284var1 JQ684046 
IT/PAR+ South East Asia ITvar60 EF158099 
Muz12R+ Papua New Muz12var1 JQ684048 
Guinea 
TM180R+* Thailand TM180var1 JQ684047 
R29R+ South East Asia ITvar9 Y13402 
Palo Alto South East Asia VarO EU9082205 
Clone 89F 
307 From strain PF13-0003 XP 001349740 
NF54. Thought 
to be from 
Africa 
Although epidemiological studies in Sub-Saharan Africa have shown an 
association between rosetting and severe disease (Carlson, Helmby et al. 1990; 
Treutiger, Hedlund et al. 1992; Rowe, Obeiro et al. 1995; Newbold, Warn et al. 
1997; Kun, Schmidt-Ott et al. 1998; Heddini, Pettersson et al. 2001), most of the 
characterized PfEMP1 variants described above are from isolates of non-African 
origin that have been in culture for a long time. Data from African field isolates 
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have shown distinct sub-groups of var genes being implicated in rosetting in 
natural parasite populations (Bull, Berriman et al. 2005; Kyriacou, Stone et al. 
2006; Bull, Buckee et al. 2008; Warimwe, Fegan et al. 2012), hence it is possible 
to isolate and characterize rosette mediating PfEMP1 variants from field isolates. 
The field isolate described in this chapter is called SA075. It was obtained from a 
patient with severe malarial anemia from Kisumu, a malaria endemic area in 
western Kenya. The predominant gene expressed in 17/37 sequence tags in 
SA075 parasites grown in culture and selected for rosetting had previously been 
characterized by DBLa tag analysis (Bull, Buckee et al. 2008) as described in 
Chapter 2, section 2.3.9.3. Interestingly, the dominant tag sequence in SA075 was 
identical to a sequence isolated in Kilifi (EMBL Accession No. CAJ40433.1), from 
a rosetting isolate 4180 that had a rosetting frequency of 46% (Bull, Buckee et al. 
2008). The sequence belonged to two var gene sequence groupings: -block-
sharing group 2 and CP2, both of which have been associated with rosetting (Bull, 
Berriman et al. 2005; Bull, Buckee et al. 2008). The tag sequences were also 
grouped into sequence signatures also known as "sig", which consisted of a string 
of amino acids at each of the PoLVs together with the cysteine count (Bull, 
Berriman et al. 2005). SA075 contained sig2-like sequence features similar to 
what was seen in two highly rosetting field isolates from Kilifi (Bull, Berriman et al. 
2005). Therefore, because of the suggested association of the SA075 tag with 
rosetting, there was need to identify and sequence the full-length PfEMP1 variant 
from SA075 parasites. Following identification of the putative gene, recombinant 
proteins were made and antibodies raised from the different domains of the 
PfEMP1 variant. Chapters 5 and 6 will focus on functional and immunological 
characterization of these anti-PfEMP1 antibodies. 
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4.2: CHAPTER AIMS 
The specific aims of this chapter were: -
1. To clone a recently culture-adapted field isolate, SA075 (Bull, Buckee et al. 
2008), by limiting dilution. 
2. To identify the dominantly expressed var gene transcript in SA075 rosetting 
clone. 
3. To clone and sequence the full-length expressed var gene encoding the 
putative rosette-mediating PfEMP1 variant from SA075. 
4. To generate individual recombinant protein domains from the PfEMP1 
variant. 
5. To raise antibodies to each recombinant domain to be used for functional 
assays as will be discussed in chapters 5 and 6. 
4.3 MATERIALS AND METHODS 
4.3.1 Parasite culture 
The parasite isolate used in this study was called SA075 (details described in 
section 4.2). The parasite, a kind gift from Jose Stoute, was highly rosetting ex-
vivo (Thathy, personal communication). Routine parasite culture maintenance and 
rosette selections for SA075 parasites were done as described in Chapter 2 
sections 2.3.1 and 2.3.4 respectively. 
4.3.2 Cloning of SA075 parasites by limiting dilution 
Cloning of SA075 parasites was done by limiting dilution as described by Francois 
et a/.,1994 (Francois, Hendrix et al. 1994), in which the culture suspension was 
first diluted to a pre-calculated probability of obtaining a given number of parasites 
per J.l.1 prior to inoculating in a flat bottomed 96-well tissue culture plate (Corning® 
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Costar®, Sigma Aldrich). The target dilution for cloning of SA075 was 0.4 parasites 
per well. A day before the actual dilution, parasites were synchronized to ring 
stage by Sorbitol method as described in Chapter 2, section 2.3.1. The next day at 
trophozoite stage, parasitaemia was determined by Giemsa stained thin smears 
(Chapter 2, section 2.3.1). The actual RBC count in the 20 ml culture suspension 
was then determined by a Coulter counter (Ac. T 5 diff CP, Beckman Coulter Inc. 
Miami Frorida USA). The culture at 5% parasitaemia and 2% haematocrit was 
then diluted in complete media down to 40 parasites in the 20ml suspension. 
200).1.1 of the diluted suspension was dispensed into each well to give a final 
parasite density of approximately 0.4 parasites/well. The outer wells around the 
plate were not inoculated with the culture suspension but were filled with culture 
media due to high rate of evaporation that occurred at the edges. Each cultured 
well was given an identification clone number after which the plate was transferred 
into a chamber, gassed for 1 minute and incubated at 37°C. Complete culture 
media was changed every 2 days and fresh, non-infected cells at 1 % hematocrit 
added after every 5 days. Giemsa-stained smears were made from each well 
every week to determine presence of growing parasites. Once detected (after 
about 3 weeks), the parasite positive cultures were transferred to 25cc culture 
flasks. The percentage rosetting frequency (% RF) was thereafter determined for 
all the clones and two of them with the highest and lowest %RF were identified for 
reverse transcriptase PCR (RT-PCR). Agglutination assays as described in 
section 4.3.3 were also carried out on all the clones as an additional phenotype 
assay. Due to the nature of results of transcript profiles as will be discussed later, 
there was need to re-clone one of the highly rosetting positive clones (Clone 17). 
The process of re-cloning was similar to the one described above. 
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4.3.3: Antibody-mediated agglutination assays 
Agglutination assay was done as previously described by Bull et al., 2000 (Bull, 
Kortok et al. 2000). Trophozoite stage culture suspension from each of the clones 
was adjusted to 4% haematocrit in 1X PBS containing 0.5% BSA and 10~g/ml 
ethidium bromide. 11.5~1 of the suspension was then incubated with 11J1 of the 
hyperimmune serum called A 1 in 96-well U-bottomed plates (Falcon, Becton 
Dickinson, USA) for 1 hour on a vertical rotor at room temperature. An unblinded 
negative control i.e. European serum on each of the clones was used as a 
reference while the assays were scored. Following the incubation, the entire assay 
volume for .each well was transferred on to the corresponding pre-labeled 
microscope slide using a P20 pipette. A cover slip sealed with petroleum jelly was 
overlaid and the agglutinates counts were determined by fluorescence microscopy 
at X40 (Nikon eclipse 80i, Japan). An agglutinate was defined as a clump of 5 or 
more intact trophozoite-infected erythrocytes. 
4.3.4 Var gene transcriptional profiling, cloning and sequencing of the full-
length PfEMP1 variant 
Following cloning by limiting dilution, var gene transcriptional profiling was done on 
the clone with the highest rosetting frequency (R+) and a non-rosetting (R-) clone 
as described in Chapter 2 section 2.3.9. The dominantly expressed var gene in R+ 
was identified for full-length cloning and sequencing by PCR walking strategy. This 
process involved PCR amplification from a known region of the DNA, in this case 
the DBLa. tag region, to an unknown region upstream and downstream of the gene 
using variant specific and degenerate primers. The strategy was previously 
described by Kraemer et al., 2003 (Kraemer, Gupta et al. 2003) and was used to 
amplify full-length var genes. Variant specific primers (listed in Table 4.2) were 
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designed within the SA075 sequence and paired up with the degenerate primers 
both upstream and downstream of the gene, a strategy illustrated in Figure 4.1. 
The variant specific primers within the tag were designed in the hypervariable 
regions so that they would be unique for the SA075 variant. 
The first set of PCRs for the amplification of full length gene from genomic DNA 
involved Ups A, Band C forward primers (Table 4.2) that were paired up with a tag 
specific reverse primer in three separate PCR reactions (PCR 1 in Figure 4.1). 
Next, tag specific forward primer was paired up with reverse degenerate primers 
(Kraemer, Gupta et al. 2003) from the downstream domains Le. DBL~, DBLy, 
DBLo and Exon II in four separate PCR reactions (PCR 2 in Figure 4.1). A product 
from any of these amplification reactions was then cloned into a vector (Chapter 2 
section 2.3.9.3) and 10 colonies randomly picked for sequencing. The new 
sequences would then be assembled with the already known tag sequence and 
new primers designed for subsequent PCRs further upstream and downstream 
(PCR 3,4, and 5 in Figure 4.1). To ensure the correct gene had been amplified, the 
new sequence was to overlap with the known tag sequence at 100% nucleotide 
identity. Sequence assembly was done using Seqman Pro, Lasergene. All 
sequencing work described in this section was done at the GenePool facility at the 
University of Edinburgh. A list of all variant specific and degenerate primers that 
were used in sequencing of the full-length SA075 gene is shown in Table 4.2. 
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Figure 4.1: Schematic representation of the PCR strategy used for sequencing of 
the full-length PfEMP1 variant in SA075 starting from the known DBLa tag region 
(represented in blue) to unknown regions upstream and downstream of the gene 
(in dotted line). Tag specific primers (in blue) were first paired up with Ups primers 
and degenerate primers (in black) upstream or downstream of the gene. The first 
set of PCR reactions (PCR 1) was done using forward primers for Ups A, B or C 
paired up with a variant specific reverse primer of the DBLa tag region, in three 
separate reactions. The reaction involving the Ups B primer yielded a product of 
approximately 1.5kb which was then cloned and sequenced. The second set PCR 
reactions (PCR 2) involved a variant specific forward primer paired up with 
degenerate primers from each of the downstream domains (/3, 1, is and Exon /I) in 
separate reactions. While other domain primers did not have any product in the 
first PCR attempt, the PCR involving DBLrprimer yielded a product (- 6kb) that 
was also cloned and sequenced. Since the product from PCR 2 was large, 
subsequent PCRs 3,4 were done using variant specific primers designed from the 
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already sequenced region that were used to amplify and sequence the region 
between the tag region and the gamma domain. Finally a PCR was done (PCR 5) 
using a forward primer designed at end of DBL r domain and paired up with exon /I 
reverse primer and the product sequenced and assembled. The full-length gene 
was finally sequenced and named SA075var1. 
Table 4.2: Sequences for variant specific and degenerate primers used for 
cloning and sequencing of full-length gene SA 075. The first 7 primers are 
degenerate primers from Kraemer et al., 2003 (Kraemer, Gupta et al. 2003). 
Primers 8-23 were variant specific designed from SA075 gene. 
Primer name Sequence 5'-3' 
1 UpsA AAT ATW ATG AAT CTT CAG 
2 Ups B TTGCCTCTDTTGTTATCTC 
3 UpsC GTGATAACYAYTATATMATATAC 
4 DBL13_3.2 AATC(GfT)TTG(A/GfT)GG(A/G)AT(A/G)TA(A/G)TC 
5 DBLL3.2 ACCA TC( GfT)( CfT)A(AJG )(A/G )AA( CfT)( GfT)G(A/G )GG 
6 DBUl_3.1 G 
CCCCATTC(A/T)T(C/G)(A/T)A(A/G)(C/G)(C/T)A(A/T)CG 
7 Exon_23.3 CCADYTCTTCATAYTCACTTTC 
8 SA075 Tag Forward ACGAACTAAATAATCTTTCATTGGA 
9 SA075 Tag Reverse CCATCTGTAAATTCCCGTTTC 
10 SA075 gamma Fow 1 (Towards exon CATCATATTAGAGACACCTCG 
2) 
11 SA075 gamma Rev 1 (Towards ATTCCTCTTATCACACTCCCACGC 
internal) 
12 SA075 gamma Rev 2 (Towards GCTGCAGATTTGATGAATGCT 
internal) 
13 SA075 alpha/gamma Fow 1 (400bp TTACTAACAGTGCTGATGACA 
from end of tag) 
14 SA075 alpha/gamma Fow 2 (200bp TTCTAGGGATAGTAAGTGTACTGC 
from end of tag) 
15 SA075 alpha -1]amma internal 2 FOW GCATAGATTATACTAACGTCACC 
16 SA075 DBL alpha _gamma internal 2 ATCTACCACTTGTTGATAGTCG 
REV 
17 SA075 DBL gamma_delta internal 2 CTCCAGGTAATGTTGATGTAC 
FOW 
18 SA075 DBL gamma_delta internal 2 CTAGATGATTTTCTGCTGCCTG 
REV 
19 SA075 Delta (outward) FOW CGAGACAGTCAAACTCGAC 
20 SA0751NT FOW (original) TAGACACCATAAAATGGGAAACCA 
21 SA075 INT REV TTCATCGCTCGACATACAGTCTGC 
22 SA075 Exon Fow TGCAGCGATGCTAAAGGAAATACTC 
23 SA075 Exon Rev GCCTTTGTATTTATCAGTACCATAG 
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For all the PCRs, a 50 /-ll reaction was set up that consisted of 1 X Pfx amplification 
buffer, 10mM dNTPs, 2.5mM Mg2S04, all from Platinum® Pfx polymerase kit 
(Invitrogen), 0.25/-lM forward and reverse primers, 100ng DNA, 1 U Pfx Taq 
polymerase all topped up to 50 /-ll with DNAse free water. The PCR machine used 
was a PCT-100 Peltier Thermal Cycler PCR machine (MJ Research) with the 
following conditions: -1 cycle of 94 °c for 5 minutes followed by 35 cycles of 94 °c 
for 5 seconds, *48 °c for 15 seconds, 60 °c for 2 minutes 30 seconds and a final 
extension at 60 °c for 10 minutes. The annealing temperature (marked in asterix) 
however varied for the different PCRs due to different melting temperature of 
primers (Table 4.3). 
Table 4.3: Annealing temperatures for the different peR reactions used to amplify 
and sequence full-length SA075 gene 
PCR Primer sequence Annealing 
reaction temperature 
(OC) 
PCR1 UpsB:TTGCCTCTDTTGTTATCTC 45 
SA075 Tag reverse CCATCTGTAAATTCCCGTTTC 
PCR2 SA075 Tag Forward 56 
ACGAACTAAATAATCTTTCATTGGA 
DBly_3.2 
ACCATC(Grr)(Crr)A(A/G)(A/G)AA(Crr)(Grr)G(A/G)GG 
PCR4 SA075 DBl gamma_delta internal 2 FOW 48 
CTCCAGGTAATGTTGATGTAC 
Exon23.3 
CCADYTCTTCATAYTCACTTTC 
PCR5 SA075 Delta (outward) FOW 50 
CGAGACAGTCAAACTCGAC 
SA075 Exon Rev 
GCCTTTGTATTTATCAGTACCATAG 
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Although Platinum Pfx offers a higher fidelity than the ordinary Taq polymerase 
enzymes, it does not add an A overhang naturally and so the PCR products 
generated by Pfx PCR above required further treatment prior to TA cloning. To do 
this, the products were first purified using the QIAquick PCR Purification kit 
(Qiagen 280006). 5 volumes of PB buffer containing guanidine hydrochloride and 
isopropanol was added to the products in a column and spun down. All 
centrifugations for this protocol were at 13000rpm for 1 minute in a bench-top 
centrifuge. 750 I.tI wash buffer PE was added to the column and spun again. The 
flow-through was discarded and the column spun one more time to remove any 
residual ethanol. Products were then collected in a fresh tube after addition of 30 
III elution buffer (10mM Tris-HCI, PH 8.5) to the column and a final spin. The 
purified product was then incubated with 1 U Taq polymerase (Invitrogen) at 72°C 
on a heating block in readiness for the ligation and sequencing as described in 
Chapter 2, section 2.3.9.3. 
4.3.4.1: Amplification and digestion of PfEMP1 domain constructs for protein 
expression 
Once the putative full-length var gene associated with rosetting in SA075 was 
identified, recombinant proteins were made from the different domains. The first 
step in protein expression involved amplification and digestion of the different 
domains of the PfEMP1 variant. The primers and restriction enzymes used for 
each domain are shown in Table 4.4. Domain boundaries for the constructs were 
retrieved from the VarDom 1.0 Server (http://www.cbs.dtu.dklservicesNarDom/). a 
software that predicts and classifies PfEMP1 domains and homology blocks based 
on analysis from 7 genomes (Rask, Hansen et al. 2010). In certain instances 
however, more than one construct was made per domain to improve on the 
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solubility of the protein. In such cases, the C-terminal of the DBL domain would be 
extended or reduced by 1 or 2 cysteine residues. 
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Table 4.4: Primer sequences and domain boundaries for the SAO 75var1 
constructs. Also shown are restriction enzymes and conditions for restriction digest 
including the NEB buffer used, incubation temperature and presence or absence 
of Bovine Serum Albumin (BSA). 
Domain Oom3in Forw3rd and r.v.rs. Conditions for 
Construct (3mlno 3cld) prim.rs 5'·3' s.qu.nc. r.strlctlon digestion 
bound3rl.s (Rntrlctlon .nzym.) (501-11 r.3ctlon) 
NTS-DBL1a 1-474 AAGGATCCATGGCGCGACGTC 25 ~ll of product in 
GTCGTGGT (BamHI) 5 1-11 NEBuffer 3, 0.5 J.l1 
1X BSA and 1.5 J.l1 of 
enzymes incubated at 
AACTCGAGTTAGGGACACACTT 37"C for 2 hours 
GGCAATATTC (Xho) 
NTS-DBL1a- 1-726 AAGGATCCATGGCGCGACGTC 25 J.l1 of product in 
CIDR1a GTCGTGGT (BamHI) 5 J.l1 NEBuffer 3, 0.5 J.l1 
(Didomain) 1X BSA and 1.5 J.l1 of 
enzymes incubated at 
AACTCGAGTTAACATGCTTCGTT 37°C for 2 hours 
TGAATTATTGTC(Xhol) 
DBL213 735-1186 AACTCGAGCCCTGTGGAAGAAA 25 J.l1 of product in 
CAATAATGGT (Xhol) 5 ~ll NEBuffer 4,0.5 J.l1 
1X BSA and 1.5 J.l1 of 
AACATATGTTATCCATCCACTAT enzymes incubated at 
TTCACACGCATC (Ndel) 37°C for 2 hours 
DBL3y 1187-1535 AAGGATCCATACTTAATGGAAA 25 ~ll of product in 
GAGCGCAACGA (BamHI) 5 J.l1 NEBuffer 2, 0.5 J.l1 
1X BSA and 1.5 J.l1 of 
AAGCTAGCTTATGCGGGCATAT enzymes incubated at 
CAACTTCAGTA (Nhel) 37"C for 2 hours 
DBL43 1697-2187 AAGGATCCCCATGTGAAATAGT 25 J.l1 of product in 
ACAAAAACTATTTAC (BamHI) 5 ~ll NEBuffer 3, 0.5 J.l1 
1X BSA and 1.5 J.l1 of 
enzymes incubated at 
AAGCTAGCTTAAACATGGTTTAC 37"C for 2 hours 
AATCTTCTGC 
(Nbel ) 
CIDR1a 475-726 AAGGATCCGATTGTGTAGTTGA 25 J.l1 of product in 
ATGTGTCGA (BamHI) 5 ~ll NEBuffer 4, 0.5 J.l1 
1X BSA and 1.5 J.l1 of 
enzymes incubated at 
AAGCTAGCTTAACATGCTTCGTT 37"C for 2 hours 
TGAATTATTGTC(Nhel) 
CIDR213 2188-2439 AAGCTAGCTCTTCATTTAAAATA 25 J.l1 of product in 
GATTGTG (Nhel) 5 J.l1 NEBuffer 4, 0.5 J.l1 
1X BSA and 1.5 ~11 of 
enzymes incubated at 
AACTCGAGTTAACACGCTTGGT 37"C for 2 hours 
TTTGG (Xhol) 
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Expression constructs were made for each of the four DBL and two CIDR 
domains, as well as a di-domain representing the PfEMP1 head structure (NTS-
DBLa-CIDRa). Primers with restriction enzyme sites incorporated at the ends 
were designed for each construct to allow for cloning into the expression vector. 
The reverse primers contained a stop codon (5' ITA 3') that would end protein 
expression for the construct. Restriction sites within the insert sequences were 
checked using the NEB cutter v2.0 software (New England Biolabs. Inc) to ensure 
that enzymes used to make the primers did not have restriction sites within the 
insert. Table 4.4 shows primer sequences and restriction enzymes that were used 
for the different constructs. 
Genomic DNA (gDNA) from SA075 was amplified using the above primer pairs in 
a 50 JlI PCR reaction that was done using the Platinum® Pfx polymerase kit 
(Invitrogen). The reaction contained 1X Pfx amplification buffer, 10mM dNTPs, 
2.5mM Mg2S04, 0.5JlM forward and reverse primers, 100ng DNA, 1 U Pfx 
polymerase, topped up to 50JlI with DNAse free water. Apart from the annealing 
temperature, cycling conditions were similar for all the constructs (Table 4.5). 
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Table 4.5: Final cycling conditions for amplification of the different SA075var1 
constructs. The annealing temperatures for the different constructs were as 
follows: - NTS-OBLa: 6SOC, Oi-domain: 6ff'C, CIORa: 6ff'C, OBLf3: 64°C, OBLy: 
6SOC, OBLt5:6SOC and CIDRf3: 6ifC. 
Amplification step Cycling conditions 
Initial denaturation 94°C for 5 minutes 
Denaturation 94°C for 30 seconds } Annealing Varied for different constructs X35 Extension 60°C for 3 minutes 
Final extension 60°C for 10 minutes 
5!J.1 of the above PCR products were run on a 1.5 % agarose gel (Chapter 2 
section 2.3.9.4.) alongside a 1 kb DNA ladder to check for presence of a band. The 
remaining 45!J.1 of PCR product was purified using QIAquick PCR purification kit 
(Qiagen) as described in section 4.3.4 in which the final elution of the purified 
product was done with 30!J.1 of elution buffer. A restriction digest of the product was 
then done on 25!J.1 of the product using respective enzymes for each construct 
(Table 4.4) to allow for cloning into the expression vector. Following the digestion 
reaction, 5 !J.I of the product was run on a 1 % agarose gel to check for the 
efficiency of digestion while the remaining 45!J.1 was loaded far away from the first 
well to avoid exposure to UV. Using a ruler, the position of the band on the non-
exposed band was determined using the exposed piece of gel and was carefully 
excised out of the gel. The product was gel purified using QiaQuick gel extraction 
kit (Qiagen 28704). This was done by first weighing the piece of gel and adding 
QG buffer to it in an Eppendorf tube at a volume three times the weight of the gel. 
This was heated at 50°C for 10 minutes before 1 gel volume of isopropanol was 
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added. The rest of the purification process on a spin column was carried out as 
described in section 4.3.4 above. 
4.3.4.2: Preparation of expression vector_modified pET15b 
The expression vector used was pET15b that was modified by Matt Higgins 
(Higgins 2008). The modification was done by insertion of DNA encoding an N-
terminal hexahistidine tag and a cleavage site for the Tobacco Etch Virus (TEV) 
protease. Unlike thrombin which is used as the protease cleavage site in the 
original pET15b vector (Novagen), TEV protease is highly site-specific, highly 
active and was easily produced and purified in the lab in large quantities. The 
modified vector also contained an additional cloning site (Nhel) located between 
BamHI and Xhol in frame with the TEV cleavage site. Figure 4.2 shows the 
cloning/expression region of pET15b showing regions that were modified. 
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Figure 4.2: Map of cloning/expression region of the original pET-15b vector by 
Novagen which was modified by Matt Higgins by the addition of an extra cloning 
site (Nhel) in between BahmHI and Xhol (blue arrow) and replacement thrombin 
with TEV as a protease cleavage site (red arrow) (Higgins 2008). 
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4.3.4.3: Cloning of purified SA075 PfEMP1 constructs into the prepared 
pET15b vector 
The purified and digested PCR products from each of the constructs described in 
section 4.3.4.1 were ligated into restriction enzyme-digested and shrimp alkaline 
phosphatase (SAP)-treated pET15b vector. SAP treatment was done to prevent 
self-ligation of the vector. The SAP reaction (Promega) was done on 30 J.l1 of 
digested vector using 3.5 J.l1 SAP 10x buffer (0.5 M Tris-HCI, 50 mM MgCI2, pH 
8.5) and 2 J.l1 SAP enzyme. The mixture was incubated for 15 minutes at 37°C 
followed by a 15 minute inactivation of the enzyme at 65°C. 
A ligation reaction was then done using a T4 DNA ligase kit (Invitrogen, UK) 
followed by an overnight incubation at 16°C. The ligation reaction consisted of 7J.l1 
of the construct product in 1 J.l1 of the SAP-treated vector using 1 J.l1 T 4 DNA ligase 
enzyme in 1 J.l1 of 10X ligation buffer (500mM Tris-HCI, 100mM MgCI2 , 10mM ATP, 
100mM Dithiothreitol, pH 7.5). The following day, the ligated plasmid was used to 
transform One Shot® TOP10F' chemically competent E.coli cells (InvitrogenTM). 
The competent cells were first thawed-out in ice and 2J.l1 of plasmid gently added 
and mixed. After a 30 minute incubation in ice, the cells were heat shocked for 30 
seconds at 42°C in a heating block and put back in ice for 2 minutes. 250 J.l1 of 
SOC media (Invitrogen) was added to the transformed cells and placed on a 
shaking incubator for 1 hour at 37°C. The cells were then plated onto Luria Bertani 
(LB) agar (Sigma) plates containing 50J.lg/ml of ampicillin (Sigma-Aldrich) as 
described in Chapter 2, section 2.3.9.3. The agar plates were supplemented with 
40 J.l1 of 20J.lg/ml IPTG and 20J.lg/ml X-gal for blue-white screening. 10 random 
white colonies were then picked and grown overnight in LB broth (Sigma-Aldrich) 
supplemented with 50J.lg/ml ampicillin at 37°C in a shaking incubator at 200rpm. 
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Plasmid DNA was extracted using a modified QIAprep Spin miniprep kit (Qiagen) 
protocol. In the modified miniprep protocol, the spin columns provided in the kit 
were avoided since the pET15b vector got stuck onto the columns resulting in 
reduced amounts of plasmid DNA (Ghumra, personal communication). 1 ml of 
bacterial cultures from individual colonies was first centrifuged at 13000 rpm for 3 
minutes. The pellet was then resuspended in 250 J.l1 buffer P1 (6.06g/l Tris base, 
3.72 gIl EDTA, pH 8.0) before lysis with 250 J.l1 of P2 buffer (8g/l NaOH, 1% (w/v) 
SDS in water) and subsequent neutralization with 350 J.l1 N3 buffer (confidential 
composition). Cell debris were removed by centrifugation at 13000rpm for 10 
minutes. According to the modified protocol, the supernatant was transferred into a 
fresh 1.5 ml Eppendorf tube instead of the columns and spun down at 13,000rpm 
for 8 minutes to remove any precipitates. This was then transferred to another 
fresh Eppendorf tube and 630 J.l1 of Isopropanol (Sigma) was added followed by 
vortexing and spinning down for another 8 minutes at 13,000rpm. A white pellet of 
DNA formed at the bottom of the tube and the supernatant was carefully poured 
out. This was followed by a wash with 200 J.l1 of 70% Ethanol (Sigma). The pellet 
was air dried for 5 minutes and then resuspended in 50 J.l1 of clean water. To 
check for the presence of inserts in the plasmids, a diagnostic digest was done on 
each of the 10 plasm ids using enzymes and conditions described on Table 4.4. 
Plasm ids that were confirmed to contain the insert were then prepared for 
sequencing to check that the insert was in the right frame and did not contain any 
PCR-generated mutations. The big dye reaction consisted of 7 J.l1 of the plasmid, 1 
J.l1 of big dye and 1 J.l1 of T7 promoter primer (TAA TAC GAC TCA CTA TAG G). 
The reaction mix was incubated for 25 cycles of 96°C for 30 seconds, 50°C for 15 
seconds and 60°C for 4 minutes. Sequencing was done at the GenePool facility at 
the University of Edinburgh. 
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4.3.4.4: Pilot protein expression 
Once the plasmid was confirmed to contain the PfEMP1 construct in the correct 
frames and without any PCR-generated mutations, a pilot protein expression 
(usually done in a small volume of 6 mls) was carried out for each of the 
constructs to optimize conditions for maximum expression. This was also done to 
determine whether the proteins were soluble or not. Once optimum conditions 
were obtained, a large scale expression of up to 4-8 litres would then carried out. 
The process was carried out as described by Ghumra et a/., 2011 (Ghumra, 
Khunrae et al. 2011). Plasm ids that had no mutations and which were confirmed to 
be in the correct reading frame were transformed in Origami B E.coli cells 
(Novagen, Nottingham, UK) (Baca and Hoi 2000) by adding 2 JlI of the plasmid 
into 50 JlI of the cells which were also already transformed with pRIG plasm ids. 
The transformation process was done as described in section 4.3.4.3 above. The 
pRIG plasm ids are important for expression of genes with biased codons such as 
the AT-rich Plasmodium falciparum (Baca and Hoi 2000). They contain genes 
coding for three tRNAs:- arginine, isoleucine and glycine, that recognize rare 
codons hence increasing the level of expression of the P.falciparum proteins in 
E.coli. 
The transformed Origami B cells were then plated onto 2XYT (Sigma-Aldrich) agar 
plates containing 50llg/ml Ampicillin. The agar plates were made by adding 35g of 
2XYT agar powder (Sigma) into one litre of water followed by autoclaving. On 
cooling down, Ampicillin was added to a final concentration of 50llg/ml and the 
solution poured out onto 100mm petri dishes for cooling. 50111 of the bacteria was 
plated and allowed to grow overnight at 37°C. The following day 10-20 colonies 
were picked and placed into 6mls of sterile 2XYT broth made by dissolving 31g of 
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the powder per litre of water before adding 50).1g/ml Ampicillin. This was grown 
overnight in a 37°C shaking incubator at 175 rpm. Following day, 0.6mls of 
overnight culture was inoculated into 6mls (1:10 dilution) of 2XYT broth and grown 
in a 37°C shaking incubator at 175 rpm. The optical density (00) measured at 
600nm was constantly monitored using a spectrophotometer (Biophotometer-
Eppendorf) in a 1 ml disposable cuvette. A blank sample (2XYT media) was first 
measured at 600 0.0 after which the cuvette was rinsed with water and 200 ).11 of 
growing bacterial culture was measured. Once the 00 reached between 0.6-0.8, a 
1 ml glycerol stock was made by adding 150 III of glycerol (Sigma) to 850 ).11 of the 
bacterial culture and storing at -80°C. The stock would be used for inoculating the 
large scale protein production, in case the protein was soluble. If not, the glycerol 
stock was discarded. 
The remaining approximately 5mls of culture from the pilot expression was allowed 
to grow up to an 00 of about 1.2 during which IPTG induction was done. 
However, just before induction, 1 ml of culture was aliquoted in an Eppendorf tube, 
centrifuged for 1 minute at 13000rpm and the pellet resuspended in 1X PBS and 
frozen down as the "uninduced control". The remaining culture was induced with 
IPTG whose concentration varied for the different constructs (Table 4.6). This was 
allowed to grow for 3 hours at 20°C and 175rpm after which a second 1 ml aliquot 
was taken and labeled "3 hours after induction". The remaining culture was left to 
grow overnight in a shaking incubator at 175rpm and the following morning the 
final pellet labeled "overnight induction" was obtained and frozen as above. The 
specific length of time and temperature for induction were optimized for each 
construct as shown in Table 4.6 
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Table 4.6: Optimized expression conditions for the different SA075 constructs 
including IPTG concentration, induction temperature and length of induction. 
Name of the IPTG Induction Length of 
construct concentration temperature (Oe) induction 
NTS-DBL1a 0.5mM 20 Overnight 
NTS-DBL1a- 0.25mM 16 36 hours 
CIDR1a 
CIDR1a 0.3mM 16 24 hours 
DBL2/3 0.3mM 16 Overnight 
DBL3y 0.25mM 16 24 hours 
DBL4& 0.5mM 16 24 hours 
CIDR2/3 0.25mM 16 24 hours 
To check for the presence of the protein and whether it was soluble or insoluble, 
the 3 pellets i.e. 1) uninduced, 2) 3 hours after induction and 3) overnight induced, 
were all thawed out at room temperature and sonicated (Branson Sonifier 450 
Sonicator) by pulsating three times for 5 seconds with gaps of 5 seconds. 20J.l.1 
was taken from each tube as the total fraction, mixed with 5J.l.1 of Invitrogen SDS-
PAGE loading buffer and reduced using 1 J..l1 of /3-mercaptoethanol (Sigma). The 
reduction reaction was done by incubating at 75°C for 15 minutes. The remaining 
sonicated lysate was spun down for 1 minute at 13,000rpm in a microfuge and 
20J..l1 suspension taken as the soluble fraction. Each pair of the soluble and total 
fraction was then run side by side on precast NuPage Novex Bis-Tris Agarose gels 
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(Invitrogen). The 4-12% gels were made of Bis-Tris-HCI buffer (pH 6.4), 
Acrylamide, Bis-acrylamide, Ammonium Persulfate (APS) and Ultrapure water. 
The 12 well gel cassette was then placed into a XCeli SureLock™ Mini-Cell 
(Invitrogen) and 800 mls of 1X MOPS running buffer (3-(N-morpholino) propane 
sulfonic acid) was added. 15JlI of the soluble and total fraction samples were 
loaded alongside the Precision Plus Prestained Standard molecular weight marker 
(Bio-Rad). After electrophoresis, the proteins were transferred onto PVDF 
membrane (Thermo Scientific) in a western blot and the protein detected using an 
HRP-conjugated anti-6X-His tag antibody (Qiagen, Crawley, UK) at a dilution of 
1 :5000. The western blot was done by first carefully placing the gels onto PVDF 
membrane that was pre-soaked in 1X NuPage transfer buffer, supplemented with 
20% methanol. Since the samples were reduced, 0.1 % NuPAGE® Antioxidant 
was added into the transfer buffer to keep the proteins in a reduced state and 
prevent re-oxidation. The membrane/gel was then carefully placed in between pre-
soaked filter papers and blotting pads which were also soaked in the transfer 
buffer. The whole assembly was then carefully locked onto an XCell UTM Blot 
Module which was then filled up with transfer buffer and run at 30volts for 1 hour. 
After the 1 hour run, the membrane was then rinsed in wash buffer (1X PBS with 
0.1% Tween-20) and blocked for 2 hours with 5 % milk in 1XPBS/0.1%Tween-20. 
This was followed by two more washes after which detection antibody, mouse anti-
rabbit conjugated with HRP was added at 1 :5000 in wash buffer. This was 
incubated for 1 hour at room temperature while gently shaking. After rinsing twice 
with 1X PBS, a substrate 1:20 dilution of DAB (3'3 diaminobenzidine 
tetrahydrochloride) (Thermoscientific) in 1XPBS was added which reacts with HRP 
in the presence of 1:1000 dilution of hydrogen peroxide to produce a brown 
coloured band. 
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Once soluble protein was detected by the western blot, a large scale of usually 4-8 
litres was prepared. The large culture was inoculated using the glycerol stock that 
was stored in -80°C during the pilot expression by taking 250 J.l1 of the thawed out 
stock into 100mls of 2XYT media containing 50 J.lg/ml Ampicillin and grown 
overnight at 37°C in a shaking incubator at 175 rpm. The following day, 10 mls of 
the culture was used to inoculate each of the 1 litre flasks and grown at 37°C while 
monitoring the 00. The rest of the conditions for the large scale protein expression 
were done as in the pilot expression (Table 4.6). 
A major modification from the original protein expression protocol by Ghumra et 
a/., 2011 (Ghumra, Khunrae et al. 2011) was the inclusion of a heat shock step, a 
strategy that was introduced prior to IPTG induction in order to improve the 
expression of soluble proteins (Oganesyan, Ankoudinova et al. 2007). Briefly, the 
bacterial culture was grown up to an 00 value of between 0.6 and 1.2. Just before 
IPTG induction, the culture was incubated at 42°C for 10 minutes followed 
immediately by a 30 minute incubation on ice and another 20 minutes incubation 
at 37°C.IPTG induction and overnight growth were done as previously described 
(Table 4.6). 
4.3.4.5: Purification of the recombinant proteins 
Bacterial pellet from the 4-8 litre preparation was harvested in 600ml wide mouth 
bottles (Nalgene) by centrifugation at 4600 rpm (Heraeus, Thermo Fisher Scientific 
Inc.) for 30 minutes at 4°C. After the first spin, the supernatant was carefully 
decanted without dislodging the pellet. The remainder of the bacteria was added 
into the same bottle and spun as before until pellet from the whole 4-8 litre 
bacterial culture was collected. After the final spin, the pellet was re-suspended in 
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lysis buffer which contained 20mM Tris pH 8, 0.3M NaCI, 15mM Imidazole, 0.5% 
Triton-X and EDTA-free protease inhibitor tablet (Mini-complete, Roche). Pellet 
from 1 litre bacterial culture was re-suspended in 15 mls of lysis buffer in 50 ml 
Falcon tubes. Sonication (Branson Sonifier 450 Sonicator) was done five times at 
15 microns power using a 9mm probe for 10 seconds, while keeping the sample 
tube cool in a beaker of ice. The lysate was then spun down at 20,OOOrpm for 20 
minutes (Sorvall centrifuge, Thermo Scientific) in NALGENE® oak Ridge Tubes. 
Supernatant was carefully aspirated and passed through a pre-equilibrated Nickel 
Nitriloacetic Acid (Ni-NTA) sepharose matrix (Qiagen) in a Bio-rad Econo-
chromatography column that had been equilibrated with lysis buffer. The Ni-NT A 
matrix allowed for the 6XHis-tagged protein to bind onto the agarose via the His-
tag. It was always used fresh but could be stored at 4°C in 20% ethanol to be re-
used for future purification of the same protein. 
The bound protein was then washed in 400mls of lysis buffer and finally eluted 
using 10 mls of buffer containing 20mM Tris pH 8, 150mM NaCI and 200mM 
imidazole. Elution was repeated 5 times with each elute being collected separately 
and later quantified by Nanodrop. Eluates with high amounts (>0.1 gIL) of protein 
were pooled together before protein buffer exchange was done using PD-10 
Desalting columns (Bio-rad). Buffer exchange was done by first equilibrating the 
desalting columns with 10mls of 1X PBS. Protein in elution buffer was added to 
the columns (2.5 mls per column) before finally eluting the protein in 3.5 mls of 
1 XPBS. TEV protease cleavage was done overnight at room temperature using 
3mM reduced glutathione, 0.3 mM oxidized glutathione buffer at an approximate 
ratio of 1 mg of protease to 10 mg of protein. The protease (usually stored in 1 
mg/ml aliquots) was added to the protein in a 50 ml Falcon tube and left overnight 
at room temperature. The following day, the mixture was passed through a Ni-NTA 
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affinity column (same one used for purification) that had been equilibrated with 1X 
PBS to remove any uncleaved protein. Since the TEV protease is His-tagged, it 
was removed from the final protein during this step. The eluted protein was finally 
concentrated using Vivaspin 20 columns (Sartorius Stedim) by first equilibrating 
the columns with 1X PBS and spinning for 5 minutes at 4600rpm at 4°C. The flow 
through was discarded and the protein added and spun down for 30 minutes at 
4°C. During the course of spinning, the concentration of the protein was constantly 
checked using a nanodrop. Once the volume reached 5 mls the protein was finally 
quantified using a nanodrop and frozen down in aliquots at -BO°C, awaiting 
immunization for antibody generation. Some proteins however required further 
spinning down to 2-3 mls to allow for a more concentrated protein solution. The 
minimum quantity of protein required for antibody production (section 4.3.5) was 
1.5 mg. 
The final protein purity was checked by SDS-PAGE on 10% bis-Tris 
polyacrylamide gels stained with SimplyBlue™ (Invitrogen) as described in section 
4.3.4.4. 2J.lg of proteins was reduced using 5% ~- mecarptoethanol by heating to 
75°C for 15 minutes and run in parallel with the non-reduced protein for 
comparison. The gel was run at 120 volts for 1.5 hours and the protein carefully 
removed from the cassette. Staining was done using SimplyBlue ™ SafeStain 
(Invitrogen) in which the gel was placed in a container with 100ml of distilled water 
and boiled three times in a microwave for 1 minute until the solution was close to 
bOiling. 20 mls of the SimplyBlue stain was then added and boiled in a microwave 
for 45 seconds. The dye was later washed off with 100mls of water on a shaker. 
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4.3.5: Generation of domain specific polyclonal antibodies in rabbits 
Immunization and generation of antibodies was done by BioGenes GmBH (Berlin, 
Germany). The immunization schedule for the protein is summarized in Table 4.7. 
Prior to immunization, five rabbits were selected and their pre-immune sera tested 
for non-specific reactivity on infected and non-infected RBCs by IFA assay 
(Chapter 2, section 2.3.10) Two of the rabbits with the leasUor no background 
were then selected for immunization which was carried out using an adjuvant that 
contained 0.23% of lipopolysaccharides of the blue-green algae Phormidium spp, 
92.8% mineral oil, 3.48% Tween-20, 3.48% Span-80. On day 28, an IFA assay 
was done on live SA075 parasites using anti-sera from the two immunized rabbits. 
The rabbit antiserum that gave the brightest positive signal was chosen for a final 
boost after which the antiserum was obtained for protein-A purification of total IgG 
(Biogenes GmbH). IgG from a non-immunised rabbit was also purified by the 
same method to be used as a negative control. All polyclonal antibodies from all 
the recombinant domains as well as the anti-serum was stored at -20°C awaiting 
functional assays as will be discussed in Chapter 5. 
Table 4.7: Immunization schedule for rabbits used in the production of anti-
PfEMP1 polyclonal antibodies. Rabbits were immunized with 250119 of protein on 
day 1 and 100119 on subsequent immunizations. 
Days 
Day 1 
Day7 
Day 14 
Day 28 
Day 35 
Day 49 
Day 56 
Procedure 
Pre-immune serum (1,5 ml per rabbit)/1 st immunization 
2nd immunization 
3rd immunization 
Bleeding (25 ml per rabbit) / 4th immunization 
Bleeding (25 ml per rabbit) 
Final immunization 
Final bleed and purification of total IgG from one animal 
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4.4: RESULTS 
4.4.1: Cloning of SA075 parasites by limiting dilution and transcriptional 
profiling of R+ and R- clones 
Unlike in Chapter 3 where var gene transcriptional profiling in field isolates was 
done on gelatin-selected isogenic parasite pairs, this chapter describes 
transcriptional profiling on cloned parasites. Cloning by limiting dilution was done 
to obtain single cell derived populations of rosette positive (R+) and rosette 
negative (R-) parasites. From the 60 wells that were inoculated with culture 
suspension during the first round of cloning, 27 (45%) wells (Table 4.8) turned out 
to be parasite positive following Giemsa staining. These were tested for rosetting 
(described in 2.3.5) and agglutination (described in 4.3.3) out of which 13 (49%) 
were rosette positive while 2 (7%) formed medium sized agglutinates. The clone 
with the highest % RF, (44.9%) (Clone 17) and one with 0% (Clone 13) were 
picked for comparison of transcript profiles. 
Table 4.8: % RF and the agglutination scores for the 27 parasite positive clones 
obtained in the first round of cloning of SA075. Clone 13 and clone 17 were 
selected for DBLa tag analysis. 
Clone 10 %RF Agglutination 
score 
Clone 3 0.0 a 
Clone 4 0.0 a 
Clone 5 12.6 a 
Clone 6 0.0 a 
Clone 7 0.0 a 
Clone 8 9.2 a 
Clone 9 0.0 a 
Clone 10 0.0 a 
Clone 11 5.0 a 
Clone 13 0.0 a 
Clone 14 0.0 a 
Clone 15 9.1 a 
Clone 16 0.0 a 
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Clone 17 44.9 0 
Clone 18 2.4 0 
Clone 19 4.3 25 
Clone 20 6.9 0 
Clone 21 0.0 0 
Clone 22 0.0 0 
Clone 23 5.0 0 
Clone 24 0.0 0 
Clone 25 0.0 0 
Clone 26 5.9 0 
Clone 27 11.3 0 
Clone 35 3.8 0 
Clone 36 8.2 0 
Clone 74 4.0 12 
The DBLa tag was successfully amplified from cDNA preparations of clones 13 
and 17, as previously described in Chapter 2, section 2.3.9. The PCR products 
were devoid of genomic DNA contamination as seen in reverse transcriptase 
negative (RT-ve) control lanes (Figure 4.3, Panel A). 
DBLa tag sequences from clones 13 and 17 were then analyzed (Chapter 2, 
section 2.3.9.5). Each unique transcript sequence was given an arbitrary identity 
as SA075_1,2,3 etc as shown in Figure 4.3, Panel C. The sequences were then 
classified based on the previously described CP classification algorithm (Bull, 
Berriman et al. 2005) with each of the 6 different CP groups being assigned a 
unique colour code (key of figure 4.3, Panel B). In the R+ clone, 18 sequences 
were obtained. Two dominant var gene transcripts: SA075_1 and SA075_2 came 
up, both of which had two cysteine residues. The two sequences belonged to CP2 
and a CP3 respectively as shown in Figure 4.3, Panel B. Note that SA075_1 is the 
same tag sequence previously been identified in SA075 (described in chapter 1, 
section 1.8). Both sequences were in equal proportions (36%_6 sequences each) 
and therefore it was not possible to identify a single predominant gene as a 
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rosetting ligand candidate. Interestingly, both these genes were missing in the R-
transcript profile which was composed mainly of Cys4 sequence types (Figure 4.3, 
Panel B). Despite not having a clear dominant gene in R+ clone, the overall 
distinction between cys2 and non-cys 2 in the R+ and R- clones respectively, was 
consistent with previous studies on the association of Group A or cys2 var genes 
with rosetting (Bull, Berriman et al. 2005; Kaest/i , Cockburn et al. 2006; Kyriacou, 
Stone et al. 2006; Warimwe, Keane et al. 2009). 
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C. 
Clone 17C Clone 13C 
Sequence Number and proportion Sequence Number and proportion 
SA075 1 6 (33 %) SA075 6 4125 %1 
SA075 2 6 (33 %) SA075 7 2112.5 o/~ 
SA075 3 2 (11 %) SA075 8 2 (12.5 %) 
SA075 4 2 (11 %) SA075 9 2 (12.5 %) 
SA075 5 2 (11 %) SA075 10 2-.L12.5 %1 
SA075 11 2 (12.5 %) 
SA075 12 2112.5 o/~ 
TOTAL 18 (100 %) TOTAL 16 (100 %) 
Figure 4.3: Amplification and transcriptional profiling of DBLa tag sequences of 
R+ (clone 17) and R- (clone 13) from SA 075. A) 1 % agarose gel showing 
products from PCR amplification of the DBLa tag region of SA075 R+ and R-
clones. The transcripts were devoid of genomic DNA contamination as seen with 
the RT- controls that were not treated with reverse transcriptase enzyme. A 3D 7 
DNA was amplified as a positive control for the PCR while the NTC represented 
the no-template negative control B) Pie charts showing transcript profiles from R+ 
and R- clones. Each slice of the chart was numbered to represent unique 
sequences (listed in Table C) and expressed as a proportion of the total 
sequences for each clone. The colours represent different CysiPoL V groups as 
shown in the key. 
It was not clear why a single dominant gene was not transcribed in the R+ clone 
as would have been expected. It is possible that: - 1) the rosetting frequency of 
44.9% observed in clone 17 was not high enough to give a clear dominant gene 
and that 2), the number of colonies picked was also not sufficient enough for 
sequence analysis. Clone 17 was therefore re-cloned in order to: -
1. Try and obtain a single dominant gene from a clone with higher % RF. 
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2. Establish whether the two dominant genes could have been undergoing 
switching. It could be that there was a preferential switch from one of these 
genes to the other over time in vitro. 
4.4.2: Re-cloning of SA075 R+ (clone 17) parasites 
Re-cloning of the clone 17 was done in a similar manner to the first round of 
cloning as described in the method section of this chapter (section 4.3.2). Of the 
60 wells that were inoculated, 10 (17%) that were parasite positive were 
transferred into culture flasks. At about 5% parasitaemia, the clones were tested 
for rosetting and agglutination. Hyperimmune serum (A 1) was used for the 
agglutination assay. Out of the 10 clones, 7 were rosetting (range 1.0-52% rosette 
frequency) and one was agglutinating. The clone with the highest rosetting 
frequency (Re-clone 2) (52%) and one with 0% (Re-clone 6) were picked for 
transcript profiling while the remaining clones were frozen down in glycerolyte at -
BO°C. Note that while the first round of cloning had more clones that were parasite 
positive with fewer rosetting clones (49%), the re-cloning process had higher 
proportion (70%) of rosette positive clones. 
Table 4.9: Results from re-cloning of SA075 clone 17 showing the 10 parasite 
positive clones with their rosetting frequency and agglutination scores. The clones 
are named "Re-c/one n to differentiate them from those of the first round clones. 
Clone 10 %RF Agglutination 
Re-clone 1 32 0 
Re-clone 2 52 0 
Re-clone 3 1.3 0 
Re-clone 4 0 0 
Re-clone 5 5.1 0 
Re-clone 6 0 0 
Re-clone 7 0 0 
Re-clone B 1.B Agglutinating 
Re-clone 9 3.2 0 
Re-clone 10 1.0 0 
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Re-clone 2 (R+) and Re-clone 6 (R-) were picked for RNA isolation and cDNA 
preparation. Prior to the RNA isolation, the R+ clone was enriched for rosettes by 
gelatin method up to a rosetting frequency of 67.1 %. A total of 16 transcript 
sequences were analyzed for R+ with sequences SA075_2 being dominant (8 
sequences) while sequence SA075_1 was the second dominant (6 sequences) 
(Figure 4.4, Panel A and B). However, the isogenic R- clone had SA075_2 hence 
it was ruled out as the gene responsible for rosetting in SA075 (Figure 4.4, Panel 
A). Analysis of genomic DNA profiles showed no evidence of primer bias. It was 
therefore concluded that SA075_1 was the most likely candidate gene involved in 
rosetting in SA075, and this sequence was renamed SA075var1. 
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Group 6 (Cys X) 
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B 
Re-clone 2 Re-clone 6 
Sequence Number and proportion Se~uence Number and proportion 
SA075 1 6 (37.5 %) SA075 2 8 (57 %) 
SA075 2 8 (50 %) SA075 6 2114%1 
SA075 3 1 (6 %) SA075 7 117%1 
SA075 13 1 (6 %) SA075 8 117%1 
SA075 14 117%1 
SA075 15 1 (7 %) 
TOTAL 16 (100 %) TOTAL 141100 %1 
Figure 4.4: A) Pie charts representing the transcript and genomic DNA sequence 
profiles for Re-c1one 2 (R+) and Re-clone 6 (R-), following re-cloning from the 
original clone17C. The pie charts are colour-coded to represent the different 
sequence groupings based on cyS/PoL V classification (Bull, Berriman et al. 2005). 
Each slice was numbered to represent unique sequence types (listed in Table B) 
as a proportion of the total sequences for each clone. Also shown are genomic 
DNA sequence profiles that were used to check for primer bias. None of the 
dominant transcript sequences. was dominant in the genomic DNA profiles hence 
ruling out possibility of primer bias. 
4.4.3: Cloning and sequencing of the full-length SA075var1 gene 
Identification of the full-length SA075var1gene was done by peR walking, cloning 
and sequencing, a strategy that had previously been used to characterize rosetting 
variants such as Muz12varlfrom the Muz12R+ parasite line (Ghumra, Semblat et 
al. 2012). The UpsB forward primer was first paired up with a SA075var1-specific 
reverse primer, to produce an -1.5kb product (Figure 4.6, Panel A), which was 
cloned and sequenced. UpsA and UpsC primers did not produce any PCR 
product. Sequencing of the 1.5kb product showed 100% nucleotide sequence 
142 
identity in the region that overlapped with the SA075var1 tag region suggesting 
that it was the correct sequence. A comparison of other randomly selected UpsA, 
Band C var gene sequences from Genebank with that of SA075 by sequence 
alignment (Figure 4.5) showed SA075var1 aligning well with the UpsB sequences. 
The sequences upstream of the initiation codon in SA075var1 also had several 
polyT15-2o stretches typical of Ups B sequences (Lavstsen, Salanti et al. 2003) 
(Nucleotide position 125-145 shown in Figure 4.5). 
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~TATT TAAATTTAc:r AT AAAAAT ATTAATATAA ATTTTTTTT 169 
TTNiMTATT TAAATTTACT AT AAAAAT ATTAATAT AT ATTTTTTT 159 
TTNiMT ATT TAAATTTATT AT AAAAAT ATTAATATAT ATTTTTTT 171 
TTATAT AAT A TTACTACATC GA1\CCCiAT AAt:.CM:. TAT ATCAT ATACA CC 135 
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Figure 4.5: Partial nucleotide alignment showing approximately 230 bp of 5'UTR 
region upstream of the initiation codon for SA075var1 against other randomly 
selected Ups A, Band C var genes. The sequences which were obtained from 
NCBI database are identified by their accession numbers. SA075var1 aligned well 
with the Ups B sequences confirming that the var gene is an Ups B type. 
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The second sets of PCR were done using SA075var1 variant specific forward 
primer and degenerate reverse primers for DBLP, y, 8 and Exonll in four separate 
reactions. The PCR involving the DBLy primer gave a product of about 6kb (Figure 
4.6 B) which was also cloned and sequenced. However due to its large size, only 
800bp of the product could be sequenced from both ends. Several sets of internal 
primers (shown in Table 4.2) were therefore designed from the already sequenced 
reg ion to furth er sequence the SA075var1 gene. 
c c c c 0 0 0 c( CD 0 0 0 c. ~ I() c 0 0 
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Figure 4.6: A) 2 % agarose gel showing products from PCR involving upstream 
primers A, Band C with tag specific reverse primers. The Ups B PCR gave an 
-1 .5kb product which was later cloned and sequenced. B) PCR products from 
amplification of SA075 DNA using tag specific forward primers paired up with four 
degenerate primers for DBLfJ, 1, 8 and exon " in separate PCR reactions. The 
DBLy PCR gave a product of -6 kb which was later cloned and sequenced. 
However, due to its large size, several rounds of PCRs and sequencing were done 
both upstream and downstream of the gamma region using designed primers 
shown in Table 4.2. The molecular weight markers used in gels A and B were a 
1 Kb ladder from New England Biolabs, UK and nvitrogen ™ respectively. An 
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amplification involving primers within the DBLa tag region (151bp) was included as 
a positive control for each peR. 
The full-length gene for SA075var1 flanked by the Ups Band Exon II primers 
(9,613 bp) was finally sequenced (Sequence in Appendix 8.5). The coding region 
of Exon I (Figure 4.7) starting from the methionine (ATG) to the end of CIDRP was 
7,455 bp long (2485 amino acids). Figure 4.8 shows the final domain architecture 
of SA075var1 Exon I with the domain boundaries derived from the VarDom 1.0 
Server (Rask, Hansen et al. 2010). 
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Figure 4.7: Top: A schematic diagram of the domain architecture of SA075var1 
Exon I. The amino acid sequence boundaries for each domain were retrieved from 
the VarDom 1.0 Server (Rask, Hansen et al. 2010). Bottom. Predicted amino acid 
sequence for the coding region of SA075var1 exon I. 
4.4.4: Comparison of SA075var1 sequences with other rosetting variants 
The SA075var1 gene was compared with sequences of other rosette-mediating 
genes that have already been characterized. These included the proven roseUe-
mediating variants encoded by ITvar60, TM284var1, HB3var6, 1 Tvar9 , Muz12var1, 
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and Var 0 and the possible rosette-mediating variant TM180var1 . The comparison 
was based on overall domain architecture and on sequence features within the 
DBLa region, which is thought to playa key role in rosetting . Comparison of the 
DBLa region, was based on the CP classification method as well as block sharing 
groups (BS) (Bull, Buckee et al. 2008) (discussed in Chapter 1 section 1.2.3.1). A 
DBLa tag sequence would fall into either BS 1 or BS 2 with BS 1 being exclusively 
group A-like sequences while BS2 contains some non-group A sequences (Bull, 
Buckee et al. 2008). The parasites were also compared based on their IgM binding 
phenotype (Ghumra, Semblat et al. 2012), which has previously been associated 
with rosetting and severe disease in field isolates (Rowe, Shafi et al. 2002). 
Results of these comparisons are summarized in Figure 4.8 and Table 4.10. 
Based on the overall domain architecture, SA075var1 gene was found to be most 
similar to TM180var1, an UpsB gene that was associated with rosetting in 
transcriptional profiling studies of parasite TM180R+ (described in section 4.1.2). 
However, a rosetting function for the TM180var1 variant has not been confirmed, 
because antibodies to TM180var1 NTS-DBLa did not inhibit rosetting in TM180R+ 
parasites (Ghumra, Semblat et al. 2012). SA075var1 and TM180var1 shared not 
only similar domain architectures but both are also derived from non-lgM binding 
parasites (Figure 4.8 from Ghumra et al., 2012) (Ghumra, Semblat et al. 2012). 
Although they belonged to the same BS group 2, they fell into different CP groups 
3 and 2 respectively. Pair-wise amino acid identities for the individual domains 
showed DBL213 to have the highest identity score while DBL48 had the lowest. The 
identity scores for the domains were as follows:- NTS-DBL 1a-45.88%, CIDR1a-
45.04%, DBL213-57.49%, DBL3y-36.71%, DBL48-20.27%, CIDR13-45.06%. The 
overall pair-wise amino acid sequence identity between SA075var1 and 
TM180var1 was 43.3%. 
148 
Ig binding p raSlles 
T>.I 
HB3vDr6 I; DOL ., CaO :y - ()IIU6 r • ",""" DeL$; I A 
TM 
TM284var1 08L2y - \c - Deli • A 
T 
ITva~ 081.1 J C 08l2J bATS 
on-Ig binding parastles 
I 
I Tvor9 ~ , C 1 :., I AT'S 
T 
uz12var1 ~ DeL' , C CIOR I AT'S 
T 
TM18Ov8r1 I AT'S 
r 
SA075var1 ~ 09 Il2 CIO 08L C ~ A 
Figure 4.8: A comparison of domain architectures for different rosetting variants 
from IgM-binding and non-lgM binding rosetting parasite strains. SA075var1 and 
TM180var1 have similar domain architectures. Figure from Ghumra et al., 2012 
(Ghumra, Semblat et al. 2012). 
Table 4.10: A comparison of various DBLa-tag sequence features in SA075var1 
versus eight rosette mediating variants. The table shows sequence classification 
features based on methods described by Bull and colleagues(Bull, Berriman et al. 
2005; Bull, Buckee et al. 2008). The distinct sequence motifs contain the 4 amino 
acid motifs at the positions of limited variability (PoL Vs), the number of cysteine 
residues between PoL V 3 and 4 and length of the tag based on amino acid count. 
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Isolate PfEMP1 CP Distinct Sequence BS_group 
Name variant group Motifs (length of tag) 
1 TM284R+ TM284var1 3 MFLP-LRED-NAL T-2-PTNL-116 0 
2 HB3R+ HB3varo 3 L YSG-LRED-RAIT-2-PTNL-126 
3 IT/PAR+ ITvar60 6 MFKP-LRED-KAIT-1 -PTNL-117 
4 IT/R29 ITvar9 1 MFKP-LRED-KAIT-2-PTNL-117 1 
5 TM180R+ TM180var1 3 LFIG-LREO-DAL T-2-L TNL-122 2 
6 Muz12R+ Muz12var1 3 L YLG-VREA-KAL T-2-PTNL-113 1 
7 SA075 SA075var1 2 L YLO-FREY-KAIT-2-PTNL-111 2 
8 3D7 PF13_0003 1 MFKS-LREA-KAIT-2-PTYL-113 
9 Palo Alto VarO 3 MFLP-LRED-KAL T-2-PTYL-117 
4.4.5: Classification of SA075var1 based on Domain cassette method as 
described by Rask et al., 2010 (Rask, Hansen et al. 2010) 
PfEMP1 sequences have recently been classified into domain cassettes, defined 
as two or more consecutive domains belonging to particular subclass and present 
in three or more of the 7 P.falciparum genomes that were characterized by Rask et 
a/., 2010 (Rask, Hansen et al. 2010). SA075var1 did not seem to fall into any of 
the 24 domain cassette groups that have been described (SA075 subdomains 
classified by Lavstsen). However, it had domain cassette 8-like features 
characterized by Ups B, followed sequentially by a DBLa2, CIDRa, DBLI3 and 
finally a DBLy domain. The specific sub-domain classes were, however, not of a 
typical DC8 sequence (Figure 4.9). TM180var1, which had an overall domain 
architecture similar to SA075var1 , also had domain cassette 8-like features but 
with different subdomain types. Its architecture was however much more similar to 
a typical DC8 with a mismatch in only the CIDRa subdomain type, unlike 
SA075var1 that had two mismatches for both CIDRa and DBLy. Both DC8 and 
DC13 have recently been implicated in pathogenesis of severe disease (Lavstsen, 
Turner et al. 2012; Bertin, Lavstsen et al. 2013). Whether SA075var1 is important 
for severe disease will be discussed in Chapter 5. 
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Figure 4.9: Schematic domain structure for a PfEMP1 containing DCB as 
described by Rask et al., 2010 (Rask, Hansen et al. 2010). Based on overall 
domain architecture, SA075var1 and TM1BOvar1 contain domain cassette B-like 
features but with different subdomain classes. 
4.4.6: Results from Protein expression work 
4.4.6.1: Cloning of the PfEMP1 constructs 
Prior to protein expression, PfEMP1 constructs were cloned into a TA vector 
fOllowed by a diagnostic digest using restriction enzymes (Table 4.4) to confirm the 
presence of the insert. An example of such an agarose gel with products for NTS-
OSLo. construct fOllowing the diagnostic digest is shown in Figure 4.10. One of 
these confirmed products was then cloned into an expression vector for protein 
expression. 
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Figure 4.10: A representative agarose gel stained with ethidium bromide showing 
products from a diagnostic digest in which plasmids were digested by a restriction 
enzyme. The 1 % gel shows products from a diagnostic digest of plasmids from 
NTS-DBLa construct. Each paired lane represents the plasmid digested with 
BamHllXhol and an undigested control respectively. The expected product size 
(1444bp) was present in all the 4 plasmids. 
4.4.6.2: Recombinant proteins from SA075var1 domains 
Using the constructs described in Table 4.4, recombinant proteins were made from 
five single domains and one di-domain of SA075var1 . CIDR2J3 did not produce any 
soluble proteins and was therefore not included in subsequent analysis. The purity 
of the proteins was checked by Coomassie blue staining described in section 
4.3.4 .5 under reducing and non-reducing conditions (Figure 4.11). All proteins 
showed a band at the expected molecular weight although some had degradation 
or appeared to form aggregations and/or impurities. This however does not affect 
antibody production or assays based on these antibodies since the responses are 
variant specific. The NTS-DBLa. protein had the highest yield (1.07g/L) and also 
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required fewer optimizations to obtain soluble proteins. This could possibly be 
explained by previous data on PfEMP1 protein expression which showed that the 
inclusion of the NTS to the DBLa. domain resulted in expression of soluble proteins 
(Ghumra, Khunrae et al. 2011). The final protein yields from the 4-8 litre bacterial 
cultures were follows: 1) NTS-DBL1a.2:1.07g/L 2) DBL21312: 0.66 gIL 3) DBL3y13: 
0.5 gIL 4) DBL4(5:1 gIL 5) NTS-DBL1a.2-CIDRa.1.8: 0.83 gIL and 6) 
CIDRa.1.8:0.87 gIL. 
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Figure 4.11: SOS-PA GE showing the predicted molecular masses different 
recombinant OBL, CIDR and a di-domain from SA075var1 expressed in E.coli. 
Two micrograms of proteins were run under reducing (R) and non-reducing (NR) 
conditions on a 4-12% polyacrylamide gel. 5 J.1I of Precision Plus Prestained 
Standard (Bio-Rad) was used as the molecular weight ladder. 
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4.4.7: Anti-SA075var1 antibodies 
Antibody generation was done by BioGenes GmBH (Berlin, Germany). Prior to 
immunization, pre-immune sera from five rabbits were screened by live cell IFA to 
check for heterophile antibodies that would react with both infected and non-
infected RBCs. The screening assay was done as described in Chapter 2 section 
2.3.10. The two rabbits whose pre-immune sera gave the lowest background were 
selected for immunization with the proteins. Figure 4.12 shows examples of IFA 
photos for pre-immune screening of sera from two rabbits with different levels of 
background staining. Serum from rabbit 6 gave punctate fluorescence over both 
infected and uninfected erythrocytes and was therefore not used for immunization. 
In contrast, serum from rabbit 7 showed only very pale, smooth background 
staining similar to that seen with secondary antibody only and therefore rabbit 7 
was chosen for immunization. 
Immunization was carried out on the two selected rabbits that gave the lowest 
background using the schedule described in Table 4.7. The anti-sera collected 
from the 2 rabbits on day 28 was tested by IFA and the antiserum that gave the 
brightest positive signal was chosen for a final immunization and protein-A 
purification of totallgG. 
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Rabbit # 6(with background) Rabbit 7# (without background) 
Figure 4.12: Immunofluorescent assay showing examples of pre-immune sera 
from two rabbits (6 and 7) tested on RBGs from SA075 culture. Serum from animal 
6 gave background and was therefore not used for immunization while serum from 
animal 7 used due to low levels of background. 
ELISA results from all the six anti-sera at day 28 showed good recognition of the 
respective antigens with the average antibody titres (defined as titres giving 50 % 
of the maximum 00) being as follows: NTS-OBL 10. 1/30,000; NTS-OBL 10.-
CIDR1o.1/70,000, CIOR1o. 1/20,000; OBL2P 1/30,000; OBL3y 1/10,000 and 
DBL48 1/35,000. Finally, IgG was purified for all the 6 domains and the final 
concentration shown in Table 4.11. 
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Table 4.11: Final concentration and volume of purified /gG from all the 5 domains 
and di-domain of SA075var1. Also shown are the 10 numbers for the two different 
rabbits selected for immunization and the 10 number for the rabbit from whose 
serum the IgGs were purified. 
Domain 10 number for Rabbit selected IgG Appr. Volume 
immunized for IgG concentration oflgG 
rabbits production (mgjml) available in 
(ml). 
NTS-DBLa 8062 8063 14.52 11.5 
8063 
DBLf3 20876 20877 12.60 23.5 
20877 
DBLy 20137 20137 12.96 17.0 
20138 
DBLD 20488 20489 12.00 18.5 
20489 
CIDRa 20878 20879 15.05 20.0 
20879 
NTS-DBL1a- 20486 20487 13.20 16.5 
CIDRla 
(Didomain) 
20487 
4.5: DISCUSSION 
Identification of PfEMP1 variants that are associated with adhesion phenotypes 
remains key in understanding the molecular mechanisms of P.falciparum 
sequestration . PfEMP1 variants associated with rosetting have previously been 
identified and their functional and immunological studies have been extensively 
carried out (Rowe, Moulds et al. 1997; Vigan-Womas, Guillotte et al. 2008; 
Albrecht, Moll et al. 2011). Due to the strong association between rosetting and 
severe disease in field isolates in Sub-saharan Africa (Carlson, Helmby et al. 
1990; Rowe, Obeiro et al. 1995; Newbold, Warn et al. 1997; Kun, Schmidt-Ott et 
al. 1998; Heddini, Pettersson et al. 2001), I sought to identify, clone and sequence 
a putative full-length var gene transcribed by a recently culture-adapted isolate 
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called SA075, from Kenya whose previous tag analysis had shown sequence 
features associated with rosetting. 
Following two rounds of cloning by limiting dilution and transcriptional profiling of 
DBLa. tag sequences, dominant var genes in R+ and R- parasite clones were 
identified. However, in the first round of cloning, two dominant sequences came up 
in the R+ clone. Although co-expression of var genes as surface antigens within 
the same parasite has previously been reported (Joergensen, Bengtsson et al. 
2010), the most plausible explanation in this case could be that the highest rosette 
frequency of 44 %, obtained during the first round of cloning, was not high enough 
to select a single dominant variant. However on re-cloning (% RF-67%), one of the 
dominant var gene (SA075_1) that was identified during the first round of cloning 
came up in R+ clone and was missing in the R- clone, whereas the second major 
R+ var gene from round 1 (SA075_2) was found to be highly transcribed in the R-
clone in round 2. The SA075_1 sequence was therefore deemed to be the most 
likely rosette-mediating variant, and was selected for further study. It contained 
two cysteine residues and belonged to Cys/PoLV group 2. Based on these DBL-1 
sequence features, the transcript would be grouped as a Group A-like sequence 
that has previously been associated with rosetting in both lab and field isolates 
(Bull, Berriman et al. 2005; Kaestli, Cockburn et al. 2006; Kyriacou, Stone et al. 
2006; Warimwe, Keane et al. 2009). SA075_1 described in this chapter is the 
same as the one previously identified in the uncloned SA075 (Bull, Buckee et al. 
2008). 
The full-length SA075var1 gene was successfully cloned and sequenced starting 
from the tag region and extending the gene both upstream and downstream using 
degenerate primers. This strategy was previously used by Kraemer et al., 2003 
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(Kraemer, Gupta et al. 2003) to sequence PfEMP1 genes and has been used to 
sequence other rosetting variants like Muz12var1 (Ghumra, Semblat et al. 2012). 
Using this method, the SA075var1 was found to encode a 5 domain gene with a 
coding sequence of 7.4 kb starting from the var gene translation initiation codon 
(ATG) up to the last domain of the coding region (CIDR213) domain. It contained 
the 5' upstream sequence that was confirmed to be of the Ups B type (Figure 4.5). 
This method however took several iterations, with some PCRs being unsuccessful 
and over 20 primer pairs were used. An alternative and faster method would have 
been whole genome sequencing of SA075 and assembly of the var genes as is 
being done by the next generation sequencing methods in Sanger. The full-length 
sequence would then be easily identified by blasting the already known tag 
sequence against the whole genome sequences. However, during the start of the 
current work, the assembly of var genes from whole genome sequencing had not 
been well established and therefore the PCR walking strategy described above 
was used. 
Features of the SA075var1 sequence were compared to those of previously 
characterized rosette-mediating variants. Interestingly, a comparison of domain 
architectures showed that SA075var1 had a similar architecture to that of 
TM180var1 variant, expressed by a rosetting parasite from S.E Asia, TM180R+. It 
is important to note that a rosette-mediating function for TM180var1 has not been 
confirmed, and antibodies to TM180var1 do not inhibit TM180R+ rosetting 
(Ghumra, Semblat et al. 2012). Despite the overall sequence identity score of 
43.3%, both variants had DC8-like features and have previously been shown to be 
non-lgM binders (Ghumra, Semblat et al. 2012). It is not known if both parasites 
use similar receptors on uninfected cells. The genes encoding DC8 are thought to 
be prevalent in the parasite population and were present in six of the seven 
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sequenced genomes that were analyzed by Rask et a/., 2010 (Rask, Hansen et al. 
2010). They are characterized as having an Ups B promoter and contain 4 
domains in tandem. Despite the high level of conservation across parasite 
genomes, the DCB domains are not identical but share between 45% and 63% 
similarity at the amino acid level (Lavstsen, Turner et al. 2012), similar to what was 
seen for SA075var1 and TM1BOvar1. Chapter 5 will explore whether the 
SA075var1 and TM1BOvar1 encode proteins eliciting cross-reactive antibody 
responses. Recently, var genes with DCB features have been associated with 
severe disease (Lavstsen, Turner et al. 2012). Interestingly, all the var genes with 
DCB features were of the Ups B type. It would also be important to study the 
clinical relevance of SA075var1 despite not having typical DCB features. 
Heterologous expression of recombinant proteins has for long been used in 
studying the antigenicity and other functional characteristics of proteins. However, 
expression of PfEMP1 proteins, especially as full-length proteins, is difficult due to 
the high molecular weight of the protein. Most studies on recombinant expression 
of PfEMP1 have thus focused on single or di- domains which are compatible with 
most expression systems. However, biochemical and physical characteristics, 
such as a high number of disulphide bridges still make recombinant expression 
difficult (Victor, Bengtsson et al. 2010). One study has however managed to 
express Var2csa as a full-length PfEMP1 protein (Khunrae, Dahlback et al. 2010) 
in an insect expression system Trichop/usia nifollowing codon optimization. 
SA075var1 domains were expressed as soluble recombinant proteins in E.coli to 
be used mainly for polyclonal antibody production. I have described the inclusion 
of a heat shock protocol that was able to enhance expression of soluble proteins 
for some of the SA075var1 domains. This strategy has previously been shown to 
improve the level of expression of recombinant proteins in a soluble native form is 
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by increasing the cellular concentration of osmolytes or of chaperones 
(Oganesyan, Ankoudinova et al. 2007). However, CIDR~ in SA075var1 could not 
be expressed as soluble proteins as it remained insoluble even after bacterial cell 
lysis. Based on the quality of the gels there was evidence of degradation and/or 
aggregated material or possible contaminating E.col; proteins within the 
recombinant protein preparations. However, some protein at the expected 
molecular weight was see~ in most cases, which shifted upon reduction showing 
the presence of disulphide bonds (Figure 4.11). This suggests the likelihood that 
some correctly-folded protein is present, and it can be hoped that antibodies 
recognizing native PfEMP1 on the surface of live infected erythrocytes will be 
obtained. 
Antibody production was successfully done for a" the recombinant domains of 
SA075var1. Whether these antibodies elicit functional and crossreactive 
antibodies will be discussed in the next chapter. A similar study was done by 
Ghumra et al., 2010 (Ghumra, Khunrae et al. 2011) on ITvar9, a rosetting variant 
in R29 strains in which the antibodies were found to have rosette inhibiting and 
phagocytosis- mediating abilities. Also of importance will be to find out the 
functional abilities of antibodies to other extrace"ular domains other than NTS-
DBLa in SA075var1. The antibodies were used for selecting for mono-variant 
rosetting parasites by cell sorting and the parasites were used to explore the 
clinical relevance of rosetting parasites, as will be discussed in chapter 6. 
In conclusion, SA075var1, a candidate gene that may encode the rosetting-
mediating ligand in SA075 parasite was cloned and sequenced. Recombinant 
proteins were made from the different domains and antibodies were raised from 
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the different domains. As has been done for laboratory isolates associated with 
rosetting eg R29 (Ghumra, Khunrae et al. 2011), Palo alto (Vigan-Womas, 
Guillotte et al. 2008) and FCR3S1.2 (Albrecht, Moll et al. 2011), the functional and 
immunological characterization of antibodies to SA075var1 recombinant domains 
will be done and discussed in Chaper 5. 
162 
CHAPTER 5 
Functional Characterization of anti-SA075var1 antibodies 
5.1: INTRODUCTION 
5.1.1: Anti-PfEMP1 antibodies 
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is an important 
immune target and would potentially be a good candidate for vaccine development 
(reviewed Beeson et al.,2013 (Beeson, Chan et al. 2013». An effective anti-
PfEMP1 vaccine would be one that ultimately leads to immune clearance of 
infected RBCs and hence protects against the disease and its consequences 
rather than against infection per se. Also of importance would be a vaccine that 
induces not only variant specific (Vigan-Womas, Guillotte et al. 2011) but also 
cross reactive responses, as has recently been reported for anti-rosetting 
antibodies (Ghumra, Semblat et al. 2012) and anti-CSA binding antibodies in 
placental associated malaria (Avril, Cartwright et al. 2010; Bigey, Gnidehou et al. 
2011 ). 
Many functional and immunological studies have therefore been carried out on 
antibodies against PfEMP1 variants that are linked to virulent phenotypes. Such 
studies have focused on single, di-domains or even full-length PfEMP1 to explore 
the ability of the proteins or their antibodies to inhibit or reverse adhesion. 
Var2CSA which mediates sequestration of parasites in the placenta is among the 
most characterized PfEMP1 variants. It is the first PfEMP1 in which the full-length 
gene has been expressed as a recombinant protein (Khunrae, Dahlback et al. 
2010) and the crystal structure for DBL3X (Higgins 2008) and DBL6e domains 
have been solved. Antibodies against different domains of var2CSA have shown 
varied inhibitory activities in both a strain specific and strain transcending manner 
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(Fernandez, Kviebig et al. 2008; Nielsen, Pinto et al. 2009; Avril, Cartwright et al. 
2010; Gangnard, Tuikue Ndam et al. 2010; Khunrae, Dahlback et al. 2010; Salanti, 
Resende et al. 2010; Srivastava, Gangnard et al. 2010; Avril, Cartwright et al. 
2011). Other adhesion phenotypes whose PfEMP1 variants have been studied 
include binding to CD36 (Baruch, Gormely et al. 1996), Intracellular adhesion 
molecule 1 (lCAM-1) (Smith, Craig et al. 2000), platelet endothelial adhesion cell 
molecule 1 (PECAM1) (Chen, Heddini et al. 2000) and rosetting (Vigan-Womas, 
Guillotte et al. 2008; Albrecht, Moll et al. 2011; Ghumra, Khunrae et al. 2011; 
Ghumra, Semblat et al. 2012). This chapter focuses on characterization of 
antibodies to the SA075var1 PfEMP1 variant described in Chapter 4. 
5.1.2 Functional characterization of anti-PfEMP1 antibodies against rosetting 
parasites 
Like in var2csa, the possibility of a limited subset of rosette-mediating variants 
raises the prospects of an anti-rosette vaccine that would inhibit or disrupt rosette 
formation. There is sufficient evidence from field studies showing the presence of 
anti-rosetting activity in serum from malaria patients (Carlson, Helmby et al. 1990; 
Treutiger, Hedlund et al. 1992; Barragan, Kremsner et al. 1998). Coupled with the 
various laboratory-based studies on characterization of anti-PfEMP1 antibody 
responses against rosette-mediating parasites (Ghumra, Khunrae et al. 2011; 
Ghumra, Semblat et al. 2012), it is evident that there are functional antibodies 
against rosette-mediating variants. Three of the well characterized rosetting 
variants i.e. Var O(Vigan-Womas, Guillotte et al. 2008), FCR3S1.2var2 (ITvar60) 
(Albrecht, Moll et al. 2011) and ITvar9 (Ghumra, Khunrae et al. 2011) have all 
shown rosette-disrupting ability of their anti-DBL 1 antibodies against rosettes in 
homologous parasites. Antibodies to rosetting variants have also been used to 
explore the antigenic relationship of rosetting parasites. Two studies by Ghumra et 
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al., 2011 (Ghumra, Khunrae et al. 2011) on the R29 clone and by Vigan-Womas et 
al., 2011 (Vigan-Womas, Guillotte et al. 2011) on Palo Alto, R29 and 3D7 all 
showed variant-specific surface-reactive antibodies. However, a follow-up study 
by Ghumra et al., 2012 (Ghumra, Semblat et al. 2012) showed induction of strain 
transcending surface reactive antibodies that were not only able to inhibit rosette 
formation but also meditated phagocytosis in heterologous parasites. However, 
the cross reactivity seemed to be limited to IgM-binding rosetting parasites, a 
phenotype thought to be virulence enhancing either by masking PfEMP1 from 
recognition by specific antibodies or aiding in the stabilization of rosettes (Vigan-
Womas, Guillotte et al. 2008; Albrecht, Moll et al. 2011; Ghumra, Khunrae et al. 
2011 ). 
While the DBLa. domain of the PfEMP1 molecule is thought to be important in 
mediating rosetting (Rowe, Moulds et al. 1997; Vigan-Womas, Guillotte et al. 
2008; Albrecht, Moll et al. 2011), little is known about the role of other domains of 
the rosette-mediating PfEMP1 variants. Very few studies have been done to 
characterize antibodies raised against other extracellular domains of rosette 
mediating variants. Recently, Ghumra and colleagues (Ghumra, Khunrae et al. 
2011) studied domain-specific antibody responses, targeted against domains 
downstream of NTS-DBL 1 a. in ITvar9 of R29 strain. Results showed that 
antibodies to all PfEMP1 domains of ITvar9 recognized the surface of live infected 
RBCs. Antibodies to all domains except the second DBL domain (DBL2y) inhibited 
rosettes and mediated phagocytosis in a strain specific manner. These findings 
cannot however be generalized to all rosetting variants and it is imperative to study 
downstream domains of other rosetting variants to understand the pattern of 
recognition and functionality. 
165 
This chapter discusses results on functional characterization of antibodies to 
SA075var1. The PfEMP1 variant was identified as a putative gene involved in 
rosetting in a recently culture-adapted field isolate called SA075 (Chapter 4). 
Subsequent experiments however failed to confirm the role of SA075var1 in 
rosetting (see later in this chapter). However. other features of this sequence 
made it suitable for further continued study. Using the recent PfEMP1 
classification method of domain cassettes (DCs) (Rask. Hansen et al. 2010). 
SA075var1 had DC8-like features (Chapter 4. section 4.4.5). With DC8 and DC13 
being linked to severe malaria in studies done inTanzanian and Benin (Lavstsen. 
Turner et al. 2012; Bertin. Lavstsen et al. 2013). the functional characterization of 
SA075var1 was of interest. Polyclonal antibodies were raised in rabbits that were 
immunized with recombinant protein from five single domains and one di-domain 
of SA075var1. Details on identification of the full-length gene. making of 
recombinant proteins from the different domains and raising of the antibodies have 
been described in Chapter 4. 
5.2 CHAPTER AIMS 
The aim of this chapter was to examine the functional and immunological 
characteristics of antibodies to the extracellular domains of SA075var1. Rabbit 
polyclonal antibodies were raised against five single domains and one di-domain 
recombinant proteins of SA075var1 as described in Chapter 4 (section 4.4.6). The 
NTS-DBL 1 a. antibody was further used in developing a cell sorting protocol that 
was used to select for monovariant-enriched cultures in SA075. This protocol was 
later adapted for use on other P.fa/ciparum strains. Five questions that formed the 
specific objectives of this chapter were: -
1. Do antibodies raised against extra-cellular domains of SA075var1 
recognize the surface of homologous parasites? 
2. What is the sensitivity/end titre of recognition by these antibodies? 
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3. Do the antibodies have the ability to induce phagocytosis? 
4. Do these antibodies cross react with other P.fa/ciparum laboratory strains? 
5. Is there a correlation between the parasites rosetting frequency and the 
percent positive population when stained by homologous antibodies? 
5.3 MATERIALS AND METHODS 
The methods used in this section were previously described in Chapter 2. These 
include: -1) antibody staining by FACS and IFA assays 2) antibody-mediated 
phagocytosis assay. Other assays used this chapter include:- Trypsinization 
experiments and cell sorting using homologous NTS-DBLa antibodies. 
5.3.1: Trypsinization experiments 
PfEMP1 has previously been shown to be sensitive to trypsin treatment (Gardner, 
Pinches et al. 1996). To check whether the anti-SA075var1 antibodies were 
targeting the PtEMP1 molecule, infected RBC were treated with trypsin prior to 
antibody staining. 20 ,.d of trophozoite stage parasites at greater than 5% 
parasitaemia were incubated in 500 J..l1 of 10J..lg/ml of TPCK-trypsin (Sigma) for 5 
minutes at room temperature. A mock trypsin treatment in incomplete RPMI was 
also included. The reaction was then stopped by addition of 500 J..l1 of 1 mg/ml of 
soybean trypsin inhibitor (Sigma) to both the trypsin-treated and mock trypsin-
treated samples followed by 5 minute incubation at room temperature. The cells 
were then washed and stained for FACs assays as described in Chapter 2.Section 
2.3.10. 
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5.3.2: Use of NTS-DBL a antibodies to select for monovariant parasite 
population by cell sorting. 
Heterogeneity of parasite populations due to antigenic switching is a common 
feature of in vitro culture in P.fa/ciparum. In rosetting parasites, it results in 
different rosette-forming parasites expressing different PfEMP1 variants in a single 
culture (Vigan-Womas, Guillotte et al. 2008; Vigan-Womas, Guillotte et al. 2011) 
which may confound studies on genotype-phenotype associations. A cell sorting 
protocol done by FAGS was optimized to select for a homogenous parasite 
population expressing a single variant. This protocol was developed with SA075 
and then adopted and used to sort P. fa/ciparum strains including PAR+, 
TM284R+, HB3R+, R29+, TM180R+ and Muz12R+. 
The cell sorting protocol involved 3 major steps: -
i. Enrichment of trophozoite stage parasites to greater than 80% parasitaemia 
by magnetic-activated cell separation (MAGS) prior to antibody staining. 
This substantially reduces the content of uninfected RSGs and cell debris in 
the pre-sorting material, and subsequently shortens the length of time taken 
for sorting. 
ii. 
iii. 
Staining of parasites with homologous NTS-DBLn antibodies. 
Gell sorting on a FAGSAria (SO Biosciences) and re-culturing of the sorted 
cells. 
Enrichment of parasites was first done by spinning down the culture suspension 
and washing it twice in incomplete RPMI. Following the washes, the culture was 
resuspended back to its original volume using incomplete RPM I supplemented 
with 200l!g/mi of Fucoidan (Sigma) to keep any rosettes disrupted. The culture 
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suspension was then carefully passed though a magnetic column that had been 
pre-equilibrated with incomplete RPMI with Fucoidan and the flow-through 
dispensed in a dropwise manner. This allowed for maximum separation of the 
hemozoin-rich trophozoites by the magnetic column. The flow-through was then 
passed through the column for a second time to ensure that all the trophozoites 
were captured. The column was detached from the magnet and MACS purified 
trophozoites were collected by passing the incomplete RPMIIFucoidan media 
through the detached column. The final pellet volume of between 1 0-20 J.l1 had a 
parasite count of greater than 80%. These were then washed three times in 1X 
PBS, after which they were resuspended in 3ml of 1X PBS/1% BSA with 25J.lg/ml 
of Fucoidan in a 15ml Falcon tube. A smaller volume of 500J.l1 suspension was 
kept in a separate 15ml tube to be used as a negative control during gating. 
Homologous NTS-DBL 1a. antibody was added to the 3 ml suspension to a final 
concentration of 25J.lg/ml. Note that the control tube was not stained with the 
primary antibody. This was incubated at room temperature for 45 minutes with 
regular flicking of the tube after every 10 minutes to in order to keep the cells in 
suspension. The culture was washed three times in 3ml sterile 1 XPBS by 
centrifuging at 2000rpm for 2 minutes. 3 ml of secondary antibody Alexa Fluor 
488-labelled goat anti-rabbit IgG (catalogue number A11034, Invitrogen Ltd, 
Paisley, UK) diluted at 1:1000 in PBS/1% Ig-free BSAl25J.lg/ml of Fucoidan was 
then added to both the sample tube and the control tube. This was again 
incubated for 45 minutes at room temperature while covered in foil to protect it 
from light. Flicking of the tube was repeated every 10 minutes. Following the 
incubation, 3 washes were done in sterile 1XPBS and the pellet finally re-
suspended in 3 ml culture medium containing 25J.lg/ml of Fucoidan. Meanwhile a 
collection tube of 5ml warm culture medium with 50% serum was prepared in 
which the sorted parasites would be collected. Sorting was done on FACSAria (BD 
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Biosciences) cell sorter. Prior to sorting, an RBC gate was set on a forward scatter 
(FSC) and side scatter (SSC) (Figure 5.1, panel 1). The gated region represented 
a tight population of cells in which dead cells and debris were excluded. Next, the 
forward scatter-width (FCS -W) parameter was used to gate out the double or 
multiple cells from single cells to avoid the possibility of stained cells sticking 
together with unstained cells (Figure 5.1, panel 2). The singlets were then gated 
based on FITC stain to separate the stained population from the unstained 
population (Figure 5.1, panel 3) and finally a sorting gate was set within the 
stained population (Figure 5.1 , panel 4). The gating strategy is summarized in 
Figure 5.1. Cell sorted parasites were then washed and re-cultured as described in 
Chapter 2, section 2.3.1. 
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Figure 5.1: An overview of the gating strategy used for cell sorting of rosetting 
parasites using homologous NTS-OBL 1 a antibodies. 1) A tight RBe gate was first 
set on FSG and SSG scatter in order to exclude debris and/or dead cells 2) Next, 
FGS (W) parameter was used to gate out the double or multiple cells from single 
cells 3) The singlets were then gated based on FITe stain to separate the stained 
population from the unstained population. 4) It is within the stained cells that the 
sorted population was gated. 5) An output from the FAGS sorting machine 
showing a summary of the sorting results including the proportion of each 
population. The different colors represent different cell populations. All events 
(100%) were first acquired as represented in black colour. Rbcs (in red) represents 
the Proportion of cells following the first gating to remove debris/dead cells. Single 
cells (in blue) were then gated before the stained population (deep green) were 
gated. A subpopulation of the stained cells was then sorted (called 'sort' and 
represented in green). "Total stained" (purple colour) represents all stained cells 
including singlets and doublets while P1 is a subset of the stained parasites, but 
which also includes singlets and doublets. 
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5.4: RESULTS 
5.4.1: Antibodies to the five single domains and one di-domain of SA075var1 
recognize the surface of SA 075 infected RBCs 
IFA and FAGS assays were carried out on live infected RBGs to determine 
whether the polyclonal rabbit IgGs recognized native PfEMP1 on the surface of 
SA075 parasites. For all the six anti-PfEMP1 antibodies, IFA slides showed a 
positive signal which appeared as dotty punctate fluorescence pattern, similar to 
previously published results on PfEMP1 staining (Vigan-Womas, Guillotte et al. 
2008; Albrecht, Moll et al. 2011; Ghumra, Khunrae et al. 2011) (Figure 5.2 A). 
Attempts to visualize intact rosettes on the stained parasites were however 
unsuccessful. The negative control Le.lgG from a non-immunized rabbit, showed a 
pale background fluorescence indicative of lack of binding. All IFA slides were 
viewed with a 100X objective using a Leica DM 2000 fluorescent microscope 
FAGS data also showed similar specific surface reactivity for all the six SA075var1 
antibodies, which was absent in the control antibody (Figure 5.2B and G). Infected 
RBGs Were stained with Hoechst 33342 (Sigma) while anti-PfEMP1 reactivity was 
visualized by Alexa Fluor 488 Goat anti-Rabbit IgG. Both the anti-SA075var1 
antibodies and the rabbit IgG control antibody were used at a concentration of 
400~g/ml. Figure 5.2B and C show FAGS plots for results for the staining of the 
samples and the control. 
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Figure 5.2: A) IFA photos showing surface staining of live infected RBGs by the 
six homologous SA075var1 antibodies and a rabbit /gG control antibody. Infected 
RBGs were stained with DAPI and anti-PfEMP1 reactivity was visualized by Alexa 
Flour 488 dye diluted at 1: 1 000. Specific staining appeared as dotty punctate 
fluorescence pattern while the control showed a pale background fluorescence (B) 
FACS plots showing the recognition of PfEMP1 on the surface of SA075 infected 
RBGs by 4 of the 6 homologous SA075var1 antibodies at 4 o OJ..Lg/m I. These were 
antibodies against NTS-DBL 1 a, NTS-DBL 1 a-CIDR1 a, DBL3yand DBL4o. 
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Infected RBGs were stained with Hoechst while PfEMP1 was visualized by 
secondary antibody Alexa Flour 488 diluted 1:1000. Also included in the assay 
were two negative controls:-one without primary antibody and one in stained with 
400J.lg/ml of rabbit IgG. C) 2 of the 6 antibodies against GIDR1 a and DBL2P 
analyzed as in B above but on a different day. 
5.4.2. Limit of dilution/sensitivity of anti-SA075var1 antibodies 
The limit of dilution or end titre for all the six anti SA075var1 antibodies was 
determined by flow cytometry. This is different from a previous study (Ghumra, 
Khunrae et al. 2011) where the end titres of anti-PfEMP1 antibodies to R29 
parasites was determined by IFA as the lowest concentration at which >50% of the 
infected RBGs in the culture showed punctate fluorescence. In this study, SA075 
parasites were incubated with a four-fold dilution of purified IgG starting with 
400Jlg/ml then 100, 25, 6.25, 1.57, 0.39, 0.10 and 0.03 Ilg/ml and analysed by 
FACS. The end titre was defined as the lowest concentration giving a positive 
signal above the rabbit IgG control as shown in the histograms (Figure 5.3, panel 
A and B). 
Results showed end titre for the anti-SA075var1 antibodies as follows: - anti-NTS-
DBL 1a (1.57 Jlg/ml), anti-NTS-DBL 1a-CIDR1a (25 Jlg/ml), anti-CIDR1a (400 
Ilg/m l), anti-DBL2j3 (25 Jlg/ml), anti-DBL3y (1.57 Jlg/ml) and anti-DBL40 (6.25 
Ilg/ml) (Figure 5.3 panel A and B). A different comparative analysis method to 
determine the end titre concentrations for the different antibodies was done using 
a FlowJo software (Tree star Inc.) with both methods showing similar results. In 
this latter analysis, the percentage positive population was calculated using a tool 
called the Overton cumulative histogram subtraction method, where the proportion 
of the negative control population i.e. rabbit IgG was subtracted from each sample 
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to give a percent of positive cells (Figure 5.3 panel C). The dotted line on the 
graph represents a cutoff at which 50% of the population remains positive 
following subtraction of the negative control. Only NTS-DBLa antibodies showed 
more than 50% positive cells at a concentration of 1.57 ~lg/ml while DBL3y and 
DBL40 showed 50% positivity at 6.25~g/ml. NTS-DBL 1 a-CIDR1 a antibody was at 
25~g/ml while CIDR1a and DBL213 antibodies did not show 50% positive cells 
even at 400~g/ml. 
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Figure 5.3: Panel A) Determination of end titre for 4 of the 6 SA075var1 
antibodies by flow cytometry. The antibodies against NTS-DBL 1 a, NTS-
DBL 1 a-GIDR1 a, DBL3r and DBL48 were diluted four-fold from 400l1glml down to 
O.0311glml and assayed for surface staining against SA075 infected RBGs. Rabbit 
IgG from a non-immunized rabbit was used as a negative control at a 
concentration of 40011glml. Infected RBGs were stained with Hoechst and surface 
staining was visualized by a secondary goat anti-rabbit labeled Alexa Fluor 488. 
The end titre was defined as the lowest concentration of antibody giving surface 
staining above rabbit IgG background levels. Panel B) 2 of the 6 antibodies 
against GIDR1 a and DBL2f3 analyzed as in A above but on a different day. Panel 
C) Histograms showing results for determination of end titre by percentage 
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positive population. Analysis was done using the Overton cumulative subtraction 
method in FlowJo. In this analysis, the proportion of negative control i.e. rabbit IgG 
was subtracted from each sample to give a percentage of positive cells. The 
dotted line represents a cutoff at which 50% of the population remains positive 
following subtraction of the negative control. Only NTS-DBLa antibodies showed 
more than 50% positive cells at a concentration of 1.57 JIg/mI. 
5.4.3: Antibodies against SA075varl bind to a trypsin-sensitive protein 
expressed on the surface of mature infected RBCs 
TrypSin sensitivity of PfEMP1 in P.falciparum strains has previously been 
described (Leech, Barnwell et al. 1984; Ghumra, Semblat et al. 2012) and has 
been used to determine the specificity of anti-PfEMP1 antibody targeting the 
surface of infected RBCs. Antibodies generated against domains of SA075var1 
were incubated with trypsin-treated SA075 parasites to determine if they were 
binding to PfEMP1. Results showed that all the six anti-SA07var1 antibodies 
bound to a trypsin-sensitive protein expressed on the surface of mature SA075 
infected cells (Figure 5.4, A and B). This was shown by the abolishment of the 
double positive-stained population shown on the upper right quadrant of the 
dotplots for trypsin treated samples compared to the mock-trypsin treated 
samples. No binding was seen with rabbit IgG control in both cases. 
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Figure 5.4: A) Flow cytometry dot plots of trypsin-treated live infected RBGs 
stained with 400J.lg/ml of anti-PfEMP1 antibodies against NTS-DBL 1 a, NTS-
DBU a-CIDR1 a, DBL3r and DBL4J. SA075 parasites were either mock-trypsin 
treated (left column) or treated with 10J.lg/ml of trypsin (right column) for 5 minutes. 
Both samples were later treated with 1 mg/ml of trypsin inhibitor to stop the enzyme 
reaction. Infected RBGs were stained with Hoechst and anti-PfEMP1 antibodies 
bound to the surface of infected erythrocytes were detected using Alexa Fluor 488 
conjugated to anti-rabbit IgG. The antibodies were shown to target PfEMP1 as 
evidenced by the lack of staining in the upper right hand quadrant of the trypsin-
treated samples compared to the mock-treated samples. B) Flow cytometry dot 
plots of trypsin-treated live infected RBGs stained with 400J.lg/ml of anti-PfEMP1 
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antibodies against CIDR1 a and DBL2P. Assay was carried out as described in A 
above. 
5.4.4: Anti-SA075var1 antibodies mediate phagocytosis of SA075 infected 
erythrocytes 
The ability of antibodies to opsonize and induce clearance of malaria-infected 
erythrocytes is an important effector mechanism that has been described in both 
humans and murine models (Shear, Nussenzweig et al. 1979; Celada, Cruchaud 
et al. 1982). In earlier studies on phagocytosis of malaria parasites, it was shown 
that the capacity of monocytes and macrophages to phagocytose infected RBCs 
increased with opsonization of the target with immune sera (Hunter, Winkelstein et 
al. 1979; Celada, Cruchaud et al. 1982). An in vitro phagocytic assay (described in 
Chapter 2, section 2.3.12) developed by Ataide and colleagues (Ataide, Hasang et 
al. 2010) was adapted and used to measure antibody-mediated phagocytosis by 
rabbit generated SA075var1 antibodies. However, it is worth noting that while 
humans have four IgG subclasses, rabbits have only one IgG (Janeway CAJr 
1996) and therefore it is possible their effector functions against human infected 
RBCs may not be directly equivalent. The in vitro assay has previously been used 
to measure phagocytosis mediated by anti-PfEMP1 antibodies in rosetting 
parasites (Ghumra, Khunrae et al. 2011; Ghumra, Semblat et al. 2012). Ethidium 
bromide-stained infected RBCs were opsonized by antibodies at four 
concentrations:- 400, 100, 25 and 6.25 Ilg/ml and incubated with monocytic cells 
(undifferentiated THP-1), to allow for phagocytosis. Results were analyzed by flow 
cytometry (FACSCalibur software) in which THP-1 cells were first gated based on 
FSC and SSC. A second gate was then set on FL3 channel to allow for gating of 
THP-1 that had phagocytosed infected RBCs and those that had not, as detected 
by ethidium bromide staining (Figure 5.5). 10,000 of ethidium bromide-positive 
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THP-1 cells were then acquired at the rate of 200-300 cells Isecond. Phagocytic 
activity was normalized against that of a rabbit anti-human erythrocyte antibody 
(ABCAM ab34858) which was the positive control. Details of the analysis are 
discussed in Chapter 2, section 2.3.12. 
Apart from antibodies to DBL2f3 and CIDR1a, all other antibodies to SA075var1 
promoted phagocytosis of the homologous SA075 parasite. NTS-DBL 1 a showed 
the strongest phagocytic activity at a concentration of 400 Jlg/ml although anti-
DBL3y was more sensitive at lower concentration of 6.25Jlg/ml (Figure 5.6). Anti-
NTS-DBL1a-CIDR1a caused moderate phagocytosis while anti-DBL4f3 was 
effective only at 400Jlg/ml. 
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ethid ium bromide 
Figure 5.5: FAGs plots for phagocytosis of SA075 infected RBGs by monocytes 
(THP1 cells). Macs purified infected RBGs were opsonized with four different 
concentrations of anti-NTS-OBLa antibody. The positive control in this assay was 
a polyclonal rabbit anti-human RBG IgG antibody used at gOj.1g/ml and the 
negative control was anti-rabbit IgG control. The Y-axis (side scatter -SSG) gates 
the monocytes while the X-axis shows monocytes stained with ethidium bromide 
on FL3. The dotted line represents the gating for the monocytes that were either 
ethidium bromide positive or negative. 
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Figure 5.6: Phagocytosis of SA075 infected erythrocytes by THP-1 cells following 
opsonization by six anti-SA075var1 antibodies. Rabbit IgG from a non-immunized 
rabbit was included as a negative control. Data are shown as a percentage of the 
positive control which was opsonized with a rabbit anti-human erythrocyte 
antibody. 
5.4.5: Antibodies to SA075var1 domains show an overall strain-specific 
response but with minimal cross-reactivity 
Antigenic relationship of PfEMP1 variants was evaluated by testing variant-specific 
antibodies against heterologous parasites to check for cross reactivity. A recent 
study on antibodies to extra-cellular domains of R29 showed a strain specific 
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response when tested against'other rosetting' P., fa/ciparumJab strains.(Ghumra., 
Khunrae et al. 2011). U$ing a similar app.r,oach,·SA07pvar1:antibbdies wer.e tested' 
by f1ow-cytometry for their ability to recognize the surfac~ of RBCs parasitiZed wit~ 
heterologous parasite strains (Figure: 5.7 .and 5.8).; The laboratory strainsteste(:j . 
were:- R29+, TM180R+.;. Muz12R+, PAR+" TM284R+; HB3R+ and. one' colture-
adapted field isolate 9197R+. The parasites were grotJped intoeithedgM'.o,r nbn-
IgM binders (Table 5.1.)., Antibodies were tested at. a contentrationof 400 'J!g/ml. 
Although generally strain.;.specific, two;. of .the 'SA075.vaF~ anUbadies' Le.,. anti-
CIDR1a, anti-DBL213 cross-reacted with TM284R+;"an IgM-binding-parasite< 
(Figure 5.88 and summary table 5.1). ,. . ~ ,,' , , -. 
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F;gure 5.7A .. Flow cytometry dot plots showing cross reactivity of anti-SA07Svar1 antibodies against non-fgM binding parasites (Muz12R+, 
R29R+, TM180R+ and a recently culture-adapted field isolate 9197R+ :-Homologous NTS-DBL 1a for each isolate (except 9197) followed 
by antibodies against SA075 var1-NTS-DBL1a, NTS-DBL1a-CIDR1a, DBL3rand DBL4t5and rabbit IgG control antibody. Infected RBGs 
were stained with Hoechst and anti-PfEMP1 antibodies bound to the surface of infected erythrocytes were detected using Alexa Fluor 488 
conjugated to anti-rabbit IgG. 
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Figure 5.7: B) GIDR1 a , DBL2f3 and rabbit IgG control antibody tested in a similar manner as A above. Infected RBGs were stained with 
Hoechst and anti-PfEMP1 antibodies bound to the surface of infected erythrocytes were detected using Alexa Fluor 488 conjugated to anti-
rabbit IgG. 
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Figure 5.8 A: Flow cytometry dot plots snowing cross reactivity or anti-SA075var1 antibodies against IgM binding parasites (TM2B4R+, 
HB3R+ and PAR+) The antibodies used were :-Homologous NTS-DBL 1 a for each isolate followed by antibodies against SA075 var1-NTS-
DBL 1 ~ NTS-DBL 1 a-GIDR1 a; DBL3yand DBL4o. Infected RBGs were stained with Hoechst and anti-PfEMP1 antibodies bound to the 
surface of infected erythrocytes were detected using Alexa Fluor 488 conjugated to anti-rabbit IgG. 
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Figure 5.88: Flow cytometry dot plots showing cross reactivity of anti-SA075var1 antibodies against IgM binding parasites (TM284R+, 
HB3R+ and PAR+). The antibodies used were CIDR1 a and DBL2f3 and rabbit IgG control tested in a similar manner as A above. Infected 
RBCs were stained with Hoechst and anti-PfEMP1 antibodies bound to the surface of infected erythrocytes were detected using Alexa Fluor 
488 conjugated to anti-rabbit /gG. 
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Table 5.1: A summary of cross reactivity of anti-SA075 antibodies against other 
rosetting parasites as determined by FAGS. As previously described in section 
5.4.2, a positive value was defined as the lowest concentration giving a positive 
signal above the rabbit IgG control. The first row represents recognition of SA075 
parasites, all of which were positive. The only cross reactivity seen was by anti-
GIDR1 a and anti-DBL2{3 against TM284, an IgM binding parasite. The ability of 
each rosetting type to bind non-immune IgM is indicated on the left as either IgM-
orlgM+. 
~ 
... 
a: j 0 
-' 
y 
cc j Rosettinlltr.in. 0 
.;. 
-' cc I- 9 z 
.." 
I-
Z 
IgM. 
IgM+ 
j 5-a: 
0 cc 
0 0 
~ ~ 
"" -' -' cc cC 
0 0 
_Positive 
~ Negative 
202 
5.4.6: Use of Anti-NTS-DBLa antibody for cell sorting and correlation of 
FACS generated % positive population with rosetting frequency 
It is possible that there can be several var genes that are involved in rosetting in a 
haploid genome. An example is in the IT genome where ITvar9 and ITvar60 have 
been shown to be involved in rosetting in different parasite clones (Rowe, Moulds 
et al. 1997; Albrecht, Moll et al. 2011). Unfortunately in in vitro culture, this may 
result in a heterogenous population in which rosettes in a single culture are 
mediated by different PfEMP1 variants. A study by Vigan-Womas et al 2008 
(Vigan-Womas, Guillotte et al. 2008) showed how a heterogenous population of 
Var 0 rosetting parasites resulted in discrepancy between the rosetting frequency 
by microscopy and % positive population by FACS. However, following panning by 
an anti-VarO monoclonal antibody, there was a high correlation between the two 
reads. It was therefore important that a homogenous population of SA075 
expressing SA075var1 be maintained in continuous culture. A cell sorting protocol 
(described in section 5.3.2) was developed that allowed for selection of a 
monovariant-enriched SA075 parasites using anti-NTS-DBL 1a antibody. Once 
optimized, the protocol was later adapted for use on other P.fa/ciparum lab strains 
using their respective homologous antibodies. All the cell-sorted parasites were 
frozen down and later used to examine clinical relevance of rosetting variants 
using plasma from previously sick children (Chapter 6). Figure 5.9 shows an 
example of 1) unsorted versus 2) cell-sorted SA075 paraSites stained with rabbit 
IgG control (left panel) and anti-NTS-DBLa antibodies (right panel). The 
percentage of the positive population is indicated on the top right quadrant. 
Results show that the cell sorting protocol was effective by causing a 50% 
increase in the positive population. 
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Figure 5_9: FAGs plots showing staining SA075 parasites before (top right) and 
after (bottom right) cell sorting. In each assay, a rabbit IgG control was included. 
The proportion of cells positive for NTS-OBLa antibody staining was 37 % in the 
unsorted population and increased to 78.2 % in the sorted population. 
Does the % positive population correlate with rosetting frequency? 
It was important to determine how the % positive population by FACS assay 
compared to the rosetting frequency (% RF) by microscopy. An ideal situation 
would be a positive correlation between the two reads thus supporting 
identification of SA075var1 as the rosette mediating PtEMP1 variant. A 
poor/negative correlation on the other hand would indicate that the PfEMP1 being 
enriched was probably not responsible for rosetting. A systematic assay was 
therefore set up to compare the % positive population by FACS and the % RF by 
microscopy for both the cell sorted and unsorted SA075 parasites (summary in 
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Table 5.2). Microscopy reads were made by two independent readers. Results 
showed inconsistencies between the % positive population by FACS and rosetting 
frequencies in both the unsorted and the cell sorted parasite populations (Table 
5.2). First, the unsorted parasites showed a discrepancy between microscopy and 
FACS with a % RF (average score of 21%) and % positive population (51%) 
respectively. One round of cell sorting however resulted into parallel reads where 
an average % RF of 38% and % positive population of 32% were observed. It is 
not clear why there was a drop in % positive population from the original 51 % to 
32%. However, in an attempt to increase the rosetting frequencies, two rounds of 
rosette selection by Percoll flotation method (Chapter 2, section 2.3.4) were later 
done on the cell-sorted parasite and this resulted in a higher average % RF 
(66.4%) that correlated well with the % positive population by FACs (69%). These 
results were encouraging and suggested that SA075var1 was indeed responsible 
for rosetting in SA075 parasites. However, a further attempt to increase the 
homogeneity of the sorted parasites by a second round of sorting resulted into an 
even bigger discrepancy between % RF (average 31%) and % positive population 
(72.9%). Table 5.2 summarizes the data comparing % RF by microscopy and % 
positive population by FACS. 
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Table 5.2: A comparison between rosetting frequency by microscopy and % 
positive population by FAGS in unsorted and cell sorted SA075 parasites 
Parasite %Rosetting % positive 
frequency by population by 
microscopy FACs 
1st Reader 2ndReader 
SA075 Unsorted 17 25 51 
SA075_First round 42 35 32 
cell sorting 
SA075_Cell sorted 62.7 70 69 
once with two 
rounds of Percoll 
selection. 
SA075 _Second 24 38 72.9 
round cell sorting 
5.5: DISCUSSION 
This chapter focused on functional characterization of six anti-PfEMP1 antibodies 
targeting extra-cellular domains encoded by putative rosette mediating var gene 
from a field isolate from Kisumu , Kenya. One key finding in this chapter was the 
possibility that SA075var1 PfEMP1 variant may not be involved in rosetting in 
SA075 parasites. In a comparison of rosetting frequency (% RF) by microscopy 
and the % positive population by FACs assay on both the unsorted and cell sorted 
SA075 parasites (Table 5.2), inconsistent results were observed that could 
suggest that SA075var1 was not the rosette mediating variant in SA075 parasites. 
It would be expected that if SA075var 1 was responsible for rosetting in SA075, 
the RF by microscopy would closely match the % positive population by FACs 
stained by an anti-SA075var1 antibody. In some instances however, the % RF 
was found to be lower than the % positive population by FACS. A possible 
explanation would be that the rosettes in SA075 are generally "weak" and that any 
slight disruption would result in lower % RF counts compared to the positive 
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population by FACs staining. It could also be that SA075var1 is indeed responsible 
for rosetting but the anti-SA075var1 antibodies cross-react with different variant 
within the SA075 genome resulting into high % positivity by FACS and low 
rosetting frequencies. This may however be ruled out by the fact that all the six 
SA075var1 antibodies to different domains recognized the same infected RBC 
population in multiple FACS experiments hence it is unlikely there is cross-
reactivity with a different variant. 
None the less, the SA075var1 antibodies were tested for their ability to recognize 
PfEMP1 on the surface of live infected RBCs and mediate phagocytosis. One of 
the antibodies was further used to develop a cell sorting protocol that was later 
adapted and used to select for monovariant-enriched parasites in other 
P.falciparum strains. 
It is known that acquired protective immunity to malaria infection relies on 
antibodies recognizing the variant surface antigens such as PfEMP1, expressed 
on the surface of late-stage-infected RBCs (Marsh and Howard 1986; Bull, Lowe 
et al. 1998). Antibodies to rosette mediating-PfEMP1 variants, and particularly 
those from NTS-DBLa. domain, have been widely examined in immunological 
studies. Only one study by Ghumra et al., 2011 (Ghumra, Khunrae et al. 2011) has 
so far done a systematic characterization of antibodies to recombinant 
extracellular domains of a rosetting PfEMP1 variant i.e. ITvar9. In this chapter, the 
specificity of six SA075var1 antibodies binding to live infected RBCs was 
evaluated by IFA and FACS assays (Figure 5.2). All antibodies to the five domains 
and one di-domain of SA075var1 recognised the native protein on the surface of 
live infected RBCs with the IFA results showing a punctuate fluorescent staining 
pattern that is typical of PfEMP1 as previously described (Baruch, Pasloske et al. 
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1995; Ghumra, Semblat et al. 2008; Ghumra, Khunrae et al. 2011). A further 
confirmation that the antibodies were targeting PfEMP1 on the surface of infected 
SA075 RBCs was in the trypsin experiment (Figure 5.4), where all the antibodies 
showed absence of binding to the trypsin-treated cells, indicating that the trypsin 
sensitive PfEMP1 had been abolished. Although all the antibodies recognized the 
surface of infected RBCs, there was a difference in the levels of binding 
sensitivities or end titres. NTS-DBLa showed the highest sensitivity, reacting with 
>50% parasite positive population at a concentration of 1.57J.lg/ml (Figure 5.3 A 
and C). The high sensitivity could perhaps be because the domain is more 
exposed in the final protein than the other domains or might simply reflect higher 
affinity antibodies due to a higher quality recombinant protein generation. On the 
other hand, there was low binding sensitivity by anti-CIDR1a and anti-DBL2J3 
antibodies (Figure 5.3 B and C). This could be attributed to several factors: -1) The 
two domains, which occur next to each other in tandem are perhaps not fully 
exposed to the surface to allow for antibody binding. 2) It could also be that the 
proteins used for immunization did not contain correct conformational epitopes 
hence the low reactivity of these two antibodies. For both CIDRa and DBLI3 there 
was very little protein at the predicted molecular weight as compared to proteins 
from the other domains (Figure 4.11). It would be interesting to find out whether 
the two domains are recognized by antibodies in ELISA, although this does not 
often correlate well with surface recognition (Vigan-Womas, Guillotte et al. 2011; 
Ghumra, Semblat et al. 2012). A previous field study done by Mackintosh and 
COlleagues (Mackintosh, Christodoulou et al. 2008) to examine the acquisition of 
naturally acquired antibodies to recombinant domains of A4U parasites showed 
evidence for age-associated acquisition of domain-specific IgG for all the domains, 
except CIDR1a and DBL213 (Mackintosh, Christodoulou et al. 2008) by ELISA. In 
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the same study, antibody responses to recombinant CIDR 1 a domain were 
significantly negatively correlated with those of intact A4U parasites. Although this 
is not indicative of conservation of CIDR1a and DBL213 sequences in SA075var1 
and A4var, it may support the idea that some PfEMP1 domains may be generally 
more exposed than others in the overall PfEMP1 protein structure. 
SA075var1 antibodies were tested for their ability to mediate phagocytosis. This 
effector mechanism is thought to be important for antibodies that recognize the 
surface of infected RBCs (Langhorne, Ndungu et al. 2008). In antibody mediated 
phagocytosis assay, only four of the six antibodies were able to induce phacytosis 
when opsonized with SA075 infected RBCs. Anti-CIDR1 a and anti-DBL213 did not 
induce phagocytosis even at the highest antibody concentration of 400~g/ml. Note 
that the two antibodies also had the lowest end titres when tested for surface 
recognition. It could be that induction of phagocytosis requires not only a certain 
threshold concentration, but also antibodies of a certain quality. One caveat in this 
assay could be in the use of rabbit generated antibodies against human RBCs. It 
is possible that the mechanism of antibody-mediated phagocytosis are different in 
humans versus rabbits considering that rabbits have only one IgG class while 
humans have 4 IgG subclasses, two (lgG1 and IgG3) of which are more efficient in 
mediating phagocytosis (Tebo, Kremsner et al. 2001; Tebo, Kremsner et al. 2002). 
To investigate the antigenic relationship of different rosetting parasites, SA075var1 
antibodies were used in surface staining assays against seven heterologous 
parasites from different geographical locations and with different IgM binding 
phenotypes. Apart from anti-CIDR1a and anti-DBL213 which cross-reacted with 
TM284R+ parasites, all other antibodies showed a variant specific-response. 
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Interestingly, these are the two antibodies that showed weak surface recognition 
and inability to induce phagocytosis. The cross reactivity by these two antibodies 
was rather surprising because a recent study by Ghumra et al., 2012 (Ghumra, 
Semblat et al. 2012) showed induction of strain transcending antibodies that 
seemed to be limited to rosetting parasites with IgM binding phenotype. This was 
not the case with antibodies from the group of parasites with non-lgM binding 
phenotype to which SA075 parasites belongs, discussed in chapter 4, section 
4.4.4. However, the antibodies tested in the Ghumra 2012 study (Ghumra, 
Semblat et al. 2012) were all from the NTS-DBLa domain and therefore the role of 
antibodies to the downstream domains of PfEMP1 variants remains unknown. At 
the sequence level, TM284var1 and SA075var1 belong to different CP groups, 
different block sharing (BS) groups (Chapter 4, Table 4.6) and have different 
domain architectures (Chapter 4 Figure 4.10). They also posses different domain 
cassettes i.e. DC11 and DC8-like respectively. The cause of the cross-reactivity by 
antibodies to the two domains therefore remains unknown. 
Antigenic switching is one major caveat in the study of var genes and their 
association with particular adhesion phenotypes. In rosetting parasites, this could 
result in a heterogenous population of rosette-forming parasites expressing 
different PfEMP1 variants. The ability of SA075var1 antibodies to react with the 
surface of live infected RBCs was exploited in a cell sorting FACS assay, in which 
anti-NTS-DBL 1a antibody was used to isolate parasites expressing SA075var1. 
The protocol was later adopted and used for all other P.falciparum strains which 
were used in examining the clinical relevance of rosetting variants as will be 
discussed in chapter 6. A similar strategy has been used for VatO expressing 
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parasites although the technique used was panning using a specific monoclonal 
antibody (Vigan-Womas, Guillotte et al. 2008) and not cell sorting. 
In conclusion, in spite of the possibility that SA075var1 does not mediate rosetting 
in SA075, this study confirms previous observations that it is possible to induce 
functional antibodies from PfEMP1 variants. Antibodies raised against NTS-
DBL1a. domains have shown greater surface reactivity, sensitivity and functional 
activity such as promoting phagocytosis of homologous parasite strains compared 
to antibodies raised against domains downstream of NTS-DBL 1 a.. Here, we also 
confirm that antibodies to non-lgM binding parasites generally induce strain 
specific responses although 2 out of 6 of the antibodies showed cross reactivity 
with TM284R+, a parasite with IgM-binding phenotype. More rosette-mediating 
variants especially from field isolates will need to be studied to fully understand the 
molecular mechanisms of rosetting and the importance of anti-rosetting 
antibodies. 
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CHAPTER 6 
Clinical relevance of rosette-mediating PfEMP1 variants 
6.1: INTRODUCTION 
6.1.1 :Immunity against rosette forming parasites 
Natural immunity to malaria in endemic areas is generally acquired after repeated 
exposure to infection (Marsh and Kinyanjui 2006; Doolan, Dobano et al. 2009). It is 
believed that immunity to variant surface antigens (VSAs) develops in a similar 
manner in which variant-specific responses develop against each VSA that the 
host encounters (Ofori, Dodoo et al. 2002). Following cumulative exposure to 
multiple parasite infections over time, a broad repertoire of strain specific immune 
responses then develops that can recognize different VSAs (Doolan, Dobano et al. 
2009). This kind of build-up in immunity has been reported for most of the surface 
antigens presented during the Plasmodium falciparum asexual cycle. As 
discussed in Chapter 1 section 1.7, the VSA described here will refer mainly to 
Plasmodium falciparum erythrocyte membrane Protein 1 (PfEMP1). 
Studies on antibody responses against rosetting strains have shown the presence 
of anti-PfEMP1 antibodies and that the potential protective mechanisms of these 
antibodies includes anti-rosetting activity (Carlson, Helmby et al. 1990; Ghumra, 
Khunrae et al. 2011; Ghumra, Semblat et al. 2012) and their ability to mediate 
phagocytosis (Ghumra, Khunrae et al. 2011; Ghumra, Semblat et al. 2012). 
Antibody responses by human plasma samples against recombinant domains of 
rosetting parasites (and particularly NTS-DBLa.) have previously been measured 
by ELISA (Mayor, Rovira-Vallbona et al. 2009; Vigan-Womas, Lokossou et al. 
2010). These results suggest that despite the extensive polymorph isms, 
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individuals do raise antibodies against recombinant domains of rosette-PfEMP1 
variants. However, one possible caveat with the use of recombinant proteins may 
be the improper folding of the proteins which could result in either absence of 
binding or differences in the recognition of linear epitopes compared to 
conformational epitopes, a concern that has been previously discussed (Vigan-
Womas, Guillotte et al. 2011; Ghumra, Semblat et al. 2012) (Angeletti, Albrecht et 
al. 2013). Recognition of the native PfEMP1 on the surface of live infected RBCs 
by anti-PfEMP1 antibodies (Ghumra, Khunrae et al. 2011; Ghumra, Semblat et al. 
2012) has therefore been an alternative approach. Analyzing immune responses 
against rosette-mediating variants may help us to understand the link between 
rosetting and severe disease and how this immunity protects against severe 
disease. The importance of such studies is that despite the consistent association 
between rosetting and severe malaria in Sub-Saharan Africa (Carlson, Helmby et 
al. 1990; Rowe, Obeiro et al. 1995; Newbold, Warn et al. 1997; Kun, Schmidt-Ott 
et al. 1998), the exact mechanisms by which rosettes cause severe disease 
remain unclear. 
An ideal way to directly link rosetting to pathogenesis of severe disease would be 
to use an animal model in which the entire process of development of severe 
disease due to rosetting and the acquisition of antibodies would be monitored. 
However, such models as reviewed by Craig et aI., 2012 (Craig, Grau et al. 2012) 
are not able to reproduce the spectrum of syndromes and protection that is seen in 
humans. This chapter focuses on examining the in-vivo relevance of rosette-
mediating variants by studying the antibody responses to cell sorted rosetting 
parasites. Using patient's plasma samples taken at the time of disease (acute) and 
2-4 weeks later (convalescent), the kinetics of variant-specific antibody responses 
were studied in patients with different malaria clinical syndromes compared to 
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uncomplicated malaria controls. An increase in antibody levels between the two 
time points would suggest that the rosetting variant being tested was antigenically 
similar to the variantls expressed by the parasite at the time of disease thus linking 
the variant to the particular syndrome. 
6.2: CHAPTER AIMS 
The main aim of this chapter was to study variant-specific antibody responses 
against rosette-mediating variants and determine whether certain PfEMP1 variants 
could have played a role in particular disease outcomes. The newly described 
SA075var1 variant (chapter 4) was also included. Using acute-convalescent 
plasma pairs from carefully matched malaria cases and controls, the kinetics of the 
antibody responses against parasites enriched for single variants were compared. 
Analysis was also done on unmatched samples in a bigger study. The results 
would reveal whether particular rosette-mediating variants were antigenically 
related to parasites that the patients were exposed to at the time of disease. 
2.1 Specific aims 
i. To compare acute and convalescent antibody responses to different 
rosetting parasites using plasma from Kenyan children who presented with 
different clinical syndromes of severe malaria. 
ii. As a follow-up to a study by Ghumra et a/., 2012 (Ghumra, Semblat et al. 
2012), to compare antibody responses to rosetting parasites with IgM 
binding phenotype versus non-igM binders. 
iii. To study the kinetics of antibody responses to rosette-mediating variants 
overtime. 
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iv. To examine the relationship between the antibody responses to rosetting 
variants with rosetting frequency, parasitaemia and age. 
v. To compare acute-convalescent antibody responses within samples that 
had rosetting scores and to correlate them with rosetting frequency. 
6.3: MATERIALS AND METHODS 
6.3.1: Parasites used in the analysis 
Cell-sorted rosetting parasites were used for surface recognition assays in this 
chapter. The process of cell sorting to select for rosetting parasites enriched for a 
single variant was done as described in Chapter 5, section 5.3.2 using facilities at 
the University of Edinburgh, Scotland. Four different laboratory rosetting strains 
and the recently culture-adapted SA075 line were used (Table 6.1). The 
importance of aiming for monovariant-enriched parasites was because responses 
to heterogenousPfEMP1 had the potential to mask the variant specific responses, 
especially when using immune sera (Vigan-Womas, Guillotte et al. 2008). 
Following cell sorting, the parasites were bulked up in culture for 1-2 weeks before 
being frozen down at both ring stage and pigmented trophozoite stage for 
shipment to Kilifi, Kenya. Prior to freezing, the cell-sorted trophozoites were 
stained for FACS assay using their respective homologous anti-NTS-DBLa. 
antibodies to check for their final PfEMP1 expression level (Figure 6.1). The 
proportion of infected RBCs that were positive for staining with the homologous 
NTS-DBL a. antibody was high, ranging between 68- 80%. The inability to achieve 
100% homogenous population could however be due to rapid switching away of 
Var genes during the 2 weeks in culture after cell sorting. 
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Table 6.1: List of parasites that were cell sorted to express single variants. Also 
shown are the PfEMP1 variants associated with rosetting in the four laboratory 
strains and their IgM-binding phenotypes. 
IgM References 
binding 
Isolate Name PfEMP1 variant phenotype 
+ (Ghumra, 
Semblat et al. 
TM284R+ TM284var1 2012) 
+ (Ghumra, 
Semblat et al. 
HB3R+ HB3vart) 2012) 
+ (Ghumra, 
Semblat et al. 
PAR+ ITvar60 2012) 
-
(Ghumra, 
Semblat et al. 
R29R+ ITvar9 2012) 
- -
SA075 SA075var1 
216 
400J.lg R.otbbit IgG 400J.l9 NTS-OB 
TM284R+ 
0 .243 0 . 1 
PAR+ 0.219 0.111 
"'::-',. 
SA075 10· 
0 .3 73 , ...... 
. ",' ~~" 0.13 
·."t' 
0, 
103 
. ", ~\ . 
.... . ' . 
. , 
' 0 
'" " ..
~ .... 
::> 102 
.... 
~ 
10 1 
102 103 
H o~chst-A 
217 
400J.lg Rabbit IgG 400~g NTS·OBLa 
R29R+ 10 4 10 4 037 .. 
.. ", 
0247 0.872 
.' .... ~: 
10 10 3 
< 
« cD 
.. ciJ 
... OJ 
... 
(; 
10 2 OJ 
~ u: ~ ;r ~ 
0( 
10 1 
I 
10 0 101 102 10 3 10' 
_eMt.,t\ 10 0 10 1 10 2 10 3 10 4 
Ho+ch~t·A 
HB3R+ 10 4 10' 
0 .198 00624 1.51 
~ 
10 3 .- 10 3 
. '. 
.. 
.. 
.. 
'" I ', ••• ~' " , < ,';' '; . .- .. .. ' < . . C) 0) Q C) 
• .. ~ 10 2 (; 10 2 :I 
L.. i: 
~ " )( .,
~ < 
10 I 10 1 
10 0 10 0 
0 .64 
10 0 10 1 10 2 10 3 10 4 10
0 10 1 10 2 10 3 10 4 
H .... eh~t.,t\ Hoochst.,t\ 
Figure 6.1: Surface staining of rosetting parasites using homologous antibodies. 
The FACS assays were done 1-2 weeks after cell-sorting just before freezing 
down the trophozoites. On the left panel are controls stained with 400fLg/ml of 
rabbit IgG antibody while the right panel has the parasites stained with 400llg/ml 
homologous NTS-OBLa antibodies. The proportion of infected RBCs that were 
positive for staining with the homologous NTS-OBLa antibody is shown on the top 
right quadrant. The FACS assay was done as previously described in Chapter 2 
section 2.3.10. 
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6.3.2: FACS assay using human serum 
The FACS protocol described here is different from the previously described assay 
which used rabbit IgGs (Chapter 2, section 2.3.10). It was adapted from a protocol 
originally described by Bejon and colleagues in 2009 (Bejon, Warimwe et al. 
2009). The aim was to examine surface recognition of PfEMP1 on different cell-
sorted parasites using acute and convalescent plasma pairs from children with 
different clinical syndromes. 
To reduce the amount of day-to-day variability in the assay, the cell-sorted 
parasites were frozen down in several vials at trophozoite stage. On the day of the 
assay, a vial of the test parasite as well as the controls (listed below) were thawed 
out as previously described (Chapter 2, section 2.3.6). The haematocrit was then 
adjusted to 4% in 1X phosphate buffered saline (PBS) containing O.S% bovine 
serum albumin (BSA) and ethidium bromide (10j..lg/ml). 11.SjJl of the suspension 
was incubated with 1 j..ll of each test plasma or serum in 96-well U-bottomed plates 
(Falcon, Becton Dickinson, USA) for 30 minutes at room temperature. This was 
followed by three washes using 1XPBS/0.S% BSA media and a further 30 minute 
incubation with 50 III FITC-conjugated sheep anti human IgG antibody (Binding 
site, UK) diluted at 1 :50. A final wash was done and the cells re-suspended in 
200lli of wash buffer. Staining by the anti-PfEMP1 rabbit antibody and the non-
immune rabbit IgG were done as previously described in Chapter 2, section 
2.3.10.1000 trophozoite-infected RBCs were acquired on a FCSOO flow cytometer 
(Beckman Coulter, UK). Data in LMD fonnat were exported to Flowjo 7.6.1 (Tree 
Star Inc.) for analysis. 
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The following controls were run simultaneously on each plate in every 
experiment:-
i. Hyper immune serum (referred to as A 1) against the test parasite at a 
dilution of 1/12.5. The serum was obtained from an adult living in Kilifi. 
ii. Five non-immune European plasma against the test paraSite at a dilution of 
1/12.5. 
iii. Hyper immune serum against A4 parasite at a dilution of 1/12.5. This is the 
only control that was the same in all assays regardless of the parasite being 
tested. It was included to check that the assay conditions remained the 
same when different parasites were being tested. 
iv. No-antibody control stained with FITC anti-Human IgG secondary antibody. 
v. 25~g/ml of rabbit anti-NTS DBL 1a antibody against the homologous test 
parasites, 
vi. 25J,lg/ml of rabbit IgG control antibody against the test paraSites. 
vii. No-antibody control stained with FITC anti-Rabbit IgG secondary antibody. 
A 96-well plate layout used to perform the FACS assays is shown in Figure 6.2 
where each half of the plate contained duplicate samples. 
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A 
B 
1 2 3 4 5 6 7 8 
European serum 
Hyperimmune serum (A 1) + Rosetting parasite being tested 
Hyperimmune serum (A 1) + Frozen A4 parasites 
No antibody control for anti-Human IgG FITC 
Anti-NTS DBLa antibody on homologous test parasites 
Rabbit IgG control antibody 
No antibody control for anti-Rabbit IgG FITC 
9 10 11 12 
Figure 6.2: A 96-wel/ plate layout showing the position of samples and controls 
during the FACS assay. Duplicate samples and controls were arranged on either 
half of the plate. 
6.3.2.1 Gating strategy 
Non-specific antibodies in immune plasma have previously been shown to bind 
various antigens expressed on the surface of RBCs (Williams and Newbold 2003). 
In these assays, it often resulted in a shift in the non-infected cell population as 
shown in Figure 6.3 A (Q4) (marked by the red dotted line). This shift in population 
was rarely seen in the European plasma tested on the same cells (Figure 6.38). A 
gating strategy was therefore used that would correct for the shift in population. 
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Figure 6.3: Non-specific binding of IgG in immune plasma resulting in a shift in 
population of cells. Panel A shows binding by immune plasma where the red 
dotted line represents the shift in population of non-infected RBGs while Panel B 
shows binding by European plasma which does not have the shift in population. 
The y axis distinguishes infected RBGs from non-infected RBGs based on 
ethidium bromide staining while the x axis distinguishes PfEMP1 binding as FITG 
positive and FITG negative. 
Gating was done as follows: -
1) All RBCs were first gated based on side scatter (SSC) and forward scatter 
(FSC) to exclude debris or lysed cells. 
2) Next, RBCs were gated by ethidium bromide_FL2 to obtain infected RBC 
and non-infected RBC populations 
3) Finally, the median fluorescent intensity (MFI) on FL 1 (Anti-Human IgG 
_FITC) was calculated for both infected and non-infected RBCs. To account 
for the non-specific shift, the MFI of non-infected RBCs was subtracted from 
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the MFI of infected RBCs. This was done for both the test samples and the 
European controls. The final variant specific IgG response was then 
calculated as shown in Figure 6.4. 
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Variant Specific antibody response= (MFI a-MFI b)-(MFI c-MFI d) 
Where:-
a= Infected RBCs stained with immune plasma 
b= Non-infected RBCs stained with immune plasma 
c= Infected RBCs stained with non-immune plasma 
d= Non-infected RBCs stained with non-immune plasma 
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Figure 6.4: Calculation of variant specific antibody response. RBCs were first 
gated based on side scatter (SSC) and forward scatter (FSC). The MFI for infected 
and non-infected cells were then determined and the variant specific response 
calculated by subtracting the non-immune response (MFlc-MFld) from the immune 
response (MFI a-MFlb). 
6.3.3: Study design 
Two approaches were used to investigate the antibody responses against cell-
sorted parasites using plasma at acute and convalescent stages from children who 
had different malaria syndromes. 
1. Matched case-control approach (nested study) 
2. Unmatched population-based approach 
6.3.3.1: Matched Case control approach 
Plasma samples were selected from children who presented at the Kilifi District 
Hospital between 2005-2010 with varying levels of malaria severity. The clinical 
clasSifications of the different syndromes was done as previously described by 
Marsh and colleagues, 1995 (Marsh, Forster et al. 1995). Ten cases of pure 
cerebral malaria (eM) defined as impaired consciousness with a Blantyre coma 
score of <3 and 10 cases of pure respiratory distress (RD) defined as hemoglobin 
level <5 g/dL and abnormal deep breathing (English, Wale et al. 1998) were 
matched to uncomplicated malaria controls (UM) by age, date of admission and 
blood group (Table 6.2). The uncomplicated malaria controls were defined as 
children Who were either seen in the outpatient department and required no 
admission or children who were admitted but did not develop any signs of severe 
disease throughout their admission. All patients had fever> 36.5 °C. FACS assays 
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were done using acute and convalescent plasma pairs for both cases and controls 
as described above (section 6.3.2). The acute plasma was collected from children 
at the time of presentation to the hospital while the convalescent samples were 
collected from the same children 2- 4 weeks later. Sample collection and 
processing were done as described in Chapter 2, section 2.2. Table 6.2 below is a 
list of the cases and controls with their date of admission, age, blood group and 
the parasite count at the time of admission. While all the cases were admitted at 
the hospital, the controls were either admitted or treated at the out-patient 
department-OPO as shown in Table 6.2. 
Table 6.2: Characteristics of samples used in the case-control study. Each severe 
malaria case (left column) was matched to an uncomplicated malaria control by 
date of admission, age, and blood group. Also shown are the parasite densities at 
the time of disease. The controls were either admitted in the hospital (admission) 
or treated at the out-patient department-OPD. All patients were assigned a unique 
identity (Sample ID) so that their clinical classification remained blinded until all 
data had been collected. 
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6.3.3.2: Unmatched-Population-based approach 
Like in the case-control approach, plasma samples were selected from children 
who attended Kilifi District Hospital with varying levels of severity and clinical 
syndromes. To differentiate it from the case-control study, this study was referred 
to as "population-based approach". It included a bigger sample size with the acute-
convalescent pairs of plasma being obtained at two time periods: 1994-1996 (53 
plasma pairs) and 2005-2010 (163 plasma pairs). However, unlike the case-
control study, this approach included children with overlapping clinical syndromes 
(See tables 6.3 and 6.4) and analysis involved comparing all severe cases against 
the non-severe cases. 
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There were important differences between the two sampling periods. First, a 
steady decline in malaria transmission that has been observed in Kilifi the last 20 
years (Okiro, Hay et al. 2007; O'Meara, 8ejon et al. 2008), and which might have 
affected host-pathogen interaction patterns between the two time-points. 
Secondly, the prevalence of clinical syndromes during the two sampling points 
(Table 6.3 and 6.4) was different: 1994-1996 samples had more SMA cases 
(18.9% versus 3.7%) while the 2005-2010 samples had more RD cases (9.8% 
versus1.8 %). Thirdly, whether or not this is due to changes in transmission 
patterns, there seems to be an overall increase the average age in children who 
present to the hospital with different clinical syndromes (mean age between 1994-
1996 was 37.07±32.45 months while the mean age between 2005-2010 was 
48.302±43.14 months). 
Patients were assigned unique identification numbers and their clinical 
claSSification remained blinded until all data had been collected. Some of the 
plasma samples, especially at the acute phase, have been used in previous 
studies by Warimwe et al., 2009 and 2012 (Warimwe, Keane et al. 2009; 
Warimwe, Fegan et al. 2012). 
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Table 6.3: Clinical characteristics and frequency of samples collected between 
1994-1996 
Syndrome 
Respiratory distress (RO) 
Impaired consciousness (Ie) (9 of 
whom were eM cases) 
Severe malarial anaemia (SMA) 
Respiratory distressllmpaired 
consciousnessl Severe malarial anemia 
(ROlle/SMA) 
Non-severe malaria (NS) 
TOTAL 
Mean Age 
(monthsL±SO 
31.0 
36.16± 22.1 
33.91±13.7 
24.0 
38.83±14.9 
Frequency 
(N) 
1.8% (1) 
22.6% (12) 
18.9%(10) 
1.8%(1 ) 
54.7%(29) 
100% (53) 
Table 6.4: Clinical characteristics and frequency of samples collected between 
2005-2010 
Syndrome 
Respiratory distress (RO) 
Impaired consciousness (Ie) (17 of 
Whom were eM cases) 
Severe malarial anemia (SMA) 
Respiratory distress/Impaired 
consciousness (ROlle) 
Respiratory distress/Impaired 
consciousness/ Severe malarial anemia 
(ROlle/SMA) 
Severe malarial anemia/ Respiratory 
distress (SMAlRO) 
Impaired consciousness/ Severe malarial 
anemia (Ie/SMA) 
Non-severe malaria (NS) 
TOTAL 
6.3.4: Data analysis 
Mean Age 
(monthsL±SO 
42.17±15.6 
47.31±32.7 
26.58±14.5 
37.02±18.4 
30.29 
42.06±25.0 
57.7 
51.09±31 .5 
Frequency 
(N) 
9.8 (16) 
18.4 % (30) 
3.7% (6) 
7.4% (12) 
1.2% (2) 
1.2% (2) 
0.6% (1) 
57.7% (94) 
100% (163) 
Data analysis was done using both Stata ™ version 11 .0 software and Graphpad 
prism 6, where P value <0.05 was considered significant for all tests. In stata , raw 
data were imported into the software and a "do-file" was written that was used for 
subsequent analyses. Spearman's rank correlation was used to test associations 
between two continuous variables while the relationships between a continuous 
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and a categorical variable were tested by either Mann-Whitney U test or Kruskal-
Wallis test. 
6.4: RESULTS 
6.4.1: Comparison of mean fluorescent intensity, median fluorescent 
intensity and % positive population by FACS analysis 
Three different FACS generated measures were used to quantify the variant 
specific IgG responses in the plasma. These were:-mean fluorescent intensity, 
median fluorescent intensity and percentage positive population. The three 
measures were compared against each other in turn to determine their level of 
correlation in each of the parasite strains that was tested. The correlation was 
done on all children's samples in the case-control study (Figure 6.5 in black) as 
well as rabbit non-immune IgG (in blue) and variant-specific IgG (in red). Figure 
6.5 shows scatter plots for results involving HB3R+, PAR+, R29+, SA07S and 
TM284R+. Spearman's rank correlation coefficient (Rho) and the P values are 
shown on each graph. 
There was a significant positive correlation for all the three measures against each 
other in all the assays (range of Rho- 0.4189-0.9841). HB3R+ and PAR+ showed 
the highest level of correlation with Rho values>0.9. However the variant-specific 
rabbit IgG response against HB3R+ formed a population of cells off the linear fit 
(Figure 6.5, Panel 1) when % percentage positive population was correlated with 
both mean and median. A positive correlation was seen for all isolates even when 
the controls were excluded from the analysis. (Range of Rho was 0.3234-0.9778). 
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Although a positive correlation would suggest that any of the three measures could 
be used in analysis, median fluorescence intensity henceforth referred to as "MFI", 
was chosen for subsequent analysis due to the wide range in some of the reads. 
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3. R29R+ 
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Figure 6.5: Correlation between mean fluorescence intensity (Mean MFI), median fluorescence intensity (Median MFI) and 
percent positive population for FACS assays carried out on different parasites. For each of the assays, correlations were done for 
1) % positive population versus Median MFI, 2) % positive population versus mean MFI and 3) mean MFI versus median MFI. 
Shown on the graphs are the Spearman 's rank correlation coefficient (Rho) and the P value. Variant specific Anti-PfEMP1 rabbit 
antibodies are represented in red while the control non-immune rabbit IgG are represented in blue. The rest of the other samples 
are represented in black. 
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6.4.2: Determination of inter-assay and intra-assay variability 
Due to the large number of samples and controls involved, assays were carried 
out on different days. Assay variability was therefore determined for all the 
isolates. Coefficient of variation (% CV) which is a measure of the dispersion of 
data points around the mean, was calculated for duplicate reads within each plate 
for all the 11 controls. Although there are no generally accepted minimal 
performance requirements for immunoassays, the industrial standard for % CV 
that has been used for ELISA is <20% (USDHHS 2001). In the current assay, an 
arbitrary %CV cut-off was set at 20 and any value less than this considered 
acceptable. Figure 6.6 shows the MFI for all the 11 controls in the different assays. 
Each point on the graph represents a read from an individual well. The table below 
each graph shows the average MFI for the duplicate reads in each plate and their 
%CV. 
Results showed that 92% of all the % CV values were within the acceptable value 
of less than 20% with the negative controls generally showing lesser variability 
than the positive controls. In most cases, the outlier reads occurred in one of the 
duplicate wells in a plate. However, data from all sample wells were included in the 
analYSis. 
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1. PAR+ 
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Intra-assay variability for Controls used in PAR+ FACS assay 
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% CV FOR DUPLICATE READS IN FACS ANALYSIS _PAR+ ACROSS 2 PLATES 
Plate 1 Plate 2 
Control Mean "CV Mean "CV 
A1 serum on PAR+ 14.200 0.996 14.000 0.000 
A4 trophs+ A 1 serum 2.485 16.788 3.580 30.812 
European 1 1.335 15.360 2.775 58.862 
European 2 1.135 3.115 1.285 3.852 
European 3 1.064 16.747 1.195 5.325 
EUropean 4 1.160 18.287 1.150 12.298 
European 5 1.135 1.869 1.200 1.179 
Antl-NTS_ DBl alpha _PAR+ 10.900 9.082 8.530 18.403 
No Ab_Antl-Human 0.928 4.955 0.917 2.313 
secondary Ab. 
No Ab_Antl-Rabbit 0.688 0.309 0.747 2.083 
secondary Ab. 
Rabbit IgG control 0.839 2.446 0.897 3.153 
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2. SA075 
o 
Intra-assay variability for contrds used in SA075 FACS assay 
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% CV FOR DUPLICATE READS IN FACS ANALYSIS 
_SA075 ACROSS 3 PLATES 
Plate 1 Plate 2 
Control Mean "CV Mean "CV Mean 
A1 serum on SA075 39.900 7.443 34.200 4.962 NO 
A4 trophs+ A1 serum 3.61 5 9.585 3.310 7.263 NO 
European 1 0.834 6.363 0.816 13.345 0.959 
EUropean 2 0.647 5.359 0.865 9.406 1.849 
European 3 0.737 3.168 0.947 7.994 0.775 
EUropean 4 0.800 10.253 1.035 0.683 0.854 
European 5 0.789 6.188 0.917 3.009 0.785 
Antl-NTS_ DBl alpha _SA075 16.150 2.189 17.400 0.000 17.600 
No Ab_Anti-Human secondary 
Ab. 
0.637 5.772 0.738 6.132 0.648 
No Ab_Anti-Rabbit secondary 
Ab. 
0.379 10.275 0.576 1.597 0.493 
Rabbit IgG control 0.584 5.938 0.769 2.023 0.134 
Plate 3 
%CV 
NO 
NO 
26.692 
78.856 
5.569 
0.331 
7.927 
0.804 
6.225 
7.609 
9.071 
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3. R29+ 
Intra-assay variability for controls used in R29R+ assay FACS assay 
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% CV FOR DUPLICATE READS IN FACS ANALYSIS R29R+ ACROSS 2 PLATES 
-
Plate 1 Plate 2 
Control Mean "CV Mean "CV 
A1 serum on R29R+ 20.600 9.441 18.350 4.455 
A4 trophs + A1 serum 2.755 1.063 3.975 0.290 
Antl-NTS-DBL alpha_R29R+ 43.050 19.831 59.050 8.980 
European 1 0.791 0.377 0.823 0.040 
European 2 0.883 0.410 0.867 0.070 
European 3 0.934 0.462 0.902 0.085 
European 4 0.972 0.482 0.994 0.052 
European 5 0.967 0.464 0.970 0.022 
No Ab_Anti-Human 0.733 0.287 0.857 0.009 
secondary Ab. 
No Ab_Anti-Rabbit 0.681 0.338 0.644 0.030 
secondary Ab. 
Rabbit IgG control 1.075 0.514 1.025 0.007 
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4. TM284R+ 
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Intra-assay variability for controls used in TM284R+ FACS assay 
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% CV FOR DUPLICATE READS IN FACS ANALYSIS 3M284R+ ACROSS 3 PLATES 
Plate 1 Plate 2 Plate 3 
Control Mean %CV Mean %CV Mean %CV 
A1 serum on TM284R+ 20.250 0.349 18.100 2.344 18.200 2.331 
A4 trophs + A1 serum 1.080 5.238 1.095 3.229 0.949 6.486 
Anti-NTS-OBlalpha_ TM284R+ 18.700 7.563 19.250 23.876 0.655 6.590 
European 1 0.679 2.397 0.702 0.101 22.050 4.169 
Europoan 2 0.693 5.616 0.684 5.582 0.685 2.169 
European 3 0.641 3.751 0.634 2.121 0.671 3.269 
European 4 0.752 3.670 0.695 5.291 0.607 7.921 
European 5 0.749 3.965 0.710 3.785 0.649 9.486 
No Ab_Anti-Human secondary Ab. 0.640 0.110 0.539 42.413 0.573 7.781 
No Ab_Anti-Rabbit secondary Ab. 0.273 23.613 0.294 9.621 0.230 20.643 
Rabbit IgG control 0.612 1.041 0.721 8.538 0.576 1.964 
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5. HB3R+ 
Intra-assay variability for controls used in HB3R+ FACS assay 
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% CV FOR DUPLICATE READS IN FACS ANALYSIS HB3R+ ACROSS 3 PLATES 
-
Plate 1 Plate 2 Plate3 
Control Mean %CV Mean %CV Mean %CV 
A1 serum on HB3R+ 20.450 1.037 20.550 5.161 18.200 2.331 
A4 trophs + A 1 serum 1.520 3.722 1.670 6.775 1.315 1.613 
Anti-NTS-DBL alpha_HB3R+ 64.900 0.872 62.250 1.477 64.500 4.166 
European 1 9.220 120.868 1.460 10.655 1.295 0.546 
European 2 1.295 2.730 1.290 0.000 1.290 4.385 
European 3 1.290 0.000 1.250 1.131 1.250 3.394 
European 4 1.430 1.978 1.385 0.511 1.480 4.778 
European 5 1.365 1.554 1.485 2.381 2.535 66.666 
No Ab_Anti-Human secondary 1.025 2.070 1.025 0.690 0.914 0.464 
Ab. 
No Ab_Anti-Rabbit secondary 0.890 2.146 0.886 1.038 0.807 2.629 
Ab. 
Rabbit IgG control 1.245 2.840 1.220 2.318 1.110 1.274 
Figure 6.6: Intra-assay variability for the 11 controls used in the case-control 
FACs assays for PAR+, SA 0 75, R29R+, TM284R+ and HB3R+. Each point in the 
graph represents an individual read. The table below each graph shows the mean 
and % CV for the duplicate reads in each plate. 
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6.4.3: Surface recognition of parasites selected to express single variants by 
IgGs from children with different malaria syndromes-case control study 
Variant-specific antibody responses to rosette-selected parasites were examined. 
Acute and convalescent plasma pairs from children who presented with pure CM 
and pure RD were compared against their matched UM controls. Figures 6.7 and 
6.8 shows the median of MFI values for antibody responses of the cases and 
controls at both acute and convalescent stages in CM and RD cases respectively. 
Each data pOint represents plasma from one patient. P value <0.05 was 
considered statistically Significant by Mann-Whitney U-test. A clinically important 
variant would be expected to show an increase in convalescent antibody 
responses in cases but not in the controls. 
Results showed a significant increase in antibody responses to the PAR+ parasite 
at acute versus convalescent in the eM cases (Figure 6.7 Panel A, P=0.0188) but 
not in the controls (P=0.2883). A similar significant increase was seen against 
HB3R+ parasites in RD cases (Figure 6.8 Panel C, P=0.0089) but not in the 
controls (P=0.0648). These results suggest that the two variants, ITvar50 
expressed by PAR+ and HB3var5 expressed by HB3 could be clinically important. 
It could be that children who presented with pure CM and RD syndromes were 
infected with parasites that were antigenically related to PAR+ and HB3R+ 
respectively. 
Interestingly, results from some of the UM cases also showed variant specific 
responses. Such results where convalescent responses were significantly higher 
than the acute responses were seen for RD controls tested against R29R+ 
(P=0.0354) and TM284R+ (P=0.0291) parasites. 
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Figure 6.7: Surface recognition of cell sorted parasite lines by plasma from 
children with pure cerebral malaria-eM (left panel) and their uncomplicated 
malaria -UM controls (right panel) at both acute and convalescent stages. Shown 
on the graph are the median of the MFls with each data point representing plasma 
from one patient. The parasites used were A) PAR+ B) TM284R+C) HB3R+ D) 
R29R+ and E) SA 0 75. (Mann Whitney U test, P<O.05). Only PAR+ showed a 
significant difference in acute versus convalescent responses in the cases and not 
in the controls. 
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Figure 6.8: Surface recognition of cell sorted parasite lines by IgGs from children 
with pure respiratory distress-RD (left panel) and their uncomplicated malaria-UM 
controls (right panel) at both acute and convalescent stages. Shown on the graph 
are the median of the MFls with each data point representing plasma from one 
patient. The parasites used were A) PAR+ B) TM284R+C) HB3R+ 0) R29R+ and 
E) SA 075. (Mann Whitney U test, P<0.05). Only HB3R+ showed significant 
difference in acute versus convalescent responses in the cases and not in the 
controls. 
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6.4.4: Surface recognition of parasites enriched in a single variant by IgGs 
from children with different malaria syndromes-Population-based study 
Due to the limited number of matched samples in the case control study, analysis 
of antibody responses was further extended to include more samples obtained 
from the hospital. Samples were obtained at two different sampling time points: -
1994-1996 and 2005-2010. Analysis included all impaired consciousness (IC) 
cases, as opposed to those with pure CM only. Also included were patients who 
presented with overlapping syndromes. Each acute sample had its convalescent 
pair that was collected 2-4 weeks later. Plasma samples collected between 1994-
1996 (N=53 pairs) were tested against 4 parasite lines i.e. PAR+, HB3R+, R29R+ 
and SA075 while samples collected between 2005-2010 (N=163 pairs) were 
tested against two parasite lines i.e. SA075 and PAR+. Due to the large number of 
samples involved, assays for each parasite were tested in 9 plates which were 
analyzed over 2 days. Variability was therefore based on both inter-assay and 
intra-assay. (Assay variability data in appendix B.6). 
Analysis was first done by pooling all severe malaria cases including those with 
pure and overlapping syndromes into one group ·severe cases" and comparing 
their antibody responses (separate acute and convalescent) against the non-
severe malaria group. In the 1994-1996 dataset, only in R29R+ was there a 
Significant difference in IgG responses between the acute and convalescent in the 
severe cases (P=0.0404) (Figure 6.9). In the 2005-2010 data, the convalescent 
antibody responses against SA075 were significantly higher than the acute 
responses in both the severe and non-severe cases (P=0.0157 and P=0.0032 
respectively) (Figure 6.10). On the other hand, convalescent responses against 
PAR+ were Significantly higher than the acute responses only in the severe cases 
but not in the non-severe cases (P=0.0131). 
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that were not statistically different. 
Secondly, analysis was done to compare acute and convalescent antibody 
responses specifically for samples that were classified to have a single 
syndromes. Data from 1994-1996 had 12 Ie cases and 10 SMA cases while data 
from 2005-2010 had 30 pure Ie cases and 16RD cases. It is important to note that 
SMA cases and some Ie cases may have undergone blood transfusion which 
could confound their true antibody response as has previously been reported by 
Bull and colleagues (Bull, Lowe et al. 1999). Figure 6.11and 6.12 shows the acute 
versus convalescent IgG responses for specific severe syndromes versus the non-
severe controls for 1994-1996 and 2005- 2010 datasets respectively. 
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Between 1994-1996, there was no difference between the acute and convalescent 
antibody responses in cases with pure syndromes and the non-severe controls 
(Figure 6.11). This was evident in all the four parasite lines that were tested (Panel 
A-D). Equally, for the 2005-2010 data, the acute and convalescent antibody 
responses in with pure syndromes and the controls were not significantly different 
(Figure 6.12). However, there was a significant difference in the acute-
convalescent response in the non-severe group against SA075 parasites. (Figure 
6.12, Panel B). 
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Figure 6.11: Data ffom 1994-1996 showing surface recognition of cell sorted parasites lines by acute and convalescent plasma 
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Figure 6.12: Data from 2005-2010 showing surface recognition of cell sorted parasites lines by acute and convalescent plasma 
pairs from children who presented with single syndromes of impaired consciousness (IC), respiratory distress (RD) and non-
severe malaria controls. Shown on the graph are the median of the values with each data point representing plasma from one 
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253 
6.4.5: Trends in antibody responses to rosetting parasites between 2004 and 
2010 
Malaria transmission in Kilifi has been declining lately as evidenced by the 
declining prevalence in parasitaemia, increased mean age in malaria admissions 
and a shift in presentation of severe disease (O'Meara, Bejon et al. 2008). This 
could have had an effect on host-parasite interaction and development of immunity 
against malaria antigens. I therefore sought to investigate whether the decline in 
malaria transmission observed in Kilifi over the last 20 years had an effect on 
antibody responses to VSAs like PfEMP1. To allow for a comparison between the 
two time periods analysis was done only on PAR+ and SA075 parasites. In this 
analysis, acute antibody responses by both severe and non-severe cases within 
each year were pooled together. There was a significant difference in antibody 
responses to PAR+ between 1994-2010 (Kruskal Wallis P=0.0254) (Figure 6.13 
A). On the other hand, there was no difference in the median antibody responses 
to SA075 over the same period (Kruskal Wallis P=0.2299) (Figure 6.138). 
254 
A Antibody responses to PAR+ over time 
+ 1000 
~ P<0.0254 
0 100 • 
-
- • LL 
• ~ • • 
-
,. 
• • • 10 • (f) • • • •• • ~ • •• •• •• •• • • ..... • • • • 5 • • ••• :< • • •• •• ••• • •• • a. 
* 
•• • ~ ••• (I) 1 • •• ". ,. • OJ • • ...., •••• • ••• .:;.a.,a ~ ..... • --...- ~ CJ ........ ·k· •• •• • • •• •• ~ • •• • ••• • , •• • • 0.1 
1994 1995 1996 2005 2006 2007 2008 2009 2010 
B 
Antibody responses to SA075 over time 
L() P<0.2299 
""" 100 0 
C3 • • 
0 • • • 
- •• •• • 
- • • 
• u:: 10 ~ .. • • • • • • • ~ •• •• ••• • • # •• • • 
-
• 
.:. , •• 
..' ...a.-- • •• • en , 
.,:. • CI.> ...... • en • ~ •••• •• •• •• 
--!:- ••• 
---
7 8 1 ..... ..... 1!r. 4 • ••• • • •• ~ •••• a. • •• •••• • . .... en •••• •• •• • •• • CI.> .. :. •• •• • •• • • ~ ... • • • •• • C> 0.1 • • • ~ 1994 1995 1996 2005 2006 2007 2008 2009 2010 
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responses by both severe and non-severe patients with each dot representing an 
individual patient. Analysis was done by Kruskal Wallis test at P<O.05. 
Since age is an important factor in the development of immunity to malaria 
antigens, the relationship between antibody responses against the two parasites 
lines and age was also examined for all samples between 1994-2010. In severe 
malaria cases, only antibody responses to PAR+ and not SA075 were significantly 
associated with age (Rho=0.2407, P=0.0176) and (Rho=0.1263 P=0.2148) 
respectively (Figure 6.14 A and B). However, there was a significant positive 
correlation in antibody responses to both PAR+ and SA075 parasites with age by 
non-severe cases (Rho=0.2199, P=0.0182) and (Rho=0.3339, P=0.0003) 
respectively. 
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Figure 6.14: Relationship between acute antibody responses to A) PAR+ and B) 
SA075 with age. Non-severe cases are represented in black dots while the severe 
cases were represented with red dots. Spearman's rank test was done to 
determine strength of the association. Shown on the graphs are correlation 
coefficients (Rho) and p value. Both severe and non-severe antibody responses 
against PAR+ were positively correlated with age. However for SA 075, only 
responses to non-severe and not severe cases were positively correlated with 
age. 
6.4_6: Association between antibody responses and rosetting: Analysis on 
48 samples with rosetting frequency data 
To further investigate the role of antibodies to rosette mediating variants, analysis 
was narrowed down to those samples that had rosetting frequency scores. Of the 
163 paired samples from the 2005-2010 data set, 48 (29.4%) had rosetting 
frequency scores ranging from (0-86.2 %). The 1994-1996 dataset did not have 
rosetting information and therefore was not included in this analysis. 
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First, rosetting frequencies (% RF) were compared between all the severe cases 
versus the non-severe cases as has been done in previous studies (Rowe, Obeiro 
et al. 1995; Newbold, Warn et al. 1997; Heddini, Pettersson et al. 2001; Rowe, 
Shafi et al. 2002). Although there was a trend towards lower rosetting frequencies 
in non-severe cases compared to the severe cases, the difference was not 
significant. (Mann Whitney U test, P=0.1572) (Figure 6.15). Analysis of % RF 
between the sub-categories of severe malaria was not done due to the small 
number of samples in each category. 
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Figure 6.15: Rosette frequencies of 48 isolates from children with severe and non-
severe malaria. There was no significant difference between the %RF in severe 
versus non-severe cases (P=O.1752). 
Secondly, analYSis was done to investigate the correlation between rosetting 
frequencies with parasitaemia and with age, two factors that are important in 
development of immunity to malaria antigens. Previous studies have shown 
positive correlation between rosetting frequency and parasitaemia in samples from 
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Kilifi (Rowe, Obiero et al. 2002; Warimwe, Fegan et al. 2012). Consistent with 
these results, there was a significant positive correlation between rosetting and 
parasitaemia (Rho=0.4235, P=0.0027) (Figure 6.16A). However, there was a 
tendency towards a negative, although non-significant correlation between 
rosetting and age (Rho=-0.2307, P=0.1188) (Figure 6.168). 
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Figure 6.16: Relationship between rosetting frequency (% RF) with A) 
parasitaemia and B) age using the 48 samples that had rosetting scores. There 
was a significantly positive correlation between % RF with parasitaemia 
(Rho=0.4235, P=O.0027) but not with age (Rho=-O.2307, P=O.1188). 
Thirdly, acute and convalescent antibody responses against PAR+ and SA075 
were assessed using the 48 samples. While the acute versus convalescent 
responses in PAR+ were not significantly different, there was a significant 
difference in SA075 responses (Figure 6.17). Results on the entire 2005-2010 
dataset (regardless of whether they had rosetting data or not) described in section 
6.4.4 had shown a significant difference in acute-convalescent response against 
SA075 only in the non-severe patients. Of the 48 samples, the non-severe cases 
represented 50% of these samples and that could partly explain the similarity 
between responses to SA075 in this data and the entire 2005-2010 dataset. 
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Figure 6.17: Surface recognition of A) PAR+ and B) SA075 using the 48 acute 
and convalescent plasma pairs from children whose rosetting frequencies had 
been recorded in between 2005-2010. Shown on the graph are the median of the 
MF/s with each data point representing plasma from one patient (Mann Whitney U 
test, P<0.05). 
Further analysis was done on the 48 samples to examine the association between 
rosetting and antibody responses to PAR+ and SA075. These results would 
highlight whether epitopes within these two parasites were similar to those of 
rosetting parasites occurring frequently in natural populations. Separate scatter 
plots were made for the acute and convalescent responses (Figure 6.18). Both the 
acute and convalescent antibody responses to PAR+ had a significant negative 
correlation with rosetting frequency of the isolates from which the children's 
plasma samples were obtained, acute (Rho=-O.232, P=O.0316) and convalescent 
(Rho=-O.3043, P=O.0472). SA075 showed a significant negative correlation 
between antibody responses and rosetting frequency at acute phase but not at 
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Figure 6.18: Relationship between rosetting frequency with acute and 
convalescent antibody responses in A) PAR+ and B) SA075 using the 48 samples 
that had rosetting scores. There was a significant negative correlation between % 
rosetting frequency and acute (Rho=-0.232, P=0.0316) and convalescent (Rho=-
0.3043, P=0.0472) antibody responses in PAR+. In SA075, there was a negative 
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correlation only at acute stage (Rho=-O.3198, P=O.0027) but not at convalescent 
stage (Rho=-O.0083, P=O.9404). 
Further analysis was done to examine whether the induced antibody responses 
(the difference between acute and convalescent responses) correlated with 
rosetting frequency. A positive correlation would suggest that the antibody 
responses were targeting parasite epitopes similar to those whose rosetting 
frequency was taken. This would be a further confirmation that the rosetting 
parasite being tested was common within the population. Figure 6.198 shows a 
significant positive correlation between responses to SA075 and rosetting 
frequency (Rho=0.2872, P=0.0478). This was not the case for PAR+ (Rho=0.007, 
P=0.9621) (Figure 6.19A). 
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6.5 DISCUSSION 
Although PfEMP1 has generally been implicated in pathogenesis of severe 
malaria, the interactions responsible for causing specific disease syndromes are 
poorly understood. Additionally the manner in which host immunity i.e. anti-
PfEMP1 antibodies are able to modulate the clinical outcome of malaria is not 
clear. There was need for more studies to explore the clinical importance of 
different PfEMP1 variants. In this study, the clinical relevance of rosette-mediating 
variants was examined in Kilifi, Kenya. 
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To achieve this objective, cell sorted parasites that were enriched to express 
single variants were used. This was important because one major difficulty in 
studies on antibody responses to native protein on the surface of infected RBCs 
has been the rapid antigenic variation of PfEMP1 which potentially results in non-
homogeneity in the surface-displayed molecule when parasites are put in culture. 
To overcome this, different parasites lines have been selected using adhesive 
molecules or antibodies specific to certain PfEMPI variants in order to generate 
parasites enriched in a single variant. More recently, studies were carried out on 
HBEC-5i and HBMEC selected parasites to examine the role of these molecules in 
cerebral malaria (Avril, Tripathi et al. 2012; Claessens, Adams et al. 2012). Similar 
studies have been carried out on panned VarO expressing rosetting parasites 
Using plasma from children in West Africa (Vigan-Womas, Lokossou et al. 2010). 
In this study, the parasites were cell sorted using their homologous NTS-DBLa 
antibodies (Chapter 5). The enriched parasites were tested against acute-
convalescent plasma pairs from children with different clinical syndromes of 
malaria. Studies have previously been carried out in Kilifi to explore the kinetics of 
antibody responses to VSAs using acute and convalescent clinical samples either 
by FACS or agglutination assays (Bull, Lowe et al. 1999; Kinyanjui, Bull et al. 
2003). However, none of these studies focused specifically on rosetting-mediating 
variants as was done in this study. 
In the matched case-control study described in this chapter, results showed an 
induction of antibodies to PAR+ and HB3R+ parasites in patients with CM and RD 
respectively (Figure 6.7 and 6.8). This would suggest that PfEMP1 variants 
expressed by the patients' parasites at the time of disease were antigenically 
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similar to PAR+ and HB3R+. A recent study by Ghumra et al.,2012 showed the 
existence of shared surface epitopes amongst rosette-mediating variants from 
parasites with IgM-binding phenotype. Interestingly, both PAR+ and HB3R+ 
parasite have the IgM binding phenotype. However, the IgM binding phenotype for 
the field isolates whose plasma samples were used was not established. It can 
only be speculated that they had the IgM phenotype hence generation of cross 
reactive antibodies. This may be supported by results from a previous study by 
Rowe et al., (Rowe, Shafi et al. 2002) in which clinical isolates in Kilifi, Kenya 
showed a positive link between IgM binding, rosetting and severity of disease. 
Although both PAR+ and HB3R+ have the IgM-binding phenotype, they have 
differences at the phenotype and sequence level as well as their geographical 
origins. PAR+ is a knobless parasite (Udomsangpetch, Aikawa et al. 1989) 
originally from S.E Asia while HB3R+, which is originally from Honduras, has 
knobs. At the sequence level, PAR+ falls into the CP6 of Cys/PoLV classification 
(Bull, Berriman et al. 2005) while HB3R+ belongs to CP3. Both however belong to 
block sharing group 1 (BS1) which is strongly linked to Group A-like sequences 
(Bull, Buckee et al. 2008). Based on domain cassette classification, PAR+ belongs 
to DC11 with a DBLa 1.8 sub-type while HB3R+ belongs to DC16 with a DBLa 1.5 
sub-type (Ghumra, Semblat et al. 2012). In the study by Ghumra (Ghumra, 
Semblat et al. 2012), the few clinical isolates that were studied showed surface 
reactivity with either antibodies to DBLa1.5 (domain cassette 16) or DBLa1.8 
(domain cassette 11), but rarely with both. It is possible therefore that the 
differences between the two parasite lines could explain their differential 
association with CM and RD. 
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It was interesting, however, to observe an induction of antibodies against some 
parasites in plasma from uncomplicated malaria cases. The responses by the RD 
controls against TM284R+ and R29R+ (Figure 6.8B and D) as well SA075 in the 
population-based study (Figure 6.12 B) all showed significant induction of 
antibodies when comparing acute versus convalescent. None of these parasites 
was associated with severe disease in this study. Two possible explanations could 
be given for this observation; 1) that some rosette mediating PfEMP1 variants are 
not directly associated with severe disease. A recent study by Ghumra et al 2012 
(Ghumra, Semblat et al. 2012) seems to suggest that rosetting parasites with the 
IgM-binding phenotype seem to playa key role in pathogenesis of severe disease, 
evidence that was supported by the positive association between rosetting, IgM 
binding phenotype and severe disease in clinical samples in a previous study 
(Rowe, Shafi et al. 2002). This fact may however be overruled by the fact that 
TM284R+ also binds non-immune IgM. 2) It could also be that apart from the mere 
presence of rosettes, the size and strength of the rosettes play a role in 
development of clinical disease. Host genetic factors are also important in 
detennining the clinical outcome. These features were however not evaluated in 
this study. 
Due to the limited number of samples in the case-control study, analysis was 
expanded to include more plasma samples collected between 1994-1996 and 
2005-2010. This analysis however included children with overlapping syndromes 
of malaria and the pure cerebral malaria-CM cases were included in the larger 
impaired consciousness-IC category. Additionally, the analysis involved severe 
malarial anaemia-SMA cases whose antibody responses may have been 
confounded by blood transfusion (Bull, Lowe et al. 1999). Apart from examining 
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the induction of antibodies between acute and convalescent time-points, data from 
this study were also used to examine temporal antibody responses over time as 
well as relationship between rosetting and parameters associated with immunity 
such as age and parasitaemia. 
By pooling all the samples with a clinical syndrome into one category of "severe" 
cases, antibody responses against R29R+ showed a significant difference 
between the acute and the convalescent in the severe group but not in the non-
severe group (Figure 6.9). None of the other parasites exhibited a significant 
difference during the 1994-1996 time period. However, in the 2005-2010 data set, 
antibody responses to PAR+ were significantly higher in the convalescent than in 
the acutes in the severe cases but not the non-severe cases (Figure 6.10). This 
effect could have been strongly driven by the eM cases who showed similar 
kinetics against PAR+ in the case-control study. In SA075, there was a Significant 
diference in the acute and convalescent responses in both the severes and the 
non-severes. However, when the severe cases were broken down into single pure 
syndromes, none of the severe malaria syndromes exhibited this difference 
between the acute and convalescent (Figure 6.11 and 6.12). The differences in the 
trends of antibody responses against the same parasite between the two time 
periods could perhaps be due to differences in malaria transmission observed 
between the two time periods in Kilifi (O'Meara, Bejon et al. 2008). An analysis of 
the var gene expression profiles during these two periods would highlight whether 
there are changes that could explain the differences seen in this study. 
Immunity to malaria has been shown to build up with age and has been shown to 
be protective against clinical malaria (Langhorne, Ndungu et al. 2008; Doolan, 
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Dobano et al. 2009). To examine whether antibodies targeting rosette-mediating 
variants also follow a similar pattern, IgG responses to PAR+ and SA075 from 
1994-2010 were correlated with age. There was a significant positive association 
between antibodies to PAR+ and age in both the severe and non-severe cases 
(Figure 6.14 A.). SA075 also showed an overall positive correlation although it 
seemed to be limited to the non-severe cases and not in the severe cases (Figure 
6.148). The results suggest that these antibodies also playa key role in the age 
dependent-acquisition of immunity to malaria. Based on the case control results 
where PAR+ seemed to be important in CM, the age build-up of immunity to PAR+ 
seems to be important in modulating CM. 
Analysis was then focused on 48 samples that had rosetting scores taken during 
the first trophozoite stage in culture. The % RF in these samples ranged between 
(0-86.2%). A comparison between the severe and non- severe cases showed no 
difference in the rosetting frequency between the two groups (Figure 6.15). 
Contrary to this result, previous studies done in Kenya, Gabon and Madagascar 
have shown a difference between severe malaria and uncomplicated malaria 
(Ringwald, Peyron et al. 1993; Rowe, Obeiro et al. 1995; Newbold, Warn et al. 
1997; Kun, Schmidt-Ott et al. 1998; Heddini, Pettersson et al. 2001; Rowe, Shafi 
et al. 2002). The differences between the current results and those previously 
published could be due to the definition of the control group. In this study non-
severe group encompasses both mild malaria and moderate malaria both of which 
have in a previous study shown differences in their rosetting frequencies when 
compared to the severe cases (Rowe, Obeiro et al. 1995). 
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There was a positive association between rosetting frequency and parasitaemia 
(Figure 6.16A). This was consistent with previous studies done in Kilifi (Rowe, 
Obiero et al. 2002; Warimwe, Fegan et al. 2012). The role of rosetting in the 
pathogenesis of severe disease is thought to be the obstruction of microvascular 
blood flow resulting into tissue hypoxia and organ damage (Kaul, Roth et al. 1991; 
Dondorp, Ince et al. 2008). It is also thought to result in increased growth rates 
caused by quick invasion of merozoites into the non- infected cells in rosetting 
parasites resulting to high parasitaemia, although an in vitro experiment showed 
contrary results (Deans and Rowe 2006). There was a negative (although non-
Significant) association between rosetting frequency and age. Age is an important 
factor in host pathogen interactions and clinical manifestations of severe disease 
tend to occur in children of different age-groups (Marsh, Forster et al. 1995). 
Cerebral malaria, which has been associated with rosetting in some studies 
(Carlson, Helmby et al. 1990; Treutiger, Hedlund et al. 1992; Rowe, Obeiro et al. 
1995). has been shown to occur in older children (Newton and Krishna 1998). 
Such studies would thus support a negative association between rosetting and 
age as was seen in this study. 
Based on the 48 samples, there was no increase in variant-specific antibody 
responses to PAR+ at acute versus convalescent time points. However, there was 
a Significant induction of variant specific responses to SA075 between the two time 
points (Figure 6.17 Panels A and B). The data on correlation between rosetting 
frequency and antibody responses to PAR+ and SA075 (Figure 6.18) is intriguing 
and supports data in Figure 6.17. The negative association between acute 
antibody responses against PAR+ and % RF was maintained even at 
convalescence suggesting that there was no buildup in antibodies against PAR+ 
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(Figure 6.18A). In SA075 however, there was a negative association at acute 
stage which was lost at convalescence suggesting that there was a change in 
response at the two time points (Figure 6.188). Further analysis (Figure 6.19) 
shows a significant positive correlation between the induced antibody responses 
and rosetting frequency in SA075 but not in PAR+. These results would suggest in 
part that rosetting parasites similar to SA075 were common in natural populations. 
However, based on the case-control data, such variants seem not to be 
associated with any clinical syndrome. PAR+ on the other hand may be a less 
common rosetting parasite in the population although its presence is associated 
with cerebral malaria in the case-control study. It could be that the common VSAs 
circulating within the population are not necessarily the virulent ones. Whether 
some rosette-mediating variants are clinically more important than others needs to 
be explored further. 
There were several shortcomings in this study. 1) Var gene expression profiles 
were not examined for the parasites whose plasma were used in the analysis. A 
study by Warimwe and collegues (Warimwe, Keane et al. 2009) showed how 
expression of var genes bearing two-cysteine residues in the D8La. tag region 
(Cys2 var genes) were associated with severe malaria and young host age. 
Additionally, the data showed that var gene expression was differentially 
associated with severe malaria syndromes (Warimwe, Keane et al. 2009; 
Warimwe, Fegan et al. 2012). Although the var gene expression profiles for all the 
rosette-mediating variants used in this study were known (Chapter 3 Table 3.1), 
the expression profile for the patients' parasites may have been used to explain 
some of the associations observed in this study. 2) While the presence of variant 
specific antibodies may be crucial in understanding the clinical relevance of the 
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rosetting variants, the exact role of the antibodies in modulating se~ere disease 
remain unknown. Field studies by Carlson et a/., 1990 (Carlson, Helmby et al. 
1990), Barragan et a/., 1998 (Barragan, Kremsner et al. 1998), and Vigan-Womas 
et al.,2010 (Vigan-Womas, Lokossou et al. 2010) showed that the mechanism of 
protection by antibodies to rosetting variants could be either cytophilic or their 
ability to disrupt rosettes. In the current study, the role of the anti-rosetting 
antibOdies was not evaluated. 3) Exposure and multiplicity of infections (MOl) 
seem to be important confounders in most studies on antibody responses to 
malaria antigens. Despite the fact that patients came from the same geographical 
location and were of the same age, some may be more exposed to infections than 
others thus increasing their antibody repertoire to malaria VSAs including PfEMP1 
variants. Schizont extract ELISA has consistently been used as a proxy measure 
of exposure. In the current study, the ELISA was not done. 
In summary, these data show that rosette-mediating PfEMP1 variants may playa 
role in clinical malaria. PAR+ and HB3R+ are rosetting strains whose variants 
seem to be linked to cerebral malaria and respiratory distress. SA075 on the other 
hand is a parasite whose variant was not directly linked to any of the syndromes of 
severe malaria but SA075var1-like variants may be common in the parasite 
population in Kilifi. Addressing some of the limitations of this study may however 
provide stronger evidence to support these findings. 
272 
CHAPTER 7 
Conclusion & Recommendations 
The main focus of this thesis was to further understand the molecular mechanisms 
of rosetting, particularly in field isolates by characterizing the PfEMP1 variants and 
to investigate the clinical relevance of rosette-mediating variants. This was crucial 
considering that rosetting has consistently been associated with severe malaria in 
African children. Secondly, association studies do not necessarily show a causal 
relationship and therefore there still remains a gap that directly links rosetting to 
any of the syndromes of severe malaria. The aim therefore was to identify and 
characterize a rosette-mediating PfEMP1 variant from a Kenyan field isolate and 
to examine the profiles of antibody responses against the rosette-mediating 
variants in a Kenyan population exposed to malaria. In the preliminary result 
chapter, the inability to identify var genes associated with rosetting highlights the 
need to carry out a more systematic identification and characterization of PfEMP1 
variants in field isolates. However, the subsequent successful identification and 
sequencing of a full length PfEMP1 variant from one of the field isolates and the 
ability to induce functional anti-PfEMP1 antibodies is crucial in the development of 
PfEMP1 vaccines. A key finding reported in this thesis was the ability of patients 
recovering from severe malaria to raise variant-specific antibody responses 
against some rosette-mediating variants. These data demonstrates the clinical 
relevance of these variants by linking them to particular severe malaria 
syndromes, thus making them important targets for vaccine development. Results 
also showed that some PfEMP1 variants associated with rosetting may be 
common in natural populations although they may not necessarily be associated 
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with severe disease. More studies need to be done on functional and 
immunological characterization of rosette-mediating variants from field isolates. 
In Chapter 3, I attempted to identify var genes associated with rosetting from 4 
culture adapted field isolates from Kilifi. However single dominant genes linked to 
rosetting were not identified in the transcript profiles of the five field isolates. 
Although the original objective was to monitor the transcription profiles in the 
COurse of the rosette selection, it is possible that the selection method was not 
efficient enough and that the differences in clones between the acute and the 
rosette selected samples based on MSP1 and MSP2 genotypes contributed to the 
lack of identification of the rosette-mediating gene. A better approach would be to 
obtain highly rosetting isolates from the field and examine their transcript profiles. 
In Chapter 4, a putative rosette-mediating gene, SA075var1 from a field isolate 
called SA075 was identified and characterized. The DBLa tag sequences for the 
SA075 var gene had been previously characterized (BUll, Buckee et al. 2008). It 
had interesting sequence features such as belonging to Cys/PoLV group 2, block 
sharing group 2 and sequence signature 2 (sig2) that have all been previously 
linked to rosetting (Bull, Berriman et al. 2005; Bull, Buckee et al. 2008). This made 
SA075 an interesting parasite to study. Unlike in Chapter 3 where rosette selection 
on field isolates were done by flotation method prior to transcript profiling, analysis 
of SA075 transcripts were done following cloning by limiting dilution. The same 
dominant var gene that was identified in the previous characterization (BUll, 
Buckee et al. 2008) was identified in the rosette positive clone. Despite a long and 
iterative process of PCR walking, cloning and sequencing, the full-length gene was 
successfully cloned and sequenced. The whole genome sequence of SA075 
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isolate is being assembled at the Sanger Institute and the next task will be to 
compare the SA075var1 sequences as generated by the two methods. Recent 
classification of PfEMP1 by domain cassettes (DCs) (Rask, Hansen et al. 2010) 
showed that SA075var1 had DC8-like features. This makes SA075 var1 to be of 
interest considering that DC8 has lately been linked to severe malaria (Lavstsen, 
Turner et al. 2012; Bertin, Lavstsen et al. 2013). 
In Chapter 5, the ability of SA075var1 to induce functional antibodies was 
examined. However, one major finding during characterization of these antibodies 
was the possibility that the SA075var1 gene was not involved in rosetting of 
SA075 parasites. There were inconsistencies between the % RF by microscopy 
and % positive population by flow cytometry following staining by anti-SA075var1 
in both cell sorted and unsorted parasites. Microscopy is open to inter-observer 
variation, and therefore could have been a huge contributor to this discrepancy. 
The strength of rosettes which was not examined in this thesis may also have 
contributed. Loose rosettes which could be easily disrupted would easily result in 
low % RF and high % positive population as was mostly the case in SA075. The 
possibility of a recombination event that may have an effect on antibody responses 
and the nature of rosettes can also not be ruled out. None the less, assays were 
carried out that showed an induction of functional SA075var1 antibodies. The 
antibodies had the ability to recognize the native surface of infected RBCs and 
mediate phagocytosis as has been done in other rosetting strains (Ghumra, 
Khunrae et al. 2011). More work needs to be done to ascertain whether 
SA075var1 is indeed involved in rosetting in SA075 parasites. This includes a 
systematic experiment to monitor the correlation between % RF by microscopy 
and high % positive population by flow cytometry. The DC8-like features of 
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SA075var1 as discussed in Chapter 4 also make it an interesting PfEMP1 variant 
to study. Although not discussed in this thesis, preliminary work to this end 
showed that some of the real time primers targeting DCa (Lavstsen, Turner et al. 
2012) were able to amplify transcripts from cDNA of SA075. 
Finally in chapter 6, I explored whether rosetting variants had any clinical 
relevance and whether children recovering from different syndromes of severe 
malaria raise variant specific antibodies against rosetting parasites. The approach 
used in this chapter in which acute and convalescent responses were analysed 
has not been used previously to examine antibody responses against rosette 
mediating variants and has provided a direct link of rosetting with severe disease 
in the absence of an in vivo model. Despite the limited number of samples in the 
case-control study, variant specific antibody responses against PAR+ and HB3R+ 
suggested that PfEMP1 variants that are antigenically similar to these two could 
be important for cerebral malaria and respiratory distress respectively. The 
findings also highlight the presence of cross-reactive antibodies in plasma from 
children who had severe malaria that had the ability to recognize antigenically 
similar parasites. Although a study by Doumbo et al 2009 (Doumbo, Thera et al. 
2009) showed that rosetting was associated with all forms of severe malaria, the 
differential link by PAR+ and HB3R+ to different syndromes is intriguing and could 
suggest that there are different types of rosetting variants associated with different 
syndromes of severe disease. What then are the differences between the two 
rosetting variants? At the sequence level, PAR+ and HB3R+ parasites belong to 
different CP groups (6 and 3 respectively) as well as different DC classes (11 and 
16 respectively). They do however belong to the same block sharing group 1 and 
both have the IgM binding phenotype. Although previous studies of rosetting have 
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shown an association between rosetting and cerebral malaria, the findings on 
antibody responses to PAR+ by cerebral malaria patients could strengthen the 
importance of rosetting in development of severe disease. The absence of case-
control plasma samples from patients with severe malarial anaemia was a caveat 
in this analysis since rosetting has in some studies been linked to low 
haemoglobin levels (Rowe, Shafi et al. 2002). This would also have been 
particularly interesting for SA075 parasites which were originally obtained from a 
patient with severe malarial anaemia. 
Despite the small sample size in the case-control study, the careful matching of 
the cases to the controls by age, date of admission and blood group minimized the 
Possible confounding effect by these factors. The population-based study on the 
other hand had the advantage of a bigger sample size but it is possible the true 
effect of the variant-specific antibody responses when comparing the cases and 
controls may have been confounded. The positive results by PAR+ and HB3R+ in 
the case-control study need ideally be confirmed in a larger study of the same 
deSign. 
The findings in chapter 6 also pose a question as to whether there are two types of 
rosetting phenotype: - those that are associated with severe disease (as in PAR+ 
and HB3R+) and those that are not (as in TM284R+, R29R+ and SA075). 
Interesting results were further seen with SA075 in which there was a positive 
correlation between % RF in 48 samples and induced antibody responses against 
the cell sorted parasites. These results suggested that the variant expressed by 
this parasite is common within the population despite not previously being 
associated with any syndrome. This raises the possibility that severe malaria is a 
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complex phenomenon that cannot be explained by examining antibody responses 
by the host to one parasite/antigen. Var gene expression profiles have also been 
shown to be modified by host immunity at the time of disease. This aspect was 
however not explored in this thesis. Other aspects of the study that would have 
been important if examined were the presence of anti-rosetting antibodies in the 
plasma of patients. It could be that anti-rosetting activity and not just the presence 
of the surface reactive antibodies is important in modulating the outcome of the 
disease. 
Overall. the findings from this thesis highlight the heterogeneity of PfEMP1 
variants associated with the rosetting phenotype as well as the heterogeneity of 
severe malaria and suggests that more studies especially on field isolates need to 
be done in order to fully understand the molecular mechanisms of rosetting. 
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CHAPTER 8 
Appendix 
APPENDIX 2.1A 
Information sheet 
(Children recruited at dispensaries or hospital) 
Integrated studies of the development of natural Immunity to malaria in children in Kilifi 
district 
Lead Investigator: Kevin Marsh, Director KEMRI-Wellcome Programme. 
What question is KEMRI trying to answer? 
KEMRI is an institution which learns more about diseases to find better ways of preventing and 
curing those diseases. An example is malaria, which causes much death and illness among 
Kenyan children. Children are protected against measles by the measles vaccine. Children could 
be protected against malaria if there was a malaria vaccine. In areas like this people become 
immune to the bad effects of malaria as they grow older. In KEMRI we are working to try to 
understand how people become immune to malaria. This information is important in designing 
vaccines against malaria. 
You have come to the dispensaryl hospital today because your child has an illness that may be 
caused by malaria. We would like to invite you to allow your child to take part in a study to help find 
out how people become immune to malaria. 
What does taking part involve? 
Normally your child would receive some blood tests to confirm the problem and then receive 
treatment. These things will happen in the normal way but I addition we will ask to take an extra 
sample of blood for research. 
If you agree for your child to be part of the study we will: 
1. Take a 5mls (one teaspoon) of blood from a vein on your child"s arm or hand. 
i. This will be used for tests that help the doctors decide how to treat your child. 
ii. The remainder will be used for research 
2. Ask permission to take a further 5 mls blood sample after your child has recovered from the 
illness. 
i. This will be approximately three weeks from now. 
ii. We will later invite some children to return at six. twelve and twenty four weeks from now 
for further blood samples. 
iii. We will make it clear to you whether we are asking you to return only once or a total of four 
times 
Whether you agree to take part or not your child will receive the normal treatment for their illness. 
Are there any risks to being in the study? 
Taking a blood sample can be uncomfortable and can sometimes cause mild bruising. The amount 
of blood taken is completely safe, even if your child is anaemic. If your child is anaemic they will 
receive treatment for this along with treatment for any other illness. 
Are there any benefits to being in the study? 
We will provide the cost of bus fare for you and your child to attend for the follow up blood 
sample(s). At that time there will be an opportunity to see a health worker, and have appropriate 
tests performed. if you have any concerns that your child is not completely recovered. This 
research may have a long term benefit to children in this community and others in similar 
communities through providing information that will help in the development of better ways of 
preventing malaria. Otherwise there are no specific benefits. 
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What happens to the blood samples taken in the study? 
In the laboratory we will examine the blood to see if it can protect against malaria. The ability to 
protect can be present from birth but can also develop as we grow older. 
Most of the tests will be done in the laboratories in Kilifi. Some of the tests cannot be done in 
Kenya and so will be done in laboratories overseas. Not all the tests will be done at the same time 
and so the blood will be stored in a freezer until the tests can be done. At the end of the study any 
blood that has not been used in tests will be stored so that further tests of the kind described above 
can be carried out in future. 
Who has allowed this research to take place? 
An independent committee in Kenya that is run by the Government and a committee in Kilifi have 
~ooked carefully at this and agreed that the research is important, that it should be safe to take part 
In and will be conducted properly. 
What if I decide not to involve my child or change my mind later? 
PartiCipation in research is completely voluntary. Nobody is obliged to take part and anyone who 
does agree can change their minds at any time. If you refuse to take part, or agree and alter 
change your mind there are no penalties what so ever, and you and your child will still be able to 
benefit from the improved level of service offered at the dispensary and at Kilifi hospital as a result 
of the research carried out by KEMRI. 
If you require further information please contact Professor Marsh or any other member of the 
research team at the KEMRI centre, Kilifi. (Telephone 012522063) 
If you want to ask someone independent anything about this research please contact 
Dorcas Kumuya at KEMRI - Kilifi, Tel: 041 522 063 
Or 
Mr. Ambrose Rachier. Chairman - KEMRIINational Ethics Review Committee 
P. O. BOX 54840-00200, Nairobi, Tel number: 020 272 2541 Mobile: 0722205901 or 0733400003 
THE PARENT/GUARDIAN SHOULD NOW BE GIVEN A SIGNED COPY TO KEEP 
OXTREC NO: 030-06 240 
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Consent form 3 
Integrated studies of the development of natural immunity to malaria in children in Kilifi 
district 
Lead Investigator: Kevin Marsh, Director KEMRI-Wellcome Programme. 
When you sign below it shows that you have read the information about the study and have been 
able to have any questions answered and that you have agreed to join the study. If you do not 
understand any part of the information sheet ask questions. Participation in the study is voluntary 
and you have the right to change your mind and withdraw from the study at any time without giving 
a reason. Do not sign until you have answers to your questions. 
I agree to take part in the study of how children develop immunity to malaria. I understand that I will 
be asked permission to take a 5ml blood sample from my child during this illness and that I will be 
asked to return to clinic in approximately three weeks time for a second blood sample to be taken. I 
understand that some of the blood samples may be exported to laboratories outside Kenya. D 
THIS SECTION TO BE READ ONLY FOR THE SUBSET OF CHILDREN INVITED TO 
PARTICIPATE IN EXTENDED FOLLOW UP: 
I understand that I will then be asked permission to return to clinic on three more occasions at 
approximately six, twelve and twenty four weeks from now D 
I ~gree to blood being stored for testing in the future. 
(tick boxes to indicate consent, place a cross in the box to indicate lack of consent) D 
Childs name 
---------------------------
Signature (or thumb print) of parent:....-____________ _ 
Name in capitals 
----------------------
Date 
--------------
I have read the information sheet for "Integrated studies of the development of natural immunity to 
malaria in children in Kilifi district" to (parent"s name) in a language 
they understands. I believe they give consent for (child"s name) to take part in 
the study. 
Signature of translator 
'--------------------
Name in capitals 
'---------
Date 
----------
Only necessary if the parent/guardian cannot read: 
I *attest that the information concerning this research was accurately explained to and apparently 
understood by the parenVguardian and that informed consent was freely given by the 
parenVguardian. 
Witness' signature: ___________________________________ Date ______ _ 
Witness' name: Time (Please print nam-e'7)---------------- -------
~ A witness is a person who is independent from the trial or a member of staff who was not 
Involved in gaining the consent. 
OXTREC NO: 030-06 241 
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APPENDIX 2.1 B 
Information sheet (Children in cohort studies) 
Integrated studies of the development of natural Immunity to malaria In children in Kilifi 
district 
Lead Investigator: Kevin Marsh, Director KEMRI-Wellcome Programme. 
What question is KEMRI trying to answer? 
KE~RI is an institution which learns more about diseases to find better ways of preventing and 
CUring those diseases. An example is malaria, which causes much death and illness among 
Kenyan children. Children are protected against measles by the measles vaccine. Children could ~e protected against malaria if there was a malaria vaccine. In areas like this people become 
Immune to the bad effects of malaria as they grow older. In KEMRI we are working to try to 
understand how people become immune to malaria. This information is important in designing 
vaccines against malaria. 
What does taking part involve? 
We want to find out why some people get more episodes of malaria and other illnesses than 
others. In order to do this we need to follow group of children over time to see how often they have 
malaria and other diseases. We also need to study how some of the components of the child"s 
blood that fight diseases change over time. We need to follow about 500 children in this 
community. We plan to follow them over the next four years. 
We are requesting your permission for your child to be one of these children. If you agree, the 
study will involve: 
.1) Weekly visits to your home. Fieldworkers living in this community will visit you and your child 
each week to ask if your child is well. At each visit we will take your child"s temperature to see if 
they have a fever. If they are unwell but donut have a fever the fieldworker will return twice over the 
n~xt 24 hours to recheck the temperature. If the child does have a fever they will collect a finger 
prick blood sample. Some of this blood will be tested immediately to see if the child has malaria. If 
your child does have malaria the field worker will report this by telephone to a KEMRI doctor and 
we will provide treatment for your child. The field worker will call someone from the dispensary to 
take a 5 ml blood sample from your child. The blood will be taken to the KEMRI laboratories for 
other tests which are described below. The fieldworkers will only be able to feed back malaria 
results, and they are not doctors. If your child has another sort of problem, the fieldworker will 
a~vise you to visit the dispensary where KEMRI staff are working with the Ministry of Health staff to 
diagnose and treat illness. 
2) Four additional blood samples at set times in the first year, even if your child is well. On 
three of these occasions the blood sample will be collected by finger prick. On one occasion a 
sample of 5mls (one teaspoon full) will be collected from a vein on your child"s hand or arm. 
3) After the first year one blood sample of 5 mls once a year for the next three years unless 
your child has malaria when an additional blood sample will be taken. 
Are there any risks to being in the study? 
Taking a blood sample by finger prick or by needle can be uncomfortable and can sometimes 
cause mild bruising. The amount of blood taken is completely safe and children are able to replace 
blood themselves. 
Are there any benefits to being in the study? 
By having a weekly visit by the KEMRI fieldworker your child will have a regular check to see if they 
~re unwell. If they have malaria they will receive immediate treatment and if they have other 
Illnesses they will be referred to the local dispensary to be seen by a nurse of clinical officer 
working with KEMRI In order to make sure that children with malaria or other illnesses have good 
access to care on days when the field worker is not visiting, KEMRI have placed extra nursing and 
~Iinical officer staff at the local dispensary. This benefits people in this community whether they are 
In the study or not in the study. 
What happens to the blood samples taken in the study? 
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We want to find out why some people get more episodes of malaria and other illnesses than 
others. In the laboratory we will examine the blood to see if it contains substances or cells which 
recognize and protect against the malaria parasite. Some of these substances are "genetic· which 
means they are present from birth and some are things that develop as we grow older after we 
have been exposed to malaria. 
Most of the tests will be done in the laboratories in Kilifi. Some of the tests cannot at present be 
done in Kenya and so will be done in laboratories overseas. Not all the tests will be done at the 
same time and so the blood will be stored in a freezer until the tests can be done. At the end of the 
study any blood that has not been used in tests will be stored so that further tests of the kind 
described above can be carried out in future. 
(To be read to parents of children who are already in the cohort recruited under previous SCC 
protocol: 
Your child has already been in this study for some time and we are now inviting you to continue in 
the study. We will ask you separately at the end of this form for permission to use continue to use 
samples already taken from your child up until this time and stored in Kilifi. 
How will my rights be protected? 
This research has been reviewed by a group scientists and doctors in Nairobi to make sure that the 
research is well designed. It was then reviewed by the Kenya national ethical committee. This is a 
~ommittee of people from different walks of life, including lawyers and religious leaders, whose job 
IS to make sure that the research conforms with national and international standards for safety and 
for protecting the rights of people who take part in the research. Any changes to the study that we 
want to make have to be approved first by the ethical committee. No tests or procedures other than 
the ones you have agreed to can be carried out. (Out of curiosity- is there a way in Swahili/Giriama 
to describe ethical?) 
What if I decide not to involve my child or change my mind later? 
Participation in research is completely voluntary. Nobody is obliged to take part and anyone who 
does agree can change their minds at any time. If you refuse to take part, or agree and change 
your mind later, there are no penalties what so ever, and you and your child will still be able to 
benefit from the improved level of service offered at the dispensary and at Kilifi hospital as a result 
of the research carried out by KEMRI. 
If you require further information please contact Professor Marsh or any other member of the 
research team at the KEMRI centre, Kilifi. (Telephone 0125 22063). You may also contact the 
National Ethical review Committee on 02 2722541 
OXTREC NO: 030-06243 
283 
Consent form 
Integrated studies of the development of natural immunity to malaria in children in Kilifi 
district 
Lead Investigator: Kevin Marsh, Director KEMRI-Wellcome Programme. 
When you sign below it shows that you have read the information about the study and have been 
able to have any questions answered and that you have agreed to join the study. If you do not 
understand any part of the information sheet please ask questions. Participation in the study is 
v~luntary and you have the right to change your mind and withdraw from the study at any time 
without giving a reason. Do not sign until you have answers to your questions. 
I wish my child to take part in the study of how children develop immunity to malaria. I understand 
that this will involve weekly visits to my house by a KEMRI fieldworker for a period of up to four 
ye~rs. I understand that in the first year I will be asked permission to take a blood sample from my 
child on four occasions and that in subsequent years I will be asked permission to do this once a 
year or when my child has malaria. I understand that some of the blood samples may be exported 
to laboratories outside Kenya D 
I c.onsent to my child"s blood being stored for testing in the future. 
(Tick boxes to indicate consent, place a cross in the box to indicate lack of consent) D 
I ~gree to blood being exported to laboratories outside Kenya for further tests. 
(Tick boxes to indicate consent, place a cross in the box to indicate lack of consent) D 
Childs name 
'---------------------------
Signature (or thumb print) of parent, ______________ _ 
Name in capitals 
-----------
Date 
------------
I have read the information sheet for "Integrated studies of the development of natural immunity to 
malaria in children in Kilifi district" to (parent"s name) in a language 
~hey understand. I confirm that they give consent for (child"s name) to take part 
In the study. 
Signature of translator 
'-----------------
Name in capitals 
'----------
Date 
"----------
If you require further information please contact Professor Marsh at the KEMRI centre, Kilifi. 
(Telephone 0415 22063) You may also contact the National Ethical review Committee on 02 
2722541 
OXTREC NO: 030-06 
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8.2: Working protocol for combined IFAlFACs 
FACSIIFA with assorted anti-NTS DBLalpha antibodies at 400 flg/ml 
date: 1 111 
Aim: A combination of FACS and IFA to test whether the anti-NTS DBLalpha 
antibodies cross-react with different rosetting strains at high concentration 
parasite smear 
Need 1.2 ml of culture suspension (mature pigmented trophs, preferably NOT 
schizonts) at 2% haematocrit. Make a 13.5J.11 working stock of Hoescht by adding 
1 J.11 of the stock to 12.5J.11 of PBS. Add 2J.11 of working stock to 1.2 ml of culture to 
get a final concentration of 1.25J.1g/ml. Incubate at 37 degrees for 20min. Spin 
down and wash 2x in PBS. Resuspend in 1.2 ml PBS/1 % Ig-free BSAl1.25J.1g/ml 
Hoescht (solution 3 on next page). Need 11x 94.6J.11 aliquots. 
Add primary Ab as below to give final conc of 400 J.1g/ml of antibody. All Abs are at 
7.5 mg/ml (cold cabinet, right hand side, 2nd shelf, red tray, Alex antibodies box. 
Red lids). 
Samples: 
1. No Ab Ctl add 5.4 J.11 of PBS 
2. Rabbit IgG control add 5.4 J.11 of Ab 
3. anti-R29 DBLalpha rabbit 5776 add 5.4 J.11 of Ab 
4. anti-TM180 DBLalpha rabbit 6221 add 5.4 J.11 of Ab 
5. anti-TM284 DBLalpha rabbit 6219 add 5.4 J.11 of Ab 
6. anti-PAR+ DBLalpha rabbit 6217 add 5.4 J.11 of Ab 
7. anti-HB3var6 DBLalpha rabbit 6223 add 5.4 J.11 of Ab 
8. anti-Muz12 DBLalpha rabbit 6283 add 5.4 J.11 of Ab 
9. anti-HB3var3 DBLalpha rabbit 6358 add 5.4 J.11 of Ab 
10. mouse anti-human IgM (Serotec) add 0.5J.11 Ab and 4.901 of PBS 
11. No Ab Ctl add 5.4 J.11 of PBS 
Incubate on ice for 1 hour, resuspend samples every 10 mins as usual. Wash 3x in 
cold PBS (750JlI per wash). Spin secondary Abs for 2 mins in microfuge 13000 
rpm before use below. 
Make 1 ml of secondary Ab Alexa488 goat anti-rabbit IgG at 1/1000 in PBS/1% Ig-
free BSA 1.25Jlg/ml Hoescht (solution 3). Add 100JlI to pellets in tubes 1-9. You 
will need to make a different secondary reagent for tubes 10 and 11. Make 300JlI 
of secondary Ab Alexa488 goat anti-mouse IgG at 1/500 in PBS/% Ig-free 
BSA,/1.25Jlg/ml Hoescht. Add 100JlI to pellets in tubes 10 and 11. 
Incubate on ice for 1 hour (protect from light), resuspend samples every 10 mins 
as usual. 
Wash 3x in cold PBS (750 JlI> as usual. At last wash, split into two sets of tubes 1-
11 (for IFA) and 1*-11* (for FACS). 
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I FA: continue as usual with tubes 1-11, by resuspending at 20-30% haematocrit in 
PBS/1 % Ig-free BSA, make smears, air dry, add DABGO/glycerol mountant and 
coverslip, and store at 4°G. 
FAGS: Remove supernatant from tubes 1*-11* and resuspend pellet in 100J.l1 of 
PBS/1 % Ig-free BSAl50J.lg/ml fucoidan. Incubate for 5 min and check that the 
rosettes have been disrupted (record). Spin down and resuspend in 200J.l1 of 0.5 % 
paraformaldehyde and incubate on ice for 20 min. Wash once in cold PBS and 
once in FAGS buffer (750 J.l1) as usual. Resuspend pellet in 500J.l1 of FAGS buffer 
and transfer into a FAGS tube, add 25J.l1 of 1mg/ml fucoidan and incubate for 20 
min at RT. Foil wrap the tubes and keep in the fridge till when you do the FAGS 
run (preferably within two days of staining). 
NB-Summary of working stocks reguired for this assay (Make 1-3 before starting 
the assay to make life easy): 
For initial staining and subseguent use 
1) Hoescht (13.5J.l1)-
1 J.l1 of stock (1 Omg/ml brown bottle) 
12.5J.l1 of PBS 
2) 5ml of PBS/1 % Ig-free BSA 
167 J.l1 of IgG-free BSA 
4.83 ml of PBS 
For primary and secondary incubations 
3) PBS/1 %BSAl1.25J.lg/ml Hoeschtl (3 ml)-
3 ml of above PBS/1 % Ig-free BSA 
5J.l1 of above Hoescht 
For rosette disruption step 
4) PBS/BSNFucoidan (1.5 ml)-
1.43 ml of above PBS/1 % Ig-free BSA 
75J.l1 of 1 mg/ml fucoidan 
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8.3 Working protocol for Phagocytosis assay 
Coat 96-well round-bottom plates with 200jJUweil of neat FBS (can be re-used for 
coating several times) for 1 h at RT. 
Wash wells with 200jJi sterile PBS (3x), let air dry inverted on a piece of paper 
towel and store at 4 degrees. (use within a month). This is all done in the hood. 
To the opsonisation plates add the desired amount of antibody for a final volume 
of opsonisation of 331lL. (e.g. for a 1/10 dilution use 3.3jJL of antibody) Freeze the 
plate with antibodies until parasites are ready to be used. The antibody samples 
are diluted down from a working stock of 4mg/ml which is made from the original 
supply stocks. Using the working stocks at 4mg/ml , each antibody sample is then 
diluted 4-fold to 400119 , 100119 , 2SIl9 and 6.2Sllg/ml. 
OPTIONAL: coat 1Sml and SOml tubes with neat FBS (these can be used to collect 
the parasites and wash them. The FBS coating prevents the adherence of pRBC 
to the sides walls of the tubes, thus minimizing losses) 
Culture your Thp-1 so that they will be at between 400,000 and 700,000 cells/mL 
on the day of the assay (usually if they are at 3S0,OOO cells/mL on the morning 
before the assay, that results in perfect SOO,OOO cells/ml on the day of the assay). 
Cell lines used: 
Any parasite culture as target of antibodies 
Undifferentiated THP-1 cells 
Solutions needed: 
Stock solution of 20mg/ml of Fucoidan 
Incomplete parasite medium 
Incomplete parasite medium + 200ug/ml Fucoidan + 2% FBS or O.S% BSA (RPMI-
F) 
FACS Buffer (PBS minus Calcium and Magnesium, 2% FBS, 2mM EDTA, 0.02% 
Azide). Addition of azide is optional. 
THP-1 complete media (RPM11640, 10% HI FBS, glutamine, Pen-Strep, 2SmM 
HEPES, SSjJM 2 P.,-mercaptoethanol). The 2ME is added to culture flask when 
changing the media at a 1 :1000 ratio. Sml each of glutamine and Pen-Strep as 
received from stores stocklist - check actual concentration later and write in. 
THP-1 complete media + 200llg/mi Fucoidan (THP-F) - used in Phago-assay. 
FACS Lysing Solution 1/10 in ddH20 
2% PFA (formaldehyde can be used) in PBS minus Calcium and Magnesium. This 
can be made up using 37% Formalin (1ml of Formalin diluted in 18ml of PBS-). 
Methods: 
1 - Parasite isolation by MACS (using Fucoidan) 
2 - Phagocytosis assay in the presence of Fucoidan 
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1- Parasite isolation by MACS (using Fucoidan) 
Method for heparin-insensitive rosettes In this modification of the standard MACS 
method (Staalsoe et ai, Cytometry 1999), rosettes are disrupted with fucoidan 
before and during purification to allow collection of rosetting PRBC free from 
uninfected red cells. 
To prepare the column 
Fit the column with the 3 way tap, 20G needle (yellow) and syringe as per 
manufacturers instructions. Cut the end off the plastic needle protector, while 
keeping the sharp end of needle covered. Fit the column into the .magnet. Add 
30ml RPMI-F to a 50mL syringe and assemble with the 3-way tap. 
Through the lower 50ml syringe force 10 ml of media up and down the column to 
dislodge any air bubbles trapped inside it. 
Open the 3-way tap and allow the medium to run through at approx 1 drop/sec 
Then run through at same speed approx 10-20 ml incomplete RPMI followed by 
5ml incomplete RPMI 2% serum with 200 ~g/ml Fucoidan (add solutions to top of 
reservoir). 
The column is now equilibrated and ready to use. Switch tap to "off' position. 
To prepare the parasites 
% parasitaemia: (yields from cultures less than 5% trophs will be poor) 
Rosetting Frequency: ____ _ 
-Take parasite culture and spin down. 
-WaSh 1x in incomplete RPMI. Pipette up and down vigorously (helps disrupt the 
rosettes)Spin down, remove supernatant and resuspend the cells in 1 mL of RPMI-
F for every 2ml of original parasite culture (if original culture at 2% hematocrit). 
-Incubate 5-10 min at RT. Check a wet prep under microscope (40x objective) to 
ensure all rosettes disrupted. 
-Add parasite suspension to column and run through at approx 1 drop/sec. 
-Collect flow through and run through the column a second time. 
-Collect final flow through put a drop on a slide, cover with a coverslip and check 
for the presence of trophs under light microscopy. Check that PRBC have been 
removed. 
-Wash column with 10-20ml of RPMI-F until flow through is completely clear. Add 
a further and final5ml wash. 
-Remove column from magnet keeping the 50ml syringe attached. 
-Force the remaining 20m I of RPMI-F left in the syringe up and down(5-10 times) 
the column to elute the adherent PRBC. Pull everything into the syringe 
-Dispense the eluate into a 50ml Falcon and smear or look at wet prep to check 
purity. Should get a good yield (usually 50-80% of "theoretical" yield) and a 
parasitaemia of 80-100%. 
-Wash the column with H20, then flow 100% methanol through it and store when 
dry or leave it in 100% methanol at 4 degrees. 
2. Phago assay in the presence of 200 p.g/ml of Fucoidan. 
-After the isolation of the parasites has taken place resuspend parasites in 1 ml of 
RPMI-F. 
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-Count parasites on haemocytometer (put 5j.J1 of parasite into 1 ml of PBS: 200x 
dilution). Haemocytometer formula: Parasite count in each of 4x4 squares/4 x 
dilution factor (200) x 10,000 = parasites/ml 
-Resuspend the parasites in an FBS-coated tube at 3.3x10"7/ml in RPMI-F + 10 
j.Jg/ml of EtBr ( 100x dilution ) (wrap in aluminium foil and work as much as 
possible in the dark from now on whenever dealing with parasites). BE AWARE 
THAT ETBR IS CARCINOGENIC. 
Wait for 15 min (optionally with gentle agitation) 
-Wash at least 3x with RPMI-F (transferring parasites to at least one new tube 
during the washes) - IF YOU HAVE A FROZEN PLATE WITH ANTIBODIES 
TAKE IT OUT OF THE FREEZER NOW 
Resuspend again at 3.3x10"7/ml in RPMI-F. 
Transfer 30j.J1 to a 96-well plate into all wells that contain antibody amounts as 
planned and also into your control wells. 
Your wells should include: 
Negative control: Control Rabbit (neg) 
Negative control: Un-opsonised (no antibody) 
Common Positive control: Rabbit anti-human RBC from ABCAM @90 j.Jg/ml and 
if using plates to be compared on different days 8 dilutions of 2x or 4x (start at 
higher concentrations when using multiple plates of human serum). 
NOTE: for Palo Alto the common positive control is always lower than for HB3, 
TM180R+,TM284R+, R29R+ ... that is a reflection of the binding of the rabbit 
antibody to the surface of the PAR pRBC. 
Samples 
THP-1 alone 
-Mix well and leave for 1 h at RT covered in foil. 
-1Smin before the hour finishes get your Thp-1 cells, count them and resuspend at 
Sx10"5 ceII s/mI in Thp1-F media. You will need to work out how many duplicate 
wells will be required and then factor up accordingly the total volume of cells 
needed. 
-Add 1S0ul of RPMI-F to your parasites and spin at 300G for 4 min at RT ( this is 
program 1 on the centrifuge ). Discard supernatant (by quickly inverting the plate 
and blotting on paper towels) - note risk of EtBr on bench and sink. 
-Repeat this 1S0ul wash and spin step 3 times. 
-Resuspend parasites in 100ul of THP-F media. 
-Transfer 100j.J1 of Thp-1 cells in DUPLICATE and SOul of parasite into each well of 
a new 96-well plate. Mix well and take to the 37°C CO2 incubator on the ground 
level culture Lab. Allow 40 min for the phagocytosis to occur. (During this 40 
minute incubation, run program 2 on plate centrifuge to lower temperature to 4 
degrees. Put FAGS Lysing Solution in 37 degrees water bath.) 
-After 40 minutes put the plate on ice.Spin down plate at 4 degrees 300G for 4 min 
(program 2 ). Discard supernatant by inversion and blotting onto tissues. 
Resuspend in 1501-11 of warm FAGS Lysing Soln. Mix well. Wait for 10 min. 
Add SOul of ice-cold FAGS buffer to each well. 
-Spin down plate at 4 degrees 300G for 4 min (program 2). Discard supernatant 
by inversion and blot onto tissues. 
-Add 1S0ul of ice-cold FAGS buffer to each well, and repeat step18. 
-Resuspend each well in 1S0j.J1 of ice-cold PFA 2% in PBS minus calcium and 
magnesium. 
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-Allow for 2h at 4 degrees before taking to the FACS machine to read. You can 
leave overnight covered in foil and at 4*C without any problems. 
Experimental Notes and results: 
Parasites Before Isolation: 
Parasitaemia: 
%RF: 
After Isolation: 
_x 200 (dilution factor) x 10,000 = _ml x 0.7 (parasite loss due to washes 
from now on): 
Final parasite: 
-----Resuspend in : 
Thp-1: ----
_ x (dilution factor) x 10,000 = ml: 
resuspend in : 
---
FACS Protocol for acquisition Phagocytosis experiments - Current rough notes 
FACS bookings online page: 
http://www.iiirflow.biology.ed.ac.uk/iiir flow index.html 
Just click on "booking diary" and then select a day and hour. You can use my 
username and password (both are ricardoataide) to book or alternatively ask 
Martin to give you a username and password. 
-If need be, restart FACS computer. 
-Switch ON FACS machine. Flick Black Toggle switch DOWN in reservoir drawer. 
-Facs machine Mode is RUN and HI 
-Click on Peoples Folders, select Ahmed, select Template Folder, select THP-1 . 
-Select ACQUIRE clickmenu link, select Connect to Cytometer. 
-Click Apple Icon and select 1, 2, 3, 4 
-Select Instrument Settings clickmenu link, select Open and double-click on file 
you want. Then click on SET, and then click on DONE 
-DIRECTORY setting is Ahmed -> New Folder -> Expt. Name with Date info as : 
YY/MM/DD Then click Create, then click Choose, Click File -> Sample ID 
-At this point, make ready the FACS machine to read samples. When cleaning or 
priming FACS machine, the Set-Up box MUST be ticked. When ready to read 
samples at any point then Set-Up box is to be unticked. 
FACS machine is Primed by flick of lever to the right, and then quickly placing a 
FACS tube of PBS into the Sample Feed Slot, making sure it is firmly in to the top 
of the slot. 
-Flick lever back to the centre position, click Acquire, run for a few seconds, click 
-Pause and then click Abort. 
-At this stage , you can check your control samples to make sure all is well with 
the assay. 
-Acquire click menu link; Counters; G ; Accept -> Collect 
Source: Mode: 
Collect: G 1 Rate: 
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Collect: G1 
-When ready to read samples. untick the Set-Up Box. type in sample 10 info • 
click Acquire and let sample run for selected Event Counts or click Pause and 
Save if counts are low or if sample is about to run out. 
-After all samples have been read • data is automatically saved into the file so no 
need to worry about saving anything. the FACS machine needs to be cleaned. 
rinsed. emptied of waste and refilled with FACS buffer. Tick the Set-Up Box. then 
run 2ml of Clean fluid with the lever set to the right. then run 2ml of Rinse fluid • 
then run dH20 for 1 minute and at same time. click Acquire to check that 0 events 
are detected. Then click Pause and Abort. Empty Waste Tank and Refill FACS 
Buffer Tank. 
-Acquire clickmenu link -> Disconnect • then CellProQuest -> Switch Off 
Flick Black Toggle Switch Back UP. Press StandBy Button and Low Button 
Switch Off FACS Machine 
8.4: FASTA sequences from rosette selected field isolates 
1. SA075 cDNA and gDNA sequences from R+ and R- clones 
Rosette positive clone (R+) cDNA sequences 
>R+ 11 cDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R+ 14 cDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R+ 10 cDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R+ 13 cDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R+ 16 cDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R+ 4 cDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R+ 8 cDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R+_1_cDNA 
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DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R+ 9 eDNA 
DIGDIIRGKDL YLDHEPGKQHLEERLERIFENIKKKNNNNELNNLSLDKFREYWWA 
LNRDQVWKAITCKAPEEDHYFKPAQNRKREFTDGHCGHRQGNVPTNLDYVPQF 
LR 
>R+ 2 eDNA 
DIGDIIRGKDL YLDHEPGKQHLEERLERIFENIKKKNNNNELNNLSLDKFREYWWA 
LNRDQVWKAITCKAPEEDHYFKPAQNRKREFTDGHCGHRQGNVPTNLXYVPQF 
LR 
>R+ 3 eDNA 
DIGDIIRGKDL YLDHEPGKQHLEERLERIFENIKKKNNNNELNNLSLDKFREYWWA 
LNRDQVWKAITCKAPEEDHYFKPAQNRKREFTDGHCGHRQGNVPTNLXYVPQF 
LR 
>R+ 12 eDNA 
DIGDIIRGKDL YLDHEPGKQHLEERLERIFENIKKKNNNNELNNLSLDKFREYWWA 
LNRDQVWKAITCKAPEEDHYFKPAQNRKREFTDGHCGHRQGNVPTNLDYVPQF 
LR 
>R+ 15 eDNA 
DIGDIIRGKDL YLDHEPGKQHLEERLERIFENIKKKNNNNELNNLSLDKFREYWWA 
LNRDQVWKAITCKAPEEDHYFKPAQNRKREFTDGHCGHRQGNVPTNLXYVPQF 
LR 
>R+ 16 eDNA 
DIGDIIRGKDL YLDHEPGKQHLEERLERIFENIKKKNNNNELNNLSLDKFREYWWA 
LNRDQVWKAITCKAPEEDHYFKPAQNRKREFTDGHCGHRQGNXPTNLXYVPQF 
LR 
>R+ 5 eDNA 
DIGDliRGRDL YRRDKGGKTKLEKNLEKIFQYIKENNKSSLESL TDEELREDWWAL 
NRDQVWKAITCHAEHSDEYFRKSRDGVYL YFDDRCGRDLSSVPTNLDYVPQFL 
R 
>R+ 6 eDNA 
DIGDIVRGKDL YLGTDKDDVEKGLKIVFQKINNGLKKIGINAYDDGSGNYYKLREV 
WWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLDY 
VPQFLR 
Rosette negative clone (R-) cDNA sequences 
>R- 9 eDNA 
DIGDilRGKDL YIRNKREKRRLEDNLQKIFKELKRGVKRKEAEKHYEDGAPEFYKL 
REDWWDANRLEVWKAITCEAQGFNYFRRTCSGGTSTTHGKCHCIGGTVPTYFD 
YVPQYLR 
>R- 2 eDNA 
DIGD(VRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R- 3 eDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R- 16 eDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
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>R- 12 eDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R- 7 CDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R- 1 eDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R- 4 eDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R- 5 eDNA 
DIGDIVRGRDMFLPNKDDKVQKGLQWFEKINNGLKKIGINAYNDGSGNYSKLRE 
VWWNVNRDQVWRAITCSAPGDVNYFRKISGDTRTFENAGKCRRHDNKVPTNLD 
YVPQFLR 
>R- 14 eDNA 
DIGDIIRGKDLFRGNNKEKKQREKLDENLKTIFANIYKDVTSSGRNVQKLQKRYND 
DNENYYQLREDWWTANRETVWKAITCSEKLSNSKYFRGTCGGDENTATRTPSH 
CRCDGKNADQVPTYFDYVPQYLR 
>R- 6 eDNA 
DIGDIIRGKDL YLGNKRQNETEREKKKLQQNLKEIFKKIYEGLKGDAQKDYKDESG 
NYYQLREDWWNANRQEIWKAMICKAPGNAQYFRNTCSNGEKPTDEKCQCIDGT 
VPTNLDYVPQFLR 
>R- 8 eDNA 
DIGDIIRGRDL YGGNKKKERLEDNLKKIFRNIYDKLLEENRTNGELKTRYQDDGSG 
NYYQLREDWWTLNRQDVWKAITCDDRLGGYSYFRATCGDSESPSMARDKCRC 
KKKNGRPDDQVPTYFDYVPQYLR 
>R- 10 eDNA 
DIGDIIRGKDLFLGYNERDRAQKKKLQDNLEKIFGKIYKDL TNGAQNHYKDENGG 
NFFKLREDWWDAXRLEVWKAITCDAGQNDKYFXQTCDDNGTSSNANHKCRCK 
KNDDTSDTDQVPTYFDYVPQYLR 
>R-_11 eDNA 
DIGDIVRGRDL YRGNNGKDKLQDNLKKIFXXXHDKLDNSIKSKYNDDTENYYKLR 
EDWWT ANRETVWKAITCEAYGTYFRA TCNSGDNRGCSQAKDNCRCKDEEGKX 
XXDQVPTYFDYVPQYLR 
>R- 15 eDNA 
DIGDIIRGKDL YIRNKREKRRLEDNLOKIFKEIYEELKRGVKRKEAEKHYEDGAPEF 
YKLREDWWDANRLEVWKAITCEAQGFNYFRRTCSGGTSTTHGKCHCIGGTVPT 
YFDYVPQYLR 
Rosette positive clone (R+) gDNA sequences 
>R+_9_9DNA 
DIGDIIRGKDLFLGYNERDRAQKKKLQDNLEKIFGKIYKDL TNGAONHYKDENGG 
NFFKLREDWWDANRLEVWKAITCDAGQNDKYFRQTCDDNGTSSNANHKCRCK 
KNDDTSDTDOVPTYFDYVPQYLR 
>R+_2_9DNA 
293 
I 
1 
DIGDIIRGKDL YRGNSKEKDNLEKKLlEYFKELHKHLDQKTKNHYTKDDPYVYKLR 
EDWWNANRKEAWKAITCKAENAQYFRNTCSMGKHSTQTNCQCIDGEVPTYFDY 
VPQYLR 
>R+_10_9DNA 
DIGDIIRGKDLFLGITQEKKSLEENLKNIFRKL YNEL TKEEENGTAIKSRYENDGPN 
VYQLREDWWALNRKEIWKAITCDTEESDTYFKQSSEGKYSFTNGQCGHNEENV 
L TNLDYVPQFLR 
> R+_3_9DNA 
DIGDIVRGKDL YRGDKGEKRRKKKLEERLKTIFGKIHEEVTNGSNGQTLQARYKD 
DKENFFKLREDWWYANRGTVWKAITCEAPESAQYFRNTCNGGEQTKGYCRCN 
DDKPDDDKANVDPPTYFDYVPQFLR 
>R+_4_9DNA 
DIGDIVRGKDLFLGNTYESARRDKLEQKLKDIFKEIHGGLKGAKTRYNGDGDNYF 
QLREDWWNANRETVWKAITCGADAGNKYFRPTCGGHNENITFRTPSQCRCSD 
NQVPTYFDYVPQYLR 
> R+_S_9D NA 
DIGDIVRGRDMFKRTDKDEVKEGLQWFKKIYNTLPSPAQNVYADESENVYKLRD 
AWWT ANRDQVWEAITCKAPQKVDYFRKGSNGESIFSNSGKCGRNETDVPTNLD 
YVPQFLR 
>R+_139DNA 
DIGDIIRGKDL YRGDSKEKDNLEKKLlEYFKELHKHLDQKTKNHYTKDDPYVYKLR 
EDWWNANRKEAWKAITCKAENAQYFRNTCSMGKHSTQTNCQCIDGEVPTYFDY 
VPQYLR 
>R+_6_9DNA 
DIGDIVRGKDL YLGDKKEKKQLEENLKTIFGNIYKEL ITENGVKARYKDTDNVYEL 
REDWWNANRNDIWKAL TCDAPKDAQYTKKGPHNHITESNRGQCRCFSGDPPT 
NMDYVPQYLR 
>R+ _14_9DNA 
DIGDIVRGKDPFYGNTQEKEKREDLENNLKTIFGKIHNGLHDKIKSKYNDDAKKNY 
YQLREDWWYANRQEVWKALTCDVDGSYFHATCNGEERTKGYCRCDGDKSKV 
GTNETDQVPTYFDYVPQFLR 
>R+ _1S_9DNA 
DIGDIVRGKDPFYGNTQEKEKREDLENNLKTIFGKIHNGLHDKIKSKYNDDAKKNY 
YQLREDWWYANRQEVWKALTCDVDGSYFHATCNGEERTKGYCRCDGDKSKV 
GTNETDQVPTYFDYVPQYLR 
>R+_8_9DNA 
DIGDIVRGKDLFRGNNKEKKQREKLDENLKTIFANIYKDVTSSGRNVQKLQKRYN 
DDNENVYQLREDWWT ANRETVWKAITCSEKLSNSKYFRGTCGGDENTATRTPS 
HCRCDGKNADQVPTYFDYVPQFLR 
>R+_16_9DNA 
DIGDIIRGKDLFRGYNEKDQEEKTKLQENLKNIFKKIHENLGDITIKSKYNDDTDKN 
VYKLREDWWDLNRDQVWKAITCEAPGDAKYKVIGSDGSITESARGQCRGVADV 
PTNFDYVPQYLR 
>R+ _11_9DNA 
DIGDIIRGKDLFLGYNERDRAQKKNYKTIWKKFSGKYIRISTKKKLQDNLEKIFGKIY 
KDL TNGAQNHYKDENGGNFFKLXEDWWDANRLEVWKAITCYAGQNDTYSINTG 
NSITEFWFGRCGRNERNVPTNLDYVPQYLR 
Rosette negative clone (R-) gONA sequences 
> R-_9_9 DNA 
DIGDIIRGKDL YLGDNGKDRLENKLKEIFKQIYDKLDGKKKKEAKARYQDDGSGN 
VYQLREDWWNNNRKMVWYAITCGAENDSTYFRNTCGSGEKGSA TTGKCRCPK 
ANANQVPTYFDYVPQYLR 
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>R-_10 _9DNA 
DIGDWRGKDLFLGNTYESARRDKLEQKLKDIFKEIHGGLKGAKTRYNGDGDNYF 
QLREDWWNANRETVWKAITCGADAGNKYFRPTCGGHNENTTFRTPSQCRCSD 
NQVPTYFDYVPQYLR 
>R-_3_9DNA 
DIGDIVRGRDL YRRDKGGKTKLEKNLEKIFQYIKENNKSSLESL TDEEIREYWWAL 
NRDQVWKAITCHAEHSDEYFRKSRDGVYL YFDDRCGRDLSSVPTNLDYVPQFL 
R 
>R-_11_9DNA 
DIGDIIRGKDLFLGTTQEKKSLEENLKNIFRKL YNELTKEEENGTAIKSRYENDGPN 
YYQLREDWWALNRKEIWKAITCDTEESDTYFKQSSEGKYSFTNGQCGHNEENV 
L TNLDYVPQFLR 
>R-_12_9DNA 
DIGDIVGRDL YSGNDEEKKQRKQLDKKLKDIFKNIKNENKDL TTLKPEEVREYWW 
DANRA TIWYAITCGAGQSDKYFRA TCGGGKTPTQGKCRCSDNPNTDPPTYFDY 
VPQYLR 
>R-_16_9DNA 
DIGDIVRGRDL YSGNDEEKKQRKQLDKKLKDIFKNIKNENKDL TTLKPEEVREYW 
WDANRA TIWYAITCGAGQSDKYFRA TCGGGKTPTQGKCRCSDNPNTDPPTYFD 
YVPQYLR 
> R-_5_9 DNA 
DIGDIIRGKDL YLRYNRKDKTDKLQEQLKKYFQKIYDQLKSQAKEYYKEDKRDGN 
FYQLREDWWTANRAKVWDAITCKAGSDSQYFRRTCGSGNNAKRTPSQCRCTT 
RWPTYFDYVPQYLR 
>R-_13_9DNA 
DIGDIIRGKDLFYGNKKEKNRREKLEDNLKRXFGHIYEELKKDRKKSALAKERYGS 
DTTNYFQLREDWWALNRDQVWKAMTCSEHLKNSAYFRPTCSDSHRSGTFSQA 
KDKCRCKDEKGKNETDQVPTYFDYVPQYLR 
> R-_7_9DNA 
DIGDIIRGKDL YRGNRKKNQNETEREKLEQKLKEIFAKIYNSLKNKEDAKKHYGGD 
APyyYQLREDWWTANRAKVWEAITCHWSGNNYFRHTCGARKDRTQTQDNCQ 
CIDQTVPTYFDYVPQYLR 
>R-_1_9DNA 
DIGDIVRGRDL YLGDKKEKDRLQSTLKRIFRKIYKNLMEDL TKSNRTKVAEAQTRY 
NGDDNYYQLREDWWEANRQEIWKAITCEHPGGTYFRQRACAGRFSTDDKCRC 
VTDVPTYFDYVPQYLR 
2. cDNA and gDNA sequences for the rosette selected samples 
9106R+ cDNA sequences 
>9106R+7 
DIGDIIRGKDLFIGYDQKEKDRRENLENKLKKIFEKIHKEVTSTSGRRNRQTLKARY 
DGDnNYYQLREDWWNANRIMVWIAMTCGAGESDKYFRKACSGGTTPTNKKC 
RCTTHDVPTYFDYVPQYLR 
>9106R-3 
DIGDIIRGKDLFIGYDQKEKDRRENLENKLKKIFEKIHKEVTSTSGRRNRQTLKARY 
DGDnNYYQLREDWWNANRIMVWIAMTCGAGESDKYFXKACSGGTTPTNKKC 
RCTTHDVPTYFDYVPQYLR 
>9106R+9 
295 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
>9106R+2 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
>9106R+8 
DIGDIIRGKDL YRGNKQEKEKREQLENKLKIYFTQIHENLGTQEKNHYNDTKNYFQ 
LREDWWTANRATVWKAITCRAGEGDRYFRATCGSGRDATRARDKCRCEGANV 
VPTYFDYVPQYLR 
>9106R+10 
DIGDIVRGRDL YLGNPQEKTKREOLEKNLKDIFKEIHDDVMKTSGRNGKKVEAEK 
RYNDTTNYFQLREDWWEENREKVWKAITCNAGGGKYFRQTVCSEGTTPTNEK 
CQCINFSVPTNFDYVPQYLR 
>9106R+11 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKEYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDOVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
>9106R+4 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKEYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
>9106R+12 
DIGDIIRGKDMFLGNNKEKKQREOLDDKLKEVFGKIHGGLlKNGRNGEAAOEYYE 
DKGKNYYKLREDWWTANRATIWEALTCHAPPDAQYFHATCGTGTGTQGRCRC 
GDGKSKVGKNETDQVPTYFDYVPQYLR 
>9106R+5 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
>9106R+6 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
>9106R+1 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
9106R- cDNA sequences 
>9106R 9 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
>9106R-2 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
yvPQSLR 
>91 06R-1 0 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDOVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
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>9106R-11 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWT ANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
>9106R-4 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
>9106R-12 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
>9106R-6 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
>9106R-1 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPQFLR 
>9106R-7 
DIGDIIRGKDMFKRTDKDDVENGLREVFGKIYKSLNGKAISHYTDTHGSIDYVKLR 
EDWWTANRDQVWRAITCYIPYYVNYFKKTSDDIIVFTNDGKCGHYEGAPPTNLD 
YVPOFLR 
9106R+ gDNA sequences 
>9106R+2gDNA 
DIGDIVRGRDMFKPNSDDKVQEGLKWFRKINDGLKKSRINDYDRDGPEYYKLRE 
DWWTANRNQVWRAITCAARYNPGYFKKSDRSTOVFSNPKCGHDEGIVPTNLDY 
VPQFLR 
>91 06R+1 OgDNA 
DIGDIVRGKDL YIRNKKKDKLEENLKNMFQYIKTKHNTKLGQL TLDQVREYWWAL 
NRKEVWKAMTCSDDNKLANASYFROTCDDNGTSSNANHKCRCKDKKGEHDTD 
OVPTYFDYVPQYLR 
>9106R+3gDNA 
DIGDIIRGKDLFRGNNKEKKOREKLDENLKTIFANIYKDVTSSGRNVOKLQKRYND 
DNENYYQLREDWWTANRETVWKAITCSEKLSNSKYFRGTCGGDENTATRTPSH 
CRCDGKNADQVPTYFDYVPQFLR 
>9106R+11gDNA 
DIGDIIRGKDL YLRYNRKDKTDKLOEQLKKYFQKIYKEL TWT ATKNGOKSAKDHY 
KDDTGDFFQLREDWWNNNRKMVWYAMTCGAGTSAQYFRKTCGSGNWTKDKC 
RCTTHDVPTNFDYVPQYLR 
>9106R+4gDNA 
DIGDIIRGKDLFIGYDOKEKDRRENLENKLKKIFEKIHKEVTSTSGRRNROTLKARY 
DGDTTNYYOLREDWWNANRIMVWIAMTCGAGESDKYFRKACSGGTTPTNKKC 
RCTTHDVPTYFDYVPQYLR 
>9106R+13gDNA 
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DIGDIIRGRDL YLGNKKKSENKREKEKLERKLKSFFKNIYDDLlNDQGKKDAAIKHY 
FDPKGNYYQLREDWWDLNRHDVWKAITCSAPNEAKYNVIASDGTTIKSNYKKC 
RNIADVTTYFDYVPQYLR 
>9106R+6gDNA 
DIGDIIRGKDL YLRYNRKDKTDKLQEQLKKYFQKIYKEL TWTATKNGQKSAKDHY 
KDDTGDFFQLREDWWNNNRKMVWYAMTCGAGTSAQYFRKTCGSGNWTKDKC 
RCTTHDVPTNFXYVPQYLR 
>9106R+14gDNA 
DIGDIVRGRDL YRRDKGEETKLEKNLKEIFRRIQGKNQSKLGALSLDKVREYWWE 
LNRETVWKAITCGHPDGTYFRNTCAGGTTPTPNKCQCIDQTVPTNFDYVPQYLR 
>9106R+7gDNA 
DIGDIIRGKDL YLRDKGKRDELEKNLKRIFGIIYGKLKNGKTNGQKSAKEYYKDDT 
DGNYYKLREDWWDANREKVWKAITCNAGGGKYFRNTCDGGQNPTETQSNCQ 
CINLDVPTYFDYVPQYLR 
>91 06R+ 15gDNA 
DIGDIVRGRDL YRRDKGEETKLEKNLKEIFRRIQGKNQSKLGALSLDKVREYWWE 
LNRETVWKAITCGHPDGTYFRNTCAGGTTPTPNKCQCIDQTVPTNFDYVPQYLR 
>9106R+8gDNA 
DIGDIVRGRDIFRGNDEEKTKRDELESKLKEIFGKIKGNNNSTLTGLPLHKVREYW 
WYANRETVWKALTCNAGGYSYFRATCGDSGSPSMARDKCRCKDENLTKETDQ 
VPTYFDYVPQYLR 
9106R- gDNA sequence 
>9106R-2gDNA 
DIGDIVRGRDMFKPNSDDKVQEGLKWFRKINDGLKKSRINDYDRDGPEYYKLRE 
DWWTANRNQVWRAITCAARYNPGYFKKSDRSTQVFSNPKCGHDEGIVPTNLDY 
VPQFLR 
>91 06R-1 OgDNA 
DIGDIIRGKDMYVGYDEKEKNRRKQLEDKLKEIFKKIHDDVMKTSGKNVDKAKAR 
YNDGSGNYYQLREDWWTLNRKDVWKALTCSAPGDAKYVKYFPSNTTTVSYNQ 
CGHNDMNVPTNLDYVPQFLR 
>9106R-11gDNa 
DIGDIVRGRDL YSGNKKKDKLEENLNKIFNDIKNKNKTKLGEL TLDQVREYWWEE 
NRQQVWKAITCNATGGKYFRNTCGSGKT ASATYDKCHCIGGEVPTYFDYVPQY 
LR 
>9106R-4gDNA 
DIGDIIRGKDLFIGYDQKEKDRRENLENKLKKIFEKIHKEVTSTSGRRNRQTLKARY 
DGDTTNYYQLREDWWNANRIMVWIAMTCGAGESDKYFRKACSGGTIPTNKKC 
RCTTHDVPTYFDYVPQYLR 
>9106R-12gDNA 
DIGDIIRGKDL YLRYNRKDKTDKLQEQLKKYFQKIYKEL TWT ATKNGQKSAKDHY 
KDDTGDFFQLREDWWNNNRKMVWYAMTCGAGTSAQYFXKTCGSGNWTKDKC 
RCTTHDVPTNFDYVPQYLR 
>9106R-5gDNA 
DIGDIIRGRDL YGGGGRGKGKDKLQDNLKKIFEKIHDDVTSGKQNGELKTRYKDD 
AKGGHFYQLREDWWT ANRHTVWKAITCKADTGNAYFRTICSDNRGFSQAHDK 
CTCNNGDVPTYFDYVPQYLR 
>9106R-14gDNA 
DIGDIIRGKDLFRGYNQKDRNEKKQLQQRLKEIFKQIHSEVTNGSNGQALKTRYQ 
DDNGGNFFKLREDWWYANRQEVWKAITCDWSGTYFHATCSERNGGCSQANN 
KCRCPMTSDGKPNDQVPTYFDYVPQYLR 
>9106R-15gDNA 
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DIGDIIRGKDLFRGYNETDKEQKVALQQHLKEIFEKIYGELKGEAQKQYKDDNGG 
NYFQLREDWWALNRRQVWKAITCKADENDRYSANIEHDRTGVSHERCGHEDD 
NVPTNLDYVPQYLR 
>91 06R-1 gDNA 
DIGDIIRGRDL YGGGGRGKGKDKLQDNLKKIFEKIHDDVTSGKQNGELKTRYKDD 
AKGGHFYQLREDWWNNNRKMVWYAMTCGAGTSAQYFRKTCGSGN~KDKC 
RCTTHDVPTNFDYVPQYLR 
8211 R+ cDNA sequences 
>8211R+9 
DIGDIVRGRDL YRGNKQEKKKRDELDENLRKIFKQIHEDVTRGRNGVNSRYKDTT 
NFYELREDWWTANRETVWKAITCGTHDGDTYFRTTCNDNGTLSDANHKCRCRS 
KNAINETDQVPTYFDYVPQYLR 
>8211R+2 
DIGDIVRGRDL YRGNRKKNQNETERDKLEEKLKDIFKQIHEDVTSTNGKTNGAEA 
RYGKDPNFFQLREDWWT ANRETVWKAITCNADTGNAYFRTTCSDGKSQSQAN 
KYCRCNDDKPGEDKPNIDPPTYFDYVPQYLR 
>8211R+10 
DIGDIIRGRDIFLGNDEEKKKREDLEKNLKEIFKNIKNENTDLKKL TTEKVREYWWY 
ANRATIWEAMTCKAEGAYFHATCSDGRGGAQANKHCRCEGANVVPTYFDYVP 
QFLR 
>8211R+1 
DIGDIVRGKDLFLGNDKEKEKRKQLDDKLKEVFGNIYNELRSTNGVKSRYENDTA 
NVYQLREDWWTANRHTVWEAITCDVKSGNNYFRRTCGTGPKRNL TNNDCRCR 
DNQVPTYFDYVPQYLR 
>8211R+3 
DIGDIVRGKDLFLGNDKEKEKRKQLDDKLKEVFGNIYNELRSTNGVKSRYENDTA 
NVYQLREDWWTANRHTVWEAITCDVKSGNNYFRRTCGTGPKRNL TNNDCRCR 
DNQVPTYFDYVPQYLR 
>8211R+11 
DIGDIVRGRDLFLGGPNQEKKLLENKLKHYFQKIYDKLVQTARDHYNDTSGNVYQ 
LRNDWWELNRQQVWNAITCGAPSDAQYFRNTCSSIKGGHYKNCHCIGGDVL TN 
FDYVPQYLR 
>8211R+4 
DIGDIVRGKDLFIGYSQKYKDEKSKLEENLKKIFKKIYETLKYKKKIEHYKDDPEEN 
FYELREDWWAVNRKEVWDALTCNAPEKAEYFVHKSGGLLKFSNRKCHNNQGA 
VL TNLDYVPQYLR 
>8211 R+12 
DIGDIIRGKDLFLGNTYESAQRKQLDKNLKRIFKKIYKEVTKTNEELKRRYEGDTK 
NVYKLREDWWTANRAKVWEALTCHVVSGKYFRQTCGDSGDEKGPSQAHDKCR 
CKDKNGSPDDQVPTYFDYVPQYLR 
>8211R+5 
DIGDIVRGKDL YRGYDDEEKKKRDELDKKLKTIFGKIHGGL TDQKAKQHYNGDTK 
NVYKLREDWWTANRHTVWEAMTCSNELKDNRYFRATCDSGDALNPSLTQGDC 
RCAAGGVPTYFDYVPQYLR 
>8211R+13 
DIGDIVRGKDMFKRTDKDKKKEGLDVVFKKITNTLPSPAQNVY AYESENVYKLRD 
AWWTANRDQVWEAITCKAPQKVDYFRKGSGGESIFSNSGKCGGKEAPVPTNLD 
YVPQFLR 
>8211R+6 
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aM a 
DIGDIVRGKDL YGGNNKRRQQLEENLRKKFANIYEELSRTPTKNGQKSAKDRYG 
QDSPNFYKLREDWWT ANRSTVWKAITCGTHDGASYFRA TCSDGQSGAQAKNK 
CTCAAGDVPTYFDYVPQFLR 
>8211R+8 
DIGDIVRGKDMFKRTDNDEVWKGLRA VFKKIHDNLSSEVKNAYPDDGSGNYYKL 
REDWWTANRNQVWRAITCAARYNPGYFKKSDTSTQVFSNPKCGHDEGTVPTN 
LDYVPQFLR 
8211 R- cDNA sequences 
>8211R-9 
DIGDIIRGKDL YIRNKQEKDRLEENLQKIFANIYEELTNGAQTYYNDDKENYYKLRE 
DWWNANRQQVWNAIICGVXKNEKYFKNKCSSKGGHYEKCRCDNGDVL TNFDY 
VPQYLR 
>8211R-2 
DIGDIVRGKDIFRGNDEEKKKREELQKNLKXXFKNIKNENTDLPKL TTEKVREYW 
WYANRATIWEAMTCKAEGAVFHATCSDGRGGAQANKHCRCEGXNVVPTYFDY 
VXXFLR 
>8211 R-3 
DIGDIVRGKDLFLGHQQRKKYLEERLGKMFXXIQEKNSRLKDLPLDKLREYWWN 
ANRDQVWKAITCYAADNDEYFTKSSTREFKFTSGKCGRNETNVPTNLDYVPQYL 
R 
>8211R-4 
DIGDIVRGKDL YLGYDDEEKNRRDQLESKLXXXFAKIHEGLKDPEKTKYNDPKKN 
YYQLREDWWDANRYDVWKAITCKA TDDDKYFXNTACAGKTPTQGKCRCKGDQ 
VXXYFDYVPQYLR 
>8211R-12 
DIGDIVRGRDL YRGNKQEKKKRDKLENKLKEIFGDIYKEL TTSRKKSAEAEARYKD 
EPDNEFYQLREDWWALNREDVWKAITCGTHDGDXYFRTTCNDNGTLSDANHK 
CRCRSKNAINETDQVPTYFDYVPQYLR 
>8211R-5 
DIGDIVRGKDLFRGYNETDKEHKVALQQHLKEIFKKIHEGL TTTKGAEARYKDDG 
GDFFQLREDWWTLNRKKVWYAITCGAGTSAQYFXKTCSNDTTDTYEKCRCVTN 
DVPTYFDYVPQYLR 
>8211R-6 
DIGDIVRGKDL YLGNPQESARRDKLENKLKEIFGDIYKEL TTSRKKSAEAEARYKD 
EPDNNFYQLREDWWALNREDVWKAL TCEAYGTYFRQTCNGGTSSTNTQCRCK 
TN DVPTYFDYVPQYLR 
>8211R-7 
DIGDIVRGKDLFLGNNESEIKRKEKLRGNLXXIFEKIKTSNTNMNTLSLDKVREYW 
WALNRKDVWKAL TCNAPYEAQYFIKSSDKEHSFSSEYCGHHNNDDPL TNLDYV 
PQFLR 
>8211R-8 
DIGDIVRGKDXFLGNDKEKEKRKQLDDKLKEVFGNIYNELRSTNGVKSRYENDTA 
NYYQLREDWWTANRHTVWEAITCDVKSGNNYFRRXCGTGPKRNL TNNDCRCR 
DNQVPTYFDYVPQYLR 
>8211R-11 
DIGDIIRGKDL YIRNKQEKXRLXXNLQXIFGXXYEEL TNGAQTYYNDDKENYYKLR 
EDWWXANXQQVWNAIICGVEKXEKYXKXTCSSXGGXYEKCRCINGDVLXNFDY 
XXXYLR 
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8211 R+ gONA sequences 
>8211 R+9gDNA 
DIGDIVRGRDL YRRDKGEETKLEKNLKKIFEKIHSDVTKTSDKNVDKAKERYNDTE 
NVYQLGED~EANRKQIWQAMTCSEKLDNSSYFHATCSDSHHKGSCSQAHHY 
CRCDGDEPKADKQNVDPPTYFDYVPQYLR 
>8211 R+2gDNA 
DIGDIVRGRDLFHGNDKEKEKRDELDKKLKTIFDKIKKSDEKL TSLKDEQIREYWW 
ALNRQDVWKAITCDWSGKYFRNTCGSGEKGSATYEKCRCNDDQVPTYFDYVP 
XYLR 
>8211R+10gDNA 
DIGDIIRGKDLFLGHQQRKIQLEERLEQMFKNIQKNNANLEGLSIEKVRE~EA 
NRNQVWNAITCGAPDNAEYFRNTCSSKSVHYRKCHCNNGDVL TNFDyvPQYLR 
>8211 R+ 12gDNA 
DIGDIIRGKDL YLGYDKKEKEQRDKLEQKLKEIFGNIYEELKKDRNLKEGAQERYG 
SDTENYFQLRED~ALNRETVWKAITCNDDNKLKDAQYFRGTCGGENTATLAK 
YKCRCEGANWPTYFDYVPQYLR 
>8211R+13gDNA 
DIGDIVRGKDL YLGNPQESARRDKLENKLKEIFGDIYKEL nSRKKSAEAEARYKD 
EPDNNFYQLRED~ALNREDVWKALTCEAYGTYFRQTCNGGTSSTNTQCRCK 
TN DVPTYFDYVPQYLR 
>8211R+14gDNA 
DIGDIVRGKDLFLGNTYESAQRKKLDDKLKGVFAKIHSEVTNGNKDAKDRYKDTK 
NVYQLRED~TANRETVWKAITCDVKSGNNYFRQTCSDDTADTHEKCRCNGD 
QVPTYFDYVPQFLR 
>8211R+7gDNA 
DIGDIVRGKDL YLGKKKKKKKXTERDXLXQXLKXXFGKIHSEVXXXNGAKXRYXG 
DTDNVYELREYXXALNXQTVWKAITCDAPXEAQXFGGTXXGEKIXTLAKYKCRC 
DDKPKTGKKPGXVNIVPTYFXYVPQYLR 
8211 R· gONA sequences 
>8211 R-9gDNA 
DIGDIVRGKDL YRGYDDEEKKKRDELDKKLKTIFGKIHSDVTKTSDKNVDKAKERY 
NDTENVYQLRED~EANRKQIWQAMTCSEKLDNSSYFHATCSDSHHKGSCSQ 
AHHYCRCDGDEPKADKQNVDPPTYFDYVPQYLR 
>8211 R-2gDNA 
DIGDIVRGRDMFKSNNDVEKGLHWFKKIQRKLNGAAKSYCNADEKGNFYKLRN 
DWWTVNRDQVWKAITCDAPRDANYFRKGSDGTLHFSSHGKCGHYEGAPPTYL 
DYVPQFLR 
>8211 R-10gDNA 
DIGDIIRGKDLYSGNSKEKKKRDELXKNLKKIVENIKKENKSKLKSLTDEQIREYW 
WELNREMVWYAITCEAPKDSKYFRPTCGSGEWTKDNCRCVKNDVPTYFDYVP 
QYLR 
>8211 R-11gDNA 
DIGDIIRGKDL YSGNSKEKKKRDELEKNLKKIFENIKKENKSKLKSL TDEQIREYW 
WELNREDVWKAITCDWSGKYFRNTCGSGEKGSATYEKCRCNDDQVPTYFDYV 
PQYLR 
>8211 R-4gDNA 
DIGDIVRGRDLFHGNDKEKEKRDELDKKLKTIFDKIKKSDEKL TSLKDEQIRE~ 
ALNRQDVWKAITCDWSGKYFRNTCGSGEKGSATYEKCRCNDDQVPTYFDYVP 
QYLR 
>8211 R-12gDNA 
301 
DIGDIVRGKDLFYGNPQEKEQREKLDEKLKTIFGKIHEGLDPKIKSNYNDAPYYYK 
LREDWWNANRETVWKAITCDVKSGNNYFRQTCGDEKTGTL TPNQCRCDGDQV 
PTYFDYVPQYLR 
>8211 R-5gDNA 
DIGDIVRGKDL YRGYDDEEKKKRDELDKKLKTIFGKIHGGL TDQKAKQHYNGDTK 
NYYKLRED~ANRHTVWEAMTCSNELKDNRXFRATCDSGDALNPSLTQGDC 
RCAAGGVPTYFDYVPQYLR 
>8211 R-6gDNA 
DIGDIVRGKDLFRGNDEEKEKRKQLEKNLKKIFGNIYKELKKKKKGRNGQIEARYK 
KDEDPYYYQLREDW~NRATVWKALTCDARNNAEHFRQTCDGSGKTGTLTP 
SQCXXXXXXVPTYFDYVPQYLR 
>8211 R-7gDNA 
DIGDIVRGRDL YGGNNKRRQQLDKKLKEIFKNIYDNLMEDLKKYPTKKVEAEKHY 
QDKNGGNFFKLREDWWT ANRHTVWEAITCDNKLAGASYFRA TCGDSESPSQA 
QNQCRCPKSRDNKPNDQVPTYFDYVPQFLR 
>8211 R-15gDNA 
DIGDIIRGKDL YSGNSKEKKKRDELEKNLKKIFENIKKENKSKLKSL TDEQIREYW 
WELNREMVWYAITCEAPKDSKYFRPTCGSGEWTKDNCRCVKNDVPTYFDYVP 
QYLR 
9197R+ cDNA sequences 
>9197R+4 
DIGDIVRGKDPFYGNTQESARREDLEKNLKEIFGNIYEELIKNGRNGVKDHYNDA 
KKNFYRLREDWWTANRATVWEALTCEVGSGTYFRPTCSDSGDRQGPSVAQKQ 
CRCPNGNNQVPTYFDYVPQYLR 
>9197R+14 
DIGDIIRGKDL YLDHEPGKQHLEERLERIFENIKKKNNNNELNNLSLDKFREYWWA 
LNRVQVWKAITCDATMNDIFSKNIXNSXTTLFYYKCGHYVYKDVPTNLDYVPQYL 
R 
>9197R+1 
DIGDIXRGKDLFRGNKQESAQRIILENNLKTIFKKIHDDVTNRKTNKEAAEARYKDE 
SGNYYQlRED~DANRATVWEAITCEAPKDSKYFRGTCSTGTATYEKCRCASG 
NVl TNFDYVPQYLR 
>9197R+6 
DIGDIVRGKDLFRGNKQESAQRIILENNLKXIFKKIHDDVTNRKTNKEMEARYKD 
ESGNYYQLREDWWDANRATVWEAITCEAPKDSKYFRGTCSTGTATYEKCRCAS 
GNVL TNFDYVPQYLR 
>9197R+13 
DIGDIVRGKDLFRGNKQESAQRIILENNLKTIFKKIHDDVTNRKTNKEAAEARYKDE 
SGNYYQLREDWWDANRATVWEAITCEAPKDSKYFRGTCSTGTATYEKCRCASG 
NVLTNFDYVPQYLR 
>9197R+11 
DIGDIVRGKDLFRGNKQESAQRIILENNLKTIFKKIHDDVTNRKTNKEAAEARYKDE 
SGNYYQLREDWWDANRA TVWEAITCEAPKDSKYFRGTCSTGTATYEKCRCASG 
NVLTNFDYVPQYLR 
>9197R+2 
DIGDIIRGKDL YLGYDEKEKDQRKQLEKNLQKIFENIYNDVTNRKTNGQALQARYE 
GDKNNNFFKLREDWWYANRRQVWKAITCDAKAFNYFRNTCNGESPTKGYCRC 
NDDKPDDDKPNTDPPTYFDYVPQFLR 
>9197R+5 
302 
DIGDIVRGRDL YSGNKKENKQRKQLEDNLKKIFENIKNENTELSTL TTEKVREYW 
WEANRETVWKAITCDXXKKLKDASYFRPTCSDSDGRSEYQTQNQCRCTKSSGA 
KADQVPTYFDYVPQFLR 
>9197R+9 
DIGDIIRGKDLFYGNPQESAQRKVLDEKLKTIFKQIHDDVMKTSSNNKEVLKTRYK 
DDTPYYYKLREDWWNANRQQVWYAITCGAGGSQYFRRTCGSGNNATQAKDKC 
RCPSYKVPTYFDYVPQYLR 
>9197R+7 
DIGDIVRGRDMFKSNEKVEIGLXKVFXKINNGLXKIGIHDXXDIXGNYYXXXDXWW 
TVNRNQVWEAITYKAPKDANYFKNV AXNIQQFTDIGKCGHGDKDVPTNLDYVPQ 
FLR 
9197R- cDNA sequences 
>9197R-13 
DIGDIVRGKDLFRGNKQESAQRIILENNLKTIFKQIHDDVMKTSSNNKEVLKTRYK 
DDTPYYYKLREDWWNANRQQVWYAITCGAGGSQYFRRTCGSGNNATRAKDKC 
RCPSYKVPTYFDYVPQYLR 
>9197R-4 
DIGDIVRGRDLFYGNTQESARRDKLEENLKRIFGKIYEEL TKDKKKTVEAKKKYKD 
ENGGNFFKLREDWWTANRETVWKAITCMKVGDTYFMESRTNSYKFSNGQCG 
HNEENVLTNLDYVPQFLR 
>9197R-14 
DIGDIVRGRDLFYGNTQESARRDKLEENLKRIFGKIYEEL TKDKKKMVEAKKKYKD 
ENGGNFFKLREDWWT ANRETVWKAITCMKVGDTYFMESRTNSYKFSNGQCG 
HNEENVLTNLDYVPQFLR 
>9197R-10 
DIGDIVRGKDLFRGNKQESARIILENNLKTIFKKIHDDVTNRKTNKEMEARYKDGS 
GNYYQLREDWWDANRATVWEAITCEAPKDSKYFRGTCSTGTATYEKCRCASG 
NVL TNFDYVPQYLR 
>9197R-2 
DIGDIVRGKDLFRGNKQESAQRIILENNLKTIFKKIHDDVTNRKTNKEMEARYKDE 
SGNYYQLREDWWDANRATVWEAITCEAPKDSKYFRGTCSTGTATYEKCRCASG 
NVL TNFDYVPQYLR 
>9197R-6 
DIGDIVRGRDLFRGNDEEKKKREDLENKLKEIFGKIHKEVTSGRTNGEIEARYKGD 
TINYFQLREDWWT ANRETVWEAITCEAPKDSKYFRGTCSTGTATYEKCRCASGN 
VL TNFDYVPQYLR 
>9197R-5 
DIGDIVRGRDL YGGGGRRKAELQDNLKTIFGKIHSGL TSGVKARYEGDKENYYQL 
QEDWWTANRHTVWKAITCNAWGDTYFHA TWRDSHRKESCCQANKYCRCGND 
KPSENNPNTDPPTYFDYVPQYLR 
>8148R-6 
DIGDIVRGKDL YGGGGRGKGKEKLXKXXKEIXXKIHEKLDSKAQTYYNDDKENYS 
KLXXDWWNANRHTVWKAITCGTHXGDTYFRTTCSMNGSGAQANNYCRCGNDE 
PGKDKANTDPPTYFDYVPQYLR 
>9197R-9 
DIGDIIRGRDL YRGNKKKKLNGKETERDQLENKLKTIFGNIYEEL TTSREKSAKAK 
ERYKKDEDGNYSKLREDWWNNNRKMVWIAMTCEAGGDKYFRNTCGSDENHPT 
ATQGNCRCVIGGVPTYFDYVPQFLR 
>9197R-12 
303 
DIGDIIRGKDL YIGNRKEKEKVKLQNNLKGIFKKIYGELKNTKAKVHYQEDGPNVY 
KLREDWWNANRQQVWKAITCNDVGAQYFGNGCGDGKQPTDTKCRCVSTDPPT 
YFDYVPQFLR 
>9197R-11 
DIGDIIRGKDLFYGNPQESAQRKVLDEKLKTIFKQIHDDVMKTSSNNKEVLKTRYK 
DDTPYVYKLREDWWNANRQQVWYAITCGAGGSQYFRRTCGSGNNATQAKDKC 
RCPSYKVPTYFDYVPQYLR 
>9197R-15 
DIGDIVRGKDLFRGNKQESAQRIILENNLKTIFKKIHDDVTNRKTNKEAEAGYQNE 
SYNYESGNYVQLPEDWWDANRATVWEAITCEAPKDSKYFRGTCXTGTATYEKC 
RCASGNVLTNFDYVPQYLR 
9197R+ gONA sequences 
>9197R+6gDNA 
DIGDIVRGKDLFLGGPKQEKKELEENLKKIFHNIQKSDSSLQRLSIEEVREYWWAI 
HRREVWDALTCNAPTDAVYFVYKPDRLRNFSNPKCGHKEGSVPTNLDYVPQYL 
R 
>9197R+3gDNA 
DIGDIVRGRDL YRGNKKKKLNGKETERDQLXNKLKTIFGNIYEEL TTSREKSAKAK 
ERYKKDEDGNYSKLXEDWWNNNRKMVWIAMTCEAGGDKYFRNTCGSDENHPT 
ATQGNCRCVIGGVPTYFDYVPQFLR 
>9197R+13gDNA 
DIGDIVRGRDL YHGKKKKKQNQNVTERDKLKDNLKKIFAKIHEELKDAKEHYKDE 
DDREKNVYKLRNAWWEANRQEVWKAITCDAAGGIYFRTTACGGHASNNKCQCL 
IGDVPTYFDYVPQFLR 
>9197R+1gDNA 
DIGDIIRGKDL YLRNKGEKKKRDELEKNLKKIFGIIYNNLFKKKGEEAQKRYNDEDK 
NFFKLREDWWALNRQHVWKAIRCRAPGDADYFIKTACAGTGTOGRCRCINYDV 
PTYFDYVPQYLR 
>9197R+2 gDNA 
DIGDIIRGKDL YLRNKGEKKKRDELEKNLKKIFGIIYNNLFKKKGEEAOKRYNDEDK 
NFFKLREDWWTANRHTVWKALTCDARDNADDKYFRKTACGEGTTSTOGKCRC 
PNGDOVPTYFDYVPOYLR 
>9197R+10gDNA 
DIGDIVRGKDL YLGDKKEKLDLEKKLKDIFAKIYGELKDAKEHYKDESRNYFOLRE 
DWWTANRHTVWKALTCDARDNADDKYFXKTACGEGTTSTOGKCRCPNGDOVP 
TYFDYVPOYLR 
>9197R+11gDNA 
DIGDIVRGKDL YLGDKKEKLDLEKKLKDIFAKIYGELKDAKEHYKDESRNYFOLRE 
DWWTANRHTVWKALTCDARDNADDKYFRKTACGEGTTSTOGKCRCPNGDOVP 
TYFDYVPOYLR 
>9197R+9gDNA 
DIGDIVRGKDLFVGYNDTDKAHKXILOORLKEIFKKIYKKLIGDL TKSSSSKADKAK 
DRYKDTENYFQLREDWWDANREKVWKAITCGVHGSDYFRQTXXNGISETNNNC 
RCAAGDVPTYFDYVPQFLR 
>9197R+4gDNA 
DIGDIVRGKDPFYGNTOESARREDLEKNLKEIFGNIYEELIKNGRNGVKDHYNDA 
KKNFYRLREDWWTANRATVWEALTCEVGSGTYFRPTCSDSGDROGPSVAOKO 
CRCPNGNNQVPTYFDYVPQYLR 
304 
9197R- gDNA sequences 
>9197R-3gDNA 
DIGDIIRGKDL YLGDKKEKLKLEKKLKKYFKNIYENLMEDL TKDNIKQQEAQKRYQ 
DDDKKNFYRLRED~ANRGTVWKALTCEAPNNAKYFRNACSNDTTETHEKC 
TCATNDVPTYFDYVPQYLR 
>9197R-1 gDNA. 
DIGDIVRGKDL YRRDNKKDKLEXNLKRIFXXIYDKLKNGKXKGKEAKDRYGKDPN 
YYQLRXD~AN~EALTCHAPPDAQYFRGTCGSKAKTATQTPSXCRCN 
XDXPDAXNPNTDPPTYFDYVPQFLR 
>9197R-13gDNA 
DIGDIIRGKDL YIGNRKEKEKEKLQNNLKSIFQKIYGELKNPEAKEHYQEDGPNYY 
KLREDWWNANRYDVWKAITCSVEDA VYFRQTCGGGHPTNKKCQCIGGTVPTYF 
DYVPQYLR 
>9197R-12gDNA 
DIGDIVRGRDLFRGNDEEKKKREDLENKLKEIFGKIHKEVTSGSNKDALKTRYNG 
DEEKNFFKLREDWWT ANRQEIWKAITCKANDDDKYFRETACGTGTPTHKQCRC 
DDKKPDKSKAGNGDVNIVPTYFDYVPQFLR 
>9197R-10gDNA 
DIGDIVRGKDPFYGNTQESARREDLEKNLKEIFGNIYEELlKNGRNGVKDHYNDA 
KKNFYRLRED~ANRATVWEALTCHAPPDAQYFRGTCGSKAKTATQTPSQC 
RCNDDKPDADNPNTDPPTYFDYVPQFLR 
8148R+ cDNA sequences 
>8148R+10 
DIGDIVRGKDL YRGNNKRRQQLEENLKTIFRDIYNEL TSGRNGKKQSLQERYKDT 
TNYYKLRED~ANRETVWKAITCGAPEHASYFRTTCSDERGFSQATKQCRCQ 
KKNGQHDTDQVPTYFDYVPQYLR 
>8148R+12 
DIGDIVRGRDL YLGGRGRDQLESNLKKIFGIIYNNLMQDL TNDQTKSAEAEARYK 
DDPDFFQLREDWWALNRQDVWKAITCNAQGFNYFRHTCDGGQNRTPTNNDCR 
CINFSVPTYFDYVPQYLR 
>8148R+15 
DIGDIIRGKDL YIGNKKENKQRKQLEHNLKXXFXNIXKSDAKL TDLNDDQIREYWW 
ELNRETVWKALTCDAPXDASYFRTTCSDTKGSSVANHKCRCKKNDGKNETDXV 
PTYFDYVPQFLR 
>8148R+7 
DIGDIVRGRDL YRGDKGEKKYLEENLKQMFENIKGNNNKLGRLSTKQVREYWWA 
LNRDQVWKAITCNDVGAQYFRNTCSNGQNKTQNNCRCDGDQVPTYFDYVPQF 
LR 
>8148R+9 
DIGDIVRGRDL YRGDKGEKKYLEENLKQMFENIKGNNNKLGRLSTKQVREYWWA 
LNRDQVWKAITCNDVGAQYFXNTCSNGQNKTQNNCRCDGDQVPTYFDYVPQF 
LR 
>8148R+13 
DIGDIVRGRDMFKPNNVDAVQEGLKWFKKIYDKLSPEVQEHYEDVDGSGNYLK 
LREAWWTANRDQVWKAITCEAPGDAHYFRKGPDGSDVFSNSGPCGRDEATIPT 
YLDYVPQFLR 
>8148R+16 
305 
DIGDIVRGRDMFKRTDNDAVQKGLRA VFKKINDNLNXKKITHXDDISGNYVKLRE 
DWWNANRDKVWRAITCYIPYYVNYFKKKSDDIIVFTNDGKCGHYENNIL TNLDYV 
PQFLR 
>8148R+2 
DIGDIIKGKDL YIRNKQEKDRLEENLRKIFKKIYEGLSKNGAQARYNGDGDNFFKL 
REDWWELNRQQVWKAITCNAQGSQYFXGTCSNDTTSAKGHCQCIDGTVPTNF 
XYVPQFLR 
>8148R+11 
DIGDIVRGRDL YRGNNRENDKLEKKLKEYFKKIYDNLVQNKEEAKDYVKDITNYV 
ELREDWWEENRETVWKAITCNAHDSHYTKMLADGSIKQSDMEKCRNIXGVPTN 
FDYVPQYLR 
>8148R+6 
DIGDIVRGRDL YGGNNKRRQQLEEKLQKIFEKIYDKLDGKKGKKSELQARYNGD 
GPEFFKLREDWWEANRETVWKAMTCSEELRGDAYFRATCDSSDKKGPSQAHD 
KCRCDGRNGTNADQVPTYFDYVPQYLR 
>8148R+4 
DIGDIVRGKDL YFGKKKKKQTERDQLESKLKEIFGDIYNEL TTTNGVKERYKDDRE 
KNYVQLREDWWALNRQDVWKAITCDAKVGDTYFRPTCSDSERSGTFSQAKDH 
CRCNGDKPKGANAVKANDNVNIVPTYFDYVPQYLR 
8148R- cDNA sequences 
>8148R-4 
DIGDIVRGRDL YFGNSKEKNRRENLENNLKEIFKNIYDDL TKDNDNAALKTRYQH 
DAPDYVQLREDWWEENRQQVWKAL TCDAGGGTYFRFTCSNDTTLAHKNCTCIS 
GDPPTYFDYVPQFLR 
>8148R-14 
DIGDIVRGRDL YGGNNKRRQQLEEKLQKIFEKIYDKLDGKKGKKSELQARYNGD 
GPEFFKLREDWWEANRETVWKAMTCSEELRGDAYFRATCDSSDKKGPSQAHD 
KCRCDGRNGTNADQVPTYFDYVPQYLR 
>8148R-11 
DIGDIVRGRDL YRGNNRENDKLEKKLKEYFXXIYDNLVQNKEEAKDYVKDIXXYV 
ELREDWWEENRETVWKAITCNAHDSHYTKMLADGSIKQSDMEKCRNIXGVPTX 
XXYVPQYLR 
>8148R-9 
DIGDIVRGRDL YRGNNRENDKLEKKLKEYFKKIYDNLVQNKEEAKDYVKDITNYV 
ELREDWWEENRETVWKAITCNAHDSHYTKMLADGSIKQSDMEKCRNIXGVPTN 
FDYVPQYLR 
>8148R-3 
DIGDIVRGKDLFLGNDKEKKQRDKLENNLKKIFENIYEELKKDRNLKEGAQKRYG 
GDPDFFKLREDWWNNNRKMVWYAITCGAPKEAKYFIKT ACAGTSQTDGQCRCS 
TRVVPTYFDYVPQYLR 
>8148R-10 
DIGDIVRGKDLFLGNDKEKKQRDKLENNLKKIFEDIYEELKKDRNLKEGAQKRYG 
GDPDFFKLREDWWNNNRKMVWYAITCGAPKEAKYFIKTACAGTSQTDGQCRCS 
TRVVPTYFDYVPQYLR 
>8148R-13 
DIGDIVRGRDPFYGNTXEKEKXEQLEXNLKXXFGKIYEKLNGAKERYNDNDENYV 
QLREYWWALNRDQVWNAITCNAQGNTYFRATCDSGDGKSQSQAKDKCXCPKX 
XXGKPXSNAGKGSGNGDVNIVPTYFDYVPXFLR 
>8148R-5 
306 
DIGDIVRGRDL YGGNNKEKKQRQQLENNLKEIFENINKSDTKLSTLEDDQIREYW 
WALNRQEIWKAITCDAPDYAKYFRGTCGSNAKTATQAKNNCRCTKPNADQVPX 
YFDYVPQFLR 
8148R+ gDNA sequences 
>8148R+1gDNA 
DIGDIIRGKDLYLGNKKQNQTDREKEKLQRNLRSIFAKIYGTLPEKKNSAYLKDGP 
NVYKLREHWWNANRQQIWNAITCGTPQDAKYFSKSNGNQYGCTHTSCHCAGG 
DVLTNFDYVPQYLR 
>8148R+2gDNA 
DIGDIIRGKDL YLGNGDYKVKLSNNLREIFKNIYDALEDTVKENYKDTTNVYKLREY 
WWNANRNDVWKAIVCDAPDEAKVYEKIDGNEYGCNYKNCSCIQGNPPTNLDYV 
PQYLR 
>8148R+14gDNA 
DIGDIXRGRDMFKRTDKDAVQKGLRA VFKKIYDNLSSSVKQHYKEDKDENVYKL 
REDWWKANRDQVWKAITCKAPQGANYFRNISGDTKVFTSAGKCRHNDNSVPTN 
LDYVPQYLR 
>8148R+9gDNA 
DIGDIXRGRDL YGGNNKRRQQLEENLRKIFANIYEELSRTPTKNGQKSAKDRYGQ 
DSPNFYKLREDWWTANRSTVWKAITCGTHDGASYFRATCSDGQSGAQAKNKC 
TCNNGDVPTYFDYVPQFLR 
>8148R+12gDNA 
DIGDIVRGRDL YRGDNREKTKLENKLKDIFENIKKENNSNLKSL TDDQIREYWWT 
ANRAKVWYAITCGAGQNDKYFXQTCSDDKADTYEKCRCVGTDPPTYFDYVPQY 
LR 
>8148R+10gDNA 
DIGDIVRGKDMYVGYDEKEKXRRKQLXNKLKDIFGNIYNDL TKKKGRNGQTLQAR 
YNGDKGNYYQLREYWWALNRXDVWKAITCDAQGFDYFXQTCCTGTGTQGRCR 
CVTNDVPTYFDYVPQYLR 
>8148R+3gDNA 
DIGDIVRGRDPFYGNTQEKEKREQLEDNLKTIFGKIYEKLNGAKERYNDNDENVY 
QLREYWWALNRDQVWNAITCNAQGNTYFRATCDSGDGKSQSQAKDKCSCPKT 
SDGKPGSNAGKGSGNGDVNIVPTYFDYXXQFLR 
8148R- gDNA sequences 
>8148R-2 gDNA 
DIGDIVRGRDL YRGNNRENDKLEKKLKKYFKKIYDNLVQNKEEAKDVYKDITNVY 
ELREDWXEENRETVWKAITCNAHDSHYTKMLADGSIKQSDMEKCRNITGVPTNF 
DYVPQYLR 
>8148R-11gDNA 
DIGDIIRGKDLFIGYNEKDQEEKRKLQENLKKIFKKIYEELlKNNINGEEAEKRYGSD 
QDPNVYQLREDWWEANRKEVWTAITCEAGNDSQYFRA TCGTGTSPTDGQCRC 
AANIDPPTYFDYVPQYLR 
>8148R-13gDNA 
DIGDIIRGKDLFIGYNEKDQEEKRKLQENLKKIFKKIYEKLIKNNINGEEAEKRYGSD 
QDPNVYQLREDWWALNRDQVWKAITCYTGPNDTYSINTGNSITEYWFGQCGRD 
GENVPTNLDYVPQFLR 
>8148R-12gDNA 
DIGDIXRGKDMYVVNKGEKRRLEDNLRKIFGNIYNELRSTNGVKDHYKGDTPEFF 
KLREDWWALNRKDVWKAITCHAGQGAQYVGL TCSEGGSSAHDKCTCNNGDVP 
TYFDYVPQYLR 
307 
>8148R-14gDNA 
DIGDIXRGKDL YLGNKGEKKKRDELEKNLKKIFKEIHGGL TKANGVKDHYQDDGP 
NYYKLREDWWTVNRHTVWKAITCNEDKKLKDASYFRKTCSDRQGESVAIHYCR 
CNGDKPDNDMVNIDPPTYFDYVPQYLR 
>8148R-4gDNA 
DIGDIVRGRDL YRGDKGEKKYLEENLKQMFENIKGNNNKLGRLSTKQVREYWWA 
LNRDQVWKAITCNDVGAQYFRNTCSNGQNKTQNNCRCDGDQVPTYFDYVPQF 
LR 
>8148R-10gDNA 
DIGDIIRGRDL YFGNNKEKKQRQQLDDKLKEIFGKIHEGL TDSGAKNHYNDPSGN 
FFKLREHWWTLNRDQVWNAITCNAQGNTYFRATCDSGDGKSQSQAKDKCSCP 
KTSDGKPGSNAGKGSGNGDVNIVPTYFDYVPQFLR 
8.5 Full-length SA075var1 nucleotide sequence 
>SA075var1 
TTGCCTCTGTTGTTATCTCTAAAATATATATATAATTAATTAAAATAAGGCGAAA 
AAAAAAAAATATTAAGGTTTATAAATAAATATATAAACATGTATGIIIIIATATG 
TATGTATTTTCGTAII IIIII II III I 1 TCTCATATATAATTTTACAAAATATATAA 
AACATAAAAAAGTAATATATAAAATTAAATATAAAAATAAAGGAATACATGAAAT 
ATAATATTTTTCATAAAATGTAATTGTTGII II I I I IIIIGTTAGAATATTTAAAT 
TTATTATAAAAATATTAATATAAATTTTTTTTAAAAATATATATATAAAACTAATA 
ATTATTATTATATACATATTAAATATTACTTATTAATATATATTATATATATATTAT 
AATATTACTACTATTATAATTACTATATATATACAAATATATATATAATACTTATA 
TATATATATTCCAACAAATACAATATTATTATTTTACCATATCACAATACTCCCA 
TAACATACATACATATATACATACATACATACCCCCACGTACGTACCAAAACAC 
CACCAAACCATGTATGCCACGATATAAACCACGTATGCATGACATAATGTAGG 
GCACGAACAAAAAGTCGACGCAAGGACGTGGTGGTGGTGGTGGTAGTAGTG 
GTGGTCGCGGTCGTGGTAGTAGTGGTGGGGGTGGTCGTGGTAGTAGTGGTG 
GTCGCGGTCGGGGTGGACGTCACCAGCAAGTGGTTCGTCGTCGTGGTGTTA 
AAATGGCGCGACGTCGTCGTGGTGCTGCTCGCGGTCGTGGTGGGGGTGCTG 
CTGGTAGTAGTGGTGCGGATAAGTATAAAAATGCCACAAATGTAAAGGACCTT 
TTGGATATGATTGGGAAAGACGTGTACGAAACAGTGAAAAACGAAGCTTTAC 
GACGTAGTAATGGTGATTTGAAAGGATTGTTGTCATTTGCAACTGCTAGTGGG 
GAAAGAGCTAGCACCACAGATCCGTGCGAGTTTGATTATACTACACGTTTTGA 
TG CTAACAGTAACAG GCATCCGTGCACAAATTTAAGTGGAAAACTAGAACCAC 
GlllltCGGATACACTTGGTGGCCAGTGCACTGATAGTAAGATGCGTAGTGG 
TGGTATAGGAGCTTGCGCTCCATATAGACGATTACATTTATGTCATCATAATTT 
GGAAACTATAGAAACAAAGTCGATGACGACGCATAAGTTGCTCGCCGAGGTG 
TGTATGGCAGCAAAATATGAAGGAGAATCATTATTAAAACAATATGAAGAATAT 
AAAAAAGAGAATTCTAATTTCAATACCAATATATGTACGATATTGGCACGAAGT 
TTTGCAGATATAGGAGATATTATAAGAGGAAAAGATTTATACCTTGATCATGAA 
CCAGGAAAACAACATTTAGAGGAACGTCTAGAAAGAATTTTTGAGAACATAAA 
AAAAAAAAATAATAATAACGAACTAAATAATCTTTCATTGGACAAATTTAGAGA 
ATATTGGTGGGCACTTAATAGAGACCAAGTATGGAAAGCTATCACATGCAAAG 
CACCAGAAGAAGACCATTATTTCAAGCCAGCACAAAATAGGAAACGGGAATTT 
ACAGATGGTCATTGTGGCCATAGACAAGGAAACGTTCCTACCAATTTAGATTA 
CGTCCCTCAA1111IACGTTGGTTCGAGGAATGGGCAGAAGAGTTTTGCCGA 
AAACGAAATATTAAATTAAAAATGGCCAAGGAAGCATGTCGTGGTGAGGGAA 
ATACAAAATATTGTAGTCTTAATGGATTTGATTGTACGAGACTTATTCGAAACA 
AAAATTATTGTTCTAGGGATAGTAAGTGTACTGCCTGTTCGAATAAATGCATTC 
308 
CTTATGACTTTTGGTTAGGGAATCAACGAAATGAATTTAAAATACAAAAAGAAA 
AATATGAAAATGAAATAAAAACATATGTAAGTAACAACGGTATACCTAATAGTA 
ATAGTAATACCAAAAAGGAATATTATAAGGAATTTTATGAAAAATATGCACAAA 
ATGACTATGAAACAGTGCAAGGTTTTTTAACCTTACTAAATAATGGAATGTATT 
GTAAAGGAGGATTACCAGGAGAAAAGGATATTACTTTTACTAACAGTGCTGAT 
GACAAAGGGATATTTTATCGTTCAGAATATTGCCAAGTGTGTCCCGATTGTGT 
AGTTGAATGTGTCGATGGAAAATGTCAACAGAAAAAAAAGAATGGTACTTGTA 
ATGAACCACAGATATATACAGTTGTACGAGATGAGACGCCTACTGTAATTAAA 
GTCCTCTTTAGCGGAGAGAACCAGGAAGATATTACAGAAAAATTAAGTTCATT 
CTGTAGCAAAGAAGAAAAAAAAAATAATAGGGACTATCAAACATGGCAATGCT 
ATTATAAAAGTAGTGATTATAATAATTGTGAAATGAAAGGTTCATCATACAAGG 
ATAAACATGATCCTAACATTATTGTATCTCATGAATGTTTTCACTTGTGGGTGA 
AAAGTTTATTAATAGACACCATAAAATGGGAAACCAAACTTAAGAATCGCATA 
GATTATACTACCGTCACGGATTGTGATAATGAATGTAACAATAATTGTGAATGT 
TTTGACAAATGGATTGACACAAAAAAAAAAGAGTGGGAAGAAGTAAGAAAAGT 
ATACAAAGATCAGGAAACAATTTTGGGCGTTTATTTTAAAAATCTTAATAATAT 
TTTTGATAGTTAIIIIIIIGAAGTTATGATTGCGCTTGACCAAGACGAAAAAGG 
AAAATGGGATCAATTTAGGAAAGATTTAGAAAAAAAATTTAAATCTCCCAAAAA 
AAATACAGATACCGAAAATTCCCAAGATGCAATAGAATTCTTATTAGATCACTT 
AAATGATAATGCCCCAACATGCAAAGACAATAATTCAAACGAAGCATGTGATT 
CTTCCAAGAATCGCCCACGAAACCCCTGTGGAAGAAACAATAATGGTGGCAA 
ACTTGTGAGAGTGAAAAGACTAGCCGAAATGATGCAACGATACACGAGGAAA 
CAATTGGAGAAACGTGGCGGCGAAAGTAAATTGAAGGGGGATGCCACCCCA 
GGAAAATATAAACGTGGTGGTGATGGAAGTAAGTTGAAGGGAGACAACATAT 
GTAACATTAGTACCAGTCATTCCAATGATCATCGTGATTCATCAAAGGATCCTT 
GTAATGGCAAAAATCAGGAAAGGTTTAAAATAGGAAAGGAATGGGAACATGG 
ACATGAAATACAATTTCCAATAAACGATTATATGCCTCCTAGACGTCAACATAT 
GTGTACTTCCAATTTAGAAAAATTAGATGTTTCTTGGTTCACTAAAGATGGTAA 
GGCTAGCCACTCATTATTGGGTGATGTGCTGCTCGCAGCAAAATATGAAGCA 
AAAAATATAAAGGACCTCTATGAAAAAAATAAGGGGCACAAGCTGCCTGAATC 
ACAAAAAATGACAAAGCAGACTGTATGTCGAGCGATGAAATATAGTTTTCCAG 
ATATAGGTGATATTATAAGGGGAAAAGATATGTGGGTACAAAACACGGATGCA 
ACAAAACTACAAGGTCATTTAAAAAATGTATTTGAAAAAATTAAAGATCATTCT 
GTCATTAAAGGAAAATATACGGATGGCGAGCCATATATCAAATTAAGAGAAGA 
CTGGTGGGAGGCTAATAGACATCAAGTTTGGAGAGCTATGAAATGTGCAATA 
GAAAATGACAAAGATATGAAATGTAATGGTATCCCAATAGAAGATTACATACC 
CCAAAGGCTTCGATGGATGACCGAATGGGCAGAATGGTTTTGTAAAATGCCA 
TCACAGGCGTATGGGGAGTTGTTGAGGGACTGTGGTAGTTGTAAGATTAAGG 
GTGAACAATGTACGAATGGTAAGAATGGTTGTGAAAAGTGCAAAGCAGCATG 
TGATAAATATAAAGACGAAATAAACAAATGGGAAAATCAATGGAAAAAAATAAA 
AAATAAATACGCACAATTATACAAAAAAGCAAAAACTGCTTTTGCTCGTACTGT 
TTTTGATGATGCCAGTCCCGACTATCAACAAGTGGTAGATTTTTTGTCAAAATT 
ACACAGAGCAAGTATTGCCGCTAGTAGTAAAAGTAGCACCACTAGGGTAACC 
GCCACCGCCCCGAACACCCTCTACAGTTCCGCCGCAGGGTACATACACCAT 
GAAATGGGACCAAACGTGGGGTGTAAAGAGCAGACGCGATTTTGTGCAGAG 
GAAAAGCCGGGTTATGCATTTAAGTATCCGCCAAAGGAGTATGAAGATGCGT 
GTGAGTGTGATAAGAGGAATAAGCCAGAACCGAAAAAACAAAAAGATGCGTG 
TGAAATAGTGGATGGAATACTTAATGGAAAGAGCGCAACGAGTGCAATAGAT 
GGGTGCAATACAAAAAATTATAATGGTTGGAATTGTAATCCAGGTCAGTTTGA 
GGAGGGTCATGATGGAGCATGTATGTCACCTAGAAGACAAAAATTATGCATAT 
ACTATTTTGGAAATCAAGGTCAAATACCAAATATAAAATCAGAAGAGGATTTAA 
GAGAAGCATTCATCAAATCTGCAGCAGGAGAAACTTTTCTCTCATGGCAAAAA 
TACAAAACAGATAACAATAATGATGCAAATCTCCAAAACAATTTAGAAAGTGG 
309 
AATAATCCCTGAAGATTTTAAACGTAAAATGTTCTACACATTTGGAGATTTAAG 
AGATTTTTTATTTGGAACAGATATATCAAAATTAAATAAACATACAAAAGCTCTT 
AAAGATAATCTACATAGAATTTTCAATGATCACGGCAAATCAGATGATAAAGG 
AAAACGTGAAACTTGGTGGAAACCATATGGTCCTCAGATATGGAAAGCAATG 
GTTTGTGGATTATCACATCATGTTAGAGACACCTCGTTACGGAAAAATCTTAT 
CGACAAGCCACAATACACCTACCCCAATGTCAAATTCACTGAAGATCCTAATA 
GCACCTCCCTTTCCACGTTTGCCGAACGACCCCAATTTTTGAGATGGATGAC 
GGAATGGGGGGATGATTTCTGCAAGAAACAAAAAGTAGAAAAGGAGGAGTTG 
AGAAAATGGTGTGCTGAGTATACGTGTAAAGGAGACAAACTAAAGGAACCTG 
AATGTAAAGAAGCATGTACAAAATATAAAAGATTTATTAAAAAATGGGAAAATT 
ATTATGAGAGTCAAAGGAAAAAATTTGAACTAGATAAAAAAAAAAAAATTTTTG 
TGAAAACTCCAGGTAATGTTGATGTACAAAATGCACAAAGTGCTCGATATTAT 
TTAAAAACCCAATTACAAACCCTTTGTAAAAATGGAGAGTGTAACTGTATGGA 
AAATACGTCGACACAAAAAAAAACAAAAGAATCTACTGAAGTTGATATGCCCG 
CATCATTGGATGATACACCTAGTGATTATAAAGAGAGATGTGAATGCATAGCC 
GAATCTCCCCCTCCTCCTCCTCCTCCCCCACCAGAAGGCCTCGGTCGCGCC 
CTAAAACCACCTGCCCCCCCCGATGACGTCGACGCCTCCTCAGAAGAAGAC 
GAAGACGACGAAGACGACGAAGACGACGAAGAAGAGGAAGAAGAAGAAAAC 
GAAGTCGCGGAAGAGGAAGGTGAAGGTGAAGACGACGACGAAAACGAAGAA 
AACGACGACGATGACCCCGACGAAGACGACGAGGAGGAGACGGTGGAAGT 
CACTGACGGCCAAAAAGACACGGACGGGGAGGAGGAGTCGGAGGAAACGC 
CAAAGGAGGAGTCGTCGTCACCAGAAGACGCGGTACCACCAGCAGCAACAC 
CAACAGTAGACAACGTGAAGCCATGTGAAATAGTACAAAAACTATTTACTAGT 
GACGACCTACAAAACACTTTTAAAGATGCCTGCAACCAAAAATATGGTCTACC 
ACAAAGACATTGGGGGTGGAAGTGTGTAACTCCTACCACTAGTAGTTCCACA 
AGTGAGAGGGGTGGAGCTAGTCGTAACAAACGTAATCTCGACTCCACTAAAT 
CTAGTGATAGTGGTAGTATTTGTGTGCCACCACGAAGACGACGATTATATGTG 
GGGAAATTAGAAGAGTGGGCGAGTCCTAGTGGTAACACAGTAGTTAGTGTTC 
AAACCACTCCGGCGCCGTCGTCCAACTTACCGCGACGAACGGCTTGCGCAA 
TGCGTTCATCCAATCTGCTGCTGTGGAAACTTTTIIIIIIGTGGCATAAATATA 
AAATGGAGAAAAAAAAGGAAAAACAGGCAGCAGAAAATCATCTAGTTGTAGAT 
ACATTATCCGAACCAGATGAACTCGATAATCAATTAAAAAAAGGTGAAATCCC 
TGAAGAGTTTAAGCGTCAAATGTTTTATACATTAGGAGATTATAGGGATATATG 
TGTGGGGAACACAAATATAGTGGTTAATGCAAGTGGTACTGAGGAGGAAAAG 
GAGAAAATGCAACAATTACAAACGAAAATAAAAGAACATATAAATAGTGGTCA 
CACACCTCGCACACCTCCTGTCCCCCAAACCCAACCTAATAGTGACAAAGAC 
CCAAAAGACCGGTGGGATAAAAATGCAAAATATATTTGGGATGGAATGATATG 
TGCACTGACATATGACACGGATAGTGGCGCAAAAGGCACAAGTGCCAAAATA 
GACAGGGATGAAGAAGTGAAAAAAAAACTTTTTGACGAAAACGGTGCCTTTAA 
CGAGCCCATCCCCAAATACAAATACGAGACAGTCAAACTCGACGAAAATAGT 
GGTATTGACGGTCCCAAACAAACCGAAGCCCCCACCCTCCTCACCGACTTCA 
TCAAACGACCCCCTTATTTCCGTTACCTAGATGAATGGGGCGAGACAGTCAA 
ACTCGACGAAAATAGTGGTATTGACGGTCCCAAACAAACCGAAGCCCCCACC 
CTCCTCACCGACTTCATCAAACGACCCCCTTATTTCCGTTACCTTGAAGAATG 
GGGTGAAACATTTTGTAGGGAACGGACGAGGAGGTTGGGGAAGATTAAGGA 
GGATTGCAAACAAGGTGATGACAAATGTAGTGGGGATGGTTTGAAATGTAAG 
GAAAAAGTTCCAGATAACAAAGAAAI II I IAAGGATTTCGATTGTCCGAGTTG 
TGCAACACCTTGTGGATTGTATAAAAGGTGGATAAGAAGGAAAAAAGACGAAT 
ATGATAAACAACAAAAGGCATATAATGAACAAAAACAAAACTGCAAAAAGGAA 
CGTAAAGCTGCTGAAAGTACTGATCATGATAAAAAATTTTGTACAAGAATACA 
AAACTTCACTGAAGCTAAAAATTTTTTAGAAAGTTTAGGATCATGTAAAAAGTA 
TAATGGAGAGGGTAATGGAAAGGTTAACAACATTTTTGAGGATATCGGTGAAA 
CGTTTAAAGATGCAGAAGATTGTAAACCATGTTCTTCATTTAAAATAGATTGTG 
310 
AAAAAGCTAAATGCAGTGATGCTAAAGGAAATACTTGCACAACAGGAAAGATT 
ACAGCAAAAAATTTTGAAAATAAGACAGATGTTAATGAAGTTGTTATGCGTGTT 
AGTGATAACGATACAACGAAATTTGATGGTGATTTAAAGAGTTTTTGTGAAGG 
TGCTGGTATATTTAAAAGTATTAGAAAAGATGAATGGAAATGTGGTAAAGTAT 
GTGGTGTAGATATATGCACTCTGGAAAAAACCAATAATGGGCAAGGTAAGGA 
ACATATCATAGTCAAAGAACTGATTAAACGATGGTTAGAATATTTTTTAGAAGA 
TTATAATAGAATTAGAACAAAATTAAAGTCATGTAAAGAAAATGGTAAAGGATC 
CACATGTATAAAAAAGTGTGTAGATAAATGGGTAGAGGAAAAAAAGAACGAAT 
GGAATAATATAAACAATAATTACCTTGAAAAATATATAAATAAAAATGATGCTG 
AATCTAATAATTTAAAAAATTTTTTGGAGACCTTGATACCTCGAATGGATCTTG 
TAAATGATAAAGGAAAGATTAAGGATTTACCTGCGTTCCTGAAGTTATATGGA 
TGTAATTGCGCTGATAACTCAAAAAGTGATGAAGATGGTACACAAAAGGATAT 
CGTAGAATGTTTGCTTAAAAAGCTTGAAGATAAAATTGGAGAATGCAAAAAGA 
AACACGACGAAACTAGTCACGAAAACCAAAACCAAGCGTGTGTTGACTTCCC 
CCCAGATTGAAAACGATGAAGAGGACTTAACCCTTGAAGAAACAGAAGAAAA 
ACCAGATGAGGCAAAAAAGAACATGATGCCGACAATTTGTGAAAAAGTGGTA 
CAAACAACAGAACCACCACCGGCAACAGATGGTAATTGTGAAGAAGCACCAG 
CACAACCAGCACCAGCACCAGCACCAGTACCAGCACCTAGTGAGGAACTGC 
AACCTCAACCACAACCCCCAGAGGAAAAAGCCCTACCCAAACCTGAGGCGC 
CTCCAGCAGCACCGTTAGCCCCTGCGGACGAACCATTCAATCGTGACCTTCT 
GGAAAAGACTATTCCTTTTGGTATTGCATTGGCATTAGGATCTATCGCTTTCCT 
TTTCATGAAGGTAATATATATATATATATATATATATGTGGTATTTATGTGTGTN 
TGCTATGTGTATATGTTATATATATATTTAATATATGTATTTATATTGAAAATGA 
AAAAAGTAATATAGGAACATATCTGTTAAAAAAAAAAAGAGAGAATTTTTAGAA 
TATTAAAAATAAATAAAAACGAAAATATATATATAAATTTTTATAAAATAAAAAAT 
GAGAAATATCTTCAAAGAAAAAAAAACATTTTTTTAAAAAAATATGTGAAAATAA 
AAAAAAAGAAAAAATTTTAACAAAAAAATGTTTAGAAAAAATTTTTTCCAAATGA 
AA T AAAAA T AAAA TTTTTT AAAAA T AAAA T AAAAAAAAAAAAATTTTTTT AAAA TA 
AAAAAAAAAAAA T AAAA T AAAA TTTTTTT AAAA T AAAA T AAAAA T AAAA TTTTTTG 
GGAAAAAAAATGGTTTTTAAAAATTTTA TTTATCCCAT 
GAGGACTTAATAGAAATTTAAATAAAAAAAAAAAGAAAGTAAAAAAATTGAGTA 
CATACACATATACATACAAACCCTTACATATATACCCAAACCTACATATATACA 
TACCCATACACATATACATACCCATACACATATACATACCCATACACATATACA 
TACCCATACACATATACGTACCCATACATACATATATATATATACCCATACATA 
CATATATATACATACCCATACATACATATATACCTACTTAAATACATACCCCTAT 
AAATCTTACATACATATATATTTATTTTTTTATTATAGAAAAAACCCAAATCACC 
TGTTGACCTCATACGTGTACTTGACATCCACAAAGGAGATTATGGAATGCCTA 
CACTGAAATCAAAAAATCGATATATACCCTATGCTAGTGATAAATATAAAGGCA 
AAAGCATATATATATATGGAAGGAGATAGTAGTGGAGATGAAAAATATGCATT 
TATGTCTGATACTACTGATATAACTTCCTCAGAAAGTGAATATGAAGGAGCTG 
G 
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------~----~~~ ~~------%-CVFORDUPLICATE READS ACROSS 9PLA TES _PAR';-'--'-'-~----"~~ -- "~-'.-"-' 
Plate 1 Plate 2 Plate 3 Plate 4 Plate 5 Plate 6 Plate 7 Plate 8 Plate 9 
% % % % % % % % % 
I Sample Mean CV Mean CV Mean CV Mean CV Mean CV Mean CV Mean CV Mean CV Mean CV 
A1 serum on PAR+ 14.80 17.20 15.75 3.14 20.15 11.58 14.85 39.52 14.30 6.92 14.95 4.26 15.80 10.74 14.20 8.96 14.05 7.55 
A4 trophs + A 1 serum 2.66 16.48 2.68 10.84 2.94 0.72 3.27 9.31 3.94 9.52 3.53 14.64 4.04 5.78 3.27 1.73 3.21 15.22 
Anti-NTS-OBL 
alpha PAR+ 14.40 3.93 14.30 3.96 15.55 1.36 15.55 0.45 14.55 0.49 13.70 8.26 15.35 6.91 14.05 2.52 13.35 3.71 
European 1 1.88 24.82 1.50 3.31 1.74 6.93 1.71 2.07 1.74 4.06 1.41 3.52 1.77 22.37 0.98 26.66 1.34 7.39 
European 2 2.94 7.70 1.50 6.15 1.37 1.03 1.33 8.00 1.52 1.86 1.50 7.09 1.38 4.10 1.20 4.71 1.26 3.94 
European 3 1.59 11.56 2.65 6.91 1.47 0.96 1.35 2.10 1.62 2.62 1.38 2.05 1.54 1.38 1.28 5.52 1.26 0.56 
European 4 1.62 3.06 1.73 1.23 1.58 6.73 1.47 0.96 1.71 0.00 1.68 0.00 1.54 0.00 1.46 11.18 NO NO 
European 5 1.35 5.78 1.45 0.00 1.34 4.22 1.23 8.05 1.44 1.96 1.36 8.32 1.22 15.71 1.25 7.38 NO NO 
No Ab Anti-Human sec. 0.97 7.60 1.00 1.41 0.94 2.62 0.91 7.15 1.02 0.70 1.03 0.69 0.94 1.59 0.92 1.53 0.91 3.59 
No Ab Anti-Rabbit sec. 0.70 2.34 0.71 1.29 0.77 0.18 0.72 9.10 0.77 3.93 0.76 3.08 0.67 5.49 0.69 2.36 0.70 4.25 
Rabbit IgG control 0.83 0.59 0.89 1.35_ 0.9~ ~~~~ 0.08 0.94 0.45 0.93 4.49 0.94 3.08 0.85 3.48 0.77 4.52 0.76 3.06 
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% CV FOR DUPLICA TE READS ACROSS 9PLA TES--SA075R+ 
Plate 1 Plate 2 Plate 3 Plate 4 Plate 5 Plate 6 Plate 7 Plate 8 Plate 9 I 
% % % % % % % 
Sample Mean CV Mean CV Mean CV Mean CV Mean %CV Mean %CV Mean CV Mean CV Mean CV 
A 1 serum on AS075R+ 30.86 10.72 37.95 21.97 23.66 0.66 27.16 7.99 26.29 4.20 22.59 1.19 25.23 1.29 26.20 1.03 25.09 0.06 
A4 trophs + A 1 serum 2.72 1.04 2.98 3.57 1.96 6.49 1.82 24.09 1.92 21.05 1.83 13.91 2.03 10.45 2.16 1.31 2.48 14.83 
European 1 0.06 12.86 0.14 1.02 0.15 2.41 0.01 9.43 0.02 35.91 0.12 17.39 0.09 19.11 0.10 7.56 0.21 10.13 
European 2 0.04 25.36 0.15 6.83 0.15 4.12 0.01 23.57 0.09 8.14 0.13 33.83 0.08 3.54 0.04 15.71 0.08 9.96 
European 3 0.14 22.48 0.14 3.03 0.14 3.03 0.01 17.85 0.09 28.95 0.09 16.97 0.11 4.56 0.04 13.56 0.09 3.14 
European 4 0.13 13.65 0.22 0.94 0.22 10.83 0.13 9.05 0.19 4.75 0.01 121.22 0.14 10.80 0.10 8.66 NO NO 
European 5 0.12 7.31 0.18 5.88 0.18 2.00 0.03 16.79 0.11 3.29 0.03 14.63 0.12 13.84 0.12 30.18 NO NO 
Anti-NTS-OBL 
alphaSA075R+ 15.38 14.88 15.94 1.00 14.14 2.54 13.40 1.45 14.25 0.73 14.51 1.94 14.63 2.79 14.11 2.02 14.56 6.28 
No Ab Anti-Human sec. 0.11 1.07 0.16 3.03 0.31 18.11 0.10 5.08 0.03 6.53 0.03 62.23 0.07 11.52 0.06 8.30 0.10 2.40 
No Ab Anti-Rabbit sec. 0.13 10.22 0.24 26.32 0.26 28.50 0.11 12.86 0.02 141.42 0.03 28.28 0.13 2.79 0.04 24.51 0.16 22.92 
Rabbit IgG control 0.28 15.54 0.34 10.15 0.37 1.74 0.08 37.49 0.18 1.21 0.11 19.31 0.24 7.32 0.20 18.57 0.25 8.59 
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